<SEC-DOCUMENT>0001558370-21-011752.txt : 20210816
<SEC-HEADER>0001558370-21-011752.hdr.sgml : 20210816
<ACCEPTANCE-DATETIME>20210816071753
ACCESSION NUMBER:		0001558370-21-011752
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		44
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210816
DATE AS OF CHANGE:		20210816

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		211174485

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>plx-20210630x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7811.37134 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 8/16/2021 11:17:01 AM -->
      <!-- iXBRL Library version: 1.0.7811.37150 -->
      <!-- iXBRL Service Job ID: eccfce8f-1dcc-4797-8934-287de53281c0 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:plx="http://www.protalix.com/20210630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:EntityCentralIndexKey" id="Tc_CEA06ZRVZkSs3Ggktmalsg_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:CurrentFiscalYearEndDate" id="Tc_Jr0YqwOjkk6H4OJMLI0YuQ_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:DocumentFiscalYearFocus" id="Tc_7zqPV-CipUS_nCqpxiLtyg_4_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:DocumentFiscalPeriodFocus" id="Tc_ztFh9LAXvECnXgLj-EVwYw_5_1">Q2</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:AmendmentFlag" id="Narr_nzMb86XTSEqB6Dh-e9Mf3g">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="plx-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_6_7_2021_To_6_7_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_hHEjR2Bo5EuYhi_31RGp8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-07</xbrli:startDate><xbrli:endDate>2021-06-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jpLE-akMakyV3Jbk_35Y5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_coEbyffChUiacKC7c4wHAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7dJe2GnFOEGyYLG5fG1hgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TInNrhsHD0-stLLDv404XQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_QRSFKQURbUe6hHXKoDRu9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zpuoYmPfdkek3USyWn91Qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zVn_KJPePkOTFIcmvJNdvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WNnhvQfFrEymbDn9Ce7FGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6nrUDBCtt06YRW-L2OEYxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8Jw06A2_s02mFX7Ni3WLQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JwuKoUeMXUSq0ARxWqpE6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_ZFXxvJmOEUaEgQwjPNZzDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZYngxRQFYkWwRhWxM0SkzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K5lGRruMjUWFHxHMZFMGmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_vViOT2LFf0axMCBfeZUuig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_c92pTwX33UuIlz_FfqiOGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QPt03YiNMEyRlDDY1cIgVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Aw21LWNb10edAAVCUPhNiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q55XKvKM6UWzjFvtkRLLmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7koqe4XbrU2iAVQ8xtCh9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4cR5rGHxsEuH26ppUkiILQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_17_2021_I73LVvhcdECPyti0oudI0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_3FiFNKmCaEy9ibcMUQ7VXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_0ROHtRtUikyYBfN1q0FG8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_lNGq93994UKs__wHyGDgeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_5O4qCJrVG0eoNBly8DogRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_9dHpxsKaGEaFqtY_iDBcKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_iX-tLkOGFEuB3AcNqYn0Rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_Ho_xcKWNEEuICmELxx2gig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_Ov94iWapwECTWXr04PGCzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_Q6m-H8y14kKGpOowck7pfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_8zn7u60jckyDuh3BmFc7oQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_y9t0G7VzUk-YnlJjmRCq3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_mYAzB56-cUCdOTNVt0yw5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_Pp2mgbyjGkO2esZcL0xKKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_4d1okvan3EClXL0thoxjqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Z_KtMWQs0Uujw0cnqYs6lQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_wgEii3xYtU2zfwp11IyUzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_0Dtxw3_Y9E6sb-ILAujQMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_vAeDA4nbuUyblocjjCUcbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_IvlRKs5dAEuQ7xeqDJDHLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_YnQnoi6e-EudGaXDEpkpwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_pMCN5439iEi2rGvtFhU0-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_17_2021_To_2_17_2021_eP-kucV1pUWTbBXr7TaMSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-17</xbrli:startDate><xbrli:endDate>2021-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0-Eu2_lbZUioiYvNP-u1Jg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gJteVLZhPUKl-E3d6202xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ED-14lWq4kqXAYP7X69qhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9IdhTME8lUGRXZwzJDuW3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_yMRhv1-EBUyjv67c4vnBIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:Notes2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_-UCWB1XwmECspjYijNZ7Jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_mufBZIm2IkKt0BdUQt8lTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_B-IrvzpQnE-E4laCHJyHig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_MB3j5xcttkmq-uspEaqDzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_TXQdyNOI60W_tZ_1z-7XnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_eC_j6cyaVEe4nMowIWMQlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_CocxRZ8sAUy7n9e-67jKfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_-tsX_jEa10aFdesmgIQc1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_NaNGoBKCkEiu7vUtu1FpeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_9pT5j3bp9kOxck8vgMJvsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_UTfTJ92Crkail7a-VOYa5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_tP37cYnQBEy-ajyGcP9j2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_wDSeLRz8j0mcVlFQpqqNGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Sxq30RrND0uqWIoDHU4HbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_B2vkFxAj30mgjYvbaeB7XQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_jyn3lwbXOESy8Z3KX8YCGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_iiC6Yn_rdkWx9W-FzaEoiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_2I_j-CG2WE-GsdeFUO0uXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5PQNzgrw3U21fmcnTdCH2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Okh2sy6Wwku5BgEkLA_q-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_hDBte-t0lUWwnjhjyGWBOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_bqX3cUtNBESnhgaklTJZew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9wfTwEjjqEi90jMNxt9LuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_PDlyFNQ9d0677vNqirp86w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_AI0MTldNw0S-WidGYq9XRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_5jiTZMuakUK7bv_eFjH6Tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4hdRC028OESAjUPcR-4qZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fmr_C6CM1EmRY2waHRcinA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gsX0p07goEqvnOBN9SVuGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h_6cg02980C2C6q1_vdErg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_36UqK7xw-keHI8meiWi3Lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_Icszi70YU0WMX60GBUG0ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ChangeInAccountingEstimateByTypeAxis_us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_zOqqkDVmMEqqtqAQg4AvEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_lC9sVFpteUu2iOBXmvyCnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_cT_q_tep9EOn9lbEWZblFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_3jQI-P9cnkOUP6jE77HynA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-23</xbrli:startDate><xbrli:endDate>2018-07-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_hO2OX0CkykSDtEZGjleYjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_eVJdA8NazEqDalQFFkRHrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-19</xbrli:startDate><xbrli:endDate>2017-10-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_10_2021_To_2_10_2021_us-gaap_TypeOfArrangementAxis_plx_SarcomedUsaInc.AgreementMember_s6R6OeOa5EigE4cD9-rsoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:SarcomedUsaInc.AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-10</xbrli:startDate><xbrli:endDate>2021-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MEoQBaAbc06IzFxMkQM1qg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5mBl3aHBi0KLliehuspORg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_12_2021_To_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wp1PKGYOf02TVwTFOgkSpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-12</xbrli:startDate><xbrli:endDate>2021-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_12_2021_To_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_0ds-0DyfXEGdaoZ3UfY54A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-12</xbrli:startDate><xbrli:endDate>2021-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_T2MIzBKUik2fuPiyDHsRSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_W0s5POha_U6du1M7Hy-NoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-13</xbrli:startDate><xbrli:endDate>2021-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_cUS14zPtB02emWZ8d9vIBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SQhCtGF5pEGEvL3YbxckPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_UXGhKrHKLEeju1LG7xvQ0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_JPKl0rb7CE-Kwx4t4a5tFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_1_2021_j5jIo3nZTky_FHNtZBcwKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_roa1qYbSR0KRZqNYmT7fsA"><xbrli:measure>plx:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_3GEBVpZPv0aBDLyXOLJfqQ_8_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_SZB0Vh2-y0ueWL3uSkF-tg_16_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_DLD9rpvbDUe1SXmJYhMFyA_19_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_xhyd6qZM0EqWTnOsnJdgUA_31_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Y_wQ9oJdU0Cs2MvW3iyoGg_6_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_5XZuCtKy4E-SGrsC5_ENoA_22_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_URYSXaY8RE6lUkg-Wo5WBw_26_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_d828K6Ue1EKmOTX4if5wtA_12_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_L-kjd32hckOMkpdSFE_lCw_13_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_kJfgoliISkuMvHZqvexXNw_27_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_pxTp2QsKZ0-w6FRLwU0S2w_33_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_0LvczoWAP0eRWIM1krg6yA_21_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_fWUbFYN1xk-LXIllRu6nHw_15_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_MOKYy9iWukWBlp9Cb8syFQ_6_6" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_M3MdaWnkm0u3iCJrBVW49Q_6_12" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_ja4zzCYhOEqCGEHrAQpQfg_6_3" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_l5BWUd-RXUGbJZRQPvUhdw_6_9" toRefs="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_SOE0M9LJqEC9irlbFTBuww_7_6" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_UJDWbfys4UWta90TrpcD1g_7_12" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_6PQnFa_8wEOkocugC-GiRA_7_3" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_j20L-um0_UeQS6WljLnoLw_7_9" toRefs="_8530ca94_6c84_4f48_984f_7cc5a2959400" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_6jhX9rTYhkan3hwzHYH8Zw_8_6" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_8pXFPCLHhEC0G7Z06IE0AQ_8_12" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_zZSlooWFp0SIFCb7s7p3xw_8_3" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_c0sXX_tWXE2Thll3DxjFZg_8_9" toRefs="_64475d15_2bf5_4e75_bed3_14deb6a39d55" order="1"></ix:relationship></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;padding-top:1pt;text-align:center;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-bottom-style:none;border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:1pt;padding-bottom:1pt;text-align:center;border-bottom:1.0pt solid #000000;margin:0pt;"><b style="font-weight:bold;">fFFAS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e8f94af2_e6f1_49bf_afb6_d7d1fdffc99a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:DocumentType" id="Narr_mskxDydf80ao09jqB_bkrA"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:DocumentQuarterlyReport" id="Narr_oRFu-dto-Ui53ztjRYgm7g"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-size:8pt;font-weight:bold;">For</b><span style="font-size:8pt;"> </span><b style="font-size:8pt;font-weight:bold;">the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:DocumentPeriodEndDate" id="Narr_t36IKXyq1UGxZ-sw2Jid7Q"><b style="font-size:8pt;font-weight:bold;">June&#160;30, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:DocumentTransitionReport" id="Narr_xykXs06lHEW3uJ1MxW0h8g"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to</b><span style="text-decoration:underline;text-decoration-color:#000000;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:EntityFileNumber" id="Narr_kkcGM1133ESMALX_kNLgPw"><b style="font-size:8pt;font-weight:bold;">001-33357</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission file number)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:EntityRegistrantName" id="Narr_QpyiNWvG1EO8JnU8U_CFlg"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a1bb36ca_e2bf_4dc9_949a_f711226b91ef"></a><a id="Tc_MVhOWSyiWEeVZzAxNwaY9Q_1_1"></a><a id="Tc_mWEWK9hoeUCrD6of3Mx3TA_2_0"></a><a id="Tc_SntHsNgph0yHDu8ez0C6ug_2_1"></a><a id="Tc_5Pla5UXPB0Oa6i4qNEotow_4_0"></a><a id="Tc_P86UCUaugUumAwCLIicVZA_5_0"></a><a id="Tc_x28tsWBM7UmiI3pRHNDsOg_5_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:EntityIncorporationStateCountryCode" id="Tc_GOP988dHFEi6BaZ2OC6qeA_1_0"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">&#160;</span><b style="font-size:8pt;font-weight:bold;">__</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:EntityTaxIdentificationNumber" id="Narr_iX83J41tFEOuIzCpUUgIYQ"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">65-0643773</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">__</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation or organization)&#160;</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:EntityAddressAddressLine1" id="Narr_4s2wLOKE80GYy_FQAH_l2Q"><b style="font-size:8pt;font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:EntityAddressAddressLine2" id="Narr_XhkrVibkjUuMPU8GOWWE8Q"><b style="font-size:8pt;font-weight:bold;">Suite 100</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:EntityAddressCityOrTown" id="Narr_OLFeqwV8KEOUkpUcUp6Hgg"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Hackensack</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">, </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:EntityAddressStateOrProvince" id="Narr_zrB_JEv91Em4s8SxBawvCA"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:EntityAddressPostalZipCode" id="Tc_fh7YdW8Yhkm5ZGVWzWRF3Q_4_1"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">(</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:CityAreaCode" id="Narr_S9wuHBTC40SXuYdBA4obMA"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">201</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">)-</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:LocalPhoneNumber" id="Narr_gPqXnkgRAkmiwbK9g_SzMQ"><b style="font-size:8pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name, former address and former fiscal&#160;year, if changed since last report)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_45e8230e_f727_4422_812c_a1e35f80e47e"></a><a id="Tc_vRQpRuGFyEy9kKiLWLPCrw_1_0"></a><a id="Tc_KJJYrRboXEaSbAG--OybSQ_1_2"></a><a id="Tc_vqiWate_AUOx6fbOzQrHjw_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"></td></tr><tr><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:Security12bTitle" id="Tc_EAzaOFeBnk-47TIzDGX57w_2_0"><span style="font-size:8pt;">Common stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:TradingSymbol" id="Tc_nBtAD13YXUi7EVilvZYzZQ_2_2"><span style="font-size:8pt;">PLX</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:SecurityExchangeName" id="Tc_qwmR-qpBw0O-dLlrvqVqTQ_2_4"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:EntityCurrentReportingStatus" id="Narr_5rdD5LEnN0iOWEQm15KjCQ"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:EntityInteractiveDataCurrent" id="Narr_5IsgIkLgP0ODvEseCkr7mw"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160; No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a975f266_f6c7_407d_aa80_42ce67244ae1"></a><a id="Tc_FYD25agFw0C3b-2r8L-LwA_1_0"></a><a id="Tc_JuGsq9mELUqMY3GqqkiSOQ_1_1"></a><a id="Tc_dA0PAwhCK0myR2OjrXhb8Q_1_2"></a><a id="Tc_G9t3G_N4TUig7AG_IWQE_A_1_3"></a><a id="Tc_HGTQp3lI1Uq_9hrNSEnDWw_2_1"></a><a id="Tc_fxqd82bbXkOv0axst5o7Lw_2_2"></a><a id="Tc_fcJKgPW_N0Cg22KUXfdgJw_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90.1%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:EntityFilerCategory" id="Tc_BlFkyZ-r30mqOaG27hJ93Q_2_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#8999;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:EntitySmallBusiness" id="Tc_IRV2OwGApUKjz5dfeO5sRQ_2_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:EntityEmergingGrowthCompany" id="Tc_qEMevcXUR0GftabPUMc27Q_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="dei:EntityShellCompany" id="Narr_fHrnChwhsE2dno3rNMq1rg"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> &#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">On August&#160;1, 2021, approximately <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_8_1_2021_j5jIo3nZTky_FHNtZBcwKw" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_9KRRpjjPs0efRaZJMdmH3w">45,556,647</ix:nonFraction> shares of the Registrant&#8217;s common stock, $0.001 par value, were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_3abebb9e_571a_44c6_a324_1e2bf53639ae"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM 10-Q</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIFINANCIALINFORMATION_363674"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:center;">PART I &#8211; FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Balance Sheets (Unaudited) &#8211; As of June&#160;30, 2021 and December&#160;31, 2020</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Operations (Unaudited) &#8211; For the Six and Three Months Ended June&#160;30, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Changes in </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Stockholders&#8217; equity (</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Capital Deficiency) (Unaudited) &#8211; For the Six and Three Months Ended June&#160;30, 2021 and 2020</span></a></p></td><td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Condensed Consolidated Statements of Cash Flows (Unaudited) &#8211; For the Six Months Ended June&#160;30, 2021 and 2020</span></a></p></td><td style="background-color:#ffffff;vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Notes to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIIOTHERINFORMATION_770480"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:center;">PART II &#8211; OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Other Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Exhibits</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_574709"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Signatures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_04ad25d3_850d_47fc_b2c6_b92e324a24be"></a><a id="PARTIFINANCIALINFORMATION_363674"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;I&#160;&#8211; FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_969154"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;1. Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_26ebb788_9b3d_4dbb_85f8_adaa92a7253b"></a><a id="Tc_rnGonWTUM0y3gTq--6lLCA_1_2"></a><a id="Tc_atgSBavuOEyt4fKu40mVVQ_1_5"></a><a id="Tc_zQcViudjA0-d7M_GXgc6Wg_3_0"></a><a id="Tc_XHSeW6Pu-EyxRiKbskm8FA_5_0"></a><a id="Tc_CUktfHV-rkmKRxNZfFJn1g_6_0"></a><a id="Tc_7sTNVBPHwESGPuO18ND_-w_6_2"></a><a id="Tc_GbD55QqkXk6SCJkX3Qez3g_6_5"></a><a id="Tc_jL9-DscJg0eYTJcxpJlaLw_7_0"></a><a id="Tc_LAbI36GcD02mKpmPLivpYQ_8_0"></a><a id="Tc_1fBfmj441US5ZYk_PSFVAw_9_0"></a><a id="Tc_yUSWz7HWBkGOsKluF29sig_10_0"></a><a id="Tc_ujyVykxpC0K7yTuVMnHqGw_11_0"></a><a id="Tc_o8KQD3fXTEWgCT_Nvhxp-g_11_2"></a><a id="Tc_KGjPLIBmSk2k-kEhKiGQjw_11_5"></a><a id="Tc_9hGDXhbzvUq3V8XFFdQr8Q_13_0"></a><a id="Tc_EiOx5II7kU6l7_MGmAE29w_14_0"></a><a id="Tc_IqTy_Z9xo0OUe8Qabm4q3w_14_5"></a><a id="Tc_b9WhctflYkubR4F2ZvMtWw_15_0"></a><a id="Tc_9__1JrTPFEWmlcc7bmHCyg_16_0"></a><a id="Tc_Dw717zJLFU-Jw-0Bt0dI_Q_17_0"></a><a id="Tc_Kua_dGdGJku6t8Uvds66tQ_17_2"></a><a id="Tc_gQavdfD3MkWbIrXTTta4qg_17_5"></a><a id="Tc_zT-31OQOiUSJHUo6nOrBlQ_19_0"></a><a id="Tc_RF5kqzSC_EmmDbRPvrSiNQ_21_0"></a><a id="Tc_5QY2CRC4yUmwxbFcS5CB-Q_22_0"></a><a id="Tc_ZzaLcA-KWkSE8JGLkiV3ig_23_0"></a><a id="Tc_SYxZ-cdTvU2K6kNZodpgzg_23_2"></a><a id="Tc_mipdH0-wo0C012OK4rhuvQ_23_5"></a><a id="Tc_mJ3KD6eiXUqO7ontAkP3GQ_24_0"></a><a id="Tc_jplMQiKjTESQ1F_kqB7EGQ_25_0"></a><a id="Tc_67hjidbAyUu-G_V5fr844g_26_0"></a><a id="Tc_90Kv8oc03kyfVOSl6_Ek7A_27_0"></a><a id="Tc_EPtUHegxYUKvrgaN1Cr5lw_28_0"></a><a id="Tc_ZZDzpQ-SKEyWbIDb12QOiw_29_0"></a><a id="Tc_8hutvVUCFEGxuBvQiREOcg_29_2"></a><a id="Tc_6FYXFk43e0yItqL5KZV7qg_29_5"></a><a id="Tc_qCNBtxTxUEujWuyWiw6s7g_31_0"></a><a id="Tc__E8Ei6ZOC0ue2Jvd5YeS7Q_32_0"></a><a id="Tc_to-UhBhsNEyNYPB7sjmnxQ_33_0"></a><a id="Tc_TVPeLyBduUSYJjOeZVLMyg_34_0"></a><a id="Tc_dbBnjmEeGU2BSPubxs3nag_35_0"></a><a id="Tc_AWvcV7snk0emH3LVSy_b1g_36_0"></a><a id="Tc_ESLgYHnv0kexiTRmLVrAiQ_36_2"></a><a id="Tc_-SAuO3WVHUuIwPXOAgE9eA_36_5"></a><a id="Tc_S2YuT7FIf02qsWlO8RlchA_37_0"></a><a id="Tc_AwAt28blMU-f-7Y2Ybl8ow_37_2"></a><a id="Tc_rt3HDCWJKkKFujyOtwp6Aw_37_5"></a><a id="Tc_T4JkaFM6M0eIv-_Lyed2XQ_39_0"></a><a id="Tc_Z1E1i-Ivv0SKDlOtfQwrVA_40_0"></a><a id="Tc_EKTyPf2HNkGZBBZDTq0cbQ_40_2"></a><a id="Tc_nrqHUe87m0W5MlPC---44g_40_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_oYDyycS-NkyzrLBQPq8nug_6_3">33,882</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_P-quLJfEQ02lUohQuzWw6A_6_6">18,265</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Short-term bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_AmGTHtXknEeK7YS5NZcbiA_7_3">43,058</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_hWqNoSRBVE61B8x04OFWTw_7_6">20,280</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts receivable &#8211; Trade</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_Z-D7bVqvK0OdxTi9pO6lIA_8_3">2,330</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_4H3VVQSI606XRI9B5Ih9RA_8_6">2,000</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_fWKZUW2ztUaX-I0XLRp6hg_9_3">3,013</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_tM-HzvLDGkqX_YolRWHtUA_9_6">2,096</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Inventories</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_IPAaO4J8W0id4tNuqArdgA_10_3">13,640</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_zoTHtde2NkihhJAMVVWRFw_10_6">13,082</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_xURScdRXM0q-ZJpk7A_1hg_11_3">95,923</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_7r3LkhFaV06iGrtp7e-tbg_11_6">55,723</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Funds in respect of employee rights upon retirement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_x_gPdOg1VEekd-17enND_A_14_3">1,884</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_m4Kh6JN7NEahb7NNKrBLKw_14_6">1,799</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_Ze9FTTgB-U6sBRkkm8fSLA_15_3">4,991</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_z-GXiANkiUyDEvgZ3ISVSw_15_6">4,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_ubG-g77DHEKigNlfubV9HQ_16_3">5,406</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_eXtoEJpTykmMxFYJ-zGlMA_16_6">5,567</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_yPmDtbKLh0G6anIwdC2Onw_17_3">108,204</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_wZtUl3ZusEKPDt0V3EkI6g_17_6">67,934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY (NET OF CAPITAL DEFICIENCY)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CURRENT LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Accounts payable and accruals:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_0agt-nFxzkGqaLZS14JuPg_23_3">6,128</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_QzpuLEhHXkWmfXwQhNFklA_23_6">7,221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_5IzUwkrZ2UupFhDT7G9RLA_24_3">14,420</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="Tc_nLqkoTzyykiNPlRb12pxug_24_6">13,926</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_tl6I-YBHi0OYB2zU1X25RA_25_3">1,235</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_wxX7_xGd6EmwLpEqjBrJag_25_6">1,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_9BYb00H2I0aMRx5J5GSk4A_26_3">18,109</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="Tc_f19DtZ36Nkm173BTtfPS5w_26_6">5,394</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Convertible notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_fP4B0HOLt06xx9XysgVwgQ_27_3">56,355</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtCurrent" scale="3" id="Tc_OY7j7QmYM0aTbvCS_t3qDQ_27_6">54,427</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Promissory note</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="Tc_qGJoO1qN0UGkXO3B_ECnRA_28_6">4,086</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_zDNZJSgHBke3eZgw-52TKA_29_3">96,247</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_0M-EtjNlC0SdgCbNzwAJEA_29_6">86,474</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LONG TERM LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Contracts liability</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_EiDTM_STN0u1DPEihx89PA_32_3">1,269</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="Tc_X_CrU-hfD0Wel8BtEU-_qA_32_6">1,716</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_k25TFj1hKkq2bLH-kws8hQ_33_3">2,302</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_HKLdw-qF7EmnY2oKLE8O6Q_33_6">2,263</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_WL1_1PNrwEay-O3kAmBrkg_34_3">4,507</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_tBPt_KtYjUS0LntD7i-W1Q_34_6">4,467</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Other long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_XKfGLf270ES8BRJza4Hxyg_35_3">38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_CnHk7ehQaUqvE2g_3evJFg_35_6">51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total long term liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_sGEh409NqE25OvfCjZIH3Q_36_3">8,116</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_ju-cd2Ho_kuKyT9GWDhpEw_36_6">8,497</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_JPB-iDhNqUOhuozyc7KQnw_37_3">104,363</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_IxN6RkCOjkySU6CarfT0QA_37_6">94,971</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">STOCKHOLDERS&#8217; EQUITY (CAPITAL DEFICIENCY)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_p_n_AIah4UiUnPmTPLOo5w_39_3">3,841</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_chpTdhNDnkuv7vwojstXOQ_39_6">27,037</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:67.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total liabilities and stockholders&#8217; equity (net of capital deficiency)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_IRadxxcXkk2YlKJ6YqIBRw_40_3">108,204</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_CvFMwQdzp0K0mMwpTR99BQ_40_6">67,934</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_56dff94e_d232_4135_ad35_06a4cde9fc08"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share and per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_245770eb_1795_4abb_94f5_de46e607fba1"></a><a id="Tc_0hbuJ-BH40eKGkk3YlkzpQ_1_2"></a><a id="Tc_IiBaJ_S-DEil9oPs6TK-vw_1_8"></a><a id="Tc_jFkN7qiVhUK3sr42ut1Q_g_2_2"></a><a id="Tc_ZDJCmjb7AEqaT8JgGkJ01Q_2_5"></a><a id="Tc_KrvR4m2GekuyfzVFOn3DcQ_2_8"></a><a id="Tc_QHGviivNz06dCYhAEGAbUQ_2_11"></a><a id="Tc_D5aTrMwSOUmZ5JJHS9Hddg_3_0"></a><a id="Tc_OX7tcPPLKE2tJO5RU_cAog_3_2"></a><a id="Tc_oQTfbDJNnUi3QWKXMUoVow_3_5"></a><a id="Tc___6w8IcQpkCOEgDnyDUf-A_3_8"></a><a id="Tc_nfGNHhVOeE-9eyhhXE9GIQ_3_11"></a><a id="Tc_KsgL6KaQFUuoa_Kg67A7vw_4_0"></a><a id="Tc_m0WnG8wA2kGp9QqB_BrgaA_5_0"></a><a id="Tc_QGSZj-2w4Ee6NIoWPAOvEw_6_0"></a><a id="Tc_Qi4kqXkcsE2EX1HsjegPYg_7_0"></a><a id="Tc_ayaI2Irw1EKdoqUPnOkNbg_8_0"></a><a id="Tc_p1d2c8HDm0mEH36rgwy7WA_9_0"></a><a id="Tc_ZsKjKhZOOU-PZ8TIinadfQ_10_0"></a><a id="Tc_zOO2Uu_Dr0CTQ2ltos59fg_11_0"></a><a id="Tc_SuKkfK74F0W2M6ACFgB6RA_12_0"></a><a id="Tc_ecJJd3Sqn0iucey-HWbVmg_13_0"></a><a id="Tc_gzNBZYaakEGNGicp-n55-A_14_0"></a><a id="Tc_xSnBE8jFVUCojKUBzYBtAA_14_2"></a><a id="Tc_uCcvo281jU6XyUeBCJs_2g_14_5"></a><a id="Tc_cvELi3PAMkirAEFbnm_7uw_14_8"></a><a id="Tc_StGQFWN4YUOd6DncJ2y_6g_14_11"></a><a id="Tc_gbd013UBK0CGT2_uOIsZ2w_15_0"></a><a id="Tc_hWwkV1hTEkCtRIkT-f0pYg_15_2"></a><a id="Tc_6LkqgzpLfE6mi-hDMMv5Qg_15_5"></a><a id="Tc_GOpTu56uXkG4Q008V7vStQ_15_8"></a><a id="Tc_-V2ocTwN906ru5vV3PQvqQ_15_11"></a><a id="Tc_RVrL-sOoB0efsU32T3prVg_16_0"></a><a id="Tc_-QQuzdDXDU2ICR3AkekrHw_17_0"></a><a id="Tc_nkypEhZuK0OC2spmAUkAYA_18_0"></a><a id="Tc_X-JOXDg9P0ugRsjnaelIPg_18_2"></a><a id="Tc_HNGSd5DZkUmwblto6Qp96Q_18_5"></a><a id="Tc_PGzqX6Bul02Ga0tvdIIFqg_18_8"></a><a id="Tc_3KO-i-_xbE-j0Qm3gjctOA_18_11"></a><a id="Tc_M71ZtZD7DkiP6xMavskTaQ_19_0"></a><a id="Tc_Iriao2CpPEWwzqDUC02v5A_19_2"></a><a id="Tc_esImkXFIdUqq2-6FJIF15w_19_5"></a><a id="Tc_ZXlPFkIb6Ea6UHcT4iZQNg_20_0"></a><a id="Tc_bblBBpSATEeCE30MwrnMew_20_2"></a><a id="Tc_cPxwtwtKtE6nyvZ1K7nqkQ_20_5"></a><a id="Tc_2nHjO264kUK4nDYItb3KFA_20_8"></a><a id="Tc_rIkqudMJQkqWzEqrAAw_4Q_20_11"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.02777481%;padding-left:0pt;padding-right:0pt;width:100.05%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:47.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM SELLING GOODS</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_8zn7u60jckyDuh3BmFc7oQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_2fvA8p4hlk2d-7ILNnbtcQ_3_3">7,754</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_IvlRKs5dAEuQ7xeqDJDHLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_LfS_FRa8sEuclDn9Z6yoaw_3_6">8,679</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_5O4qCJrVG0eoNBly8DogRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_aFMyzxKWQU2Du3_HgF0oHA_3_9">3,243</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_4d1okvan3EClXL0thoxjqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_wpEDY0w-80ysHAB_9MwD6w_3_12">3,648</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM LICENSE AND R&amp;D SERVICES</b></p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_y9t0G7VzUk-YnlJjmRCq3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_Dt377lxP9kCqpBwwXa-OpA_4_3">9,993</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_YnQnoi6e-EudGaXDEpkpwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc___R-AtSu40aXX83BVNdQUw_4_6">23,934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_9dHpxsKaGEaFqtY_iDBcKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_-4Sz0kbUhEOJpCCv6GmAVA_4_9">3,184</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Z_KtMWQs0Uujw0cnqYs6lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_ugiXj-CrDk6sjkTV-euRQQ_4_12">7,319</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL REVENUE</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_EouYs3DR8EmTfQijLsEweg_5_3">17,747</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_8cctxc8CdEajwKvRqWMdaA_5_6">32,613</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:middle;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_nua3PHVrVEuXY3H7rknjfA_5_9">6,427</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_wQVpaF7CvEOdR1oLZYpxsg_5_12">10,967</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COST OF GOODS SOLD (1)</b></p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_ja4zzCYhOEqCGEHrAQpQfg_6_3">9,498</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_MOKYy9iWukWBlp9Cb8syFQ_6_6">5,253</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_l5BWUd-RXUGbJZRQPvUhdw_6_9">4,733</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_M3MdaWnkm0u3iCJrBVW49Q_6_12">1,827</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES (2)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_6PQnFa_8wEOkocugC-GiRA_7_3">14,811</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_SOE0M9LJqEC9irlbFTBuww_7_6">19,526</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_j20L-um0_UeQS6WljLnoLw_7_9">7,689</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_UJDWbfys4UWta90TrpcD1g_7_12">9,186</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES (3)</b></p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_zZSlooWFp0SIFCb7s7p3xw_8_3">6,309</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_6jhX9rTYhkan3hwzHYH8Zw_8_6">5,381</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_c0sXX_tWXE2Thll3DxjFZg_8_9">3,171</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_8pXFPCLHhEC0G7Z06IE0AQ_8_12">2,194</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OPERATING INCOME (LOSS)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_192CDiW0FUGSNkaSOKiiLQ_9_3">12,871</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_A-fSIf6_nkaBXv-ptX7pzg_9_6">2,453</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_p7KRejpdzUiK_0AScxXZ5Q_9_9">9,166</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_Lkn50MLR2k-meiNQlrFDig_9_12">2,240</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES</b></p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_fWb4bftimU-yvpA0FtKdQg_10_3">4,240</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_eGr1KFOACUyCGTpgaHfeUg_10_6">5,177</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_F4oDvflQFkazpgaVhMaO0Q_10_9">2,203</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_H6SItsFK5k2So-Hd2YCHIQ_10_12">1,948</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_gTJ8lvkFE0m-cU6ZZ2lC-A_11_3">344</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_AYwZQAqqz0aFJyNiDgXcBg_11_6">241</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_y1bHzz8mmUusB6_4ZAlelg_11_9">128</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_e52TU4Ek60uwCAioCGGsxQ_11_12">38</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES &#8211; NET</b></p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_J_29MhfnZEeO-cumpvig_w_12_3">3,896</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_erPbEcoBiUus4-pIGZG4Dw_12_6">4,936</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_bLrEcwn7JkaOdb9q72AVdQ_12_9">2,075</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_z-wD7r6d8EabEMtaMvSzIg_12_12">1,910</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OTHER INCOME</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="3" id="Tc_rEwwiTjt80OLf8B9Vpt4Aw_13_3">51</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET LOSS FOR THE PERIOD</b></p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_DlQdogv42k6E_ViMQpb0tA_14_3">16,716</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_wKH2GpjhQEeg4iSDU9v7Xg_14_6">2,483</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_p864BxPahEK1Jsr__hFQDw_14_9">11,241</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_4Fn0LZbMHUKpQuNAY5oSMg_14_12">4,150</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LOSS PER SHARE OF COMMON STOCK &#8211; BASIC AND DILUTED</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_WkkUVrHczkaM9dBkexVMqA_15_3">0.39</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_7CZt9odpGEO3vWEugZLV5A_15_6">0.12</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ" contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_S0Nah-0V702tHI7EPTiD9Q_15_9">0.25</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ" contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasicAndDiluted" sign="-" scale="0" id="Tc_SfRfgYgzM06CB6ayH0Ot6w_15_12">0.13</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK </b></p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USED IN COMPUTING LOSS PER SHARE &#8211; BASIC AND DILUTED</b></p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_BUFyFq4DIU6c6QjSXYtf5g_17_3">42,744,426</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_2FcaSaeaykqqwZ0i6wWbBg_17_6">19,923,935</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_8bUyIq2TiUiAWpc5k8VmiQ_17_9">45,436,907</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="Tc_BcsZeTKpx0uIc08jJavmDg_17_12">32,442,636</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"><b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</b></ix:footnote></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_2I_j-CG2WE-GsdeFUO0uXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_YLxcM57nLE6fHSSQ2cp6EA_18_3">152</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_B2vkFxAj30mgjYvbaeB7XQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_GOzQj4y1qkCmVnPFZ96pgQ_18_9">43</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_8530ca94_6c84_4f48_984f_7cc5a2959400"><b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</b></ix:footnote></p></td><td style="vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_iiC6Yn_rdkWx9W-FzaEoiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Cn6gmWtGfU6BvBCnXotl5w_19_3">370</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_bqX3cUtNBESnhgaklTJZew" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_hfK1SP-rUkurhJ2pU1WebQ_19_6">73</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Sxq30RrND0uqWIoDHU4HbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_6L59W8fuwkODdIBVszNqnw_19_9">160</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Okh2sy6Wwku5BgEkLA_q-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" sign="-" scale="3" id="Tc_2asen8q9iEupcsLJs-cRhw_19_12">5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:47.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><ix:footnote xml:lang="en-US" id="_64475d15_2bf5_4e75_bed3_14deb6a39d55"><b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</b></ix:footnote></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_jyn3lwbXOESy8Z3KX8YCGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_NF-yfjTgLUG2NitONkSdCA_20_3">872</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_hDBte-t0lUWwnjhjyGWBOA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_RpkMgThRo06HcpefASkrew_20_6">625</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_wDSeLRz8j0mcVlFQpqqNGw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_qdmsySA110Gzkny74Ilm-w_20_9">375</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5PQNzgrw3U21fmcnTdCH2w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_gsFuvlVnsEWMJSW8qIpAYw_20_12">272</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a2186376_8326_492a_9bb4_566b9aa28013"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STOCKHOLDERS&#8217; EQUITY (CAPITAL DEFICIENCY)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_51b0fa27_d06a_4470_84d5_013b9f213bd8"></a><a id="Tc_ck3Fm42SWEi9S14NN1FuRw_1_7"></a><a id="Tc_QJhAIbJXQUSN70SLT5C2gw_2_2"></a><a id="Tc_bTThoIBxbEeQ0_llC1XICg_2_4"></a><a id="Tc_qQE6WpptiEm1Zhj-w-btow_2_7"></a><a id="Tc_9ZCEzkHkNUaON9cHnQYcDw_2_10"></a><a id="Tc_0kPTmb8Snk6bJTckrl5XZQ_3_2"></a><a id="Tc_pOedNzcN4kidVlbbFJ7yUg_3_4"></a><a id="Tc_Dl1EGLfHXkCOxOu8jt4SGQ_3_7"></a><a id="Tc_BBMKIBRxPUu18n90SVFAIA_3_10"></a><a id="Tc_LuQHe6ytOUO6fHi65nRGuw_3_13"></a><a id="Tc_c_INPa6O1kyhGFlzfLgI7g_4_2"></a><a id="Tc_JMW6fyD9n0G19dIfolsLTQ_5_2"></a><a id="Tc_rMLNoCzdbEulaDLMn8LLNg_5_4"></a><a id="Tc_zqv9w-lxtEeF2Sq2hEOitg_6_0"></a><a id="Tc_JyrlQUEDRUuZSr4DWrDe_g_6_4"></a><a id="Tc_-AGmAtEyQEeHwOYORKAxHQ_6_7"></a><a id="Tc_B2oVAh5P2kKfzHKLuxaR9w_6_10"></a><a id="Tc_xaWcg9SGLE2yscGZowEZqQ_6_13"></a><a id="Tc_BLpZFokzMEu8eXtnXBI1Ig_7_0"></a><a id="Tc_Qw6TFarmi0qkiNVBFi0yUA_8_0"></a><a id="Tc_kqWrg_juPUCqQZK9dCbbxg_9_0"></a><a id="Tc_dwwLZNygNEi6RehixDUq3g_10_0"></a><a id="Tc_vARF6jdt3UOD6ETGactmpg_11_0"></a><a id="Tc_uK-CqhfBdEKS3Mz7AwRn0g_12_0"></a><a id="Tc_LfxBTkAI9U6m1lv2BB5m4w_12_4"></a><a id="Tc_qO3D0W9BB0K6SSa5QrQ4rg_12_7"></a><a id="Tc_rtvu-XO-K0C29NNjhpyirw_12_10"></a><a id="Tc_z_l_Wy705UC40Rept95V-g_12_13"></a><a id="Tc_vRao9UitbEa5k5PfEpXCRA_13_0"></a><a id="Tc_QEa6udipCE2WmqQo6gJ1jA_13_4"></a><a id="Tc_AsXgjxcxN0-bdacjGwSi8Q_13_7"></a><a id="Tc_X5cN5Ds4yUe570o6JiY5_A_13_10"></a><a id="Tc__uWtHYttJUW5d5qs4zOD4w_13_13"></a><a id="Tc_qvmVJ0g1bk-n5-a2U7eGfA_14_0"></a><a id="Tc_6jL4GnPyYE25TdFTntvq1Q_15_0"></a><a id="Tc_AKav2ccskESVaGpEX5zkZA_16_0"></a><a id="Tc_MBSi2EY8FEyPDnthTFw3DA_17_0"></a><a id="Tc_dbPJgeF2A0ygEZsiVr__pg_18_0"></a><a id="Tc_t_4sG64EHkGTS4LS94Ih9w_19_0"></a><a id="Tc_1pJ4inLF6Ui8bJuSeI1FmQ_19_6"></a><a id="Tc_A7ssjRXoMkuSQLTWZk-7SA_19_8"></a><a id="Tc_KB1P234-UEeY6YSbpFCF1w_19_11"></a><a id="Tc_k97J6FbuN0Cj4dL-ZjiInA_19_14"></a><a id="Tc_4t6-ZELwlk-_RR-7hiCpTw_20_0"></a><a id="Tc_s67xAVrj5kCBSqPrFodqzw_21_0"></a><a id="Tc_ktaIo0YosEK26uT4UZ6RNA_21_4"></a><a id="Tc_Hg4lTsrZVUimbbWnsDGB5A_21_7"></a><a id="Tc_3XYFnWzE9EidG8mHaolI6g_21_10"></a><a id="Tc_3KSeFAja8k-7Dndz8hwN8w_21_13"></a><a id="Tc_JZI77jma4EqqmWzdURPb8Q_22_0"></a><a id="Tc_cv2raMS4e0WKwCkYuB754A_22_4"></a><a id="Tc_RFRifG2wH0uLGS8YeCAdfA_22_7"></a><a id="Tc_0Ypcw2HzsUqlPepZ_k5Esw_22_10"></a><a id="Tc_186Md5QKUESYz-46199K8A_22_13"></a><a id="Tc_kBuqbzlujUysUsu3cdvQyg_23_0"></a><a id="Tc_ECVYIPUo4U-NkbpCSESL0w_24_0"></a><a id="Tc_GXdFN8ToRkiWCwaRcZ6eRA_25_0"></a><a id="Tc_iw4MtH3ypkmh1IA420mfXA_26_0"></a><a id="Tc_gNYL4T2roUmsqs3X98VPlA_26_4"></a><a id="Tc_2AxTb-kwwk2y9VzaLp8xPA_26_7"></a><a id="Tc_dD_PODU-PUyW4VUFSLU5TQ_26_10"></a><a id="Tc_ZRJ454IqQUyZp1DJDHod2Q_26_13"></a><a id="Tc__VUJwcbwKEGu9p0t_adK4Q_27_0"></a><a id="Tc_RWqFAJABiUuiNYqWiqJniA_27_4"></a><a id="Tc_pXvpHnhFs0eHrU1K8jrXyA_27_7"></a><a id="Tc_eeXCf2-lOkCUSCZmwYLe4A_27_10"></a><a id="Tc_fIKnkkW-c0KcWNyYpY4fbA_27_13"></a><a id="Tc_BtQIIhCgSk2ASldU3y13LA_28_0"></a><a id="Tc_KxLf4SzFT06nIVDrVX-8ag_29_0"></a><a id="Tc_MjAAk5FcrUSU4Zi2DUTl0A_30_0"></a><a id="Tc_WhRyl8X340Kq__ql3p-h8g_31_0"></a><a id="Tc_2QpN33Ge60qp81aFVgjf-w_31_6"></a><a id="Tc_NrOEHc70_UK0u4Qsc5eB1Q_31_8"></a><a id="Tc_6CjZbdTAfkm0l166HhYKSA_31_11"></a><a id="Tc_QlgBttPlfEadWlEMi-GF8Q_31_14"></a><a id="Tc_0H79PQSFWU6MeQHCj8rQdg_32_0"></a><a id="Tc_Wa25Bf0wnk2G2A6xuFzPEw_33_0"></a><a id="Tc_A3uYmmNQtkmL-YCMmSn5eA_33_4"></a><a id="Tc_eKNmu1cxXkalGcs3LJoDtw_33_7"></a><a id="Tc_8zByR0ibw0WUCaDlFdyWyg_33_10"></a><a id="Tc_v3YY0V57jEe5ESn1UkE66Q_33_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock (1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4cR5rGHxsEuH26ppUkiILQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_Y_wQ9oJdU0Cs2MvW3iyoGg_6_2">14,838,213</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4cR5rGHxsEuH26ppUkiILQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_qx6djsyPxEibxqAViCF7kA_6_5">15</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K5lGRruMjUWFHxHMZFMGmg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_HK1RYSYU10-VLuRFY6jXBA_6_8">270,492</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZYngxRQFYkWwRhWxM0SkzA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_QOetX-qrzE6Ca6PEP5ESXw_6_11">340,829</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2019_tP37cYnQBEy-ajyGcP9j2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_A8ZkGXfEv0CsywiFZt0kiQ_6_14">70,322</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the six-month period ended June&#160;30,&#160;2020:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock and warrants, net of issuance cost</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MEoQBaAbc06IzFxMkQM1qg" decimals="INF" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" scale="0" id="Tc_3GEBVpZPv0aBDLyXOLJfqQ_8_2">17,604,423</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MEoQBaAbc06IzFxMkQM1qg" decimals="-3" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" scale="3" id="Tc_3p0KdHyldE2K7MQdDzh95g_8_5">18</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SQhCtGF5pEGEvL3YbxckPA" decimals="-3" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" scale="3" id="Tc_v68_VkMrKEyPlBvRRc54_Q_8_8">41,325</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" scale="3" id="Tc_QGhGkkuUP0aXTySRjtuZ4w_8_14">41,343</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Note receivable from issuance of common stock and warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SQhCtGF5pEGEvL3YbxckPA" decimals="-3" format="ixt:numdotdecimal" name="plx:AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" scale="3" id="Tc_2s86sOY4A0ipOvPx5sdvvA_9_8">4,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="plx:AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" scale="3" id="Tc_BwrMt41Zn0-ydoZVIhUg7A_9_14">4,000</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SQhCtGF5pEGEvL3YbxckPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_wtGa9m7F60u-GHmbL-zxIw_10_8">698</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_oEqtjCkOlES8f67mgWyrCw_10_14">698</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9IdhTME8lUGRXZwzJDuW3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_o6wDMW8M9Ui6rBwUWoDM8A_11_11">2,483</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_h8KYwr9u60ua2XTZVhDhTQ_11_14">2,483</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q55XKvKM6UWzjFvtkRLLmQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_d828K6Ue1EKmOTX4if5wtA_12_2">32,442,636</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q55XKvKM6UWzjFvtkRLLmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Rd0sxG7V60a--gvNicRKJg_12_5">33</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6nrUDBCtt06YRW-L2OEYxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_r3F9jJB3ikSnO90GpK0ZFA_12_8">308,515</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WNnhvQfFrEymbDn9Ce7FGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_2Q6aDGpsxkChHS9ejp_Pjg_12_11">343,312</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2020_UTfTJ92Crkail7a-VOYa5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_tMXiMT7aGku5FGguGEklpA_12_14">34,764</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Aw21LWNb10edAAVCUPhNiA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_L-kjd32hckOMkpdSFE_lCw_13_2">34,765,280</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Aw21LWNb10edAAVCUPhNiA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_UlvM9qM78kiAzC7JssEfDw_13_5">35</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zVn_KJPePkOTFIcmvJNdvw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_fAyeECfvwUC_yZB1e1thtQ_13_8">320,280</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zpuoYmPfdkek3USyWn91Qw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_PuuNkH_6KUuqsvOvMZY0rg_13_11">347,352</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_TxdH0dmLd0KD6xOsxwbCkw_13_14">27,037</ix:nonFraction>)</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the six-month period ended June&#160;30,&#160;2021:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock, net of issuance cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fmr_C6CM1EmRY2waHRcinA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_fWUbFYN1xk-LXIllRu6nHw_15_2">8,749,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fmr_C6CM1EmRY2waHRcinA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_SZZLozZTWkG_GDEI_QaWMQ_15_5">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h_6cg02980C2C6q1_vdErg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_5MRZKfh6vkW4u_8lNTQFxw_15_8">37,616</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_P3MjYIhKa0qaRu8a9Jhrpg_15_14">37,625</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fmr_C6CM1EmRY2waHRcinA" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesSalesAgreement" scale="0" id="Tc_SZB0Vh2-y0ueWL3uSkF-tg_16_2">1,867,552</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fmr_C6CM1EmRY2waHRcinA" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_d2LZkdagqkSFg0t_8Lwgwg_16_5">2</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h_6cg02980C2C6q1_vdErg" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_WBu60lNzx0aQJNnHZ59pBg_16_8">8,573</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodValueSalesAgreement" scale="3" id="Tc_0YNk0Iv0sEag3H3Ssc_K9w_16_14">8,575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h_6cg02980C2C6q1_vdErg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_8QUkSZ7QqE-OVknEwcZjyg_17_8">832</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_2O_Zd97tpkS-UXr9yA_opg_17_14">832</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h_6cg02980C2C6q1_vdErg" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_29HeWklg1k-Va5WxfkdfHQ_18_8">562</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc__J00KLo4IU2ObPclobYMwg_18_14">562</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fmr_C6CM1EmRY2waHRcinA" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_DLD9rpvbDUe1SXmJYhMFyA_19_2">173,816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gJteVLZhPUKl-E3d6202xw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Vi9MBbhbY02OtHYED8u3kw_20_11">16,716</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_1uSjA1PcGkeD4jHxpUZz0g_20_14">16,716</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_c92pTwX33UuIlz_FfqiOGA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_0LvczoWAP0eRWIM1krg6yA_21_2">45,556,647</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_c92pTwX33UuIlz_FfqiOGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ygEQZQyRAk--zs5_0h8JzA_21_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_coEbyffChUiacKC7c4wHAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_DMBorGRo8U29lvKDDhVIkw_21_8">367,863</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jpLE-akMakyV3Jbk_35Y5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_4dw9XJwIF0KKT2kj3ICTHg_21_11">364,068</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Au2GeM7ctky7cY-9l2JstQ_21_14">3,841</ix:nonFraction></b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7koqe4XbrU2iAVQ8xtCh9A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_5XZuCtKy4E-SGrsC5_ENoA_22_2">32,442,636</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7koqe4XbrU2iAVQ8xtCh9A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_r0L0kobOSkuj-ecNRizByQ_22_5">33</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JwuKoUeMXUSq0ARxWqpE6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_MGDysUTFZ0qJlIxkcVNXRw_22_8">308,248</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8Jw06A2_s02mFX7Ni3WLQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_pkKd2s2qEESxqM2kcwK45Q_22_11">339,162</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_3_31_2020_ZFXxvJmOEUaEgQwjPNZzDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_xhBsnRE7l0yxCKhEyCPQnA_22_14">30,881</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended June&#160;30,&#160;2020:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9wfTwEjjqEi90jMNxt9LuQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_CUyGegf6mEa4suEx3YEmyA_24_8">267</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_jJt5neZLY0GR929XMQHRvg_24_14">267</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ED-14lWq4kqXAYP7X69qhA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_cikzyb2lPkCTen4BWtjoaQ_25_11">4,150</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_mwkcKGHzO0OV-8UHi5TEVg_25_14">4,150</ix:nonFraction>)</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2020</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q55XKvKM6UWzjFvtkRLLmQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_URYSXaY8RE6lUkg-Wo5WBw_26_2">32,442,636</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q55XKvKM6UWzjFvtkRLLmQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_r181hvLGe02FWq0sGGEsOQ_26_5">33</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6nrUDBCtt06YRW-L2OEYxQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_w35ltaFoDU2o9nYDAAu1Qw_26_8">308,515</ix:nonFraction></b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WNnhvQfFrEymbDn9Ce7FGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_LWv0EP4fUUaSqpe4vQzdtA_26_11">343,312</ix:nonFraction>)</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2020_UTfTJ92Crkail7a-VOYa5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_pL_EwypfpUKq6h9hlgpNSQ_26_14">34,764</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QPt03YiNMEyRlDDY1cIgVA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_kJfgoliISkuMvHZqvexXNw_27_2">45,382,831</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QPt03YiNMEyRlDDY1cIgVA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_7LGLB9ycj0megTGq9q_V4Q_27_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TInNrhsHD0-stLLDv404XQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1KBxiaM-ckGT2GwFngeW5A_27_8">367,285</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7dJe2GnFOEGyYLG5fG1hgg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ewDWS7gOBEqaIjj4p04keg_27_11">352,827</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_3_31_2021_QRSFKQURbUe6hHXKoDRu9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_nVMvEDa-tEykkVt5XMSyyQ_27_14">14,504</ix:nonFraction></b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended June&#160;30,&#160;2021:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gsX0p07goEqvnOBN9SVuGQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_lnHnO3dOd02y1jEwt_87dw_29_8">322</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_XmWxBiWi-EuLrpH_xrGrXQ_29_14">322</ix:nonFraction></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gsX0p07goEqvnOBN9SVuGQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_a5USoUyGBkO3QM5yJ4CO-w_30_8">256</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ" decimals="-3" format="ixt:numdotdecimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_LZQs6fhWl0qscMhOhvMirQ_30_14">256</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4hdRC028OESAjUPcR-4qZA" decimals="INF" format="ixt:numdotdecimal" name="plx:StockIssuedDuringPeriodSharesWarrantsExercises" scale="0" id="Tc_xhyd6qZM0EqWTnOsnJdgUA_31_2">173,816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0-Eu2_lbZUioiYvNP-u1Jg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_dEqgTBqQ1ECLVbitYTC45w_32_11">11,241</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_nD-FWaWr9kaE23wRgl4s8A_32_14">11,241</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_c92pTwX33UuIlz_FfqiOGA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_pxTp2QsKZ0-w6FRLwU0S2w_33_2">45,556,647</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_c92pTwX33UuIlz_FfqiOGA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_HLLJFfuVrUu9IpvsO_GnMA_33_5">46</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_coEbyffChUiacKC7c4wHAw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_bX_a8XfIUU6S0Kvk8o6gOw_33_8">367,863</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jpLE-akMakyV3Jbk_35Y5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ABOpezugTE-zQIhDtz25Kw_33_11">364,068</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_sxhXmnWWqkeZbLIaBVGvRQ_33_14">3,841</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">*</span></span>Represents an amount equal to less than $1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(1)&#160;<ix:footnote xml:lang="en-US" id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ" contextRef="As_Of_6_30_2020_UTfTJ92Crkail7a-VOYa5g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_MN6oR9tva0eOko_DwSn37Q"><ix:nonFraction unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ" contextRef="As_Of_6_30_2020_UTfTJ92Crkail7a-VOYa5g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_48WV2mIZ-U-kBvBAE1SB-A"><ix:nonFraction unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_2Ee2NnAypka5Z0dgoPfOlA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_8-yiVwrMtUacMGDXQy6VMA">0.001</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> par value; Authorized &#8211; as of June&#160;30, 2021 and 2020 - <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="As_Of_6_30_2020_UTfTJ92Crkail7a-VOYa5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_f9UCpOua8EKN2vXVgRS2PQ"><ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_3aZh5KRNc0i8Jd9RA5hI9g">120,000,000</ix:nonFraction></ix:nonFraction> shares.</ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_004e5329_c978_4ce0_a9d9_4bdc971effbe"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_036b0258_18a7_4ba6_9dee_ce3a7dd27b55"></a><a id="Tc_7TVnfJ3a00O10Ex-eduW5Q_1_2"></a><a id="Tc_VY9dL5iVrE293lLD0LM6dA_2_2"></a><a id="Tc_Guicp2BhV0-Rr5BvA8mGSg_2_5"></a><a id="Tc_8mAnIhTjdkSWnGq7M7sQBQ_3_0"></a><a id="Tc_s6_r4byVY0uCJU7w4Hnw-Q_4_0"></a><a id="Tc_1LrEHpPZqUuYS9Iqfy0qpw_4_2"></a><a id="Tc_pNoikdxVC02ppr-Uxw4rJg_4_5"></a><a id="Tc_siGsQQUONkS__bV7GP3mVQ_5_0"></a><a id="Tc_IiTRrFoL-Ey5TGT5Mtl66Q_6_0"></a><a id="Tc_hBLCFk8xa0uxCxnRfWkXXQ_7_0"></a><a id="Tc_K5ZwpiGWSkWF3L3-UyYHqg_8_0"></a><a id="Tc_2-e5ozhGzUOFKCr2v7rodw_9_0"></a><a id="Tc_YffPLi6T2kO-uKFph3WeKA_10_0"></a><a id="Tc_26o7mWBnK0yxiSDWmr5OAw_11_0"></a><a id="Tc_-jpfYi4ZJUK40CHoQ1-jRQ_12_0"></a><a id="Tc_ONs6t0-yskmPDLguCpe1QQ_13_0"></a><a id="Tc_9sLgJKZFoE6MsDJfrx6wnA_14_0"></a><a id="Tc_8mF8H3Cj5UiVR1QaEUk68g_15_0"></a><a id="Tc_ZDu8vePyTkiZpBb2r1eUGg_16_0"></a><a id="Tc_V8GhjmaVuUaNJwfHYQBdMQ_17_0"></a><a id="Tc_Fi55sWOuQ0Sb-JegmLngrg_18_0"></a><a id="Tc_QDkOXldZ70S7GmZBMKjZ3A_19_0"></a><a id="Tc_iRG6X9WJO0S9hbeudX15vA_20_0"></a><a id="Tc_a_yjXXMx8EOH5VliDY15TQ_20_2"></a><a id="Tc_k_kmJyiryEqRaUgJBCiMTQ_20_5"></a><a id="Tc_0iTh06GHVkejSrYFKx75Kg_22_0"></a><a id="Tc_7nJHx9HY20i5LwPnYs954w_23_0"></a><a id="Tc_LuxSdk2pfUqgaZTXqVUkCA_23_2"></a><a id="Tc_d7ovf5lb-kmGsNEQJMw5mw_23_5"></a><a id="Tc_ZsxxdItgokais9IbqvclJw_24_0"></a><a id="Tc_LVr2H2xCMEqoZbdyQiTJlQ_25_0"></a><a id="Tc_s9HNAi65U0KWAC9BY8iSPA_26_0"></a><a id="Tc_uvnZaV0fe0iT2cUqIKtROA_27_0"></a><a id="Tc_h07ODInFDEW1fu5YYlgp9Q_28_0"></a><a id="Tc_mvilXehzq0qo0Y7rtmXLUw_29_0"></a><a id="Tc_-2NUXQSq60qrhD4ZXy69xw_29_2"></a><a id="Tc_qGDch_LLfUqCgIrWZxXdCw_29_5"></a><a id="Tc_5QpBf9YbhUiqcFgiPBx3vw_31_0"></a><a id="Tc_RgOWwGoMw0WmsVXI9P20sg_32_0"></a><a id="Tc_KDEiJmKwdUu4KTFGkoWQPg_32_2"></a><a id="Tc_PJUwY-h01EykNq5d0Py1-g_33_0"></a><a id="Tc_BnXVTO49akKGBg-G80qU_w_33_5"></a><a id="Tc_4b0VCBxuzU2dNyvc0soX-g_34_0"></a><a id="Tc_8I6r4C1dZ0-TimhtoTQcTQ_35_0"></a><a id="Tc__ruvhIJ9AUePsjNgDVj2-Q_35_2"></a><a id="Tc_o9pSJEa5A0e5jxEqfUMP4g_35_5"></a><a id="Tc_jACqzRWFJUSxWpFAIR1HZg_36_0"></a><a id="Tc_U26I3mMieEqH5DXgUd0nXQ_36_2"></a><a id="Tc_Wb6BWeEpd0iLVL0hPs8tLA_36_5"></a><a id="Tc_tCWobU7vyUe3yc1XgC-Qjw_37_0"></a><a id="Tc_8FRqkR85SEOnnZ8QYKyrJQ_38_0"></a><a id="Tc_49PJVx_UEUKrLoaB-2j77w_39_0"></a><a id="Tc_6U4fMqk_9U28kfwh46npmw_39_2"></a><a id="Tc_oKkFvEiZkUugjFnu0WhiTg_39_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_TlRLxf7Q3EaY2TWHu58Yhg_4_3">16,716</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_VAuGlRv9mkCvbypCIr5Jig_4_6">2,483</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Adjustments required to reconcile net loss to net cash used in operating activities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_ggE5FcNOP0e3Au9wDuDyYg_6_3">1,394</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_yhoWoRExE0aCp6bJo-AH7Q_6_6">698</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_u54pJXgxjEupa5jwXDZBXA_7_3">574</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_hj-_JXxXKUGmiff6BwA0dA_7_6">710</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financial income, net (mainly exchange differences)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_kJQ4Xynklky7Ezvbq-D_LA_8_3">121</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_lJEC8iQkL0q04Sf1ZatXBg_8_6">250</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in accrued liability for employee rights upon retirement</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_Aq6N-7AnokaSeQyFEkGuLA_9_3">70</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_S08ad_yk_kqeVBviHZr_XA_9_6">107</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss (gain) on amounts funded in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_ZM0W5AD3t0yDBsrSfXOzuQ_10_3">56</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" sign="-" scale="3" id="Tc__IDWrZSBgEifk32Ovt-OcQ_10_6">22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gain on sale of fixed assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="Tc_DpT6BGHft0SM_B96zliDWg_11_3">51</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of debt issuance costs and debt discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_evhDwYKnsUmpvp4ruYSe-A_12_3">1,928</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="Tc_P8uAUDupdkqeEQKrrNZ_qA_12_6">1,665</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase (decrease) in contracts liability (including non-current portion)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_tsBVJLcxT0KXfBCY-820xQ_14_3">12,268</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="3" id="Tc_vMxylCRdK066dT_5udKdBw_14_6">10,841</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase in accounts receivable and other assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_qF7CJuWOhUmieS5bb8gSNw_15_3">1,587</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_BhdvTXQgAk2lWldWa4nfyg_15_6">1,621</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Changes in right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_ZyErllxORE6nO4N3dgDW2A_16_3">94</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_UdSOQxuonUCJryx6ztuO2A_16_6">27</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase in inventories</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_jGcVTSAyO0mJDoDgmatv2w_17_3">558</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_1fBrcTxZ4kmCOhTcJG-13Q_17_6">2,910</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase (decrease) in accounts payable and accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_5oMyMM1NBkCtzNHSaAKO8A_18_3">544</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="Tc_KJ1KotEH3kyV9kOgei3_7Q_18_6">309</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease in other long term liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="3" id="Tc_EnpIBGLrIkOZIldtYBHZfA_19_3">13</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="3" id="Tc_ToVhfW5pHU69c63WyGx-Sg_19_6">385</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_oYNItzAOwEWGvhP4PSLSuw_20_3">3,318</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_PxXcOHtNFU-2DtXUilhM4Q_20_6">14,952</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of bank deposits</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_BJ-72eVGh0GLAyekHn58ew_23_3">37,835</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInBankDeposits" scale="3" id="Tc_qgjmA-yxL0aFOSZjyOZxYQ_23_6">35,000</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of short-term deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromSaleOfShortTermDeposits" scale="3" id="Tc_TN6RyEa3LEu-MTsksE4Aig_24_3">15,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_RkNvgTRDZU64TbrSd1P9rw_25_3">667</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_vC9NYmf6QE-3QhRPcU-1nA_25_6">278</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_b_hbfKpsTkaxNGJyNhqUCg_26_3">53</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Decrease in restricted deposit</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseDecreaseInRestrictedDeposit" sign="-" scale="3" id="Tc_Aw74M6bg00GOauG_QLmiMA_27_3">359</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amounts funded in respect of employee rights upon retirement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_4RnT_CPq4Eqk6cFuGvdNvw_28_3">54</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_i3gMpc8L1EyxR5WN7bq24A_28_6">69</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in investing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_L8c_oMuwrU6ihwTYJOMMJg_29_3">23,144</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_QYxT0-Qp-kqugRyfXcgIPw_29_6">35,347</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net payment for promissory note</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="Tc_lvvMpyJ2EUugTg_XmXs-_Q_32_3">4,086</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of common stock and warrants, net</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" scale="3" id="Tc_hSEjzVfv_Uevch2wdlenNg_33_3">37,625</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" scale="3" id="Tc_cBany3g_rEi96Qcin_vDTQ_33_6">37,343</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Proceeds from issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_4CU_mFKk-k-Eor62rvA3eg_34_3">8,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by financing activities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_JHcSkxac2EixiIVH9y7S0w_35_3">42,114</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_Ko-HsQIO0EuqH11e5zaFyA_35_6">37,343</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" sign="-" scale="3" id="Tc_8pLARPLHxUanUPMy5hUbSQ_36_3">35</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="3" id="Tc_p6lh24zApkOm2VzfLi9viQ_36_6">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_akdVF0WP90y7grRuUtOJ9w_37_3">15,617</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_A0aipssqlkO_sRsF8dvgVA_37_6">12,949</ix:nonFraction>)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_nLHiGCB5nEuNxUkLciS5Cw_38_3">18,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2019_tP37cYnQBEy-ajyGcP9j2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_R54jhFTBlU61ptuHFE26Gw_38_6">17,792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:66.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:13.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_0lKeG9nL3USJM8OTj1TSww_39_3">33,882</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2020_UTfTJ92Crkail7a-VOYa5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_33yc4DL_vE-hxMELva9e_Q_39_6">4,843</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Continued)&#160;&#8211; 2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_46a503f9_bdde_4384_ae1e_7932ccc325a6"></a><a id="Tc_hdUoF4S2xkiCWzYvvDzwvA_1_2"></a><a id="Tc_Gi33p6WRbkGdyTGC7WE0Xg_2_2"></a><a id="Tc_KS7uvvMafk62PSkJ6FFwLQ_2_5"></a><a id="Tc_LPZTi2WiCkuTSqHoh3t13A_3_0"></a><a id="Tc_nxxni1cep0eTVrxCc13WFQ_4_0"></a><a id="Tc_qtcVB8rnh02EOuQFxsijfQ_4_2"></a><a id="Tc_D7QwIV8Kj0KIZprpmIeLrg_4_5"></a><a id="Tc_l37iFrHEwk6fMDeZ9YYmRw_5_0"></a><a id="Tc_SU5l_XpGS0O72AJEtVyaqA_5_2"></a><a id="Tc_PETLC09xJ0OZyME4aneVWg_5_5"></a><a id="Tc_4E5jMnLTR0SfKmuwu-WenA_6_0"></a><a id="Tc_884zW73APkyzkUzacv_7zw_6_5"></a><a id="Tc_9DRUS2d4AkutwA7Hhxy9eQ_8_0"></a><a id="Tc_XUAZ78Q2dkWL3DoWs82IKA_9_0"></a><a id="Tc_ROkwF26oHEKiO4sq1RMTsQ_9_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</b></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment" scale="3" id="Tc_KH8nsF4u10-6-vZPjC2CWw_4_3">372</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment" scale="3" id="Tc_paYEHVLHFEWGjVPe2mRaiA_4_6">50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Right of use assets obtained in exchange for new operating lease liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_T3q9hdY4DUqp7AapEGhCcQ_5_3">232</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_da7qFnTYJUupCPlnJBRnoQ_5_6">362</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Note receivable from issuance of common stock and warrants, net of issuance cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="-3" format="ixt:numdotdecimal" name="plx:NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" scale="3" id="Tc_UFmE5N2CIUKriQZjQJT55A_6_6">4,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:71.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest received</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="-3" format="ixt:numdotdecimal" name="plx:InterestReceivedNet" scale="3" id="Tc_XVtqcwAQM0SAcYN9dwDkZg_9_3">307</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#212529;font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="color:#212529;font-weight:bold;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="color:#212529;">(Unaudited)</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_KYfz-pb650KCeRDzdf1zJQ" continuedAt="Tb_KYfz-pb650KCeRDzdf1zJQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="plx:NatureOfOperationsPolicyTextBlock" id="Tb_ZUUXfGrr8ESuQsimGH-9uA" continuedAt="Tb_ZUUXfGrr8ESuQsimGH-9uA_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies: the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The studies are designed to evaluate the potential superiority of PRX-102 over current therapies in a head-to-head study and a switch-over study, evaluate the potential for improved efficacy and better quality of life for patients with Fabry disease and evaluate the safety of our drug/therapy. The <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies have been completed, and the <i style="font-style:italic;">BALANCE</i> study is fully-enrolled. See Part&#160;1, Item&#160;2, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Pegunigalsidase Alfa (PRX-102) for the Treatment of Fabry Disease for details regarding the current status of these studies and of available clinical trial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">A BLA for PRX-102 for the treatment of adult patients with Fabry disease was submitted to the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, which was subsequently accepted by the FDA and granted Priority Review designation. The FDA also indicated in its BLA filing communication letter that it did not plan to hold an advisory committee meeting to discuss the application. Based on the interim analysis of the 12-month data generated from the <i style="font-style:italic;">BALANCE</i> study that the Company announced in June 2021, and in combination with previously reported positive data from the <i style="font-style:italic;">BRIGHT</i> and <i style="font-style:italic;">BRIDGE</i> studies, the Company and Chiesi intend to submit a Marketing Authorization Application (an &#8220;MAA&#8221;) to the European Medicines Agency (the &#8220;EMA&#8221;) for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On April&#160;28, 2021, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), announced that they received a Complete Response Letter (CRL) from the FDA regarding the BLA. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#8217;s manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#8220;COVID-19&#8221;), the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (the &#8220;FFDCA&#8221;) in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to the foregoing, in the CRL, the FDA noted that agalsidase beta (Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>), a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102. The Company intends to work collaboratively with the FDA to identify the most expeditious pathway to approval, and is confident that it will be able to work with the FDA to resolve these issues and provide a new, alternative drug to Fabry patients. On August&#160;2, 2021, the Company <span style="letter-spacing:-0.15pt;">announced that a Type A Meeting request has been submitted to the FDA to discuss the CRL. The Type A Meeting is expected to occur within 30 days of the FDA&#8217;s receipt of the meeting request</span>; however, the Company cannot anticipate the timing of such a meeting nor the additional steps that may be required in connection with any potential resubmission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p></ix:nonNumeric></ix:nonNumeric></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_KYfz-pb650KCeRDzdf1zJQ_cont1" continuedAt="Tb_KYfz-pb650KCeRDzdf1zJQ_cont2"><ix:continuation id="Tb_ZUUXfGrr8ESuQsimGH-9uA_cont1" continuedAt="Tb_ZUUXfGrr8ESuQsimGH-9uA_cont2"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which is subject to an exclusive worldwide license agreement with SarcoMed USA, Inc. (&#8220;SarcoMed&#8221;) for use in the treatment</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat refractory gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July 2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ" contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_NaNGoBKCkEiu7vUtu1FpeQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_1OabiNxmr0GRUF_a0g9oFw">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_36UqK7xw-keHI8meiWi3Lw" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_dqKOktjaUkqeVpzU5MfdpA">20.0</ix:nonFraction>&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). The Company sold a total of <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_36UqK7xw-keHI8meiWi3Lw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_GshUqNSWokCRIhu1pJrR5w">3,296,123</ix:nonFraction> shares of common stock pursuant to the sales agreement with BofA Securities for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_36UqK7xw-keHI8meiWi3Lw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_BJ_zcN8yCkeID3m2lxpDxA">13.8</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;10, 2021, the Company entered into an exclusive worldwide license agreement with SarcoMed with respect to PRX-110 for use in the treatment of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery. Under the terms of the agreement, SarcoMed will be responsible for the identification and selection of pharmaceutical candidates under the license, and the clinical research and development of such candidates. The Company is entitled to an initial cash payment of $<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_2_10_2021_To_2_10_2021_us-gaap_TypeOfArrangementAxis_plx_SarcomedUsaInc.AgreementMember_s6R6OeOa5EigE4cD9-rsoA" decimals="-5" format="ixt:numdotdecimal" name="plx:LicenseAgreementInitialCashPayment" scale="6" id="Narr_zhD_-mW0UUOunyeteQ3oSw">3.5</ix:nonFraction>&#160;million, subject to certain conditions, and to additional regulatory and commercial milestone payments and tiered royalties on net sales of products that are commercialized under the license agreement. In addition to the foregoing, the parties agreed to commence negotiation of clinical and commercial supply agreements for alidornase alfa. As part of the arrangement, the parties agreed to negotiate and sign a supply agreement within <ix:nonNumeric contextRef="Duration_2_10_2021_To_2_10_2021_us-gaap_TypeOfArrangementAxis_plx_SarcomedUsaInc.AgreementMember_s6R6OeOa5EigE4cD9-rsoA" format="ixt-sec:durwordsen" name="plx:TermToSignSupplyAgreement" id="Narr_R6gsLslJDkGQMPSgMLNbEQ">60 days</ix:nonNumeric> of the execution of the license agreement, and SarcoMed has the right to terminate the license agreement if the parties do not successfully do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;17, 2021, the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="Duration_2_17_2021_To_2_17_2021_eP-kucV1pUWTbBXr7TaMSA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_NyBq1s4VU0GrdyvkGfm-bg">8,749,999</ix:nonFraction> shares of its Common Stock in an underwritten public offering raising gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_2_17_2021_To_2_17_2021_eP-kucV1pUWTbBXr7TaMSA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_8Rcw4VjYtkK347nqxLcJiA">40.2</ix:nonFraction>&#160;million at a price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ" contextRef="As_Of_2_17_2021_I73LVvhcdECPyti0oudI0A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_-LYFBnry_UG3m6ZUUfvVcA">4.60</ix:nonFraction> per share, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities acted as book-running manager for the offering with Oppenheimer &amp; Co. acting as co-manager.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_5jiTZMuakUK7bv_eFjH6Tg" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNonCreditablePaymentReceivable" scale="6" id="Narr_BNnFeUkUwUeNBDTn2gch1w"><ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_AI0MTldNw0S-WidGYq9XRg" decimals="-5" format="ixt:numdotdecimal" name="plx:UpfrontNonrefundableNonCreditablePaymentReceivable" scale="6" id="Narr_bOnj7Rk-oE21Nk2jWnde-Q">25.0</ix:nonFraction></ix:nonFraction>&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_JPKl0rb7CE-Kwx4t4a5tFQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_kEooiGmDU0yzgk_W5ffh3Q">25.0</ix:nonFraction>&#160;million in pegunigalsidase alfa development costs, capped at $<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_JPKl0rb7CE-Kwx4t4a5tFQ" decimals="-5" format="ixt:numdotdecimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_dKkyV0WJHkiqKR0U8sIMUw">10.0</ix:nonFraction>&#160;million per year, and to receive additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_JPKl0rb7CE-Kwx4t4a5tFQ" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_bZ79yioZyUKcnHy3A4w7uw">320.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_UXGhKrHKLEeju1LG7xvQ0w" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountsPayableToCoverDevelopmentCosts" scale="6" id="Narr_zYZsZWj9YUuaiOvF5geLhQ">20.0</ix:nonFraction>&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_UXGhKrHKLEeju1LG7xvQ0w" decimals="-5" format="ixt:numdotdecimal" name="plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear" scale="6" id="Narr_XqC6MykOc0WnMBp1bCFbCA">7.5</ix:nonFraction>&#160;million per year, and to receive additional payments of up to a maximum of $<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_UXGhKrHKLEeju1LG7xvQ0w" decimals="-5" format="ixt:numdotdecimal" name="plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_lLdoaSWSy0abYVOVAzxNXA">760.0</ix:nonFraction>&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.</p></ix:continuation></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_KYfz-pb650KCeRDzdf1zJQ_cont2" continuedAt="Tb_KYfz-pb650KCeRDzdf1zJQ_cont3"><ix:continuation id="Tb_ZUUXfGrr8ESuQsimGH-9uA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_hO2OX0CkykSDtEZGjleYjg" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_WvPt1IxOuUaAMTFbPzSR5Q">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q" contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_eVJdA8NazEqDalQFFkRHrg" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_ICcNU38xZEyBUg61sPcBig">35</ix:nonFraction>% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of <ix:nonFraction unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_cT_q_tep9EOn9lbEWZblFQ" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_qcfgvH3GNEmFWWQbaXAqnw">15</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q" contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_3jQI-P9cnkOUP6jE77HynA" decimals="INF" format="ixt:numdotdecimal" name="plx:PaymentOnNetSalesPercentage" scale="-2" id="Narr_RafWJnAD90y-8OV__ySjWA">40</ix:nonFraction>% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_cUS14zPtB02emWZ8d9vIBw" decimals="-5" format="ixt:numdotdecimal" name="plx:AgreementAmendmentPaymentReceivable" scale="6" id="Narr_7MEalrDUaU2FdwG0vL5YsQ">10.0</ix:nonFraction>&#160;million payment to the Company before the end of the second quarter in exchange for a $<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_W0s5POha_U6du1M7Hy-NoA" decimals="-5" format="ixt:numdotdecimal" name="plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" scale="6" id="Narr_u8XQ1_9xnkKjuRI-ibx5aw">25.0</ix:nonFraction>&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for <ix:nonFraction unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q" contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_T2MIzBKUik2fuPiyDHsRSA" decimals="2" format="ixt:numdotdecimal" name="plx:CollaborativeArrangementRevenuesExpensesSharingPercentage" scale="-2" id="Narr_87cGcWsZ0kSoiLzmG1AyXQ">100</ix:nonFraction>% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#8217;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. We continue to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company believes that its cash and cash equivalents and bank deposits as of June&#160;30, 2021 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued. See also Note&#160;6 regarding the exchange agreements relating to the <ix:nonFraction unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q" contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_eC_j6cyaVEe4nMowIWMQlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_M3yu-HyoJkW4zpTX8SpC5g">7.5</ix:nonFraction>% convertible secured promissory notes due 2021 (the &#8220;2021 Notes&#8221;) signed in August 2021 which are subject to certain closing conditions.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_IQCzmrfOeUCWPkDCmg6vHw" continuedAt="Tb_IQCzmrfOeUCWPkDCmg6vHw_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_KYfz-pb650KCeRDzdf1zJQ_cont3" continuedAt="Tb_KYfz-pb650KCeRDzdf1zJQ_cont4"><ix:continuation id="Tb_IQCzmrfOeUCWPkDCmg6vHw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed by the Company with the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2020.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_5yLby7RZhUygB61nWKhtBQ" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr__Nw57U9up0WxCyhkf0e6Vw">18,445,764</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_IuSyqm0w5kS3HukfJeLyow">26,322,164</ix:nonFraction> shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of outstanding 2021 Notes and outstanding warrants for the six months ended June 30, 2020 and 2021, respectively, and <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_EvC6_dR2DEePmp3e9NGjUg">25,997,289</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_gHrrn_DoJUKhC97TAmc73w">25,874,641</ix:nonFraction> shares of Common Stock underlying outstanding options and shares issuable upon conversion of outstanding 2021 Notes and outstanding warrants for the three months ended June 30, 2020 and 2021, respectively because their effect would be anti-dilutive.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Tb_hFekH7RbbUC2KJpmsjn3zw" continuedAt="Tb_hFekH7RbbUC2KJpmsjn3zw_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenues from selling products</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified <ix:nonFraction unitRef="Unit_Standard_agreement_roa1qYbSR0KRZqNYmT7fsA" contextRef="As_Of_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_Icszi70YU0WMX60GBUG0ew" decimals="INF" format="ixt-sec:numwordsen" name="plx:RevenuePerformanceObligationNumber" scale="0" id="Narr_-m4xc5H2HkaYdUh-8qGLyw">two</ix:nonFraction> performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_KYfz-pb650KCeRDzdf1zJQ_cont4"><ix:continuation id="Tb_hFekH7RbbUC2KJpmsjn3zw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><a id="_5b31fb9c_2090_4681_83b1_6f700ccf3b30"></a><a id="Tc_EOjzMWJVokiQ0a5mMOJ8rg_1_2"></a><a id="Tc_ErkjqG6Wg06Bv8ayiWlFrg_1_5"></a><a id="Tc_z0r4eCZcrEaKs0EwlmJzeg_2_0"></a><a id="Tc_LxSBaN2Gv0-wr5tPEDYsXA_2_2"></a><a id="Tc_LKJoCYAb7k-kAElC4XSetQ_2_5"></a><a id="Tc_c-g_HdxaOkm2Bps0_qqlzA_3_0"></a><a id="Tc_CSEqsLNwKk61RtsPtDSEEg_3_2"></a><a id="Tc_LAdZPhBu4UaCVwX2_ztyxQ_3_5"></a><a id="Tc_1GdMBk8LNEOMfR9K3XEA0Q_4_0"></a><a id="Tc_AVuSYXsiKk6nqrjxlS0n_g_5_0"></a><a id="Tc_QG5z_a9vbECoLIOjhSHvyg_6_0"></a><a id="Tc_JxaRYY6xS0yns65sER0xtw_6_2"></a><a id="Tc_MXeEMJCe50Cq5zCIbmpEXg_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_6sty8IRiUUWGJKyeJm59Ew" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Tb_CrpPvSGH8UWdDPRJVL6sdw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at June&#160;30, 2021 and December&#160;31, 2020 consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_AOYT8AhT9E2g5aCA2ydaTg_3_3">3,046</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_Q8XEbWlTv0C4BhvJ6bfHvw_3_6">3,347</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_-251H_nGOUq604XydKSxrw_4_3">3,065</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_lZGe9yEQxk2PBSuKi6edUA_4_6">2,887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_MMEA2CyLl0eEO32f8b_5Hg_5_3">7,529</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_rx-w7WyKe0WeUH12H8nx7g_5_6">6,848</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_ZkGAKezIDkextUVHCcbr8w_6_3">13,640</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="Tc_ZAavO0uwVEycZClUjIUnQQ_6_6">13,082</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_KnyX-Uf5Zku6hDLWmEmPeQ" continuedAt="Tb_KnyX-Uf5Zku6hDLWmEmPeQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d002d227_bf39_47c7_97b0_43f3ca0805ef"></a><a id="Tc_5g7Jc0EHykOgDG1l8aLeDw_1_2"></a><a id="Tc_nEouyp1HyUGMonrAGHaC3Q_2_0"></a><a id="Tc_oOxRzOYiDkKNMRG8Idas8w_3_0"></a><a id="Tc_OgsW4LdSZ0eVNuRNHnA_Qg_4_0"></a><a id="Tc_1DvCB_C5ik-nhGpqxiiqoA_4_3"></a><a id="Tc_03RzsrQZEkGmVMecc4NUrw_5_0"></a><a id="Tc_56PpIBXeR06CH3WB4CSl5w_5_3"></a><a id="Tc_W2OXxIdiVEarCV7JlEvOLQ_6_0"></a><a id="Tc_vV7O2sXpYU-z0bOHVVhOZA_6_3"></a><ix:continuation id="Tb_KnyX-Uf5Zku6hDLWmEmPeQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">As of June&#160;30, 2021, the carrying amounts of short-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">The fair value of the $<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_-tsX_jEa10aFdesmgIQc1g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" scale="6" id="Narr_t1v17gkiRU6FAGh1dwKVRA">57.9</ix:nonFraction>&#160;million aggregate principal amount of the Company&#8217;s outstanding 2021 Notes as of June&#160;30, 2021 is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_-tsX_jEa10aFdesmgIQc1g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="Narr_lQC17fBPxUWMFNub7R-V7A">57.6</ix:nonFraction>&#160;million based on a Level 3 measurement.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_yMRhv1-EBUyjv67c4vnBIA" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_O-xnjDlMjEO9ertSea_7Vw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The Company prepared a valuation of the fair value of the Company&#8217;s outstanding 2021 Notes&#160;(a Level 3 valuation) as of June&#160;30, 2021. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ" contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_-UCWB1XwmECspjYijNZ7Jw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_I_kH3BkMtU6-yk5k1VVPZw_2_2">1.91</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q" contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_MB3j5xcttkmq-uspEaqDzA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_qn65mnA6PEql57yTXzMKWg_3_2">0.38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q" contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_mufBZIm2IkKt0BdUQt8lTg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_goNXD8iK10SoOdzPhQ5NpA_4_2">0.05</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q" contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_B-IrvzpQnE-E4laCHJyHig" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_c_sDCPQlukSL67lGLDeXVg_5_2">77.42</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q" contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_TXQdyNOI60W_tZ_1z-7XnA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentMeasurementInput" scale="0" id="Tc_r3GwqCjat0mf347flyAxxg_6_2">11.16</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_37bdf232_f28d_4755_b2b5_4a1dbd36dd54"></a><a id="Tc_oZuFrlAv60yQpHWQx0EqXg_1_2"></a><a id="Tc_FUjmNEi5xkqrUul3Sl0Xtg_1_8"></a><a id="Tc_j21ZDASPsUuxWQKoaqPKPA_2_0"></a><a id="Tc_4UgqRQAMoUmxqeF6_2-o_Q_2_2"></a><a id="Tc_AjjUOGdn7EaCW6TNqTHitw_2_5"></a><a id="Tc_urKM_MzKhE22PxW2KWI5vA_2_8"></a><a id="Tc_N2nOnLAfcUepLao1z1X3bA_2_11"></a><a id="Tc_RTAqx0uOTUKlrJDhNE-CqA_3_0"></a><a id="Tc_WoUktxs5u0uLQv7GxUzfrQ_3_2"></a><a id="Tc_Mq9-GzXYCk2c3WOiHkGANw_3_5"></a><a id="Tc_dR7QsgkVIkS80bZHf53Lbw_3_8"></a><a id="Tc_JBodboHizU2H0YIZpFIuvQ_3_11"></a><a id="Tc_hFLxQY-vgEaDgIWOwraY4w_4_0"></a><a id="Tc_x7PJaWOjg0Wehe_qGjsqmg_4_2"></a><a id="Tc_UGuy_MrrckqLUF-YMOA5Iw_4_5"></a><a id="Tc_bxrpV8NXzECVDWtpfYXB0A_4_8"></a><a id="Tc_GxXJlf8spkaNMv1Nn0rH-Q_4_11"></a><a id="Tc_ZX2OA2NUwEK6woik_3g-gg_5_0"></a><a id="Tc_ZHb-6DIjO0mNkaABS3GcIQ_5_2"></a><a id="Tc_3LHde39ai0mKSmxD3pjRWA_5_5"></a><a id="Tc_pU1sphpP9EeuUH-s5SSOcQ_5_6"></a><a id="Tc_Tk7LbfCD1UqUuO6K_eNuRw_5_8"></a><a id="Tc_mScTOf-_CEax2MELp6A7RQ_5_11"></a><a id="Tc_2qYQv61vukiG16L_BVl7tw_5_12"></a><a id="Tc_2GX7pxxVekyBUBYwKH75ww_6_0"></a><a id="Tc_vy7mFM3f7EaLRWZo4iNmyg_6_2"></a><a id="Tc_HBijQI5kqE2cpZ3R3ZMCQA_6_5"></a><a id="Tc_uE_y_bs1hUeztYn-GIJnow_6_8"></a><a id="Tc_E7P8cjiqRkORrSD0qv9-9g_6_11"></a><a id="Tc_S-pLgEdaxUuDVTSm1TNeeg_7_0"></a><a id="Tc_Pp-STgmsPUC63SzeCuNY3w_7_2"></a><a id="Tc_zRA8YQQYT06CoThfTxwcGQ_7_5"></a><a id="Tc_n6ZWkfr2B06XKFy1C2oAxw_7_8"></a><a id="Tc_PkIr0VtP60e7ZJRYHxZesg_7_11"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="plx:RevenueDisclosureTextBlock" id="Tb_ItCXELvKjEGVifnxh-IzHQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;4&#160;&#8211; REVENUES</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="Tb_xV85TSXMHE--8uVdcxoMBA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The following table summarizes the Company&#8217;s disaggregation of revenues:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_3FiFNKmCaEy9ibcMUQ7VXg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_znKvUkrsukG7JhhqgFuYBQ_3_3">2,237</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_mYAzB56-cUCdOTNVt0yw5A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_gl2dCgXppUqJdZce6AmXkw_3_6">663</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_Ho_xcKWNEEuICmELxx2gig" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_vo9Mdr2oVUOdmdk-xQzieg_3_9">6,748</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_0Dtxw3_Y9E6sb-ILAujQMA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_1X2928liu0Ov0j2khiIDjQ_3_12">2,679</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_lNGq93994UKs__wHyGDgeg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_rNeYgJ2Snkujrz8XVvjAug_4_3">988</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_Pp2mgbyjGkO2esZcL0xKKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_i_F6UpcsCUqscizffuqaUg_4_6">2,985</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_Q6m-H8y14kKGpOowck7pfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_e9NZsKZfvUO5Nba3JGnz9A_4_9">988</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_vAeDA4nbuUyblocjjCUcbw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_ifTlH_40p0ar6Y_337mz1w_4_12">6,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_0ROHtRtUikyYBfN1q0FG8Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_ziec0Vdo4Ea1dRMnsEeDQw_5_3">18</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_Ov94iWapwECTWXr04PGCzQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_PV5GCMu5Y0uQvKvNu7ladA_5_9">18</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_5O4qCJrVG0eoNBly8DogRQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_bTj3DyV0QE-t1LpGYUbYzA_6_3">3,243</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_4d1okvan3EClXL0thoxjqQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_q8411OMrAUKP2Ktocs7RNw_6_6">3,648</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_8zn7u60jckyDuh3BmFc7oQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_qCBZvmMkC0GhqRIz3CA0rw_6_9">7,754</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_IvlRKs5dAEuQ7xeqDJDHLg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_rvq8aZnGqEyazxe_jeSyLw_6_12">8,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_9dHpxsKaGEaFqtY_iDBcKQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_rI5bCE4fj0uY7VLEVlVJ9Q_7_3">3,184</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Z_KtMWQs0Uujw0cnqYs6lQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_N4bZ9bFEd0W20D4NwwAxBA_7_6">7,319</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_y9t0G7VzUk-YnlJjmRCq3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_wxaNK6wl3kuR6oFwecNcFQ_7_9">9,993</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_YnQnoi6e-EudGaXDEpkpwA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_WCue0PNsbkefEiKcjU1-fg_7_12">23,934</ix:nonFraction></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 36pt;">During the six months ended June&#160;30, 2020, and following the CRL received from the FDA, the Company changed its estimate for total costs expected to be incurred until satisfying the performance obligation under the Chiesi Agreements. This resulted in a reduction to accumulated revenues recognized in respect of this performance obligation in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ChangeInAccountingEstimateByTypeAxis_us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_zOqqkDVmMEqqtqAQg4AvEw" decimals="-5" format="ixt:numdotdecimal" name="plx:ReductionToAccumulatedRevenueRecognized" scale="6" id="Narr_MuKx6M6xLkumo_uHPCWgbQ">4.1</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 36pt;"><span style="background-color:#ffffff;">During the six months ended June 30, 2021 and 2020, the Company recognized revenues of approximately </span><span style="background-color:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_PDlyFNQ9d0677vNqirp86w" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="Narr_FzSxGM5oXkSXdTcL90xCcQ">0.9</ix:nonFraction></span><span style="background-color:#ffffff;">&#160;million and </span><span style="background-color:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_pMCN5439iEi2rGvtFhU0-Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="Narr_wmil8nVCMEuSWH_FixMa9A">1.2</ix:nonFraction></span><span style="background-color:#ffffff;">&#160;million, respectively, and during each of the three months ended June 30, 2021 and 2020, the Company recognized revenues of approximately </span><span style="background-color:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_wgEii3xYtU2zfwp11IyUzQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="Narr_x_9W5D6xfkikc6J_7hQCTg"><ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_iX-tLkOGFEuB3AcNqYn0Rw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="Narr_ypzPMRXeA0WT6kPE89adVg">0.5</ix:nonFraction></ix:nonFraction></span><span style="background-color:#ffffff;">&#160;million all related to a </span><span style="background-color:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_PDlyFNQ9d0677vNqirp86w" decimals="-5" format="ixt:numdotdecimal" name="plx:VariableConsideration" scale="6" id="Narr_Yv5y7n4RVUSa5P6CKnk0Xw">10.0</ix:nonFraction></span><span style="background-color:#ffffff;">&#160;million future milestone payment, which was accounted for as a variable consideration. The </span><span style="background-color:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_lC9sVFpteUu2iOBXmvyCnQ" decimals="-5" format="ixt:numdotdecimal" name="plx:ProceedsFromVariableConsideration" scale="6" id="Narr_IEE9VJia30C2b4KwH7UxFA">10.0</ix:nonFraction></span><span style="background-color:#ffffff;">&#160;million payment was received in June 2021.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_FMVZFX5Lt02Sk7qTGTFv4g" continuedAt="Tb_FMVZFX5Lt02Sk7qTGTFv4g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; STOCK TRANSACTIONS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On June&#160;7, 2021, the Company issued </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="Duration_6_7_2021_To_6_7_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_hHEjR2Bo5EuYhi_31RGp8A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_VzGuVH-Fwkqc7GNs71Aofg">173,816</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> shares of Common Stock in connection with the cashless exercise of a warrant to purchase </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"><ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_9pT5j3bp9kOxck8vgMJvsA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" id="Narr_ZeNo0zeF3UCmztbmrpVZoA">2,816,901</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> shares of Common Stock issued on March&#160;18, 2020, as part of the Company&#8217;s private placement of Common Stock and warrants. The Company did not generate any proceeds from the cashless exercise.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On July 2, 2021, the Company entered into the Sales Agreement with the Agent. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent ATM Shares having an aggregate offering price of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_36UqK7xw-keHI8meiWi3Lw" decimals="-5" format="ixt:numdotdecimal" name="plx:SaleOfStockMaximumOfferingPrice" scale="6" id="Narr_eZyA0EiCbE2YNGbTYa4VyQ">20.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;million. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The ATM Shares will be issued pursuant to the Company&#8217;s shelf registration statement on Form&#160;S-3. The Company intends to use the net proceeds from the offering, after deducting the Agent&#8217;s commissions and the Company&#8217;s offering expenses, for general corporate</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> purposes. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;text-align:left;top:0pt;vertical-align:top;">SM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_FMVZFX5Lt02Sk7qTGTFv4g_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g" name="us-gaap:SubsequentEventsTextBlock" id="Tb_KKtOkvYUQU6wfA3m34QVHg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">As of June&#160;30, 2021, the Company has outstanding $<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_vViOT2LFf0axMCBfeZUuig" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShortTermBorrowings" scale="6" id="Narr_lvSRvP9970mbJhxa3LAnVg">57.9</ix:nonFraction>&#160;million aggregate principal amount of 2021 Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On August&#160;12, 2021, the Company entered into definitive agreements relating to private exchanges (the &#8220;Exchanges&#8221;) of an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_CocxRZ8sAUy7n9e-67jKfA" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_jAOz1E3qIUSMMOzXopFnIw">54.65</ix:nonFraction>&#160;million principal amount of the Company&#8217;s outstanding 2021 Notes for an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="As_Of_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5mBl3aHBi0KLliehuspORg" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_DJMNTpNsB06FZX8Av-yZJA">28.75</ix:nonFraction>&#160;million principal amount of <ix:nonFraction unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q" contextRef="As_Of_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5mBl3aHBi0KLliehuspORg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_rPFVg1RajUKD39hDjEBibw">7.50</ix:nonFraction>% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;), $<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_0ds-0DyfXEGdaoZ3UfY54A" decimals="-4" format="ixt:numdotdecimal" name="plx:DebtConversionConvertedInstrumentAmountCash" scale="6" id="Narr_UytZL8CW302EGuN59vU0Sw">25.90</ix:nonFraction>&#160;million in cash, and accrued and unpaid interest through the issue date. The Exchanges are expected to close as soon as practicable, subject to satisfaction of certain closing conditions. The initial conversion rate for the 2024 Notes is <ix:nonFraction unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g" contextRef="As_Of_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5mBl3aHBi0KLliehuspORg" decimals="4" format="ixt:numdotdecimal" name="plx:DebtInstrumentConvertibleConversionShareNumber" scale="0" id="Narr_-DL1sTZKhE-jYU8jd5Qz8g">563.2216</ix:nonFraction> shares of Common Stock for each $<ix:nonFraction unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw" contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wp1PKGYOf02TVwTFOgkSpw" decimals="0" format="ixt:numdotdecimal" name="plx:DebtInstrumentConvertibleBaseValueForConversionRate" scale="0" id="Narr_TLuUeHwsOUOLOiunqINnvg">1,000</ix:nonFraction> principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ" contextRef="As_Of_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5mBl3aHBi0KLliehuspORg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_erPg1M9uukyXSJeWnt1Kdg">1.7755</ix:nonFraction> per share of the Common Stock), subject to adjustment in some events, which is based on a <ix:nonFraction unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q" contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_0ds-0DyfXEGdaoZ3UfY54A" decimals="3" format="ixt:numdotdecimal" name="plx:PercentageOfPremiumToClosingPriceOfStock" scale="-2" id="Narr_IaR00lQU6UumRqG6Q2iQmw">32.5</ix:nonFraction>% premium to the closing price of the Common Stock on the NYSE American at the close of trading on August&#160;13, 2021, the exchange date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The 2024 Notes will be issued pursuant to an indenture to be entered into between the Company, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent. Interest on the Notes will be paid semi-annually at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q" contextRef="As_Of_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5mBl3aHBi0KLliehuspORg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_GZU49VaWbEe9Va_KLcR-TA">7.50</ix:nonFraction>% per annum. The Notes will mature <ix:nonNumeric contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_0ds-0DyfXEGdaoZ3UfY54A" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_cIzXv0IZt0WQ1_l-brZikA">three years</ix:nonNumeric> after the issuance thereof, unless earlier purchased, converted, exchanged or redeemed and will be guaranteed by the Company&#8217;s subsidiaries. The 2024 Notes will be secured by perfected liens on all of the assets of the Company and its subsidiaries.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_15dece23_c783_4698_9748_cef9ee2f1ec4"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS<br />AND RISK FACTORS SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial statements and the related notes included elsewhere in this Form</i>&#160;<i style="font-style:italic;">10-Q and in our Annual Report on Form</i>&#160;<i style="font-style:italic;">10-K for the year ended December</i>&#160;<i style="font-style:italic;">31, 2020. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements within the meanings of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and words or phrases of similar import, as they relate to our company or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements as a result of several factors including those set forth under &#8220;Risk Factors&#8221; in our Quarterly Report on Form</i>&#160;<i style="font-style:italic;">10-Q for the quarter ended March</i>&#160;<i style="font-style:italic;">31, 2021.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Examples of the risks and uncertainties include, but are not limited to, the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks related to the timing and progress of the preparation of an updated BLA addressing the CRL for PRX-102;</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the timing, progress and likelihood of final approval by the FDA of a resubmitted BLA for PRX-102 and, if approved, whether PRX-102 will be commercially successful;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the FDA, the European Medicines Agency, or EMA, or other foreign regulatory authorities may not accept or approve a marketing application we file for PRX-102 or any of our other product candidates;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and or lack of sufficient funding to finance our clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will have undesirable side effects or other unexpected characteristics;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to make required payments under our outstanding convertible notes, including the 2024&#160;Notes, or any other indebtedness as they come due and our ability to obtain additional financing and raise capital as necessary should the regulatory approval process become more extended;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks associated with the COVID-19 outbreak and variants, which may adversely impact our business, preclinical studies and clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our evaluation and pursuit of strategic alternatives;</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks relating to our ability to manage our relationship with our collaborators, distributors or partners; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks relating to changes to interim, topline or preliminary data from clinical trials that we announce or publish;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>our dependence on performance by third-party providers of services and supplies;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>the impact of development of competing therapies and/or technologies by other companies;</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks related to our supply of drug product to Pfizer;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks related to our expectations with respect to the potential commercial value of our product and product candidates;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks relating to the compliance by Fiocruz, an arm of the Brazilian MoH, with its purchase obligations under our supply and technology transfer agreement, which may have a material adverse effect on us and may also result in the termination of such agreement;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>potential product liability risks, and risks of securing adequate levels of related insurance coverage;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>the possibility of infringing a third-party&#8217;s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><span style="font-family:'Times New Roman';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#9679;</span></span>the possible disruption of our operations due to terrorist activities and armed conflict, including as a result of the disruption of the operations of regulatory authorities, our subsidiaries, our manufacturing facilities and our customers, suppliers, distributors, collaborative partners, licensees and clinical trial sites.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recent Company Developments</b></p><div style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On August&#160;2, 2021, we <span style="letter-spacing:-0.15pt;">announced that a Type A Meeting request has been submitted to the FDA to discuss the CRL. </span>The FDA has scheduled the Type A meeting for September&#160;9, 2021.</div><div style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On July&#160;2, 2021, we entered into the Sales Agreement with the Agent. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent ATM Shares having an aggregate offering price of up to $20.0&#160;million. Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities.</div><div style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On June&#160;2, 2021, we, together Chiesi, announced topline results from an interim analysis of the phase&#160;III <i style="font-style:italic;">BALANCE</i> clinical trial. The initial top-line results show that the lower boundary of the confidence interval for the mean difference between the two treatments (PRX-102 and Fabrazyme) was below the non-inferiority margin pre-specified for this interim analysis in the ITT analysis set and above such limit in the PP analysis set. At the time of this analysis, two patients discontinued participation due to treatment emergent adverse events (TEAEs). Of these two patients, one discontinued participation due to a related adverse event. No deaths were registered. Overall, safety data appears favorable and consistent with what was observed in previous clinical studies with PRX-102.</div><div style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:4.5pt;margin-top:0pt;padding-bottom:10pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On May&#160;13, 2021, we signed a binding term sheet with Chiesi pursuant to which we amended the Chiesi Agreements in order to provide us with near-term capital. Chiesi agreed to make a $10.0&#160;million milestone payment to us before the end of the second quarter in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. We also agreed to negotiate certain manufacturing related matters. We received the payment in June&#160;2021.</div><div style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 4.5pt 0pt 0pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On April&#160;28, 2021, we, together with Chiesi, announced the receipt from the FDA of a CRL in response to the PRX-102 BLA.</div><div style="margin-top:10pt;"></div><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">We continue to actively advance all our clinical programs. We are in close contact with our principal investigators and clinical sites and our clinical research organizations, which are primarily located in the United States and Europe, and to date, our clinical trials have not been materially adversely affected by COVID-19. In light of recent developments relating to the COVID-19 pandemic, the focus of healthcare providers and hospitals on fighting the virus, and consistent with the FDA&#8217;s updated industry guidance for conducting clinical trials issued on March&#160;18, 2020, we and our contract research organizations have made certain adjustments to the operation of our clinical trials in an effort to ensure the monitoring and safety of patients and minimize risk to trial integrity during the pandemic and generally, and we may need to make further adjustments in the future.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">In response to the local spread of COVID-19 at the end of March 2020, and with local directives issued in response thereof, we restructured the work day within our facilities to consist of two shifts thereby reducing the number of employees present in the facilities at any time and facilitating their ability to practice social distancing. Employees that were able to work from home were instructed to do so. Such efforts resulted in minor delays in the performance of administrative activities outside of the clinical programs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:207.26pt;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">In June 2020, after local directives allowed more flexibility with respect to social interactions, we returned to a regular work day. Since then, as the pandemic&#8217;s effect locally continued to change, and local Israeli directives continued to evolve to address the changing effects, we returned temporarily to the two-shift work day schedule and to again encourage employees that are able to work from home to do so for parts of September 2020. Our facility currently operates on a regular schedule with adherence to local guidelines.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We will continue to evaluate the impact of the COVID-19 pandemic and its variants on our business as we learn more and the impact of COVID-19 on our industry becomes more clear. We intend to continuously assess the impact of COVID-19 on our trials, expected timelines and costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx: Our Proprietary Protein Expression System</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>ProCellEx is our proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expressions in suspension. ProCellEx consists of a comprehensive set of proprietary technologies and capabilities, including the use of advanced genetic engineering and plant cell culture technology, enabling us to produce complex, proprietary, and biologically equivalent proteins for a variety of human diseases. Our protein expression system facilitates the creation and selection of high-expressing, genetically-stable cell lines capable of expressing recombinant proteins.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>Our ProCellEx technology allows for many unique advantages, including: biologic optimization; an ability to handle complex protein expressions; flexible manufacturing with improvements through efficiencies, enhancements and/or rapid horizontal scale-ups; a simplified production process; elimination of the risk of viral contaminations from mammalian components; and intellectual property advantages.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-family:'Times New Roman';min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression. Our ProCellEx platform uses flexible polyethylene disposable bioreactors and is optimized for plant cell cultures. As opposed to the large stainless-steel bioreactors commonly used for recombinant protein production, our ProCellEx bioreactors are easy to use and maintain and allow for the major advantage of rapid horizontal scale-up.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Plant Cell Production Advantages</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:12pt;"><img src="plx-20210630x10q005.jpg" alt="Graphic" style="display:inline-block;height:207.26pt;width:540pt;" /></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:234.03pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Plant Cell in Suspension Expression System for Therapeutic Proteins Development and Industrial Production: Executive Summary</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20210630x10q006.jpg" alt="Graphic" style="display:inline-block;height:233.28pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:540pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Product Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;"><img src="plx-20210630x10q007.jpg" alt="Graphic" style="display:inline-block;height:164.64pt;left:0%;padding-bottom:0.4pt;position:relative;top:0pt;width:540pt;" /></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Pegunigalsidase Alfa (PRX-102) for the Treatment of Fabry Disease</span></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">PRX-102 is our lead product candidate and we expect it to be the primary subject of our development efforts in the short-term. It <span style="letter-spacing:-0.15pt;">is our proprietary, investigational, plant cell culture expressed enzyme, and a chemically modified stabilized version of, the recombinant &#945;-Galactosidase-A protein, a </span>lysosomal enzyme,<span style="letter-spacing:-0.15pt;"> under development for the treatment of Fabry disease. </span>Fabry disease is a serious life-threatening rare genetic disorder. Fabry patients lack &#945;-galactosidase-A resulting in the progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide, or Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>, in blood vessel walls throughout their body. The abnormal storage of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> increases with time and, as a result, Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> accumulates, primarily in the blood and in the blood vessel walls. The accumulation leads to a narrowing of the blood vessels, which in turn leads to decreased blood flow and tissue nourishment. The ultimate consequences of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> deposition range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of the kidneys, but also of the heart and the cerebrovascular system. Fabry disease occurs in one person per 40,000 to 60,000 males. The global market for Fabry disease is forecasted to be approximately $1.9&#160;billion in 2021 (Global Data) and to continue to grow at a CAGR of approximately 9.5% (Global Data).</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A BLA for PRX-102 for the treatment of adult patients with Fabry disease was submitted to the FDA on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, which was subsequently accepted by the FDA and granted Priority Review designation. The BLA submission includes a comprehensive set of preclinical, clinical and manufacturing data compiled from our completed phase I/II </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">clinical trial of PRX-102, including the related extension study succeeding our phase I/II clinical trial, interim clinical data from our phase III <i style="font-style:italic;">BRIDGE</i> switch-over study and safety data from our on-going clinical studies of PRX-102 in patients receiving 1&#160;mg/kg every other week.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">As discussed above, on April&#160;28, 2021, we, together with Chiesi, announced the receipt of a CRL from the FDA regarding the BLA. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of Protalix&#8217;s manufacturing facility in Carmiel, Israel, including a subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to COVID-19, the FDA reviewed records under Section 704(a)(4) of the FFDCA in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">In addition to the foregoing, in the CRL, the FDA noted that Fabrazyme, a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102. We intend to work collaboratively with the agency to identify the most expeditious pathway to approval, and are confident that we will be able to work with the FDA to resolve these issues and provide a new, alternative drug to Fabry patients. </p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On August&#160;2, 2021, we <span style="letter-spacing:-0.15pt;">announced that a Type A Meeting request has been submitted to the FDA to discuss the CRL. </span>The FDA has scheduled the Type A meeting for September&#160;9, 2021; however, we cannot anticipate the additional steps that may be required in connection with any potential resubmission. We intend to provide further updates on next steps after the meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based on the interim analysis of the 12-month data generated from the <i style="font-style:italic;">BALANCE</i> study, which are described below, and in combination with previously reported positive data from the <i style="font-style:italic;">BRIGHT</i> and <i style="font-style:italic;">BRIDGE</i> studies, Protalix and Chiesi intend to submit an MAA to the EMA for the review of PRX-102 for the proposed treatment of Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">In December 2017, the European Commission granted Orphan Drug Designation for <span style="font-family:'Times-Roman';">PRX-102</span> for the treatment of Fabry disease. Orphan Drug Designation for <span style="font-family:'Times-Roman';">PRX-102</span> qualifies Chiesi for access to a centralized marketing authorization procedure, including applications for inspections and for protocol assistance. If the orphan drug designation is maintained at the time <span style="font-family:'Times-Roman';">PRX-102</span> is approved for marketing in the European Union, if at all, we expect that <span style="font-family:'Times-Roman';">PRX-102</span> will benefit from 10 years of market exclusivity within the European Union. The market exclusivity will not have any effect on Fabry disease treatments already approved at that time.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In January 2018, the FDA granted Fast Track designation to PRX-102. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs and vaccines for serious conditions that fill an unmet medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Key Trials and Design</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our phase<span style="letter-spacing:-0.15pt;">&#160;</span>III clinical program of PRX-102 for the treatment of Fabry disease includes three individual studies; the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. Enrollment has been completed in all three studies. In 2015, we completed a phase<span style="letter-spacing:-0.15pt;">&#160;</span>I/II clinical trial of PRX-102. In the phase&#160;III clinical program, we are studying two alternative doses and regimens for PRX-102; 1<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every two weeks, with the potential for improved efficacy and safety offering a potential alternative to existing enzyme replacement therapies, and 2<span style="letter-spacing:-0.15pt;">&#160;</span>mg/kg every four weeks, which has the potential to lower treatment burden versus existing treatments and potentially provide a better quality of life for a subset of Fabry patients. Final results from the <i style="font-style:italic;">BRIDGE</i> study were released in December 2020 and topline results from the <i style="font-style:italic;">BRIGHT</i> study were released in February 2021. Interim one-year data from the <i style="font-style:italic;">BALANCE </i>study was released in June 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Patients that completed the phase<span style="letter-spacing:-0.15pt;">&#160;</span>I/II clinical trial were offered, and patients that complete the <i style="font-style:italic;">BALANCE, BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies are offered, the opportunity to continue PRX-102 treatment as part of a long-term extension study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In February 2020, we, together with Chiesi, announced an agreement with the FDA for the Initial Pediatric Study Plan (iPSP) for PRX-102. The joint announcement was made after completion of discussions with the FDA and receipt of confirmation from the FDA in an official &#8220;Agreement Letter&#8221; which outlines an agreed-upon approach to evaluate the safety and efficacy of PRX-102 in pediatric Fabry patients in a clinical trial to be performed by Chiesi with our collaborative efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase III BALANCE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background-color:#ffffff;">The </span><i style="font-style:italic;">BALANCE</i> s<span style="background-color:#ffffff;">tudy is a 24</span>-<span style="background-color:#ffffff;">month, randomized, double blind, active control study of PRX</span>-<span style="background-color:#ffffff;">102 in Fabry patients with impaired renal function. We have completed enrollment of 78 patients in the trial, which is </span>designed to evaluate the safety and efficacy of PRX-102 </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">compared to agalsidase beta (Fabrazyme) on renal function in Fabry patients with progressing kidney disease previously treated with Fabrazyme infused once every two weeks. <span style="background-color:#ffffff;">Patients previously treated with </span>Fabrazyme <span style="background-color:#ffffff;">for approximately one year and on a stable dose for at least six months were screened and then randomized on a 2:1 ratio to 1</span><span style="letter-spacing:-0.15pt;">&#160;</span><span style="background-color:#ffffff;">mg/kg of PRX-102 or 1</span><span style="letter-spacing:-0.15pt;">&#160;</span><span style="background-color:#ffffff;">mg/kg of </span>Fabrazyme<span style="background-color:#ffffff;">. Randomization is being stratified by urinary protein to creatinine ratio (UPCR) of &lt;</span>&#160;<span style="background-color:#ffffff;">or</span>&#160;<span style="background-color:#ffffff;">&#8805;</span>&#160;<span style="background-color:#ffffff;">1</span>&#160;<span style="background-color:#ffffff;">g/g by spot urine sample. The study was designed such that no more than 50% of the patients enrolled in the study would be female. Approximately 40% of the enrolled patients were female.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The primary endpoint of the <i style="font-style:italic;">BALANCE</i> study is the comparison in the annualized rate of decline of eGFR slope between Fabrazyme and PRX-102. eGFR is considered a reliable and accepted test to measure the level of kidney function and stage of kidney disease. Additional parameters being evaluated include: cardiac assessment, Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> (a biomarker for monitoring Fabry patients during therapy), pain, quality of life, immunogenicity, Fabry clinical events and pharmacokinetic and other parameters. The study also evaluates the safety and tolerability of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In June 2021, we, together with Chiesi, announced topline results from an interim analysis of the <i style="font-style:italic;">BALANCE </i>study. The primary endpoint of the interim analysis is the comparison of mean annualized changes (slope) of the eGFR<sub style="font-size:7.5pt;vertical-align:sub;">(CKD-EPI)</sub> after completion of at least 12 months of treatment between the two treatment arms (Fabrazyme and PRX-102). The interim efficacy analysis was conducted on two pre-defined analysis sets: Intention to Treat (ITT), consisting of all randomized patients who received at least one dose (77 patients), considered as the primary analysis for this interim review; and the Per Protocol (PP), consisting of all patients who completed at least 12 months of treatment with no major protocol violations (74 patients). The patient population (ITT analysis set) of the study is comprised of 47 males (61%) and 30 females (39%) with a mean age of 44.3 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The initial top-line results show that the lower boundary of the confidence interval for the mean difference between the two treatments was below the non-inferiority margin pre-specified for this interim analysis in the ITT analysis set and above such limit in the PP analysis set. At the time of this analysis, two patients discontinued participation due to treatment emergent adverse events (TEAEs). Of these two patients, one discontinued participation due to a related adverse event. No deaths were registered. Overall, safety data appears favorable and consistent with what was observed in previous clinical studies with PRX-102. Unblinded final data is anticipated to be released in the second quarter of 2022 after all remaining patients have completed the 24-month treatment period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based on the interim analysis of the 12-month data generated from the <i style="font-style:italic;">BALANCE</i> study, and in combination with previously reported positive data from the <i style="font-style:italic;">BRIGHT</i> and <i style="font-style:italic;">BRIDGE</i> studies, Protalix and Chiesi intend to submit an MAA to the EMA for the review of PRX-102 for the proposed treatment of Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Patients enrolled in the <i style="font-style:italic;">BALANCE</i> study will continue to be treated for a total of 24&#160;months, at which point the data will be analyzed to test for superiority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIDGE Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background-color:#ffffff;">The </span><i style="font-style:italic;">BRIDGE</i> study was a 12-month open-label, single arm switch-over study evaluating the safety and efficacy of pegunigalsidase alfa, 1&#160;mg/kg infused every two weeks, in up to 22 Fabry patients. The trial, which is was completed in December 2019, enrolled patients then being treated with agalsidase alfa, marketed by Takeda Pharmaceutical Company Limited (acquired Shire&#160;Plc) as Replagal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, for at least two years and on a stable dose for at least six months. Patients were screened and evaluated over three months while continuing Replagal treatment. Following the screening period, each patient was enrolled and switched from Replagal treatment to receive intravenous (IV)&#160;infusions of PRX-102 1&#160;mg/kg every two weeks for 12&#160;months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.4pt 10pt 0pt;">Final results of the data generated in the study showed substantial improvement in renal function as measured by mean annualized estimated Glomerular Filtration Rate, or eGFR, slope in both male and female patients who were switched from agalsidase alfa to PRX-102. Twenty of 22 patients completed the 12-month treatment duration. Eighteen of the patients who completed the study opted to roll over to a long-term extension study and continue to be treated with PRX-102.<span style="font-size:12pt;"> </span>In the study, the mean annualized eGFR slope of the study participants improved from -5.90&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year while on agalsidase alfa to -1.19&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year on PRX-102 in all patients. Male patients improved from -6.36&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -1.73&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year and female patients improved from -5.03&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -0.21&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year. Following the switch to PRX-102, there was a decrease in patients with progressing or fast progressing kidney disease, and most patients achieved a stable status post-switch.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 24.75pt 10pt 0pt;">PRX-102 was well-tolerated in the study, with all adverse events being transient in nature without sequelae. Of the 22 patients enrolled in the <i style="font-style:italic;">BRIDGE</i> study, the majority of treatment <span style="letter-spacing:-2.9pt;"> </span>emergent adverse events were mild or moderate in severity, with two patients (9.1%) withdrawing from the therapy due to hypersensitivity reaction that was resolved. The most common moderate treatment emergent adverse events were nasopharyngitis, headache and dyspnea.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 8.05pt 10pt 0pt;">An immunogenicity assessment indicated that four out of 20 patients (20%) developed persistent antidrug antibodies over the course of the study, of which two had neutralizing activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.15;margin:0pt 5.2pt 10pt 0pt;">Baseline characteristics of the 20 patients that completed the study, ranging from ages 28 to 60 years, were as follows: mean eGFR 75.87&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in males, and 86.14&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup> in females and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> were<span style="vertical-align:super;"> </span>51.81&#160;nM and 13.81&#160;nM in males and females, respectively. While lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels remain slightly high, particularly within the male cohort, continuous reduction in lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels was observed of 19.55&#160;nM (32.35%) in males and 4.57&#160;nM (29.81%) in females.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data from the interim analysis of the <i style="font-style:italic;">BRIDGE</i> study, which were first announced in February 2020, were used to support the PRX-102 BLA filing with the FDA, and we anticipate that the final analysis will be used to support a Marketing Authorization Application, or MAA, with the EMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase&#160;III BRIGHT Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background-color:#ffffff;">The </span>phase&#160;III <i style="font-style:italic;">BRIGHT </i>clinical trial of PRX-102 for the treatment of Fabry disease, or the<i style="background-color:#ffffff;font-style:italic;"> </i><i style="font-style:italic;">BRIGHT</i> study, was a 12-month, open-label, switch-over study designed to evaluate the safety, efficacy and pharmacokinetics of PRX-102 via IV infusions of 2&#160;mg/kg administered every 4 weeks. The trial, which was completed in June 2020, enrolled up to 30 patients with Fabry disease previously treated with a commercially available ERT (Fabrazyme or Replagal), for at least three years and on a stable dose administered every two weeks. To determine eligibility for participation in the study, candidates were screened to identify and select Fabry patients with stable kidney disease. Patients who matched the criteria were enrolled in the study and switched from their current treatment of IV&#160;infusions every 2 weeks to 2&#160;mg/kg of PRX-102 every 4 weeks for 12&#160;months. Patients participating in the study were evaluated, among other disease parameters, to determine if their kidney disease had not further deteriorated while being treated with the 4-week dosing regimen as measured by eGFR and Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub>, as well as other parameters. In addition, participating patients were evaluated to assess the safety and tolerability of PRX-102.</p><a id="_Hlk64553510"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We announced topline results in February 2021. The topline results indicate that 2&#160;mg/kg of PRX-102 administered by intravenous infusion every four weeks was found to be well tolerated among treated patients, and stable clinical presentation was maintained in adult Fabry patients. No new patients developed treatment-induced anti-drug antibodies, or ADA, following the switch to PRX-102 treatment.</p><a id="_Hlk64641068"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIGHT</i> study enrolled 24&#160;adult males and 6&#160;adult females. The most common Fabry disease symptoms were acroparesthesia, heat intolerance, angiokeratomas and hypohydrosis. All 30&#160;patients received at least one dose of PRX-102, and 29 patients (mean [SD] age was 40.5&#160;[11.3]&#160;years, ranging from 19 to 58&#160;years) completed the 12-month study. Of these 29 patients, 28 received the intended regimen of 2&#160;mg/kg every four weeks throughout the study, while one patient was switched to PRX-102 1&#160;mg/kg every two weeks per protocol. One patient withdrew from the study after the first infusion due to a traffic accident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Following screening, patients were enrolled and switched from their then current ERT to IV&#160;infusions of 2&#160;mg/kg of PRX-102 every four weeks for 52 weeks (a total of 14&#160;infusions). First infusions of PRX-102 were administered under controlled conditions at the investigation site. Based on the protocol-specified criteria, patients were able to receive their PRX-102 infusions at a home care setup once the Investigator and Sponsor Medical Monitor agreed that it was safe to do so. Safety and efficacy exploratory endpoints were assessed throughout the 52-week study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Study outcome measures showed plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentrations remained stable during the study with a mean change of 3.01&#160;nM from baseline (19.36&#160;nM) to Week&#160;52 (22.23&#160;nM). Mean absolute change of eGFR values were stable during the 52-week treatment period, with a mean change from baseline of -1.27&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Following a survey of participants using the Quality of Life EQ-5D-5L questionnaire, responses indicate that patient perception of their own health remained high and stable throughout the 52-week study duration, with overall health mean (SE) scores of 78.3 (3.1) and 82.1 (2.9) at baseline and Week 52, respectively, in a 0 to 100 scale. Using the short-form Brief Pain Inventory, or BPI, questionnaire, approximately 75% of study participants had an improvement or no change in average pain severity at Week&#160;52 (compared to baseline). The short-form BPI interference items also remained stable during the study. Pain-related results indicate that there was no increase and/or relapse in pain. No Fabry clinical events were reported during the study.<span style="background-color:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, substantially all of the patients who completed the study opted, with the advice of the treating physician, to continue treatment under the 4-week dosing regimen in a long-term extension study.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">COVID-19 Impact on PRX-102 Clinical Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, the COVID-19 pandemic has had a minimal effect on the performance of the phase&#160;III clinical trials of PRX-102 as many of the patients were already treated in home care settings. In a minimal amount of cases, patients that completed a trial were not able to be transferred into an extension study due to the pandemic restrictions, and, accordingly, the main trial was prolonged for the patients to permit the continuation of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Phase I/II Study</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our phase&#160;I/II clinical trial of PRX-102, which we completed in 2015, was a worldwide, multi-center, open-label, dose ranging study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy parameters of PRX-102 in adult Fabry patients. Sixteen adult, na&#239;ve Fabry patients (9 male and 7 female) completed the trial, each in one of three dosing groups, 0.2&#160;mg/kg, 1&#160;mg/kg and 2&#160;mg/kg. Each patient received IV&#160;infusions of PRX-102 every two weeks for 12 weeks, with efficacy follow-up after six-month and twelve-month periods. A majority of the patients who completed the trial opted to continue receiving PRX-102 in an open-label, 60-month extension study under which all patients were switched to receive 1&#160;mg/kg of the drug, the selected dose for our <i style="font-style:italic;">BALANCE</i> and <i style="font-style:italic;">BRIDGE</i> studies of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The adult symptomatic, ERT-na&#239;ve Fabry disease patients enrolled in the phase&#160;I/II study were evaluated for Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels in kidney biopsies and for plasma Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentration by the quantitative BLISS methodology. Biopsies were available from 14 patients. The outcome of &#8805;&#160;50% reduction in the average number of Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions per kidney PTC from baseline to Month 6 was demonstrated in 11 of 14 (78.6%) of the patients treated with PRX-102. The overall results demonstrate that PRX-102 reaches the affected tissue and reduces kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions burden and Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>in the circulation. A high correlation was found between the two Fabry disease biomarkers, reduction of kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>inclusions and the reduction of plasma Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> over six months of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data was recorded at 24&#160;months from 11 patients who completed 12&#160;months of the long-term open-label extension trial that succeeded the phase&#160;I/II study. Patients who did not continue in the extension trial included: female patients who became or planned to become pregnant and therefore were unable to continue in accordance with the study protocol; and patients who relocated to a location where treatment was not available under the clinical study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Results show that Lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels decreased approximately 90% from baseline. Renal function remained stable with mean eGRF levels of 108.02 and 107.20 at baseline and 24&#160;months, respectively, with a modest annual eGFR slope of -2.1. An improvement across all the gastrointestinal symptoms evaluated, including severity and frequency of abdominal pain and frequency of diarrhea, was noted. Cardiac parameters, including LVM, LVMI and EF, remained stable with no cardiac fibrosis development detected. In conclusion, an improvement of over 40% in disease severity was shown as measured by the Mainz Severity Score Index, or MSSI, a score compiling the different elements of the disease severity including neurological, renal and cardiovascular parameters. In addition, an improvement was noted in each of the individual parameters of the MSSI.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The majority of adverse events were mild-to-moderate in severity, and transient in nature. During the first 12 months of treatment, only three of 16 patients (less than 19%) formed anti-drug antibodies (ADA), of which two of these patients (less than 13%) had neutralizing antibodies. Importantly, however, the ADAs turned negative for all three of these patients following 12&#160;months of treatment. The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.</p><a id="_DV_M79"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements with Chiesi Farmaceutici</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have entered into two exclusive global licensing and supply agreements for PRX-102 for the treatment of Fabry disease with Chiesi. The agreements have significant revenue potential for Protalix. Under the agreements, Protalix Ltd. has received $50.0&#160;million in upfront payments and was entitled to development cost reimbursements of up to $45.0&#160;million, up to more than $1.0&#160;billion in potential milestone payments and tiered royalties of 15% - 35% (ex-US) and 15% - 40% (US). To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the two Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On October&#160;19, 2017, Protalix Ltd. and Chiesi entered into the Chiesi Ex-US Agreement pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize PRX-102. Under the Chiesi Ex-US Agreement, Chiesi made an upfront payment to Protalix Ltd. of $25.0&#160;million in connection with the execution of the agreement, and Protalix Ltd. was entitled to additional payments of up to $25.0&#160;million in development costs in the aggregate, capped at $10.0&#160;million per year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $320.0&#160;million in regulatory and commercial milestone payments. Protalix Ltd. agreed to manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase PRX-102 from Protalix Ltd., subject to certain terms and conditions. Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales, as consideration for the supply of PRX-102.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On July&#160;23, 2018, Protalix Ltd. entered into the Chiesi US Agreement with respect to the development and commercialization of PRX-102 in the United States. Protalix Ltd. received an upfront, non-refundable, non-creditable payment of $25.0&#160;million from Chiesi and was entitled to additional payments of up to a maximum of $20.0&#160;million to cover development costs for PRX-102, subject to a maximum of $7.5&#160;million per year. Protalix Ltd. is also eligible to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Chiesi is also required to make tiered payments of 15% to 40% of its net sales under the Chiesi US Agreement to Protalix Ltd., depending on the amount of annual sales, subject to certain terms and conditions, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On May&#160;13, 2021, we signed a binding term sheet with Chiesi pursuant to which we amended the Chiesi Agreements in order to provide us with near-term capital. Chiesi agreed to make a $10.0&#160;million milestone payment to us before the end of the second quarter in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. We also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Elelyso</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-style:italic;font-weight:bold;"> for the Treatment of Gaucher Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso (taliglucerase alfa), our first commercial product, was approved by the FDA in 2012 for injection as an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type&#160;1 Gaucher disease. In August 2014, the FDA approved Elelyso for injection for pediatric patients. Elelyso is the first plant cell derived recombinant protein to be approved by the FDA for the treatment of Gaucher disease and is now approved in over 20 markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gaucher disease, also known as glucocerebrosidase, or GCD, deficiency, is a rare genetic autosomal recessive disorder and one of the most common Lysosomal Storage Disorders, or LSD, in the world. It is one of a group of disorders that affect specific enzymes that normally break down fatty substances for reuse in the cells. If the enzymes are missing or do not work properly, the substances can build up and become toxic. Gaucher disease occurs when a lipid called glucosylceramide accumulates in the cells of the bone marrow, lungs, spleen, liver, and sometimes the brain. Gaucher disease symptoms can include fatigue, anemia, easy bruising and bleeding, severe bone pain and easily broken bones, and distended stomach due to an enlarged spleen and thrombocytopenia. Epidemiology of Gaucher disease varies; recent literature provides that prevalence of Gaucher disease ranges from 0.70 to 1.75 per 100,000 in the general population. In people of Ashkenazi Jewish heritage, estimates of occurrence vary from approximately 1 in 400 to 1 in 850 people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gaucher disease is a $1.5&#160;billion global annual therapeutic market that includes Sanofi&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Shire&#8217;s (acquired by Takeda Pharmaceutical Company Limited) Vpriv<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Sanofi&#8217;s Cerdelga<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization Agreements for Elelyso</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have licensed to Pfizer the global rights to Elelyso in all markets excluding Brazil. Pfizer retains 100% of revenue and reimburses 100% of direct costs.<span style="font-family:'Times-Roman';"> </span>We manufacture drug substance for Pfizer, subject to certain terms and conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">For the first 10-year period after the execution of our Amended Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods subject to certain terms and conditions. In a subsequent amendment, we agreed that after the completion of the first 10-year supply period, the supply term would automatically extend for a five-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We maintain distribution rights to Elelyso in Brazil (marketed as BioManguinhos alfataliglicerase) through a supply and technology transfer agreement with Fiocruz, an arm of the Brazilian MoH. In 2020, we generated $8.0&#160;million from sales of BioManguinhos alfataliglicerase to the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alidornase Alfa (PRX-110)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Alidornase alfa is our chemically-modified plant cell expressed recombinant human DNase I, administered via inhalation. Recombinant human DNase I enzymatically cleaves DNA but its activity is inhibited by actin, which is present in the blood and other target organs. PRX-110 is designed to be less susceptible to actin inhibition and have higher affinity to DNA, thus enhancing enzymatic activity. In-vitro studies have shown PRX-110 to have a highly improved catalytic efficiency and affinity to DNA, compared to dornase alfa (Pulmozyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, currently the only commercially available DNase therapy), even more so in the presence of actin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On February&#160;10, 2021, we entered into an exclusive worldwide license agreement with SarcoMed with respect to PRX-110 for use in the treatment<span style="direction:rtl;"> </span>of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On July&#160;21, 2020, the FDA granted Orphan Drug Designation for alidornase alfa for the treatment of sarcoidosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">PRX-115</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-115 is our plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme under development for the potential treatment of refractory gout. Gout is the most common inflammatory arthritis in the<span style="direction:rtl;"> </span>United States, affecting<span style="direction:rtl;"> </span>an estimated 9.2&#160;million<span style="direction:rtl;"> </span>adults. Gout is caused by factors that elevate serum uric acid, or sUA, levels, which may include diet or genetic predisposition and environmental factors leading to hyperuricemia and tissue deposition of monosodium urate crystals, tophi, in joints and soft tissues, causing acute and chronic inflammation, and is characterized by recurrent flares. Gout flares lead to substantial morbidity by causing severe pain, reduced quality of life, decreased physical function, increased healthcare costs, and lost economic productivity. Furthermore, gout is strongly associated with metabolic syndrome, and may contribute to myocardial infarction, type&#160;2 diabetes mellitus, chronic kidney disease, or CKD, and premature mortality.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currently available urate-lowering therapies, or ULTs, can be effective in treating gout. Refractory gout patients are those whom, despite treatment with existing ULTs, have high flare frequency, consistent tophi, and the inability to maintain therapeutic goals of urate levels. An estimated approximately 2% of the gout population is considered to have chronic refractory disease and are in need of other therapeutic options. One option may be a therapeutic use of the uricase enzyme which converts uric acid to allantoin, which is easily eliminated through urine. The uricase enzyme does not exist naturally in humans. To date, two variants of recombinant uricases are approved for marketing: (i)&#160;Krystexxa<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> for treatment of chronic gout refractory to conventional therapy (no longer approved in the European Union) and (ii)&#160;Elitek<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, indicated for the treatment of tumor lysis syndrome but not gout. Both have a black box warning for anaphylaxis, induce strong immunogenic reactions and have other major side-effects. We use ProCellEx to express an optimized recombinant uricase enzyme under development for the potential treatment of refractory gout which we are designing to have an improved half-life, reduced immunogenicity and potentially longer term efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;">PRX-119</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-119 is our plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases. NETs, Neutrophil extracellular traps, are web-like structures, released by activated neutrophils that trap and kill a variety of microorganisms. NETs are composed of DNA, histones, antimicrobial and pro-inflammatory proteins. Excessive formation or ineffective clearance of NETs can cause different pathological effects. NETs formation has been observed in various autoimmune, inflammatory and fibrotic conditions, diverse forms of thrombosis, cancer and metastasis. According to scientific literature, animal studies have demonstrated that DNase treatment reduces NETs toxicity. Our proprietary modified DNase I design for long and customized systemically circulating in the bloodstream, may potentially enable effective treatment of acute and chronic conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Intellectual Property</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A key element of our overall strategy is to establish a broad portfolio of patents to protect our proprietary technology, proprietary product and product candidates and their methods of use. As of June&#160;30, 2021, we hold a broad portfolio of over 90 patents in Europe, the United States, Israel and additional countries worldwide, as well as over 30 pending patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Scientific Presentations</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Dr. Camilla T&#248;ndel, a principal investigator in our phase<span style="letter-spacing:-0.15pt;">&#160;</span>III clinical program of PRX-102 for the treatment of Fabry disease, delivered a mini oral presentation entitled &#8220;A subgroup analysis of female patients in a phase 3 open-label study to assess the safety and efficacy of pegunigalsidase alfa in patients with Fabry disease previously treated with agalsidase alfa&#8221; at the 58th ERA-EDTA Virtual Congress (European Renal Association - European Dialysis and Transplant Association). The Congress took place virtually from June&#160;5 through June&#160;8, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research &amp; Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We continuously work on the further development of our ProCellEx plant cell expression technology and bioreactor system. In addition, we are working on the development of new products, each in different initial stages of development, for specific products for which there are unmet needs in terms of efficacy and safety. Our development strategy focuses on the utilization of different modification approaches and development improvements, customized for each protein product, in all stages of expression and development.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our significant accounting policies are more fully described in Note&#160;1 to our consolidated financial statements appearing in this Quarterly Report. There have been no material changes to our critical accounting policies since we filed our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S.&#160;generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The full extent to which the COVID-19 pandemic will directly or indirectly impact our financial condition, liquidity, or results of operations will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and its variants and the actions taken to contain or treat COVID-19 and its variants, as well as the economic impact on local, regional, national and international customers and markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Three months ended June</span>&#160;<span style="font-style:italic;font-weight:bold;">30, 2021 compared to the three months ended June</span>&#160;<span style="font-style:italic;font-weight:bold;">30, 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $3.2&#160;million during the three months ended June&#160;30, 2021, a decrease of $0.4&#160;million, or 11%, compared to revenues of $3.6&#160;million for the three months ended June&#160;30, 2020. The decrease of $2.0&#160;million in sales to Brazil, resulting from timing differences, was partially offset by an increase of $1.6&#160;million in sales to Pfizer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $3.2&#160;million for the three months ended June&#160;30, 2021, a decrease of $4.1&#160;million, or 56%, compared to revenues of $7.3&#160;million for the three months ended June&#160;30, 2020. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements. The decrease resulted primarily from an updated costs estimation throughout the trials until completion in the amount of $4.1&#160;million and from revenues recognized in connection with the progress of our clinical trials that have been completed during 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $4.7&#160;million for the three months ended June&#160;30, 2021, an increase of $2.9&#160;million, or 161%, from cost of goods sold of $1.8&#160;million for the three months ended June&#160;30, 2020. <span style="background-color:#ffffff;">The increase in cost of goods sold was primarily the result of certain one-time manufacturing costs incurred while preparing for the then anticipated FDA approval of the PRX-102 BLA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Research and development expenses were $7.7&#160;million for the three months ended June&#160;30, 2021, a decrease of $1.5&#160;million, or 16%, compared to $9.2&#160;million of research and development expenses for the three months ended June&#160;30, 2020. The decrease is primarily the result of the completion of two out of the three phase III clinical trials of PRX-102 and reduced costs related to the <i style="font-style:italic;">BALANCE</i> study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect research and development expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $3.2&#160;million for the three months ended June&#160;30, 2021, an increase of $1.0&#160;million, or 45%, compared to $2.2&#160;million for the three months ended June&#160;30, 2020. The increase resulted primarily from an increase in corporate costs related insurance and funding.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Financial Expenses, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial expenses net were $2.1&#160;million for the three months ended June&#160;30, 2021 and $1.9&#160;million for the three months ended June 30, 2020. <span style="background-color:#ffffff;">The increase resulted primarily from an increase in amortization of debt issuance costs and debt discount. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Six months ended June 30, 2021 compared to the six months ended June 30, 2020</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $7.8&#160;million during the six months ended June&#160;30, 2021, a decrease of $0.9&#160;million, or 10%, compared to revenues of $8.7&#160;million for the six months ended June&#160;30, 2020. The decrease of $5.0&#160;million in sales to Brazil, resulting from timing differences, was partially offset by an increase of $4.1&#160;million in sales to Pfizer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $10.0&#160;million for the six months ended June&#160;30, 2021, a decrease of $13.9&#160;million, or 58%, compared to revenues of $23.9&#160;million for the six months ended June&#160;30, 2020. Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements. The decrease resulted primarily from an updated costs estimation throughout the trials until completion in the amount of $4.1&#160;million and from revenues recognized in connection with the progress of our clinical trials that have been completed during 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $9.5&#160;million for the six months ended June30, 2021, an increase of $4.2&#160;million, or 79%, from cost of goods sold of $5.3&#160;million for the six months ended June&#160;30, 2020. <span style="background-color:#ffffff;">The increase in cost of goods sold was primarily the result of certain one-time manufacturing costs incurred while preparing for the then anticipated FDA approval of the PRX-102 BLA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Research and development expenses were $14.8&#160;million for the six months ended June&#160;30, 2021, a decrease of $4.7&#160;million, or 24%, compared to $19.5&#160;million of research and development expenses for the six months ended June&#160;30, 2020. The decrease is primarily the result of the completion of two out of the three phase III clinical trials of PRX-102 and reduced costs related to the <i style="font-style:italic;">BALANCE</i> study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect research and development expenses to continue to be our primary expense as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $6.3&#160;million for the six months ended June&#160;30, 2021, an increase of $0.9&#160;million, or 17%, compared to $5.4&#160;million for the six months ended June&#160;30, 2020. The increase resulted primarily from an increase in corporate costs related mainly to insurance and funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Financial Expenses, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial expenses net were $3.9&#160;million for the six months ended June&#160;30, 2021, a decrease of $1.0&#160;million, or 20%, compared to financial expenses net of $4.9&#160;million for the six months ended June&#160;30, 2020. <span style="background-color:#ffffff;">The decrease resulted primarily from a decrease in expenses related to our outstanding convertible notes equal to $1.3</span>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our sources of liquidity include our cash balances and bank deposits. At June&#160;30, 2021, we had $33.9&#160;million in cash and cash equivalents and $43.1&#160;million in short-term bank deposits. We have primarily financed our operations through equity and debt financings, business collaborations, and grants funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the six months ended June&#160;30, 2021, we raised gross proceeds equal to approximately $8.8&#160;million from sales of common stock under our ATM program through the sale of 1,867,552 shares of our common stock. In addition, we raised gross proceeds of approximately $40.2&#160;million from a public offering of our common stock before deducting the underwriting discount and estimated expenses of the offering. In connection with the offering, we issued 8,749,999 shares of our common stock at a purchase price per share of $4.60.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that our cash and cash equivalents and bank deposits as of June&#160;30, 2021 are sufficient to satisfy our capital needs for at least 12 months from the date that these financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, as of June&#160;30, 2021, we have outstanding 2021 Notes amounting to $57.9&#160;million which are due on November&#160;15, 2021, unless the notes are refinanced, restructured or converted before that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On August&#160;12, 2021, we entered into definitive agreements relating to the Exchanges of an aggregate of $54.65&#160;million principal amount of our 2021 Notes for an aggregate of $28.75&#160;million principal amount of 2024 Notes, $25.90&#160;million in cash, and accrued and unpaid interest through the issue date. The Exchanges are expected to close as soon as practicable, subject to satisfaction of certain closing conditions. The initial conversion rate for the 2024 Notes is 563.2216 shares of our Common Stock for each $1,000 principal amount of 2014 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of our Common Stock, subject to adjustment in some events, which is based on a 32.5% premium to the closing price of our Common Stock on the NYSE American at the close of trading on August&#160;13, 2021, the exchange date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The 2024 Notes will be issued pursuant to an indenture to be entered into between us, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent. Interest on the Notes will be paid semi-annually at a rate of 7.50% per annum. The 2024 Notes will mature three years after the issuance thereof, unless earlier purchased, converted, exchanged or redeemed and will be guaranteed by our subsidiaries. The 2024 Notes will be secured by perfected liens on all of our assets, including those of our subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Cash Flows</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operations was $3.3&#160;million for the six months ended June&#160;30, 2021. In response to the COVID-19 pandemic, a higher number of subjects in our ongoing clinical trials opted for home care treatments over in-site treatments which resulted in an immaterial amount of additional expenses. The net loss for the six months ended June&#160;30, 2021 of $16.7&#160;million was increased by a $1.6&#160;million increase in accounts receivable and other assets, and was partially offset by a $12.3&#160;million increase in contracts liability, a $1.9&#160;million of amortization of debt issuance costs and debt discount and $1.4&#160;million in share-based compensation. Net cash used in investing activities for the six months ended June&#160;30, 2021 was $23.1&#160;million and consisted primarily of a net increase in bank deposits. Net cash provided by financing activities was $42.1&#160;million resulting from the sale of common stock under our former ATM program and from our public offering of common stock, net of the promissory note payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Net cash used in operations was $15.0&#160;million for the six months ended June&#160;30, 2020. In response to the COVID-19 pandemic, a higher number of subjects in our ongoing clinical trials opted for home care treatments over in-site treatments which resulted in an immaterial amount of additional expenses. The net loss for the six months ended June&#160;30, 2020 of $2.5&#160;million was increased by a $10.8&#160;million decrease in contracts liability, a $1.6&#160;million increase in accounts receivable and other assets and a $2.9&#160;million increase in inventories, partially offset by an increase of $0.3&#160;million in accounts payable and accruals, and $1.7&#160;million amortization of debt issuance costs and debt discount. Net cash used in investing activities for the six months ended June&#160;30, 2020 was $35.3&#160;million and consisted primarily of an increase in bank deposits. Net cash provided by financing activities was $37.3&#160;million resulting from our issuance of common stock and warrants on March&#160;18, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Future Funding Requirements </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As a result of our significant research and development expenditures and the lack of significant revenue from sales of taliglucerase alfa, we have generated operating losses from our continuing operations since our inception. Our outstanding <span style="font-family:'28mugxoulnobhnx';">2021 Notes are </span>secured by a perfected lien on all of our assets<span style="font-family:'28mugxoulnobhnx';">. Under the terms of the indenture governing the 2021 Notes, and the indenture to be entered into in connection with the proposed issuance of the 2024 Notes, we are required to maintain a minimum cash balance of at least $7.5</span>&#160;<span style="font-family:'28mugxoulnobhnx';">million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to continue to incur significant expenditures in the near future as we increase our research and developments efforts with respect to our product candidates given the receipt of the CRL from the FDA discussed above, we expect to incur additional expenses in connection with any resubmission. We cannot anticipate the costs or the timing of the occurrence of such costs. In addition, to the extent we need to obtain additional financing in connection with this process or with any additional clinical testing that may be required, it may be more difficult for us to do so given the volatility of the price of our common stock. Our material cash needs for the next 24&#160;months will include, among other expenses, (i)&#160;costs of preclinical and clinical trials, (ii)&#160;employee salaries, (iii)&#160;payments for rent and operation of our manufacturing facilities, (iv)&#160;fees to our consultants and legal advisors, patents and fees for service providers in connection with our research and development efforts and (v)&#160;payment of principal and interest on the 2021 Notes that remain outstanding and on the 2024 Notes we anticipate issuing in August 2021, and other debt. We believe that the funds currently available to us are sufficient to satisfy our capital needs for at least 12&#160;months.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As discussed above, we may be required to raise additional capital to develop our product candidates and continue research and development activities. Our ability to raise capital, and the amounts of necessary capital, will depend on many other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our efforts, combined with those of Chiesi, to file for resubmission with the FDA and to commercialize PRX-102;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the progress and results of our clinical trials, particularly the PRX-102 </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;text-align:left;">BALANCE </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">study;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">our progress in commercializing BioManguinhos alfataliglicerase in Brazil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">the costs associated with any litigation claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to finance our future cash needs through corporate collaborations, licensing or similar arrangements, public or private equity offerings and/or debt financings. We currently do not have any commitments for future external funding, except with respect to the development-related payments and milestone payments that may become payable under the Chiesi Agreements and under our agreement with SarcoMed. On July&#160;2, 2021, we entered into the Sales Agreement in connection with a new ATM program pursuant to which we may sell from time to time through the Agent ATM Shares having an aggregate offering price of up to $20.0&#160;million. On the same date, we terminated our former ATM program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Effects of Currency Fluctuations </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currency fluctuations could affect us through increased or decreased acquisition costs for certain goods and services. We do not believe currency fluctuations have had a material effect on our results of operations during the six months ended June&#160;30, 2021 and June&#160;30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have no off-balance sheet arrangements as of each of June&#160;30, 2021 and June&#160;30, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_49512cbc_1861_4c30_9041_f862bf58b610"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Quantitative and Qualitative Disclosures about Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Currency Exchange Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The currency of the primary economic environment in which our operations are conducted is the U.S. dollar. Most of our revenues and approximately 52% of our expenses and capital expenditures are incurred in dollars, and a significant source of our financing has been provided in U.S. dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are recognized in the statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Approximately 43% of our costs, including salaries, expenses and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S.&#160;dollar cost of our operations in Israel. If the U.S.&#160;dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations in Israel. A revaluation of 1% of the NIS will affect our loss before tax by less than 1%. The exchange rate of the U.S. dollar to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year&#160;Ended&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:63.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average rate for period</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.265</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.509</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.442</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rate at period-end</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.260</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.466</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.215</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S.&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due to the impact of inflation in Israel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Interest Rate Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our exposure to market risk is confined to our cash and cash equivalents. We consider all short term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase, that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents. The primary objective of our investment activities is to preserve principal while maximizing the interest income we receive from our investments, without increasing risk. We invest any cash balances primarily in bank deposits and investment grade interest-bearing instruments. We are exposed to market risks resulting from changes in interest rates. We do not use derivative financial instruments to limit exposure to interest rate risk. Our interest gains may decline in the future as a result of changes in the financial markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cbd581d0_a049_491c_8cb7_459cb0bf8bdf"></a><a id="Item4ControlsandProcedures_865226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form&#160;10-Q. The evaluation was conducted under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form&#160;10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based on the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form&#160;10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management, including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Inherent Limitations on Effectiveness of Controls</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company have been detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended June&#160;30, 2021 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_78afcf9b_5794_496d_a0ba_eea562432fc8"></a><a id="PARTIIOTHERINFORMATION_770480"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></p><a id="Item1LegalProceedings_676392"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1.  Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are not involved in any material legal proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_29405085_26a8_4630_a027_faae09a60641"></a><a id="Item1ARiskFactors_983377"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1A.  Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 18pt 0pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.29;margin:0pt 18pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><a id="_5a03379a_42ed_4eca_844e_dd82bc27af55"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Unregistered Sales of Equity Securities and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On June&#160;7, 2021, we issued 173,816 shares of Common Stock in connection with the cashless exercise of a warrant to purchase 2,816,901 shares of Common Stock issued on March&#160;18, 2020, as part of our private placement of Common Stock and warrants. We did not generate any proceeds from the cashless exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_eab5750c_6b3b_45a9_a2af_2ab07bed7b66"></a><a id="Item3DefaultsUponSeniorSecurities_505234"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Defaults Upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b676af25_620b_457f_b38d_cb2d140730e7"></a><a id="Item4MineSafetyDisclosure_204781"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Mine Safety Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_7199df58_6089_46a4_b796_743d39f95856"></a><a id="Item5OtherInformation_679200"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">5.  Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_1c2b11fb_4187_4aab_bea2_e3597a341b4a"></a><a id="Item6Exhibits_829552"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">6.  Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:6.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:15.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:6.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:13.5pt;"><td style="vertical-align:bottom;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:41.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration:underline;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Number</b></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File Number</b></p></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed or Furnished Herewith</b></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">1.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465921088982/tm2121219d1_ex1-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">At the Market Offering Agreement, dated July&#160;2, 2021, between the Company and H.C.&#160;Wainwright &amp; Co., LLC</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">1.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;2, 2021</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;1, 2016</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Second Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">October&#160;17, 2018</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.4</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Third Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;19, 2019</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Bylaws of the Company</span></a> </p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Restricted Stock Agreement/Notice</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">July&#160;18, 2012</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Indenture, dated as of December&#160;7, 2016, between Protalix BioTherapeutics, Inc. the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">December&#160;7, 2016</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of 7.50% Convertible Note due 2021 (Issued in 2016 Financing)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;7, 2016</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.4</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416138423/v454581_ex4-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of 7.50% Convertible Note due 2021 (Issued in 2016 Exchange)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.3</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;7, 2016</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420417038121/v471411_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">First Supplemental Indenture, dated as of July</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">24, 2017, by and among Protalix BioTherapeutics, Inc., the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee, and Wilmington Savings Fund Society, FSB, as collateral agent</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;25, 2017</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.6</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420417061920/tv480506_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Second Supplemental Indenture, dated as of November&#160;27, 2017, by and among Protalix BioTherapeutics, Inc., the guarantors party hereto and The Bank of New York Mellon Trust Company, N.A., as trustee, registrar, paying agent and conversion agent</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">December&#160;1, 2017</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032540/tm205240d1_ex4-7.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Description of Capital Stock</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.7</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.8</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920032169/tm2012488d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Warrant</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;12, 2020</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.9&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Stock Option Agreement (Executives)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.8</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.10</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Stock Option Agreement (Standard)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">4.9</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">10.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837021011566/plx-20210812xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Form of Exchange Agreement, dated as of August&#160;12, 2021 among Protalix BioTherapeutics, Inc. and the holders named therein</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt -5.65pt 3pt 1.75pt;">10.1</p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;12, 2021</p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="plx-20210630xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="plx-20210630xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="plx-20210630xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;" href="plx-20210630xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</span></a> </p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.INS</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">XBRL Instance Document - <span style="background-color:#ffffff;color:#333333;">the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background-color:#ffffff;">Inline XBRL Taxonomy Extension Schema Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background-color:#ffffff;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background-color:#ffffff;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background-color:#ffffff;">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="background-color:#ffffff;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:6.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">104</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;">COVER PAGE INTERACTIVE DATA FILE (formatted as Inline XBRL and contained in Exhibit 101).</p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="8" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:10pt 0pt 10pt 0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f99fdc85_6d4a_4710_930f_180d5c22febb"></a><a id="SIGNATURES_574709"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.9pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTALIX BIOTHERAPEUTICS, INC.</p></td></tr><tr style="height:10.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant)</p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;16, 2021</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr style="height:20.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style="height:17.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;16, 2021</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer, Treasurer and Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:458.2pt;"></span><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>plx-20210630xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 8/16/2021 11:16:42 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Dror Bashan, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:98.94%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;16, 2021</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>plx-20210630xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 8/16/2021 11:16:46 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Eyal Rubin, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 36pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 10pt 24.45pt;">a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;">b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;16, 2021</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President &amp; Chief Financial Officer,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasurer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>plx-20210630xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 8/16/2021 11:16:49 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended June&#160;30, 2021 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Dror Bashan, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.5pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;16, 2021</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>plx-20210630xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 8/16/2021 11:16:52 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration:underline;text-decoration-color:#000000;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended June&#160;30, 2021 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Eyal Rubin, Senior Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 24.45pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August&#160;16, 2021</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>plx-20210630x10q005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20210630x10q005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &?!#@# 2(  A$! Q$!_\0
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M?^]3:* '>8_]ZCS'_O4VB@!WF/\ WJ/,?^]3:* '>8_]ZCS'_O4VB@!WF/\
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M+BQ@FEB:*1XPS(Q!()'MQ5B@ HHHH **** "BBB@!5^\*M557[PJU0 4444
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M;5%<W#XI"6-L]S:R><\0EF"N@V*>_+<YQG R:U+/51?7<L4-O*8H^#.2NPG
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ML!L)P<YW=>GM6[10!!9QS0V4,5P\;RH@5FC4JI(] 22*GHHH **** "BBB@
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MOGZTV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBLK6/$.G:%):)?RNC74GE
MQ!4+9/OZ"@#5HHKG?$NI:E87VF#3\.K.[30X'[U%7) /8^E '145S9\1QQZC
M/<-.SZ>+%)XT1026+8X[Y[8K0TW6OMUR]I/87-C=*GF"*XVDLG3(*DCZCJ*
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M 4444 %%%% !1110 4444 %%%% !1110!6?[Y^M-IS_?/UIM !1110 4444
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M))SZFNDM].:#6+V^,JE;E44(!RNT>M7Z*+@%%%% "K]X5:JJOWA5J@ HHHH
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH K/\
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M5V%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKQ)(;5F^09 ( R3@#Z4_QE96X\6>#[,0K]F64H(\9&T%<"O0HXTBB2.- B(
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MYFVX.&X^7(/;- '345@MKUQ#>P6]S:V\'F;?G><A6SV0E,$CT)%;U !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5G^^?K3
M:<_WS]:;0 445 ]W&DA3!)'7% $]%1PS"9E"@C<">:6>3R8W8+O*_P (.,T
M/HK.N]8CL].DO'@D(CV[HP1N&<?AWJG:>*(+P@):3J?<K2OK8#=HK*N-=CMX
MR[6LQ ]"*RV\<6:9S8W7'NO^-#:6X'4T5QW_  L2PRP-A=@KU&Y/\:!\1-//
M_+C=_P#?2?XTN9#LSL:*Y(>/[ _\N5U_WTO^-'_"?V'_ #Y77YK_ (T<R"S.
MMHKCI_B+I]O"9&L;L@=@R?XTZ/XA6$D2R"QNP&&0"R?XT^9"L=?17(_\+!L/
M^?*Z_P"^E_QI1X_L#_RY77_?2_XTN>([,ZVBN67QS8M_RZ7/YK_C3'\>V"W,
M=NMG<O(_0*5X'J>:%),5CK**PX_$T$G_ "Z3CZ%3_6K<>MV3_>,D7^_&:::8
M&C159-1L9/N7D)/]W=@G\Z47:-)%&H+2.N[:/X1ZFF!8HJ&XN%M@A8$[GV<=
MJAO=1BLHXG96?S"  I&14N<4[7"Q<HJI#J5M/&&5^HS@TY+^W=<B0?3-8_6Z
M%[<R+]G+L6:*K27T$<6\N#T. >:6:[BACDDSO"1F0[>X':JCB*4G920G%K=%
MBBJ,>JPO>&V961@NXL2,=,_UIZ:G:S32PV[//+%]](HSE?KG _6MB2W151;U
MVB:1;&Z*J2#D*#QU_BJ1+H,8P\$\9D^[O3KQGL30!/1110 445C:[J.K6$EB
MNF:5]N6:8).V['E+Z_\ U^E &S2,ZI]YE7ZD"EKD_%\,4^IZ,DVDC54,DG^B
M_)\WR'GYR!Q0!U892,AEP>ASQ2UPATV2RM)9AIJZ7:37=OY5D'5MI#<MA25&
M?0>E6)?$VH1ZW"J7$5Q:2W7V<I'8R!$&<9\XG!/L!B@#LZ*XZSUG76%I>7%Q
M9FUN+QK40I;D,HW$!MV[VZ8J]X2:[CT2ZEO+D7!%S,01'M( 8Y[G/]* .CH)
MP,GBN4MM:UE; :Q<-926$T;R+;HI22/&=H!R=Y..1@8K/@US6;^RNDO;*X-M
M/:NXD;3V@6([<@;BQW@^O% '= @]"#]#2UPD-WJ5E;7DFF0L\A%L)&2#SFC3
MR^6"9&[Z9KIM"U)M1TGSY+B&:1&97=(FBP1_>1N5/J* -6BN)@\3ZC_:\$9N
M(KFUN2ZJ4L)(D0@$C;(Q^?IZ4A\1:W%HEC<LR37&HMB);:Q,AA49R=H;YSQZ
MC% ';T5C^']0O[[3I'U"UF@FC8J&EMS#Y@QPVPDX_,UC66N:VJ6-]>2VDEI<
MS/#Y$<!5U )PV[/)XZ8H [&BN2BUC6O*L[^::S-I?R>5'"D)#PYR%;=GYNG(
MP*M^%#?+X:WSS+=3[Y2GR;,X8\'D]Z .BHKB;3Q3J5M%>MJFT7$4+2K:/9/"
MX([*V2LB^_!IL'B77ELKR6>TFPMN98YIM.:!$;LO+'</?B@#N*"0.I ^M<HF
MJ>(+=I8)?LM[<RV?VF!(83'M;C*GYCNZ^U4H]=NKFP,5Y);SW*7,(,4]@T#I
MD]2C$CCLP- '<$@=2!GUHK@[&748Y )9[>YDDU21(FDM^8R!U!)/M5^7Q5<I
M9B9(D=[>V:2Z0+G]X#M"CTYYHZ!UL=;17,>'-8UB]O6AU"TN?*:/>L[V#6RJ
M?[O+-N^O%4[V_P!1TWQ'JUPEQ'*@BA2*%XR I8X!)ST'?CF@#LZ*Q--N]2AU
M>32]3FM[B3R1,DT$1BXS@J5R?SK/U+6]5L/$'ES%+73]RJCR6;R1R@]<RJ?D
M/L1B@#JZ*XU=9U^3%Q'/8>0]ZUHD;0'.,\,6![>F.?6IVUK4H--N8KB\M%O(
M;K[.)EM7?S!C/RQ*22WMG% '5$@=2!]32@@C(((]JX)-6N]4CMEO1F6VOS'O
M,!A+C83DH2=IK:L[\Z7X&BO$0.T4.54]"=Q S[4=+@=&2 ,D@?6BN+UEM:&C
MO'?SV$[.\,D+QH4*DL."N3D#^]WJT^LZE8KJ-K>WEE]H@,9CN!;/M(?MY:DE
MF].>: .JHKA8_$VM&VN8%>)[J*YBB2:>R:#<K^L9.1^=7FUG6+9Y]-EFM);X
M7"0Q7 @*H XSDID\CTSS0!UE%<1=^)-:TY[JRF\JYNUG2"*2VM"W!7);R]V2
M?;-2_P!N>(VT9G&GW*3),$>=M.8,8\??$&[GTX:@#LJ 01D'(]JQ=-U)M0\.
MRW+S07$BHX<I$R D \,C<@^HK"M=4UN> 1Z?+86L,%@MP5:VW GGY0 PP./P
MH [>BJNG71O=-MKIE"M+&'('0$U:H 5?O"K555^\*M4 %%%% !1110!7-C ;
M\7I4^>(_+W;CC;G/2L^?P[9F%_(B42D-M,C,R@L<G@$=_P JV** ,/3?#L=M
M,;JZ<RW)E$H(=R%(7;U8Y/'K6C'IMM#9O:QATB=BQVR,#DG.0<Y%6Z* ,L>'
M[((>9_-+;_/\YO-SC'WLYZ5-!I-I;3QS0JZ.D?EY\PG<,YY]>>]7J* ,R[T&
MQO;AIIEERY4NJRLJL5Z$@'DC%0:3X>ATX*\LCS2H[NN6;:I8Y)"DX!K:HH S
M[C1;*YN_M,D;;B074.0KD="R]#BF1Z!81,2JRC@J@\YL1 ]=G/R_A6G10!E+
MX?L05<^<TH??YS3,7)QCELYQCBK%II5O9SO.IEDE9=N^:4N0O7 )Z"KM% &9
M'H&G1&4K$P,L;1/^\;E6))[^I-/71-/6Z6Y^S@RK!]G!))^3T([UH44 92>'
MM/0$%)'Z!=\K-L .0JY/ S4CZ%I\DEVY@^:[*F8AB-VW&/IT[5HT4 9AT*Q^
MSK$L7"2/*@=BPW,"#D9Y')XJOI&A/8WSW<\H:3RQ$BJSE0H)/\1..O2MNB@#
M+F\/V$TK2[94=BQ9HY64L&^\#@]#Z4S_ (1ZS@LIX+2)5,J(G[TLXPO"]\]N
MH.>]:]% &!9>&HT6:2[E=[B5PXDCE<%"%VC#$YZ5IG2[4Z:^GE&-O(I5P7)9
ML]<MG.?>KE% &6OA^P7!9))&#J^Z25F/ ( R3T )XIA\-::T;(T<CH0%4-*Q
MV*"&PO/ R!6O10!GS:-:3W/GL)02075)659".A90<'&!4"^&]-657,4C*A<I
M&TK%$W## +G&#Z5KT4 9*>'=/3!"S%U961S,Q9=N< '/ Y/'O2-X:TUD>-HY
M&C92BH96VQ@]0HS\N<=JUZ* *%SH]K=2*TIF*#;F+S6V-CIE<X/05? P,"BB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M*S_?/UIM.?[Y^M-H Y[Q1JIL$MH VWSB22>F!69#K#(T@W9^;)P>.H%4_B1,
M\,^GLDC)MCE8@$C.,5S#ZE=K.XW12AE8E98QG /8C!KQL53FZDY1DT]#TJ$8
MN$$UW/5-$O8[S[G\&<X]ZLM@O,N\'YQD'C'6N ^'.KFYU:ZA;"@IE0"<<?7Z
MUT$^M6\=UJL1G D#C:&!&,9[]/UKIAB*L:$)O5V=_D<]2A'VLH+0NZQ EQIT
MEO(ORN\0(!P?O =:YF0C1]9E2V9WC1R/*E.>!Z-U'ZBMM;UKJ 1'L(7!^KBL
M7Q!',?$:.5:6"/S0Z @9RORC.,^O?O75"?M8*:T9S2BXRY6=7)%%?V"S1@E9
M%R,CFN5N-(+;P%Y%=E!-IFGVT5J\RHX3<$F;#,.Y&>OX53TFZMM;EN/]!EAC
M0X5\GYO;ZUI*SLGN39GEM];F&5N,$'!JFN0:])\5^%H8[![NU,NY?OJ3D8]:
M\[\IMH8$?E6<HV*3)%/%-+<TY0X'134+L0WW/UI6&5]3;-NB#JS 5;)V1JHZ
M 8JC<L#=6VX8 ;..YJ:68'H&_$$4/8%N.:7%"3<U1>8#N*1)OFZU%AW-.6]6
MWB:1CTZ#U-,TYFC=KJ<YGDY_W1Z5E"7[3<;V_P!5&?E'J?6I9;S:O!IO06[.
M^TBUU#4$6:*&06^[:9=N0/?'7'O72?V4=OF6=U)<1YP2L8]<'!R,XKS?PIXC
MU*35;'2;=@MM))B5.?G&<DGTXXKU2PL/-S]L*2[BLAQ&$PZG(Z>E73BFKV%)
MV9DW?E6^M1Z65DDF8!A*4XQZ@ 'I[FM^:[M-,L8I2!E>F!R215N\NXH$9 I+
M$8^G%<T@6ZFMYKLAH<(50^N.II5YJE!MNQ5.//*Q'JVI7#:<UP<JZ76P*.<?
M+G^M0)!J C2[O% MVME\O+?,&]QVXK0N[N("1E5502L['L21C^549K\SV/RX
MP>/TKCIU(2JQC&-_,WE&2@VS$TGPWK,MM/>2:HD!+L88.H9<\$GM69+IGB)+
M07,"2*\3G<DAY93W'/:M:#78E@6/S?F7*[0#G@U8CN[[4T9K0*8!E9-V<@XX
MQ7DQJ3K5.6%)+5G=*+IPO*78Q;N+Q-;^4C6<S(0,LAW#_P#75RPN];/VB66T
MN([9(RK&52..<]?P_.K=SXD19H8Y&=,!0=R'L?2KUEXBBN_-595?,/3OU]**
M7L_;+FA;7?[A5.?DZ,U=$D\SQ/<@+A1$.WL*V[)R^H78/1>!^=96CJI\37;)
MT\L<?@*T],(:[O&'7=C]37U"V/(9/ ";&;/=G_F:<RY-G['_ -E-,A<+I[DG
MJ7_F:1I1]ILTSV)/_?-+F2TN!-Y?EC&2>2<FDI%8N@8]32U0!1110 57FLH)
M[JWN9%)EMRQC.XC&1@\=^*L5D:OJ]U87MG9V>GB\GN@^T&81A=HSR2#Q0!H7
M=G!>Q+'.I9%=7 !(Y!R*RO\ A$=&^UK<^3/O27SHU^TR;(WSG*KG S["JH\5
M7$TEI;V^E;KJ9I$DBDN HB9,;LM@Y&#3X_%$Q>.XDTPII<DWDI=>>"V[.,E,
M?=SQG.?:@#471K%+>" 1-Y<$WGQC>>'R3GWY/2I+'3+73A.+9759I#(ZM(64
M,>N >GT%<W>:_J%U-I\D-G);V$M\L:7"SC,@!((9 . <<<FM*+Q&)+"RNC:[
M1<W1MROF?<P2-W3GITH!DUOX8TBVNVN8[4EVW85Y&9$W?>VH3A<]\"DMO"^D
MVGF>5#,0Z&/#W#N$4]0@).T?2J<?B+4+N)YK;1G^R2+)]GN/.!R5SRZX^13C
M@\UGV'B6XAM+2YU.&5IVLFE*QW&5D.\ ?+@#<<]>U &]-X;TR:)HVBE&[8=R
M3NC*5&%*L#D'%6['3+33[0VUO&1&Q)?>Y=G)ZEF.23]:Q+CQ3=V$%R+_ $CR
M;N*(31PQW D61<@?>P,$9Z8J_I6KW-Y?3V5]IXL[B-%E4+,)0R'WP,'U% $4
M/A'1H+F.X2&<R1$F+=<R,(P>H4$X ]A5F70-.FTR'3GA?[/#S%ME970^H<'(
M/O523Q!<G4)H[729+FSMY1%/.DHW*W?:F/F [G(J./Q/,TD<[Z8R:9+-Y,=U
MYX+%LX!*8X4GOG\* ->PTVUTVV-O;(P0DEB[L[,3W+$DDU&FC6*06T*Q-Y=M
M)YL0WGAN3^/6LBR\575Q+;//I/D65Q.UND_V@,=X)'W<=#CKFJ]YK^H7<MB\
M%E);V,MZL:7"SC=( <$,@' ...30&QL6WAK2;2^^V0V["0$LBM*[1H3U*H3M
M4GV%6;/2K2PMY;>!'\F5F=D>1F&3U R>!["N5CU[4&OK>.**0V+0W#R;[O,F
M58C(.W/':KT/B6Y-JILM+DNXK>!)+F22Z 9<C.!D?.V.>U'0#2M/#.E6;NR0
M2R;T,>V>=Y513U50Q(4?2FP>%M)MXIHTAF994\L^9<.^U?[JY)VCV%9\WBVX
M,MRUEI)N;2WCCFDF-P$.QAGA2.2/3-/?Q;G6UT^"TB<$(Q,MVL4C!AG*(P^8
M#ZT :]QHUA=-NGA+_N?(P7(^3T^O'6JT'AC2X(R@CGD)=7+S7#R/\IR!N8DX
M'ITH\0ZZ-"MH9/)CD::3RPTTWDQK[LY!Q^5-L]>>YN[.W>T$;7,+RDK.L@7;
MZ%>"#Z_I0!/'H&GQ7ANDCD$AF\_'G,5#XQD+G J2+1=.A-Z4ME_TUMUP"<AS
MC'X5DCQ1<7$<"6&E_:+N4.YB,X1516QG<1U/88JM+KNJ1ZQ/+!IL\L8LTE>V
MGF$7D\\\8.6_G0!N:;H.GZ3*TEJDN]AM#2SO*57^ZNXG ]A2W.A:?>7<MS/"
MSO+%Y4@\Q@KKVRN<9'8]:D_M /HZZA!"TH>(2+'O52<CH23@?6N?B\;CR+\S
MV<!FM(Q)MM;Q9T()QRP VX[\4/S!&[IFB6.DF1K6.3?)@-)-*TKD#H-S$G ]
M*BN?#FF7=\;R:*4R,0SHMPZQN1T+(#M;\12Z%J[ZQ9M.\,$>#@-;W2SQL/4,
M,?D0*H^,;K[+IMJS7=U:Q/=(LLEJS!]IZXV@G\A0P---&L4B6-8F"+/]H WG
M[_K_ /6J.Z\/Z=>)(LL<H,DOG%XYF1U?&,JP((_"N5^W3Q6>I2:5J&K7-BEM
MN\Z]WAEER,!&<!NGX5T>D:Q=75V;&^L/LLP@69")A)O4\9. ,'VYH#^OZ^\=
M:^%])LUVP02*/-\[F9FR^,9))YJ\FGVL>G?8!$&M=A3RW.<@]C5JN2N?$UUI
M>IZP]_%']AMA&(<3@?,W3.0,9[DGB@#4@\*Z1;Q.B02MO*DM).[MA3D $DD*
M/3I4]YH.GW[SO<1.7GV[V65E(*_=*D'Y2/45@P>.XI[*=X[:WGN8713%:WBR
MHP8X&' '/L15A_%.H1>>)M#V_99%6Y(NE(56Z%>/F/J./K0!>M_"ND6N\QPS
M;GD61V>X=RS+T))))-&LZ&MY;736L,#W-PRLXN'<*VWI@J<H?<54E\47:3W;
M)I!DLK241S3BX 8 XY"8YZ\\UTBL'564Y# $&@#F-)\(PQ6-U%J4:,]S()"L
M4\CF,@8!$C'>6]^*T/\ A&-*^Q"U\N< /YGFBYD\W=Z^9G=G\:R9?'UC%J[6
MF+4PK-Y#,;Q1-NSC(BQDC/?/X46?B34X_M:7%DD]P]ZT%I$EP #[$[> !WYH
MW#8Z*TTRTLK%K."-A"P.[<Y9FSU)8\D^]1V^B6%JKK%$P#PB!LN3\@[?KUJ3
M3;NXO+4O=64EG.K%6C<[AQW5OXA[U<H BMK>*TMH[>%2L4:A5!.<#ZU+110
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MQ"ZR+&P5 [[2"-W/J#GFNA.G637ANS:PFX(P9"@SZ?RID6D:= I6*R@0%P^
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MR, <YXQU%:%EX@UA;6]-_$\(CCWQW5WI[VZ!LXV[0S%O;')H ["BN&A\5ZG
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MUQ4EU%YK)K*&\-N8!"0[+N SOSP1Z8YJI%J/]FLDWV>*3;/=/EDRPP.Q[>]
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M:-+]Q>?:C;BU*H2(^0'QC.>C9Z57MM>U2[N8X1.RBY86T>(P"DB']ZW3T]:
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M:2X1Y4/DL,= HR@Y(PQ_K1?ZO=I?'_B8FWD&H10):@(1)"2/FP1GG)Y!]J+
M=?14:7$,A 26-B<X 8'..#^524 %%%% !1110 4444 %%%% %9_OGZTVG/\
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MWTFVDO1<N96(8.(VE8H&'0A>E7J* (C;0F>.;RQOC#!3Z9QG^52T44 %%%%
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M 1M#-=?9VD!+8/RQD@KZ9'XUT6I7-WHWAJ:?[2UU<QK_ *Z5%')/4A0!@9H
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MD61'+!75BIP<'.#0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNZ'G[.F"?;>*ZK0K:,31W!?]X@**1_=[9]ZU1FSL8-+BGTU(Y6F65HP&*OD
MXYQ7+ZW9PPW5PBR,PAP5W'))X']377P2_NA\U<KJUO=WFHZ@&BAC@95\F56+
M,3QG(QQW[UI$EG3:78V1TFU?;)N:)2?WC=<>F:\GU6[87+G;M1I#'L?[R@\'
MC_/6O3K.2:#38(G(8I&%W>N!7&^)+!KHM*D8+ [BJ@Y8CICW_G4.S&K]#EBH
M%G< ,IQ(B#:<C&0O]*AT]!_;]FS#!>X.,#K@XSUI';RXU4L%V#,HQDER>!Z@
MCTJUI[1G7X2T;XC;*;>@+'(S^=9RC9(N,M[G6WORS'_:9?Y&L'5_]4HR!G<.
M3[5OW@!G;/4.@'Y&N?U:,S20QJ<%\J.#CGCM2JZQ"GN;>M/!!X?2 -OEE\L!
MEZ85>OZ5F^'()I-7CDC5Q$KMYKA> NP@YI/$#*(;")&!5=X&.F -H_E4_A_5
MF@,EDXE;S"XC*MPORDGC\*QGK629K'^&RCX%T:.X-]J"*Z26ER%.\Y#@DG@8
M&#@#J:FG+274S"VM+C#\C=M..?<5TWA?39]%\(W#7.5GNIGN-IZA?X0??_&N
M+NB?.ER/^6F?YT8E\D4.A%2DR6^N+42C?IWS,<CR[A@$'H.N?QKIO"&FPOX<
MEO[9'BA<'<DC[CD#UQ7,66GRZIJ,MNL@7;EMS D# X'YUV_A;1KS2=!O+6ZE
M0Q/S&R-T.WD_RHH2;ES6'6BHQY;GGT0T<>26^W.Y.3M9?E/H<@?I4T7]DPO&
M(!>R9'&60 <?3ZUEH!]H4 [AN;GUZ\T^W.&C]E;_ -!K!SUV-G'0MW:P)/+@
M3G]T."RCCCVZU5>6 6YVV[']VWWYB?Y 58NH\1I-NW!X5!]01BJ,G_'N/]QO
MYUIS69G;09XL'[G0T3CM^BU8\0(9TL=15@KRKY4JJ<?.AQG'N,57\2D_:-#7
MW'_LM%X YO%7'[J59 /8\&NJ6QSQT:*T#/\ -EW.(S_$:L6XD<PC<W+-DECC
M''6H+56D9E498QX %77*Q6D,41#!BQ=P/O8[#V_G7*FS>1[#\'3&=)U(1+\J
MS(-QZO\ +U->E5YI\&E*Z+J!Q@&9"/?Y:]+KMCLCF>X44450@J%[6"6XBN'B
M5IH@1&YZKG@XJ:L/6;W48]6TVPL)H(?M7F%Y)8?,VA1G@9% &DNFV2)"BVT8
M6%R\8Q]UCG)'UR:IP>%]"M;G[3!I5K'-N+!U7!!/7'I7/VGBC6KK4U>.PN9;
M,SF$HFGMM"@X+^=NQGOC;BI[;6M;$4>HSS6;V37C6Q@2$A\;]H;=GK[8H Z2
M#2[&V.8+6.,^7Y/R@_<SG;],U%_86E%HF-A 3%$84RO1#U7Z?6N>MM9URXM8
MG%Q9B2\NFM8 ;<XBVL<LWS?,<#IQ4IUK5UG;1S):'4/M"PB[\DB/:REMQCSU
MX/&:-PV-2V\+Z#:;Q;:7:Q[E*/M!R5/4'GI5S^RK#R)H?LL?E3X\U></@8&?
MP%<KIE[J%CJUQ#*\#RSZHD,[I'@,/+Z@9^4_G5R;7=1DO9;"U>W2=[[[-%+)
M'N6-0FXD@$;C^(H_K^OO UM9TB+5H[2&8Q>3#,LCQR+D.H[5+!HVF6MO!##9
M01Q0/YL2J,!6_O?7ZUR^M75]Y M]02QDN!;W"F6)<D@+P1W3/<<TZ74-4L-,
M%O?FRNHI]/,L2K 0$VJ/E8$G>,=^*/Z_K[@L=)/HFD76HI?S6-K)=IC;*R@M
M[?6DNO#^D7MX;NZTVWEN" #(R?,<=*Y2*X=;H^7';AY;N$!FB#",F'JH[8JS
MH>IWVEZ/92ZC<QSVTJ2X?RMI5P20"<G.<&C8#HI_#VCW-XUY/IMO)<, &D*\
MG'2GOHFEOJ:ZDUA;F]7I,4^;_P#7[U)IDMQ/IEO-=[?/D0.P5< 9Y _+%6Z-
M@*$&BZ9;3&:&RA20NS[@#]YA@G\:CMO#VCV;3M;:;;1&X!$I1,;@>H]A]*TZ
M* *ZV-JDD$BP('@39$?[B^@K,D\,6-UK-QJ%];P71<H8E=,F,K[]ZVZ* ,N]
M\-Z+J-U]IO-,MIYMNW>Z9.*LQZ98Q+,J6L0690L@QD. , '/M5NB@#(M_"VA
M6@;[/I5M'N4HQ53DJ>H)STJ^;"U+ES FXQ>23ZI_=^E6** ,RZ\/:/?" 76F
MV\H@ 6+>OW0.WT]C4SZ/ILEP9WLH&D,7DEBO5/[N.F*NT4 9=OX<T:TMI+>#
M3;>.*0AG55^\1R,GK6E)''+$T4B*\;#:RL,@CTIU% &9#X<T:WLYK.+3+9;>
M8YDC"<-]:DM]$TNTMXK>WL8(XHI!(BJN,/\ WO<_6K]% %"ZT33+Y)TNK&"9
M9V#2!USN8=#]?I31H&DK;6]NNGVXAMWWQ(%P$;U'O6C10!DP>&-#MKK[3#I5
MM'/N+B15P03UQZ5<73;)(X(UMHPENVZ(8^X?45:HH K6>GVFGI(EI;I"LCF1
MPG0L>IJS110 @ 48  'H*JMIED\<T;6T92=Q)*#GYV]35NB@##UGP\E_9M!:
MI91[Y?-E2YMS*DA]3@A@?<$4_1/#EKI%K$A2)YXW:0.D>Q5+==JYX'YULT4
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MT4S.BE%?)X!ZBIJ //[>]GMM(C6QOII6\EC/&<'R2&&W Q\O?ZU%>-</:W$
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M#2O;P:=:I&NG&?SY_.E=W4@YP@/ !/N,5T5% !P. ,#THHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** %7
M[PJU55?O"K5 !1110 4444 %%%% !112&@!:*;D9J-[B&)@))40G@!F S0!-
M15:&]MK@D0S+)@X)7D?G4@FB,GEB1"^,[=PS^5 $M%9]QJD,4[01K)<3J 6C
MA&XJ#Z] *?::C!=LZ#>DJ<M'(,,/Z?E3LQ71=HJI=W]M9!/.D :0[40#+.?0
M <FJ8NM7N2?(L([=.SW4F6_[Y7/ZD4K V:],:14^\P ]S65+'=QKOO-6$8)P
M%@A"Y/H,[CFGVUI+YOF!-H_OW#&20_KA?I3L%S4!R*6FH&5<,VX^N,4ZD,**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH K/]\_6FTY_OGZTV@#R#XVI/+=:
M'%"DC[EFRJ*3GE?2O+[?P]JTD,F;&6)?-4[I\1+C:W.7(KU/XU7EY;S:)':7
M<L!=9MPCE*%_N^G6O&COD2=IBSN)$R9"2>C>M<U2W,S>%^4V] M!;>)8@UU;
MN^<;(I-Y'XCC]:Z#Q)J@N;C[ 86+VJ*WF$@*03TXY/6N2\-_+XEM_J/YUOZQ
MQXDO?>V4_J*F3_=#M^\&FZ=[5,1H Z21 *N<# [GGO4\R :'/G_EG<1M],J1
M52$;K>)<D8\W! R2=HP*VEM&DTZXC?CS)X4!([X.1CUHI7G!HFI:,C)N7$7A
MRV(&[$!8*3@9+ =:Q;-9;N73)7<R*B7;R. <#C;QZ#G%6++4VOK#4EDM1)#9
M6NT(^5R/-ZY'.<59T^UO[N*SATR!5MH7=I81+P&/3<3U//3H*[(QLC!N[-/P
ME;+-:))M(0*JJK @C Z'->A:?;8 PM96EZ8840,H!P-P!SS]:ZFUB  H0@>
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M5T.KA1XIGW@E3;#('>L#3G8ZWIQ?&5;:,#MN!'\S70Z]@>(GXQF#[V?8T/\
MAA]LSRS+8QLAPW[S'UP*[6>$+86<6[<\MPD^%Z@# S^IKCH$W1QJ02%\QV]
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MQVUP>) &4G[H(R.?6JIPO&S)J2]ZZ#0[]-7?4DM8!;VPM&\IF'[QBO<G//\
M3-=C:P_;H84("I<VA5F4<J>"O/MDUPGA!HDU>Y8#:DMC)\Q_B)/'X5Z-HK*+
M&QCW+O\ +!QGD@8']:W226ADW?<MZ3IZ65JD*%V"#&YSDD^I-:B1^U.AAVC
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ML?R'%3@5RW-K7W(H;6"W7$,4<8]$4#^52XI:*104444 %%%% !1110 4444
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M?W>O2K:VENMS]I6)1-L$>_OM':IJ* "BBB@!5^\*M557[PJU0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 5G^^?K3:<_P!\_6FT %!&1@\CWHHH 3:O]T?E1@>@
M_*EHH ,>U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 &!Z"
MDP/0?E2T4 )@>@_*C ]!^5+10 F!Z#\J,#T%+10 F!Z"C ]!^5+10 F!Z"EH
MHH **** "BBB@ JCJ6D6>K1HEVCDQMN1XI&C=#[,I!%7J* ,ZTT/3K%@;:W\
MO$)AX8_=)R?Q)YSUJK-X2T>X2-'@F"QQ^5M2YD0.G]U\$;ASWK;HH SK70["
MS0I!$RJ8!;D&0GY!T'/UZUA:UX3FNY(HK*"S^S+ (-TEQ-&ZKZ-L.)![-BNN
MHH R(?#FGQQ0JZ.[QI$F_>1GR_NG'UIFLZ&MY;736T,#W-P4+BX=PK;>F"IR
MA]Q6U10]06A@^&="DT:.ZDG\L37+AF2.5Y0N!C[[_,Q]S4>E>%+6TE-S=IYE
MS]H>9=LKF,9.0=GW=P]<5T5% &:V@Z<^G/8/ 3;O(9<;VW!R<Y#9R#GTJ)?#
M.E+I\EE]G=HY'#N[3.92PZ-YA.[(]<UKT4 8H\*Z0MG-:B"79*XD9O/??O'1
M@^<@^^:</"VD"SEM1;OY<KB1CYS[PXZ,&SD'WS6Q10!DKX:TM(((DAD402&5
M'69PY8\$LV<MGOFF3^%=(GBAC:"51$"JM'.Z,5)R5)4C(SV-;-% %&+2+&!V
M>*#9NA$!"D@!!V [4KZ39OI:Z:T;?954*%WG. <CGK5VB@"C<:/87<LTEQ!Y
MC31"%PS'!0'.,?UJM!X:TJ"VGM_(DE2<;9#<3O*Q Z#<Q) 'M6O10!D0^&=*
MAM9[;R))4G $C3SO(Y Z#<Q)&.V*9'X3T>.*>,0S-YX42.]S(SG;T.XG((]<
MUM44 4M.TJTTN)TMEDRYW.\LK2.Y]V8DFKM%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 *OWA5JJJ_>%6J "FR<1MCT-.H(!&#TH8'E&F7-_
M;W&GWLAOXHY+O8]R^IF9) 21M\@GC\N*UT\=WXU6=3!;SV7ES/$8HW4YC_VB
M?F]_E&/>NKM_#.A6EX+RWT>QBN021*D"ALGOG%2QZ%I,-TUS%IEHD[,6,BPJ
M&)/4YQ0!QNIZWK\N@K*-2TF.622%U^S%]ZHQZ,N[I[YY]!4T?C+6&\0M9BPB
M>SCF^SO( %);&=P)?_QW:>.]=4GA[1HK:>WCTJR6&<YEC6!0KGW&.:>NB:4M
MXMXNG6@N538LPA7>%],XSB@#D8M?U6;^R+[4#:I%-+*56$R(%55/+?,0W3T.
M*N>%O%6H:QK$UI=QV_D^2)X9(HV3@G&/F))'O@?2NF&EV 2%!9P;8,F(>6,)
MGKCTJ.ST72].E\RRT^UMW((+11!2<\GI0!RT_C*_3Q0ME"EK+8M.]ON$;[E9
M5S]\D GV"_C45KXPUJ.VBN[VWLI()K26>-(%=6!3U))X/Z5UK:%I+7C7;:;:
M&Y9@S3>2N\GUSC-2QZ781"()9P*(E*Q@1CY0>H'L:.@=3D]!U/4[WQ:GVZ[M
M9%?3UE$=HS!!ECU4D\^])J=MJL?B5='M[^5;'4F^T,YE;S(0OWD0]@>/IS74
MV6B:5ILIELM.M;:0C!:&)5)&<]JLO:V\ES'<O#&T\8*I(5^90>H!I]@.)B\9
MZD/$$EJ-/0:9#,UN9'(##:,[BQ?)Z=-OXU7MO'6L3->*+>RDQ;B>V;:T2G+8
MQEV^;V^[FNW.CZ:=0-^;"V^V%=IG\I=Y'IG&:AB\.Z+ '$6DV2"0%7"P*-P/
M)!XYI <9)XCUO4(M/1;NUMKA-06&X40R)D%<@,I;CCT8YXYK>\1RR3:OI6FS
M7DMK9W(<R20RF)I& &$W#D=SP<UK)X?T>.R%DFEV:VJN)!"(5"AAWQCK5F\L
M+/4+4VUY:PW$!ZQRH&7\C0!Q>H:_/H%M;V&B73ZO)++(/,G<3&(+R4SN7)'J
M6S]:S[_6]0O%NKIGFM7>QMG\J.8X1C+@X(..?45WCZ!I$M@EA)I=FUHARL!@
M4H#[#&*D?1]-DSOL+8@HJ',8Y53D#Z TPZ',^-9+DQ:+%!]I<RSD/%!=FW,@
MV9QO!&*JW&KWGA3PY%>BU* SE9+:[OFNI&R."KY. .I'IFNPU#2-.U6%(=0L
M;>ZB0Y5)HPX!]@:AM?#NC66P6NE6<(0L5$<*C!(P<?44@[',7WBC6H)#'#<:
M.3%IXO':17Q)URJ?-TXZ\TC^,-7%KJ>HK;VOV.SC0K"4;S&9U4C)W8 !/I^5
M;I\'Z,VH+<O90/&D2QQV[1*8TP200,<'FM86%HHG MH<3_ZT;!\_&.?7B@#A
MD\8>(GTU@;"VCO!.(\L%Y4KG(B$I)/MNZ<T77C?5196=S;)8-&83)=/M=]I5
ML$;<AT'!^;#5UP\.Z*-/-@-)LOL9;<8/(79GUQCK2S>']&N(K>*;2K*2.W_U
M*M I$?\ N\<4 <M+XFNK>]O?LH@+W%U##%)/(YB3='NW$$]/88S3H_%.MW,]
MO86ZZ=]K-W+:R3E7:)MB@[E ;/X9_&NMETG3IDG26QMG2XQYRM$"'P,#/K1#
MI.GVZ6Z0V-O&MMDPA(P!'GKMQTH J^&M4N-7T.&[NHXTG)97$>=N02,C/TK6
MJ*VM8+.$0VT*11@DA$7 R>34M !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 5G^^?K3:<_WS]:;0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !116-KLNO126(T6WMID:8"Y,QP53VYH
MV:KW>H66GHKWMY;VR,<!IY50$^Q)JQ7,>*8;F?4]%2TCLY)C-)A;Q2T?W#U
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M0!V]%<1_:FK"/3M0.KY2]N&1K41( @&>%.,]N<U-I%]K"OHUS>:HUS'?LR/
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M/R1XZ'@9W8YZYJ."345_LZ><7EQ<[(P8'$L9'."0P^7/<A_2NWHH !THHHH
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M>H733M=2(6B2/ 0'[K!L_I4.N:*9OME]$MQ//(D82* JKH4.0REN"?8UT-%
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AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>plx-20210630x10q006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20210630x10q006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '3!#@# 2(  A$! Q$!_\0
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M/&>IK?D\,VLVIB\EO-0DC$PN!9O<%H!(#D,%(SP><9Q[46?AFUL+U9X+S41
MCEX[,W)\B-CDDA>O<\$D>U)=+@[:G/76J:MJAT.^>*UBTRXU6+R5C=O.4 N
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M:&*5)+Y95$^\ D+*H*(5SCYNIJO<:WK>F:MX@E#6ES&M[:06\3[P%\P*!SG
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MK9=UQ]H=9RY#,>I#*=RGW%;M%"D[W!Q35C&\/Z,^DI=M*T7F7,OF%(<[$ &
M 3R?J:V:**&VW=A&*BK(****0PHHHH **** "BBB@ HHHH **** "BBB@"&Z
M_P!4/]X40_=IMY_J1_O"E@^Z* )Z*** "C)]:** #)/>BBB@ R?6BBB@ K*U
M308=4G29KW4+9PNQOLER8Q(N<X8=/7D8/O6K10,BMK>&SM8K:W01PQ($1!T4
M#@"HM2L(=5TVXL+DOY,Z%'V-@X]C5JB@0#@ 9/%%%% !1110 9/K1D^IHHH
M**** #)%%%% ",-Z,I)P00:KZ=8Q:9IMM86Y?R;>,1IO.3@=,FK-% !D^M&2
M:** "@\]:** *MEI\-A)=O"7S=SFXDW-GYB ./0845:HHH&&3ZT9/K110(**
M** $8;U*G.",&J^GV,6F:=;V-N7\FW01IO;)P/4U9HH **** "ER?4TE% !D
MFC)]:** "C)]:** "C)'>BB@ S1D^M%% !D^M%%% &=JNCQZJ(BUW>VLL1.V
M6SG,38/4'J"..XJQ86%OIEE':6RLL29/S,68DG)))Y))))-6:*!BY/J:3)-%
M% @R1WJ*YA^TVLL'FRQ>8I7S(6VNN>ZGL:EHH&5K"Q@TVQBL[8,(HQ@;FRQ)
M.22>Y)))/O5FBB@09/K1110 9)[T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 /A_U@HHA_P!8**3+B6"JMU&:3RT_NBG44AC?
M+3^Z*/+3^Z*=10%AOEI_=%'EI_=%.HH"PWRT_NBCRT_NBG44!8;Y:?W11Y:?
MW13J* L-\M/[HH\M/[HIU% 6&^6G]T4>6G]T4ZB@+#?+3^Z*/+3^Z*=10%AO
MEI_=%'EI_=%.HH"PWRT_NBCRT_NBG44!8;Y:?W11Y:?W13J* L-\M/[HH\M/
M[HIU% 6&^6G]T4>6G]T4ZB@+#?+3^Z*/+3^Z*=10%BI?(@@'RC[PI;>--OW1
M1?\ ^H'^\*6V^Z* L3^6G]T4>6G]T4ZB@+#?+3^Z*/+3^Z*=10%AOEI_=%'E
MI_=%.HH"PWRT_NBCRT_NBG44!8;Y:?W11Y:?W13J* L-\M/[HH\M/[HIU% 6
M&^6G]T4>6G]T4ZB@+#?+3^Z*/+3^Z*=10%AOEI_=%'EI_=%.HH"PWRT_NBCR
MT_NBG44!8;Y:?W11Y:?W13J* L-\M/[HH\M/[HIU% 6&^6G]T4>6G]T4ZB@+
M#?+3^Z*/+3^Z*=10%AOEI_=%'EI_=%.HH"PWRT_NBCRT_NBG44!8;Y:?W11Y
M:?W13J* L-\M/[HH\M/[HIU% 6&^6G]T4>6G]T4ZB@+#?+3^Z*/+3^Z*=10%
MAOEI_=%'EI_=%.HH"PWRT_NBCRT_NBG44!8;Y:?W11Y:?W13J* L-\M/[HH\
MM/[HIU% 6&^6G]T4>6G]T4ZB@+#?+3^Z*/+3^Z*=10%AOEI_=%'EI_=%.HH"
MPWRT_NBCRT_NBG44!8;Y:?W11Y:?W13J* L-\M/[HH\M/[HIU% 6&^6G]T4>
M6G]T4ZB@+#?+3^Z*/+3^Z*=10%AOEI_=%'EI_=%.HH"PWRT_NBCRT_NBG44!
M8;Y:?W11Y:?W13J* L-\M/[HH\M/[HIU% 6&^6G]T4>6G]T4ZB@+#?+3^Z*/
M+3^Z*=10%AOEI_=%'EI_=%.HH"PWRT_NBCRT_NBG44!8;Y:?W11Y:?W13J*
ML-\M/[HH\M/[HIU% 6&^6G]T4>6G]T4ZB@+#?+3^Z*/+3^Z*=10%AOEI_=%'
MEI_=%.HH"PWRT_NBCRT_NBG44!8;Y:?W11Y:?W13J* L-\M/[HH\M/[HIU%
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MUH<;%TJ\:OP_\#[R6BBBD;!1110 4444 %%%% !1110 4444 %%%% !1110
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M1>< H,D6X;<C@<<Y/O[4 =;17*3>-4L]+EFOK,6U[%=?9#;R7"!-Y7<#YAP
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M@C< K@8.0>O48-'6P'=T5RD/B*6-'M[.RN+V]EO+E(XI)U "QM\S%B/E49
MP>N*&\87$LEI;6>CRS7TQGCD@>94\F2+;N!;D8^88(]J .KHKFFUUY]+T_6$
M22!!<BWN;=B#MW/Y;9QW5L$'_&I-<U74;+Q!HEM;0J]K<22>>QD"\!<]QV'S
M>^,4 =#17-67BJ2YN+1YM+E@TZ^?R[2Z,BG>2"5W(.5#8XZ]NE6-;U0:=J5F
M2LS?N+F7:L@5&V(#AACGV]/>@#=HKDX?%VHW'E)'X>F\ZYMQ<VJM<( Z<;MQ
M_@QN&.N<]J</%US=/:1Z9H\MU+<68NPK3+'L&[:5)/?T]: .JHKF(_%S7=W9
MQ66G/(D]L+J1Y)1'Y*!]K[AZ@]AUI;7Q5<3R6SR:1+#9WV193M*I\QMI90RC
ME-P''7\* .FHKG6\76J6=I=-$PCEM)+N?YN850#(/J=QV_G47A_QG;ZWJ)L6
M2".9HS+$(;N.?*C&0VT_*W(X_6CR Z>BN2NM9U.R\4:G%;6,U_#%;02&-950
M1CY]Q&>K' X[XZBG-XH@CO)[B".ZN/.M[5K>$. )&E+;0 ?NGCDD]![4 ]#J
MZ*Y&[\07D\(MIK:33]0AO+02QK*'#1R2  AAU!PP/TJS_P )9(+CSO[,E_LC
M[1]F^W>8OW]^S.SKLW<9_2@#I:*Y>3Q;.LZ/'I,KZ?)>+9I=>:HRYDV$[>NT
M'.#WQVJ.V\23):P6]C97%]?3S7.V*6X482.0JS%R.!G  Q[>] '6456T^[-]
M80W+6\UNTBY,,R[70]P15F@ HHHH **** "BBB@ HHHH Q=5\.IJ>H)>K?WE
MI,D?E9MW"Y7.?2FQ>%[2*Q%MY]P[?:5N7F=@SR.IR,G\*L:KKUII+Q12)--<
M2@E(($WN0.IQZ5)I>LVFK0220%T:)MLL<J[7C/H0:I.5M#D<,,ZK3MS/_+_+
M\"I<>&+2XGG/GW"6]Q())[9& CD;U/&1G'.#S4DWAVRN'U RF1EO1'O4'&PH
M,*5]#6E-<16\$L\KA8XE+.?0"H(-1CN1:O#%*T-Q'YBRX&U1@$ \YR<TKLMT
MJ*=FE=_\-^OXF;+X=C%I>M(TNH74\'D[KB0*2O900,#GG..M9NE:'J$NI)/>
MI<11QV;6Q,\R2,2V/N[>  .YY-==O3^\.F>O:HY;CRYH4$,CB4D;UQM3 SD\
M_P LT^9DRPU)M2[?CKUZF2WAF 0VH@N[FWFMX/LXFB8;FC]#D8K6M;9;2UBM
MT:1EC7:&D8LQ^I/6I!(C' =2?0&D:6-49RZ[4&6.>E)M]36%*G!WBA]%4;75
M8;V*TFMHY98;G)$@  0#NV3D9J[N4MMR,^E)JQ<9QDKQ8M%-WJ3C<,].M.H*
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EJG_'JO^^*+/[@I-5_X]5_
MWQ_6BR^X* +U%%% %/5;$:II%Y8&3RQ<P/#OQG;N!&<=^M9&G:-XBLY;<3^(
MX)[:+ :(:<$+*!C&[><?E71U%/<16MM+<3.$BB4N['HH R31L&^AR6I>%);?
M2M1N;:YEGU"XM+A+O$?_ !^%E.T8S\I4X"]<#CO4MCX2DNK1!K5_+>)]B-K%
M"8EC,*NH#Y(^\W &>/I721W]M-<_9XY5:7REFV=]C$@'\<'\JAU#6+73%D>Z
M\U8XXQ(SB)BH!8+C(&,Y(XZ]Z/(##@\(72V5[:W.KK,D]L]M'LLHXR@88W,1
MRS#V*CVJY?>%H-16SCN)V,,%G+:.@7!<.JJ3G/!&W/>M[(QFHKJZ@LK66YN9
M!'#$NYW/0"@+',Q>#[HV%]:76KK,EQ;/;1E+&.(H&&-S$<LWT*CVJ_?^&(-1
MGC:XF8PC3Y;%XPN"ROM^;/8C9^M;@8$ ^M+GF@$<H?"%U=V<L&J:[<79"(MN
M1"J+$48,KE>0[Y R3QC(P,U)'X3G?3;B"\U027#NDD,UO:1P"%D.Y6"C.3GK
MDD'T%=/1GG% &'HVA76G:C>:A>ZF;ZYNHHXW/DB-5V;ON@$X'S=/UJ.+PNL>
MJQWWVLDIJ$M]L\OKOB\O;G/;KFN@SS1D4 <W)X4?[2+FWU#RIEU-K]280PPR
M;&3&?3//;/2H['PC)IVHJ]OJ2KIZ2F5;;['&7!+%MOFGG;D^F?>NF>01QLY!
M(4$D*,G\!WIL,RSP1RJ'42*& =2K#/J#R#[&A 8-OX56#3;"S^V%OLFH&]W^
M7]_+NVW&>/OXS[5#JO@[^TGOI5OA')<745T@>W$B*R)LPRDX<=^W./2NBBNX
M)KB>".0-+ 0)5'\)(R,_A4V10'6YR6F^"6L7:234O.9KZ*].VV6, HFW: IP
M!_+WZUI:UX=&L7/G&Z,7^@W%G@)N_P!;M^;KVV].^:U+F[@M(A+/($0NJ GN
MS$ #\214]&_]>5OR#8Q+GPXEU/;N]RP6*PELBH7E@X4;LYXQMZ>]97_"%721
MVKPZO$MY%;K;33/8I(LJ(3L^4GY6 .,YP?2NGN;Z"TDMHYF(:YE\J/"DY;:6
M_#A35G-']?U]X>7]?UH8<'AN*+49KF6X:9);!+%XV0+N +$L2N!SN/  JA;>
M$+N*ZLGN-<DN(+%)(K:)K=5*HR;!N8'YF QSQ].]=7FC(H>H'&7G@26\TRST
MQ]51K*"V2W>.6Q20_*,;HV)S&QQ[X.,5=G\*7 OYI+#6;BRM;HHUU"B N[*
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MWU[5YI#)#=_V[8V\T<EI)I#S&*VOY;E3*K9!WMWZ9"\>M>N]13%AB0 +&B@
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M9HM1MO.EU-?#YEB8S.V9-S*.,X/'8]_>O42JD@D D=,CI2+&B$%448&!@=J
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M]>M)@<YK<CQ^&M-*.R$W-F,JV.#(F17.I9&1([W[;>K/+KLMJ66Y8 1-(P*
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MDCN2)#"X;>#PISG&,<5HVL]SMNH)TNI1X=M)H6\LE7FD880J>Y\H Y[%J[W
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M4.H"_AN;VZDO9;>1D660Q9*\'(7H,>@%0D6UO;QV6IRS+X?MM3NX)"TK[5
M,2NP.=H);OZ5Z,% Z #\*7 QC P:0CEO!&S^R=2-JTCQ_P!I7'E&;.XC(VYS
MSZ=:YG3IK#^TO#RQW%P=?>\/]HQR2/G>$?[ZG@8/W>G%>GXK%L_#5K:7Z71N
M[^X\IBT$5S<;TA)!!*C&<X)').,T=A]&<+X7^V/KUG)-J5JNIEV^VP!;AIV&
M&RL@)**.F#@#@8J]H>GK8V?A74K=YS?7<KQ3N\S,)%*2$*03C (7'TKT;'.>
M])@<<#CIQ0%SRWPO]K?7;-Y=2M1J)9OMT 6X,[##960$E% /0X X&*?%'96/
M@32)KE"S:@1]IGN;N6.(;0VWS"N3CL%&.<5ZAWSWI,#&,#'IBBV@7/*-/6SN
M=-TZ6_*M:VGB QHV^0)%&R94 L=VW=MQG^1JY"]DWV=?$4TB:.9;W!:1UC,X
MN#@,5/\ =^Z.G6O2\#T'Y48&,8&/3%']?@']?G_F>>:9IO\ ;>HZ/;:J;N6U
M^QW3(DLCHTD?G*(R^""3MP>?:MC3)9G^&DYDDD>1+2YC#LQ+$+O"Y/7. .:Z
MSOGOZT8&,8&*&M+ G9W/+Y+%;C3-;OWEN1<V=I926S),R^6_D*=P ."?KFK7
MB"SCTF'7K>UDN8X'MK.=L2NS>89\,P)).X@=J]%P/0?E574M.@U6Q>TN"XC=
MD8E#@_*P8<_4"F]7<$>>:@;/[!K2Z!<7!TPQV^]UE<A;@SC.UFYW;?O8[XK2
MU>TT/3=9-EK#S6VE1VJFP432A3*68R$$')D^[@$_2N\(!SP.3GI1C/6E8#SU
MY]6L=+T]Y?/-]K-DMB=P.4GR=CMZ'8S9]UK*U>"Y@\075O)J-M9S0.D>G>=]
MH:7RPJA3$$.ULG.>"<YS7J_6CN#W'2GUN'0\P\4&R9->&J33C60P%FBLX!@P
MGW5'RE2=V[/2NH\;,BZ)9&62:.(W]N)&A)#!<\XQSTKI\ ]0*JWVGPZ@D"S%
MP()TN%V''S*<C/M2[?(1Y[-':S6[P:3-.VAR:K9)"RROC))$H1B<[>G?J34F
MKPZ7976JVU[)<P7ENBKHD<<L@(41C;Y8!^9M^<YS[UZ/@8Q@8I?3VHZ#N>8>
M(FMVMM9&O2SIK'V1?L2([@%?*&[8H^4_/OW9S5C5M2BTZT\5VD\SI<W=G$]I
M&-V7'D!25]@0<XZ5Z/@'J!1@'L/2@%I8\[OY+ :S>'6+F^BOD\@Z4+9FWE-B
M_P"J7[K,6W!LYXZU0NK+3K>UUV 7<=DZZR6F2<RF)XRN4$A4Y522Q!SU KU/
M'Z4F!SP.>O'6@%H<SX2U.W_L.UBDQ!YEQ)!; SM*LV.<QLPR5QG&?2DU^QAU
M+Q9H5I=>8ULT5RTD:R,H; 0C."._-=))!'*\3.N3$V].>AP1G\B:DP,YQ3$>
M5Z;]N?Q3$]QJ5I#JPOB)(BMPTYC#GY=H.S85QSC ZYS4E]<6BZ?9VE['$(GN
M+QP]U<2Q0Y$Y 7$8R[^@],UZACG/>DP/0>O2E;2P[ZW/+=*"SQ^%;ZX)>^^S
MWD$$DK.,RJ?W2\GKUX//KTIOA?[<=0CDMM2M6U$V\ANK=%N&F=]AP)=Y*J0^
M,' ]!7JF!Z#\J7U]^M%@/-M$.E-XA\-FQFN)+XB8Z@)7=B)O)YWAN%?.>!CB
MK_BRW6+Q3;WD"[=2?2[E+-]S9:88VA1G!;:6P*[K SG HP#VH>H(X7PZ^F?\
M)!9#P]/<2Q-;2'4MTCN ^%VE]W23=GCTSQ7=48Q13$%%%% $D/\ K111#_K1
M14LI#KC[R_2H:FN/O+]*AIH3W.0UFWO;KQI%'8/:I*+ DFYBWKC?Z>M1RZ9<
M:1'HFF)?RH;J]D,[P'8#N7) '8>E=AY,7G^?Y2>=MV^9M&[;Z9]*'ABE>-Y(
MT=HSN1F4$J?4>E:*>B1DZ=VV<9?74T<^L++JUQ:MIT2?9$\P#S/ESN;/W\GB
MEDO)[O6EBO\ 4I]/5M+29HXY-@$G4]?Y5U\MG:SRI)-;0R2)]QGC!*_0GI5&
M70[>?6I-0G"3!X%A,,D89>#G//>FIKJ)P?0Y(ZMJ][!I4<LYB$MF\I?[0+?S
M&#8!+8/;!QWS6A;R7^H:KH]M<ZC(HDL'DE:TFPLA#<$$?A75SV=K<QK'<6T,
MJ+]U9(PP'T!IWV>'S5E\J/S$78K[1D+Z ^E/VB[?UJ)4WU?;]#AK*&>UTW7+
MBSNKC[3::@TIC,N=Z*03D>XSSWP*Z'P_=R:I/?ZF)9#:2R".UC)^4(HY;'J3
MG\JO7FG":&X%JZ6EQ. ))TA5F8>ASUJ73[&'3=/@LH 1%"@5<]3[FDYIH:@U
M+R_K_,LT445F:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 9VM?
M\>*_]=%_K3-.^X*?K?\ QX#_ *Z+_6H].^X* -4=**!THH J:I?+IFE7=\R[
MQ;PM+M_O8&<5CVUCXB7[-?'65FE<HTUFT*K"%/W@C ;@0#P23G'3FMZYMXKN
MUFMIEW13(8W7U!&#7/QZ'KC"&RN=;C?3H64YCA*7$BJ<A6?. .!D@9/XTEN'
M0D;Q9"MV?] N_P"SA<?9CJ&%\H2;MN,9W8W<;L8S4)\9QB8C^R=0,(NGLQ,J
MJ5:920% SDYQUQ@=S36\+WI9K :C$-%:Y^TF'R3YV=_F% ^<;=WMG'%6H_#T
MJ6L,)N4)CU5K\G:>079MOUYZT+I?^MO^"-_U^/\ P"$^+T6VC9M+O1=->&R:
MT 4R+*%W#D'!!&.0>]2CQ7#]A,C6%VM\+C[+]@POFF7&X#.=N-O.[.,5GZOH
MU]%J-M+9S 2W&L&Z5_*+K$/(*X<>F5]NM6?^$9O&@-V=0B_MG[6+L3B$^4&"
M;-FS.=NWCKGO0OZ_#_@A_7Y_\ =-XQMX+(O+874=ZMPMJUDY17$A7<,L3MP5
MYSG%,O\ Q%-'!:W$5I?17$D%RZVCJ@W-&H/S$GD=P5.#1)X9OYK"[,UY8SWU
MY,DDXGM-]NRJNU4"$Y '7.<YJ*P\&O:16B-=Q[8A=;TC1@B^<H7;&"3A1C."
M>]#O9@K70FG^*2MK!>:F+F%O[+2ZDA"H58E]H*@<[F.,#.,$=ZL3^,H[*UNG
MO]*OK2XMT27[-)L+21LX0,I!(."1D=15>/P?<2V:0WM]$733TLUD@C(VE)-Z
M/@GM@9'UIUUX7U+5$GFU/4;:2[9(XHC# R1HBRK(Q())+-M'L*?42_K\#7TK
M6SJ-W=6DUA<V-U;JKF*?:2R-G:P*DCL>.HJI>>*X;2ZN1]@O);*TD\NZO8PO
MEPMQD$9W'&1D@'%:$>FLGB.ZU3S%*36L< CQR"K,V<_\"_2L>]\,7T[W]I;Z
MC%%I6HRF6YB: M*"V-X1LX ;'<<9.*0Q=%U'4]1\6:RMPMS#969$,49\LQDD
M [B1EMQ!R.V#ZU#IVM7B>-=6L[VXSIY9DM@5 \IHT5V&>^58GG^Z:W-.TPV-
M]J<_F*RWDR2*H'W L:I@^O2LG4?"DE]'J 6\$,EU>K<HZJ<HFP1NO_ EW#\:
M/\@*GA_Q!J,L.L75W%<7>+B-K6VAC&Y(Y$#*O;C!!))XI-0\9W/]ERR6>F3I
M?6][!;SV[M&Q0.1CD-M.0<#!X)YJWJ/A26[CU);>ZBC%S/!-'$Z$Q[8T"['
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M:4.FW>[$DELX)[=:<MW8%;2YK:;XP@OC;O/I]Y96]S;-<P3SA=LB*H9NA)&
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MQ(O 5T!>LUSIL)N=/DL]EK:M&JDD$,222W3G/X4/?^O/_@ O/^MO^";4/BV
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MBX6*]%6/(7U-'D+ZFBX6*]%6/(7U-'D+ZFBX6*]%6/(7U-'D+ZFBX6,76_\
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M -=%_K3--^X*?KO_ !XK_P!=%_K3--^X* -8=**!THH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M73?GKR0-PZ]: )E\;:-*)Q#+,[QPO,@-O(HF51DE"1\_;IFI?#_B>UURTLB
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M5_LXW1\[S/)W>6WE^9_<WXV[O;.:L:OKMAH<<+WTCIYS%(PD;.68 G "@DG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*:$0.7"@,P +8Y.*=10 4444 %%%% !1110 4444 1I!#'(\B1(KORS*H!;Z
MGO4E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!FZY_P >*_\ 71?ZTS3?]6*?K?\
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M?;^$M-MTA^:YDDCF:<S2R[GD=HS&2Q/7Y3@>F!6]10!SEAX*TK3]HC>[D2.
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M9=Z;A@X]Q^%6LC.*8!10"#29'//2@!:**KW=[;V-L;BYD"1!E7=[L0H'YD4
M6**,\XHR,XH **3(QG-+UH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6-;FTGMSYD!(5U9P1UY%7]6\->;%#'9AF$FHK=S[I,$#&#M-7?\ A&K$VES
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI3Z* &>4GI1Y2>E/HH 9Y2>E'E)Z4^B@!GE)Z4>4GI3Z* &>4GI1Y2>E/HH
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M <#HN@W2WFA&\L&V6\NHN_F*"$WR90GZCI4NE:!+9VOATC3_ "I;>_GDF(0
MHC"4 D^AROZ5W-% =SS+PO:S7VG:#!!H[0FVNC=R:@0H5E#/D ]2S9P14,OA
M_5+>/3+J6WU/RUM'MVCLEC:1&,K-RK@\$$<CTYKTVUM(+*V2WMHEBA3.U%&
M.<_UJ:@.MSA-.\-/!>PI-8RO#%HA@0W&V1E<R,=F1QG!'3M3%\-W1TW2+>VM
M?LL_]BSVTD@7;Y<C(@ 8^N0?UKOJ*'K_ %Z_YA_7Y?Y'E^G>'[TV]SNM-86>
M#39[91<>2L99DQM38 7&1P>G%:UYX<F\G3H;.P5,:+<6LFU  '*)M5OQ!KNJ
M*'K_ %Z_Y@M/Z]/\CS"]M=9N+&S@BT:[B1]-6!1#;1&3> 0RR,WW%Z$8]2:>
MVC:FFG11G3)VEF\-?8RP0$I,H/RMW!.0!7IE%-N]_/\ X/\ F"TM_7;_ "//
M;_3;V$:O:'07OI-5B18+@!2L7[H)M<GE0K D?7UI9_#=S_8WBE7LC/>3>4()
M"@+2E(8QE3_O _C7H-%%]Q6V.>\465S=6%A-%:F[%I=1W$MJ,9E4 @@ \$@D
M$#VKGGTB]OS/?KI+VL-SJ5E*EJZC>%C8;Y&4<#(_1:]"HI(9S_B^.];1X_L%
MIYY6=&<+$LCH@S\R*W!;./IS7""QO[5#)?:;<N+C7;::.&X5 TP\HCH/E!XZ
M?3->MU#/:071B,\2R>3()8]P^ZPZ$>_)H6C_ *_KH!YSJ-K/^[U&31VBAO-8
MMI(]/<*&;9&P+%>@)(Z>PK0@TN^N+R/44TR2SAN-6@G%LP 9$2,JTC <#)Q^
M0KMI[6"Y,1FB5_*D$D>X?=8="/?DU-33M_7I_D)_U^/^9YQ8Z9?:3%I5Y=:+
M-?QI9S6KVR*K/$[2E@VT]F'!-5M;TO6WMGL8=%DACDT]88H[*..10=IRCROR
M ,@#]*]0HI/:Q5];GFRV%];RWOG>')KXWFFVMLC%5^5Q&P8-GH 2,FG:CX9U
M62TGA59Y#"NGEFB*[I_*5@X7=P2"0>?2O1Z*;=]1(Y3P9ITEJ+Z[DBU*,W+)
M_P ?_EAFV@C.U ,>G/7%9%QX:OI_#&H1QVTD=RVL273*@4231"7<,%N#Q@C/
M' KT*BEUN'2QYDFDS1:9/?O;Z@P:\MI7@U)HD:X$9/RA5  /(QGK@5%$D^IZ
MCJ^HV6D31?9[ZPN?LH"B1PBMNX!QNP<XZUZ7>65KJ%J]K=P1SP.,-'(N0:9I
M^FV6E6HMK"UBMX0<[(UP,^M%_P"ON_R XN.RU2^U>YOI-,GMTFU6RG5' R(U
MCP2<>G?TK,;3]=N-<T\RZ9<QBVU59I1%!&D"IN;YE8?,_!!)]SFO4:*=]OZ[
M?Y ><Q:;?64J7#Z+-<16&IW<KP*B_O5E)*2(.C;0<>HR:GLM"NY-4TRZFTOR
M;:34[B[^SL 1 C0[5W#H"6&<=B:[^BD#U.,6R=_'!T^/:UA%)_:C@'[LI!0+
M_P!] O6EJFG277C#1+EK;S;>WAN-[E<A&(3;^/!K8MM/M+.6XEMK>.*2X?S)
MF5<%V]35FCL#/,M,\-7\&LP6UW%J[M#?&Z\Y#"+<C>6#;L;NAP5SGJ*)K6?3
MVT?3KG2&6:WUF.0Z@0NV7=(Q!!ZDD$9':O3:AN+6"Z$8GB63RY!(FX?=8=#]
M:%I8.YP4%EJT,=CH_P#9-QLM-:^TO<\>6T32NX*\Y/##/I5C0=#NX];T^:[L
MF5(H;X;W4'8SW&Y?Q*\UW=%']?A8'K_7S/,O#_AN^M=5L+:\BU=I+*X,S39A
M%N>6^8-C<V0>1G//-:.D^&VBL_"XFTQ0\%Q/)<[HQE=RR8+?B5_2N\HH \TO
M_#VHI#:W$=O>I#:WUZQBLU0R!9'RCJK@@C /OAJO:3X<DBOM >6RNF@B>[F<
M7FQFC9PNW(4;1GGCM7>T4+0'J<!;:3>65SI4ITR1X8-5O/D1!^[CD+!&QV7G
M/M3?"^FZC8>(88H=/NH-/A219!>Q1GRL]!%(O+ GU[=Z]!HH6@'!^(="U&[\
M63ZI;0R2):VMO)' 0/+N61W)0^X!R/0D4FH:'/>Z?XPG&FL;F]V-:[HQO;$*
M8Q[AL_B*[VBA:*P[ZW//M5TV^#:[8?V))>RZLVZWO %VQYC50'8\KL()'Z5H
MWV@WS3O'%EX5C%XK@XW7:*%48]\;OK7844"..MM"G;7M$NKVT61A!=37+%0R
MQS2&,X_ 94>PK4\)V4UEH'V6X@,6VYN-L;#HAE<KQZ8(K=HH \WTNPOM*@TR
MZN-!N+E+*.>UDMUC4LKLX82J#U! QFNI\,Z;<67AYH+F!86EEFE6WR"(5=RR
MIZ< _2M^BC=6 X'PQHMP+C0_MVE/&MEILUM)YT8P)-Z<CZ@'![BLD^'M5MK+
M1[F2#4A'!;2V[0V2QM)&3*2#M<$;2N!QZ"O5**=_Z_KU P]%TU]/\)16(CG5
MEA<".9E9QG) )7COVKA]!T5HXM&CL_#5_8ZI;M"9KV?(C &/,ZL0<C(P!WKU
M2C%*^MPMI8\^BTV^TZXAU*;2)KV&&\O\VZ*&<>;+E)%4]> 1]&HM=%O[2;2+
MM]-=$;4+F3R(P&-HDP(3/8 'DXZ9KT&BCI8.MSS+PYX;O[;4=/M[J+5Q-8LS
M&9C"+?.&&Y6 W-G/3.>>>E26VE7JZ%_9)\.,+RSL[F)KXD .S(PRA'+ER1D'
MI7I-%'2P+1W.4T[2)+/6M!EBLA#'%I;PSLB  -^[(4_B&_6J7B?1;O4-7O2M
MF\UO*E@O3(8)<%G'X+R:[BBG?5,5M&CAM7T*Z;4]6DM-/#VY:QG$( 5;CRV8
MNOIG&WKZ"J$^F:A?OK=_;Z)/:B5K&>*!@JO+Y3EGXZ!L=OI7I%%):#//;NRO
M=7DUN]N=&OXXIULW@C0JLP,98E@#D$J3G::BAL-8.BPSW&FRS+!JT-RB&W1+
MB2,##%U7C.?Q(%>CT4+0'J<39Z*8/!VHBXB6TNA=SW22. "&$I>-B?3@?A6Q
MX2CE?1O[1N8RESJ4ANY%/)4-C:OX*%%:M]86FI6IMKVWCGA)#%'&02#D?K5@
M *    .@%" 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** (+O\ U0_WA1#]T4MS_JA_O"B$?+0!-1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSJ.S="/S!H$7Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2:]EFNA?)>S3LH!E9%V@8'"C%=!12 Y;5_!IU2ZFF34Y(!+=+<O'Y(=&*H$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M '11L7^Z*** #8O]T4;%_NBBB@ V+_=%&Q?[HHHH -B_W11L7^Z*** #8O\
M=%&Q?[HHHH -B_W11L7^Z*** #8O]T4;%_NBBB@ V+_=%&Q?[HHHH -B_P!T
M4;%_NBBB@ V+_=%&Q?[HHHH -B_W11L7^Z*** #8O]T4;%_NBBB@ V+_ '11
ML7^Z*** #8O]T4;%_NBBB@ V+_=%&Q?[HHHH -B_W11L7^Z*** #8O\ =%&Q
M?[HHHH -B_W11L7^Z*** #8O]T4;%_NBBB@ V+_=%&Q?[HHHH -B_P!T4;%_
MNBBB@ V+_=%&Q?[HHHH -B_W11L7^Z*** #8O]T4;%_NBBB@ V+_ '11L7^Z
M*** #8O]T4;%_NBBB@ V+_=%&Q?[HHHH -B_W11L7^Z*** #8O\ =%&Q?[HH
MHH -B_W11L7^Z*** #8O]T4;%_NBBB@ V+_=%&Q?[HHHH -B_P!T4;%_NBBB
L@ V+_=%&Q?[HHHH -B_W11L7^Z*** #8O]T4;%_NBBB@!0J@Y  HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>plx-20210630x10q007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20210630x10q007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %*!#@# 2(  A$! Q$!_\0
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M_*I[T :U%4(-9T^YM+>Z@N1+!<2"*-XU+98]C@<=#G.,=ZOT %%%% !1110
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M0 4444 %<O=:C9:?X[9KV]M[97TU0IFE5 3YK=,GFNHJM<Z?97CAKFT@F8#
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MV\FCV6M65FMM-]K_ +0:4*_R_)M$C$[@><CMFKOA[6M5AMM)MK^UM_)NM/\
M,MW6<ER412?,)&.0<Y'3O1_7Y_Y =E17$Z=XUNKC4I+62*PO&:VEGB33IGD.
M4 .PDJ%).< K26'CIVTC4+Z]6Q?[+&)/*MI7$BDG:$='4,.2/FQCK0!V]%<M
MX7\52:W>SV<Z0F1(_-66W64)C.-I\Q%.X<=.M1^)-.19VN(KR\DUB=@NGQ)<
M,JQ$8R=BD J.2Q8'T]!0!UM%(,[1GKWI: "BBB@ HHHH @M_O3_]=#_(5/4%
MO]Z?_KH?Y"IZ "BBB@ HHHH *,UD^*'>/PKJSH[(ZVDI5E."#M/.:Y31H$.H
M:8^BV&NVL@=6NY;UIA"\6T[AB1B"2<8P*%JP>UST&BN&\-:QJMM::2EU!"]A
M=SRVZ2F9FFW[I""01C;\N,9STJ:U\97#^([>PF&FR17,K1*EK.TDD1 )^8[=
MAZ8P#P3[4 =G17%Z3XVFN9+UK^*SA6WADF:V65UN8@G)#(ZC=]5X!I_AOQI)
MK&JI9S0P8G1I(S LW[O !VN7103@]5..* .QHKE?&&G3/;R7\0U*XFCCVP1V
MEQY:V[<DRD C?VX^;I@"NAT^=;K3K:=)A.LD2N)5& ^0.<=LT 6:*** "BBB
M@ J"X^_!_P!=/Z&IZ@N/OP?]=/Z&@">BBB@ HHHH **** .=\90Q7&EVD$P#
M12W]NC@]P7 -<I<R27MK!%<-N;19[>T8D8S,9U&?^_:J?^!UZ6\:2@"1%8 A
M@&&<$=#3#;0,&!AC(9@[94<L.A/OP.:%H#U/-=0UPKXBBGM;^=)/[42W*3:G
MR5\S:RBV P%ZX+8..<U)>)/)X>OK\W4]Q<_VR((HY[AO*4+=#:,=!SWQG'%>
MAM8VC3/*UK 9'QN<QC+8Y&3CG&*?]F@*%/)CV%]Y78,;LYS]<\YH6EOZ[ _Z
M_$\[OM3OUT:VC:[:.ZEOWAU1I[QH%B<*2$#J#Y:'Y=I &01SDDU&5:YLM%DU
M'5(Y(8=9$<4MMJ+R*B&,G:TI"[B&& >>#C/)KTA[6WD$H>"-A* ) R [\>OK
M^-(;.V-NMN;>(PKC;&4&T8Z8'2A ]3@[,7.L:AIEI/J=\D4C:@91#<LC.%F
M49!R ,]NG2H[74/M T^VUG7+FTM(XY]EQ]I\DS21S%!N?N0H!V]\]#7H*6T"
M,K)#&K+G!"@$9.3^9K+U;0#J/D_9[Z:R$9)*111NC9.<[74@-G^(<\FET0=R
M+P7<27?A&PGEN)+AW5CYLARSC>V"?PK>JMIUA!IFGPV5N&\J%=J[CDGU)/J3
MS5FJ8D%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4&BD:@!112"E
MH **** "BBB@".>0Q6\D@ )52PS["N/MO$'B&+2[#5[XZ3)9W1A!@@21)1YA
M &TEB"1GICG!KL+A&DMI47[S(0/KBN>\-^#]+TFRL9GTJS34XH5$DRH"V_')
M#?UH6X/8N#Q5H_F7:?:7'V0LL[&%]JL&V[=V,%L]%')S3X_$NE2:=/?&Y:*&
MW($HFB>-T)Z HP#9.1CCGM6%<>%KRZT"_M&"+,VJO>Q*)F02+OW %EY7([CD
M&H8/"UX=/FGBL(K.]%Q!/'%-J$MUYOE,2%=VS@')Q@<=Z -E?%%O>7.GKI[J
M\<]Q)!.)8V1XBL;/@J<%3P.HZ&HD\::3;VEN;V\WSR6ZW#&WM92I0DC?C!(7
M@YST[U''I^L7VH65_>6=I;%+EY&BBDW,J^2R L^!O.3Z<"H=!\/7U@C?:(X@
MQTF*T&'S\ZF0D?3YAS0PZ_UW-AM>M(;FY>:^MUM(K6.Y)VL"%8G#%NA!QP!S
M^8J-/%NC/9270N7"QR")HF@D$H<C('EE=V2.1QR*P?\ A%=3DL/)/DI*FG6<
M:;GRIEA<N5./X3P,^]6;ZV\3WUK)<+:VUI(TJ;K:VNMDLD:@Y!GV\<D$ #H"
M,\T/^OO!?U]QI?\ "2P70T]].821W%[]EF$L;(\9V,Q!4X(/ ZCH:WJX?1O#
MFJVLJ/<PQK_Q-A>'_2FF(C\DKRS<ELG_  XKN* "BBB@ HHHH **** (+GI%
M_P!=%J>H+GI%_P!=%J>@ HHHH ****  C(Q5/2].BTG3+>P@9VB@38K.06(]
M\5<HH QW\.VLEG<6QEF"3W@O&((R'#J^!QTRHJE-X+M9IV;^T=12#[4+M;59
M5$2R[]Y.-N3D\X)(YXKI:*%H!AGPS"^II=SZA?SQ13>?%:S2AHXY.>1QNXR<
M#=@>E+8>&HM.NTD@U'4?LL9)BLC/^YCSG@ #)'/ )('I6W10!4U/3XM5TNYL
M)F=8KB,QLR$;@#Z9JTJA5"CH!BEHH **** "BBB@ J%?^/R7_<3^;5-4*_\
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M&68[N#QT^<]/:J5KX+M;6YLY%U+4GBLI-]M;O*OEQC!&W 49&">22?>NEHH
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M IK]*=3).@^M "BG4Q>E/H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7_"T+;_H%R_]_1_A1_PM"V_Z!<O_ ']'^%>:T4>RB']M8S^;\$>E?\+0MO\
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M"TT874PMUGD N0FS)QCD<\U"_BV>6UTY[#2VN)[TR+Y+3!"A3[PSC![TV_\
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MH'R[CEL= /:E32[JWT>\AGO9=0G='\MY44,N5Q@8K..GWEMI_AVZ6UDEDT]
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MUKOI:_\ ?W_ZU)_PKK7?2U_[^_\ UJ.>/<?]G8O_ )]LY.BNL_X5WKOI:_\
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M*#_O]_\ 6I/^$0UC_GE!_P!_O_K4>TCW#^S<7_S[9A45N?\ "(ZQ_P \H/\
MO]_]:D_X1+6/^>4/_?[_ .M1[2/</[-Q?_/MF)16W_PB>L?\\H?^_P!_]:D_
MX1/5_P#GE#_W^_\ K4>TCW#^S<7_ ,^V8M%;7_"*:O\ \\8?^_W_ -:C_A%=
M7_YXP_\ ?[_ZU'M(]P_LW%_\^V8M%;/_  BNK_\ /&'_ +_?_6H_X175_P#G
MC#_W^_\ K4>TCW#^S<7_ ,^V8U%;/_"*ZO\ \\8?^_W_ -:C_A%=7_YXP_\
M?[_ZU'M(]P_LW%_\^V8U%;7_  BNK_\ /&'_ +^__6I/^$5U?_GC#_W^_P#K
M4>TCW#^S<7_S[9C45L_\(KJ__/&'_O[_ /6I?^$4U?\ YXP_]_?_ *U'M(]P
M_LW%_P#/MF+16U_PBFK_ //&'_O]_P#6H_X1/6/^>,/_ '^_^M1[2/</[-Q?
M_/MF+16W_P (EK'_ #RA_P"_W_UJ7_A$M8_YY0_]_O\ ZU'M(]P_LW%_\^V8
M=%;G_"(ZQ_SR@_[_ '_UJ7_A$-9_YY0?]_O_ *U'/'N']FXO_GVS"HK>_P"$
M.UG_ )Y0?]_O_K4O_"&ZS_SR@_[_ '_UJ.>/</[-Q?\ S[9@45T'_"&:R?\
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M ._Z?XT<\>XG@,4O^7;^XYFBNF_X0'Q#_P ^D?\ W_7_ !H_X0#Q#_SZ1_\
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M+_PKW7_^>,'_ '^%'/'N']GXK_GV_N.5HKJO^%>Z_P#\\8/^_P */^%>Z_\
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M?E_^^5_PH\F7_GY?_OE?\* )Z*@\F7_GY?\ [Y7_  H\F7_GY?\ [Y7_  H
MGHJ#R9?^?E_^^5_PH\F7_GY?_OE?\* )Z*@\F7_GY?\ [Y7_  H\F7_GY?\
M[Y7_  H GK/U8XAB_P!_^AJSY,O_ #\O_P!\K_A6?J\4@@B_TE_O_P!U?0^U
M $UF?E%: Z5D64<FT?Z0_P#WPO\ A6B(9?\ GY?_ +Y7_"@">BH/)E_Y^7_[
MY7_"CR9?^?E_^^5_PH GQ28J'R9?^?E_^^5_PH\F7_GY?_OE?\* )L4FVHO)
ME_Y^7_[Y7_"CR9?^?E_^^5_PH EVTFP5'Y,O_/R__?*_X4>3+_S\O_WRO^%
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M_P"?E_\ OE?\*/L\G_/R_P#WRO\ A0!G_P!GCTI?L"^E7_L\G_/R_P#WRO\
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ME_\ OE?\*/)E_P"?E_\ OE?\* )=HHVU%Y,O_/R__?*_X4>3+_S\O_WRO^%
M$V*,5#Y,O_/R_P#WRO\ A1Y,O_/R_P#WRO\ A0!/BC%0>3+_ ,_+_P#?*_X4
M>3+_ ,_+_P#?*_X4 3T5!Y,O_/R__?*_X4>3+_S\O_WRO^% $]%0>3+_ ,_+
M_P#?*_X4>3+_ ,_+_P#?*_X4 3T5!Y,O_/R__?*_X4>3+_S\O_WRO^% $]%0
M>3+_ ,_+_P#?*_X4>3+_ ,_+_P#?*_X4 3T5!Y,O_/R__?*_X4>3+_S\O_WR
MO^% $]%0>3+_ ,_+_P#?*_X4>3+_ ,_+_P#?*_X4 3T5!Y,O_/R__?*_X4>3
M+_S\O_WRO^% $]%0>3+_ ,_+_P#?*_X4>3+_ ,_+_P#?*_X4 3T5!Y,O_/R_
M_?*_X4>3+_S\O_WRO^% $]%0>3+_ ,_+_P#?*_X4>3+_ ,_+_P#?*_X4 3T5
M!Y,O_/R__?*_X4>3+_S\O_WRO^% $]%0>3+_ ,_+_P#?*_X4>3+_ ,_+_P#?
M*_X4 3T5!Y,O_/R__?*_X4>3+_S\O_WRO^% $]%0>3+_ ,_+_P#?*_X4>3+_
M ,_+_P#?*_X4 3T5!Y,O_/R__?*_X4>3+_S\O_WRO^% $]%0>3+_ ,_+_P#?
M*_X4>3+_ ,_+_P#?*_X4 3T5!Y,O_/R__?*_X4>3+_S\O_WRO^% $]%0>3+_
M ,_+_P#?*_X4>3+_ ,_+_P#?*_X4 3T5!Y,O_/R__?*_X4>3+_S\O_WRO^%
M$]%0>3+_ ,_+_P#?*_X5*@*J 6+'U/>@!U%%% !1110 4444 %%%% !1110
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M 'S2_P!IW/\ >7_OF@#<HK$_M*Y_O+_WS2_VE<_WE_[YH VJ*Q?[1N/[R_\
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MW+*N>!NP< 4MK:3G6+F;[(ADMT\T0Q#*LQ'RX]CG- &'15_6+0VFH./+9%D
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M^9_QI1H-I_S[+^9_QKI=O_3O-^2_XT8_Z=YOR7_&@#G!H%G_ ,^R_F?\:<-
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M+_GVC_6E_LNR_P"?:/\ 6I_/;_GWF_(?XT>>W_/O-^0_QH A_LNR_P"?:/\
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M2N>QZT . P,#I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&'MXG;T5Q']O:G_S\_\ CB_X4O\ ;VI?\_/_ (XO^%'(P]M$[:BN)_M[4O\
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MW_\ '1_A1_:]]_SW_P#'1_A1RL/:HZJBN6_M>]_Y[_\ CH_PI?[6O?\ GO\
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M'3CT(/YUJU-BT[A1110,**** "BBB@ HHHH **** "BBB@ KDOB/_P BC/\
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MFES3,TN: 'YI<TW-+F@!V:7--S2YH&.I<TW-+2 =FG U'FG9IC'YI:9FE!I
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M+L.2/8Y3^RD_YYTG]E+_ ,\_UKK/LR^E'V9?2B[#DCV.3_LI?^>?ZT?V6O\
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M?E1]CM_^>*?E4]% $'V.W_YXI^59^K6EOY$?[E/O^GL:UZH:J,PQ_P"__0T
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M\4_*IZ* (/L=O_SQ3\J/L=O_ ,\4_*IZ* (/L=O_ ,\4_*C[';_\\4_*IZ*
M(/L=O_SQ3\J/L=O_ ,\4_*IZ* (/L=O_ ,\4_*C[';_\\4_*IZ* (/L=O_SQ
M3\J/L=O_ ,\4_*IZ* (/L=O_ ,\4_*C[';_\\4_*IZ* (/L=O_SQ3\J/L=O_
M ,\4_*IZ* (/L=O_ ,\4_*C[';_\\4_*IZ* (/L=O_SQ3\J/L=O_ ,\4_*IZ
M* (/L=O_ ,\4_*C[';_\\4_*IZ* (/L=O_SQ3\J/L=O_ ,\4_*IZ* (/L=O_
M ,\4_*C[';_\\4_*IZ* (/L=O_SQ3\J/L=O_ ,\4_*IZ* (/L=O_ ,\4_*C[
M';_\\4_*IZ* (/L=O_SQ3\J/L=O_ ,\4_*IZ* (/L=O_ ,\4_*C[';_\\4_*
MIZ* (/L=O_SQ3\JE1%C4*H 4= *=10 4444 %5-4N)+32[JXBQYD<3,N1D9
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M7_[Z-1TM%@N/\V7_ )ZO_P!]&CS9?^>K_P#?1IE%*P$GFR_\]7_[Z-'FR_\
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MZFER?4TE+0 N3ZT9/K0**!BTN:2BD M+24M !1110 HHH%% !1112 6BBB@
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MVGC:6(('MUJO9HS]J^W0[*BBBLC<**** "BBB@ HHHH **** "BBB@ HHHH
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M&/XC@_2NG    Z"JD$!:***DL*6DI: "BBB@8M%%%(!110** %%% HH&.%%
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5A^+QGPU=_1?\
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MY%[_ ,_ _P"_0I?(O?\ GX'_ 'Z%+VL0]E(LTHJL(+W_ )^!_P!^A2^1>_\
M/P/^_0H]I$?LI%J@57$-Y_S\#_OT*407G_/P/^_0I>TB'LY%BEJN(+S_ )^!
M_P!^A3A;W?\ SW'_ 'Z%'M(C]G(GI14(M[O_ )[C_OT*<+>Z_P">X_[]BCVD
M0]G(FI140MKK_GN/^_8IXMKG_GN/^_8I>TB'LY#Z44T6MQ_SW'_?L4\6D_\
MSV'_ '[%'/$?)(*6E%I/_P ]O_'!3Q9S?\]O_'!2YT/D8P4X4\6<O_/;_P <
M%/%G)_SU_P#'*.=!R,BI14PLG_YZ_P#CM.%DW_/7_P =I<R'RL@I15@63?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>plx-20210630.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/16/2021 11:17:11 AM-->
<!--Modified on: 8/16/2021 11:17:11 AM-->
<schema xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:plx="http://www.protalix.com/20210630" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns="http://www.w3.org/2001/XMLSchema" targetNamespace="http://www.protalix.com/20210630" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesDetails" id="DisclosureInventoriesDetails">
        <link:definition>40201 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" id="StatementCondensedConsolidatedStatementsOfOperationsParenthetical">
        <link:definition>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency">
        <link:definition>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical">
        <link:definition>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" id="DisclosureFairValueMeasurementTables">
        <link:definition>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" id="DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails">
        <link:definition>40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" id="DisclosureFairValueMeasurementAdditionalInformationDetails">
        <link:definition>40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" id="DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails">
        <link:definition>40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" id="DisclosureStockTransactionsDetails">
        <link:definition>40501 - Disclosure - STOCK TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>40601 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10201 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>10301 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenues" id="DisclosureRevenues">
        <link:definition>10401 - Disclosure - REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactions" id="DisclosureStockTransactions">
        <link:definition>10501 - Disclosure - STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>10601 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>30203 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" id="DisclosureRevenuesTables">
        <link:definition>30403 - Disclosure - REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://fasb.org/us-roles/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
  <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
  <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
  <element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <element id="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" name="IncreaseInLiabilitiesForPropertyPlantAndEquipment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_RevenueDisclosureTextBlock" name="RevenueDisclosureTextBlock" nillable="true" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element name="NatureOfOperationsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <element name="Notes2021Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_Notes2021Member" substitutionGroup="xbrli:item" />
  <element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <element name="AmendedPfizerAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ChiesiUSAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiUSAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ChiesiExUSAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ChiesiExUSAgreementMember" substitutionGroup="xbrli:item" />
  <element name="ProtalixBioTherapeuticsIncorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
  <element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <element id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" name="CollaborativeArrangementRevenuesExpensesSharingPercentage" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" name="AdditionalAmountsPayableToCoverDevelopmentCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element name="MaximumEntitlementOfDevelopmentCostsToCoverPerYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" substitutionGroup="xbrli:item" xbrli:balance="debit" />
  <element name="PaymentOnNetSalesPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_PaymentOnNetSalesPercentage" substitutionGroup="xbrli:item" />
  <element name="SevenPointFivePercentageConvertibleNotesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SevenPointFivePercentageConvertibleNotesMember" substitutionGroup="xbrli:item" />
  <element id="plx_PfizerMember" name="PfizerMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_DebtInstrumentConvertibleConversionShareNumber" name="DebtInstrumentConvertibleConversionShareNumber" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="plx_DebtInstrumentConvertibleBaseValueForConversionRate" name="DebtInstrumentConvertibleBaseValueForConversionRate" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_ChiesiMember" name="ChiesiMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" name="UpfrontNonrefundableNonCreditablePaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" name="ChiesiUsAgreementAndChiesiExUsAgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_DebtConversionConvertedInstrumentAmountCash" name="DebtConversionConvertedInstrumentAmountCash" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_ShortTermBankDeposits" name="ShortTermBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_IncreaseDecreaseInBankDeposits" name="IncreaseDecreaseInBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" name="IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" name="IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" name="NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_ChiesiAgreementsMember" name="ChiesiAgreementsMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_MeasurementInputYieldMember" name="MeasurementInputYieldMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_IncreaseDecreaseInRestrictedDeposit" name="IncreaseDecreaseInRestrictedDeposit" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_SaleOfStockMaximumOfferingPrice" name="SaleOfStockMaximumOfferingPrice" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_LicenseAgreementInitialCashPayment" name="LicenseAgreementInitialCashPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_AtMarketEquityOfferingMember" name="AtMarketEquityOfferingMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_InterestReceivedNet" name="InterestReceivedNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_TermToSignSupplyAgreement" name="TermToSignSupplyAgreement" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" name="AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" name="AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" name="ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_SarcomedUsaInc.AgreementMember" name="SarcomedUsaInc.AgreementMember" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_StockIssuedDuringPeriodSharesSalesAgreement" name="StockIssuedDuringPeriodSharesSalesAgreement" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_StockIssuedDuringPeriodValueSalesAgreement" name="StockIssuedDuringPeriodValueSalesAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_ProceedsFromSaleOfShortTermDeposits" name="ProceedsFromSaleOfShortTermDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_AgreementAmendmentPaymentReceivable" name="AgreementAmendmentPaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <element id="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" name="ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_RevenuePerformanceObligationNumber" name="RevenuePerformanceObligationNumber" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <element id="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" name="SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" nillable="true" type="nonnum:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <element id="plx_StockIssuedDuringPeriodValueWarrantsExercises" name="StockIssuedDuringPeriodValueWarrantsExercises" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_StockIssuedDuringPeriodSharesWarrantsExercises" name="StockIssuedDuringPeriodSharesWarrantsExercises" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_PercentageOfPremiumToClosingPriceOfStock" name="PercentageOfPremiumToClosingPriceOfStock" nillable="true" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <element id="plx_ProceedsFromVariableConsideration" name="ProceedsFromVariableConsideration" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="plx_VariableConsideration" name="VariableConsideration" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <element id="plx_ReductionToAccumulatedRevenueRecognized" name="ReductionToAccumulatedRevenueRecognized" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>plx-20210630_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/16/2021 11:17:11 AM-->
<!--Modified on: 8/16/2021 11:17:11 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureInventoriesDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesDetails" />
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637647094305568076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_637647094305568076" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637647094305568076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637647094305568076" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637647094305568076" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_637647094305568076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637647094305568076" xlink:to="plx_ShortTermBankDeposits_637647094305568076" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637647094305568076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637647094305568076" xlink:to="us-gaap_AccountsReceivableNetCurrent_637647094305568076" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637647094305568076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637647094305568076" xlink:to="us-gaap_OtherAssetsCurrent_637647094305568076" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637647094305568076" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637647094305568076" xlink:to="us-gaap_InventoryNet_637647094305568076" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637647094305578014" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637647094305578014" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637647094305578014" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637647094305578014" order="3" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637647094305578014" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637647094305578014" order="4" use="optional" weight="1" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637647094305578014" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_Liabilities_637647094305578014" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637647094305578014" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637647094305578014" xlink:to="us-gaap_LiabilitiesNoncurrent_637647094305578014" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637647094305578014" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637647094305578014" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637647094305578014" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637647094305578014" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637647094305578014" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637647094305578014" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637647094305578014" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637647094305578014" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637647094305578014" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637647094305578014" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_637647094305578014" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637647094305578014" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637647094305588016" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637647094305578014" xlink:to="us-gaap_LiabilitiesCurrent_637647094305588016" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637647094305588016" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637647094305588016" xlink:to="us-gaap_AccountsPayableTradeCurrent_637647094305588016" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637647094305588016" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637647094305588016" xlink:to="us-gaap_AccountsPayableOtherCurrent_637647094305588016" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637647094305588016" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637647094305588016" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637647094305588016" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637647094305588016" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637647094305588016" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637647094305588016" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_637647094305588016" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637647094305588016" xlink:to="us-gaap_ConvertibleDebtCurrent_637647094305588016" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637647094305588016" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637647094305588016" xlink:to="us-gaap_NotesPayableCurrent_637647094305588016" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637647094305598239" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_StockholdersEquity_637647094305598239" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637647094305598239" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_637647094305598239" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637647094305598239" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637647094305598239" xlink:to="us-gaap_CostOfRevenue_637647094305598239" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637647094305598239" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637647094305598239" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637647094305598239" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637647094305598239" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637647094305598239" xlink:to="us-gaap_Revenues_637647094305598239" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637647094305598239" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637647094305598239" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637647094305598239" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637647094305598239" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense_637647094305598239" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637647094305598239" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637647094305598239" xlink:to="us-gaap_OtherNonoperatingExpense_637647094305598239" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637647094305608028" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_637647094305598239" xlink:to="us-gaap_OtherNonoperatingIncome_637647094305608028" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome_637647094305608028" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherIncome_637647094305608028" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637647094305608028" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637647094305608028" order="1" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637647094305608028" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637647094305608028" xlink:to="us-gaap_NetIncomeLoss_637647094305608028" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637647094305608028" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637647094305608028" xlink:to="us-gaap_ShareBasedCompensation_637647094305608028" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637647094305608028" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637647094305608028" xlink:to="us-gaap_Depreciation_637647094305608028" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637647094305608028" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637647094305608028" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637647094305608028" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_637647094305608028" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637647094305608028" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_637647094305608028" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637647094305608028" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637647094305608028" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637647094305608028" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637647094305618051" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637647094305608028" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637647094305618051" order="7" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637647094305618051" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637647094305608028" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637647094305618051" order="8" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637647094305618051" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637647094305608028" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637647094305618051" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637647094305618051" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637647094305608028" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637647094305618051" order="10" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_637647094305618051" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637647094305608028" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_637647094305618051" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637647094305618051" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637647094305608028" xlink:to="us-gaap_IncreaseDecreaseInInventories_637647094305618051" order="12" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637647094305618051" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637647094305608028" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637647094305618051" order="13" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637647094305618051" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637647094305608028" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637647094305618051" order="14" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637647094305618051" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637647094305618051" order="2" use="optional" weight="1" priority="7" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_637647094305618051" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637647094305618051" xlink:to="plx_IncreaseDecreaseInBankDeposits_637647094305618051" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_637647094305628065" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637647094305618051" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_637647094305628065" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637647094305628065" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637647094305618051" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637647094305628065" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637647094305628065" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637647094305618051" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637647094305628065" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637647094305628065" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637647094305618051" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637647094305628065" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_637647094305628065" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637647094305618051" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_637647094305628065" order="6" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637647094305628065" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637647094305628065" order="3" use="optional" weight="1" priority="8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637647094305638107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637647094305628065" xlink:to="us-gaap_RepaymentsOfNotesPayable_637647094305638107" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637647094305638107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637647094305628065" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637647094305638107" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637647094305638107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637647094305628065" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637647094305638107" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637647094305638107" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637168086008773890" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637647094305638107" order="4" use="optional" weight="1" priority="7" />
  </calculationLink>
  <calculationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637647094305647835" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637647094305647835" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637647094305647835" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637647094305647835" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637647094305647835" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637647094305647835" order="3" use="optional" weight="1" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>plx-20210630_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/16/2021 11:17:11 AM-->
<!--Modified on: 8/16/2021 11:17:11 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637647094305647835" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_637647094305647835" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637647094305678080" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_637647094305678080" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637647094305678080" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_637647094305678080" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" xlink:label="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637647094305708034" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_637647094305708034" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_Notes2021Member" xlink:label="plx_Notes2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_Notes2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637647094305718074" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637647094305718074" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SarcomedUsaInc.AgreementMember" xlink:label="plx_SarcomedUsaInc.AgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_SarcomedUsaInc.AgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637647094305718074" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_637647094305718074" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637647094305728072" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_637647094305728072" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637647094305728072" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_637647094305728072" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637647094305748798" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637647094305748798" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtMarketEquityOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_637647094305748798" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_637647094305748798" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_LicenseAgreementInitialCashPayment" xlink:label="plx_LicenseAgreementInitialCashPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_LicenseAgreementInitialCashPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_TermToSignSupplyAgreement" xlink:label="plx_TermToSignSupplyAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_TermToSignSupplyAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SaleOfStockMaximumOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AgreementAmendmentPaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_PaymentOnNetSalesPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConvertibleDebtCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_RevenuePerformanceObligationNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637647094305898116" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637647094305898116" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637647094305898116" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_637647094305898116" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="plx_MeasurementInputYieldMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMeasurementInput" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiExUSAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_PfizerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_BR" xlink:label="country_BR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="plx_ChiesiMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ChangeInAccountingEstimateByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_637647094305938096" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_637647094305938096" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" xlink:label="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ReductionToAccumulatedRevenueRecognized" xlink:label="plx_ReductionToAccumulatedRevenueRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ReductionToAccumulatedRevenueRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_VariableConsideration" xlink:label="plx_VariableConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_VariableConsideration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ProceedsFromVariableConsideration" xlink:label="plx_ProceedsFromVariableConsideration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ProceedsFromVariableConsideration" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_AtMarketEquityOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="plx_SaleOfStockMaximumOfferingPrice" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637647094305968039" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_637647094305968039" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_DebtConversionConvertedInstrumentAmountCash" xlink:label="plx_DebtConversionConvertedInstrumentAmountCash" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_DebtConversionConvertedInstrumentAmountCash" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_DebtInstrumentConvertibleConversionShareNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_DebtInstrumentConvertibleBaseValueForConversionRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_PercentageOfPremiumToClosingPriceOfStock" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_PercentageOfPremiumToClosingPriceOfStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>plx-20210630_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/16/2021 11:17:11 AM-->
<!--Modified on: 8/16/2021 11:17:11 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShortTermBankDeposits" xlink:to="plx_ShortTermBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term bank deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - Trade</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Funds in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY (NET OF CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableOtherCurrent" xlink:to="us-gaap_AccountsPayableOtherCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Accounts Payable, Other, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableOtherCurrent_lbl" xml:lang="en-US">Other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible Debt, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleDebtCurrent_lbl" xml:lang="en-US">Convertible notes</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Promissory note</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US">Contracts liability</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other long term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity (net of capital deficiency)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Products And Services [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Goods [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License And Service [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and R&amp;D Services [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">TOTAL REVENUE</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF GOODS SOLD</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING INCOME (LOSS)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">FINANCIAL INCOME</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES - NET</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">OTHER INCOME</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS FOR THE PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss for the period</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC AND DILUTED</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKOLDERS' EQUITY (CAPITAL DEFICIENCY)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Ending balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" xml:lang="en-US">Represents issuance of common stock, net of issuance cost, value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" xml:lang="en-US">Issuance Of Common Stock And Warrants, Net Of Issuance Cost, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_lbl" xml:lang="en-US">Issuance of common stock and warrants, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" xml:lang="en-US">Represents issuance of common stock, net of issuance cost, in shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" xml:lang="en-US">Issuance Of Common Stock And Warrants, Net Of Issuance Cost, In Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_lbl" xml:lang="en-US">Issuance of common stock and warrants, net of issuance cost (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" xlink:label="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" xlink:to="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants_lbl" xml:lang="en-US">Amount of decrease in additional paid in capital (APIC) resulting from receivables from sale of common stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants_lbl" xml:lang="en-US">Adjustments To Additional Paid In Capital Receivables From Sale Of Common Stock And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants_lbl" xml:lang="en-US">Note receivable from issuance of common stock and warrants</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance cost (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued (in shares)</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Value, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Sales Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation related to stock options</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Value of shares issued during period for exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Number of shares issued during period for exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Exercise of warrants (in shares)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Unrealized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial income, net (mainly exchange differences)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Loss (gain) on amounts funded in respect of employee rights upon retirement</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on sale of fixed assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt issuance costs and debt discount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (decrease) in contracts liability (including non-current portion)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase in accounts receivable and other assets</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Change in Operating Lease Right Of use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Changes in right of use assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase in inventories</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (decrease) in accounts payable and accruals</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Decrease in other long term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInBankDeposits" xlink:to="plx_IncreaseDecreaseInBankDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Amount of increase (decrease) in deposits held with banks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Increase (Decrease) in Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInBankDeposits_lbl" xml:lang="en-US">Purchase of bank deposits</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromSaleOfShortTermDeposits" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Amount of cash inflow from sale of short-term deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from Sale of Short-term Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds from sale of short-term deposits</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property and equipment</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseDecreaseInRestrictedDeposit" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">Increase (Decrease) In Restricted Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_lbl" xml:lang="en-US">Decrease in restricted deposit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts funded in respect of employee rights upon retirement, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Net payment for promissory note</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net of issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Proceeds from issuance of common stock and warrants, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock under the Sales Agreement, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase in liabilities for property, plant and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Increase In Liabilities For Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right of use assets obtained in exchange for new operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:to="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Note receivable from issuance of common stock and warrants, net of issuance cost.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Note Receivable from Issuance of Common Stock and Warrants, Net of Issuance Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_lbl" xml:lang="en-US">Note receivable from issuance of common stock and warrants, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_InterestReceivedNet" xlink:to="plx_InterestReceivedNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Amount of cash received for interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest Received, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest received</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenueDisclosureTextBlock" xlink:to="plx_RevenueDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure pertaining to revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">Revenue Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_RevenueDisclosureTextBlock_lbl" xml:lang="en-US">REVENUES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">STOCK TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCK TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="plx_NatureOfOperationsPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">General</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Loss per share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_Notes2021Member" xlink:label="plx_Notes2021Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_Notes2021Member" xlink:to="plx_Notes2021Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_Notes2021Member_lbl" xml:lang="en-US">Notes2021 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_Notes2021Member_lbl" xml:lang="en-US">Notes 2021 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of liability component based on income approach</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Company's disaggregation of revenues</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_LicenseAgreementInitialCashPayment" xlink:label="plx_LicenseAgreementInitialCashPayment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LicenseAgreementInitialCashPayment" xlink:to="plx_LicenseAgreementInitialCashPayment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_LicenseAgreementInitialCashPayment_lbl" xml:lang="en-US">The amount of initial cash payment under the license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_LicenseAgreementInitialCashPayment_lbl" xml:lang="en-US">License Agreement, Initial Cash Payment</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_TermToSignSupplyAgreement" xlink:label="plx_TermToSignSupplyAgreement" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_TermToSignSupplyAgreement" xlink:to="plx_TermToSignSupplyAgreement_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_TermToSignSupplyAgreement_lbl" xml:lang="en-US">Term To Sign Supply Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_TermToSignSupplyAgreement_lbl" xml:lang="en-US">Term To Sign Supply Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_TermToSignSupplyAgreement_lbl" xml:lang="en-US">Term to sign supply agreement</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SaleOfStockMaximumOfferingPrice" xlink:to="plx_SaleOfStockMaximumOfferingPrice_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale Of Stock Maximum Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SaleOfStockMaximumOfferingPrice_lbl" xml:lang="en-US">Sale of stock, maximum offering price</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:to="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_lbl" xml:lang="en-US">The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_lbl" xml:lang="en-US">Upfront Nonrefundable Non-Creditable Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">The maximum amount payable to the entity to cover development costs under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_lbl" xml:lang="en-US">Additional Amounts Payable To Cover Development Costs</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">The maximum amount payable to entity to cover development costs in any year under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_lbl" xml:lang="en-US">Maximum Entitlement Of Development Costs To Cover Per Year</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AgreementAmendmentPaymentReceivable" xlink:to="plx_AgreementAmendmentPaymentReceivable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AgreementAmendmentPaymentReceivable_lbl" xml:lang="en-US">Agreement Amendment Payment Receivable</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">The total amount payable to entity for the achievement of regulatory and commercial milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_lbl" xml:lang="en-US">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PaymentOnNetSalesPercentage" xlink:to="plx_PaymentOnNetSalesPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Represents the payment as a percentage of future net sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PaymentOnNetSalesPercentage_lbl" xml:lang="en-US">Payment On Net Sales Percentage</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues Expenses Sharing Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues and Expenses Sharing Percentage</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_RevenuePerformanceObligationNumber" xlink:to="plx_RevenuePerformanceObligationNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_RevenuePerformanceObligationNumber_lbl" xml:lang="en-US">Revenue, Performance Obligation, Number</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal amount</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageConvertibleNotesMember" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" xml:lang="en-US">Seven Point Five Percentage Convertible Notes [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_lbl" xml:lang="en-US">2021 Notes [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value Inputs Level3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US">Debt Instrument, Measurement Input</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Short-term Debt</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Segment Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerMember" xlink:to="plx_PfizerMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Global except for Brazil</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_BR" xlink:label="country_BR" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="country_BR_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BR_lbl" xml:lang="en-US">B [R]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_BR_lbl" xml:lang="en-US">Brazil [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ReductionToAccumulatedRevenueRecognized" xlink:label="plx_ReductionToAccumulatedRevenueRecognized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ReductionToAccumulatedRevenueRecognized" xlink:to="plx_ReductionToAccumulatedRevenueRecognized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ReductionToAccumulatedRevenueRecognized_lbl" xml:lang="en-US">Amount of reduction to accumulated revenues recognized in respect of performance obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ReductionToAccumulatedRevenueRecognized_lbl" xml:lang="en-US">Reduction To Accumulated Revenue Recognized</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_VariableConsideration" xlink:label="plx_VariableConsideration" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_VariableConsideration" xlink:to="plx_VariableConsideration_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_VariableConsideration_lbl" xml:lang="en-US">Amount of variable consideration payable under the contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_VariableConsideration_lbl" xml:lang="en-US">Variable Consideration</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ProceedsFromVariableConsideration" xlink:label="plx_ProceedsFromVariableConsideration" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromVariableConsideration" xlink:to="plx_ProceedsFromVariableConsideration_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromVariableConsideration_lbl" xml:lang="en-US">Proceeds From Variable Consideration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromVariableConsideration_lbl" xml:lang="en-US">Proceeds From Variable Consideration</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_DebtConversionConvertedInstrumentAmountCash" xlink:label="plx_DebtConversionConvertedInstrumentAmountCash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtConversionConvertedInstrumentAmountCash" xlink:to="plx_DebtConversionConvertedInstrumentAmountCash_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtConversionConvertedInstrumentAmountCash_lbl" xml:lang="en-US">The value of the financial instrument(s) that the original debt is being converted into in a cash transaction. "Cash" refers to that portion of the transaction resulting in cash receipts or cash payments in the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtConversionConvertedInstrumentAmountCash_lbl" xml:lang="en-US">Debt Conversion Converted Instrument Amount, Cash</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentConvertibleConversionShareNumber" xlink:to="plx_DebtInstrumentConvertibleConversionShareNumber_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber_lbl" xml:lang="en-US">Debt Instrument Convertible Conversion Share Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber_lbl" xml:lang="en-US">Debt Instrument Convertible Conversion Share Number</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:to="plx_DebtInstrumentConvertibleBaseValueForConversionRate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate_lbl" xml:lang="en-US">Debt Instrument Convertible Base Value For Conversion Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate_lbl" xml:lang="en-US">Debt Instrument Convertible Base Value For Conversion Rate</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_PercentageOfPremiumToClosingPriceOfStock" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PercentageOfPremiumToClosingPriceOfStock" xlink:to="plx_PercentageOfPremiumToClosingPriceOfStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock_lbl" xml:lang="en-US">Percentage of premium to closing price of stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock_lbl" xml:lang="en-US">Percentage of Premium to Closing Price of Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock_lbl" xml:lang="en-US">Percentage of premium to closing price of stock</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Debt Instrument, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Mature term</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost Of Sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US">Cost of Sales [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expenses [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling General And Administrative Expenses [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid In Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="plx_AmendedPfizerAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiAgreementsMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUSAgreementMember" xlink:to="plx_ChiesiUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi U S Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiUSAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiExUSAgreementMember" xlink:to="plx_ChiesiExUSAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex U S Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiExUSAgreementMember_lbl" xml:lang="en-US">Chiesi Ex US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SarcomedUsaInc.AgreementMember" xlink:label="plx_SarcomedUsaInc.AgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SarcomedUsaInc.AgreementMember" xlink:to="plx_SarcomedUsaInc.AgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SarcomedUsaInc.AgreementMember_lbl" xml:lang="en-US">Represents information pertaining to SarcoMed USA, Inc. licensing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SarcomedUsaInc.AgreementMember_lbl" xml:lang="en-US">Sarcomed Usa Inc. Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SarcomedUsaInc.AgreementMember_lbl" xml:lang="en-US">SarcoMed USA, Inc. Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">Chiesi Us Agreement And Chiesi Ex Us Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_lbl" xml:lang="en-US">Chiesi US Agreement and Chiesi Ex US Agreement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AtMarketEquityOfferingMember" xlink:to="plx_AtMarketEquityOfferingMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">Represents the information pertaining to At The Market equity offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">At Market Equity Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AtMarketEquityOfferingMember_lbl" xml:lang="en-US">ATM Shares</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short Term Debt Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input Share Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input Expected Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input Risk Free Interest Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input Price Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_MeasurementInputYieldMember" xlink:to="plx_MeasurementInputYieldMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Measurement Input, Yield [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Measurement Input Yield [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_MeasurementInputYieldMember_lbl" xml:lang="en-US">Measurement Input, Yield [Member]</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiMember" xlink:to="plx_ChiesiMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Global except Brazil and Italy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Chiesi [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Chiesi [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="us-gaap_ChangeInAccountingEstimateByTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_lbl" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_lbl" xml:lang="en-US">Change In Accounting Estimate Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_lbl" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" xlink:label="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" xlink:to="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_lbl" xml:lang="en-US">Change In Accounting Method Accounted For As Change In Estimate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_lbl" xml:lang="en-US">Change in Accounting Method Accounted for as Change in Estimate [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">Represents the information pertaining to seven point five percentage senor secured convertible notes due 2024.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">Seven Point Five Percentage Senior Secured Convertible Notes Due2024 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">7.50% [Senior] Secured Convertible Notes due 2024</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>plx-20210630_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/16/2021 11:17:11 AM-->
<!--Modified on: 8/16/2021 11:17:11 AM-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#StatementCondensedConsolidatedStatementsOfOperationsParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureInventories" roleURI="http://www.protalix.com/role/DisclosureInventories" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureFairValueMeasurement" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureRevenues" roleURI="http://www.protalix.com/role/DisclosureRevenues" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureStockTransactions" roleURI="http://www.protalix.com/role/DisclosureStockTransactions" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureSubsequentEvents" roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureInventoriesTables" roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureFairValueMeasurementTables" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureRevenuesTables" roleURI="http://www.protalix.com/role/DisclosureRevenuesTables" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureInventoriesDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureFairValueMeasurementAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <roleRef xlink:type="simple" xlink:href="plx-20210630.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <presentationLink xlink:role="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637647094305998028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_637647094305998028" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_637647094305998028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_637647094305998028" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637647094305998028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_637647094305998028" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637647094305998028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_637647094305998028" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637647094305998028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_637647094305998028" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637647094305998028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_637647094305998028" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637647094305998028" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637647094305998028" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637647094306008098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637647094306008098" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637647094306008098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_637647094306008098" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637647094306008098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_637647094306008098" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637647094306008098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_637647094306008098" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637647094306008098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_637647094306008098" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637647094306008098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_637647094306008098" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637647094306008098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_637647094306008098" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637647094306008098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_637647094306008098" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637647094306008098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_637647094306008098" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637647094306008098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_637647094306008098" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637647094306008098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_637647094306008098" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637647094306008098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_637647094306008098" order="19" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637647094306008098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_637647094306008098" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637647094306018071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_637647094306018071" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_637647094306018071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_637647094306018071" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637647094306018071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637647094306018071" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637647094306018071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_637647094306018071" order="24" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637647094306018071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_637647094306018071" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637647094306018071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_637647094306018071" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637647094306018071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_637647094306018071" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637647094306018071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_637647094306018071" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637647094306028058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_637647094306028058" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637647094306028058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_637647094306028058" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637647094306028058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_AssetsAbstract_637647094306028058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637647094306028058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637647094306028058" xlink:to="us-gaap_AssetsCurrentAbstract_637647094306028058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637647094306028058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637647094306028058" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637647094306028058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_637647094306028058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637647094306028058" xlink:to="plx_ShortTermBankDeposits_637647094306028058" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637647094306028058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637647094306028058" xlink:to="us-gaap_AccountsReceivableNetCurrent_637647094306028058" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637647094306028058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637647094306028058" xlink:to="us-gaap_OtherAssetsCurrent_637647094306028058" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637647094306028058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637647094306028058" xlink:to="us-gaap_InventoryNet_637647094306028058" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637647094306028058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637647094306028058" xlink:to="us-gaap_AssetsCurrent_637647094306028058" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_637647094306038094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637647094306028058" xlink:to="us-gaap_AssetsNoncurrentAbstract_637647094306038094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637647094306038094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637647094306038094" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_637647094306038094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637647094306038094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637647094306038094" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637647094306038094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_637647094306038094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_637647094306038094" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_637647094306038094" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637647094306038094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637647094306028058" xlink:to="us-gaap_Assets_637647094306038094" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637647094306038094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637647094306038094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637647094306038094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637647094306038094" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637647094306038094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637647094306038094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637647094306038094" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637647094306038094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_637647094306038094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637647094306038094" xlink:to="us-gaap_AccountsPayableTradeCurrent_637647094306038094" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="us-gaap_AccountsPayableOtherCurrent_637647094306038094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637647094306038094" xlink:to="us-gaap_AccountsPayableOtherCurrent_637647094306038094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_637647094306038094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_637647094306038094" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_637647094306038094" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637647094306038094" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637647094306038094" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637647094306038094" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_637647094306048056" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637647094306038094" xlink:to="us-gaap_ConvertibleDebtCurrent_637647094306048056" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_637647094306048056" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637647094306038094" xlink:to="us-gaap_NotesPayableCurrent_637647094306048056" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637647094306048056" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637647094306038094" xlink:to="us-gaap_LiabilitiesCurrent_637647094306048056" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_637647094306048056" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637647094306038094" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_637647094306048056" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_637647094306048056" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637647094306048056" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_637647094306048056" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637647094306048056" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637647094306048056" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_637647094306048056" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_637647094306048056" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637647094306048056" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_637647094306048056" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637647094306048056" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_637647094306048056" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637647094306048056" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_637647094306058197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637647094306038094" xlink:to="us-gaap_LiabilitiesNoncurrent_637647094306058197" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637647094306058197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637647094306038094" xlink:to="us-gaap_Liabilities_637647094306058197" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637647094306058197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637647094306038094" xlink:to="us-gaap_StockholdersEquity_637647094306058197" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637647094306058197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637647094306038094" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637647094306058197" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_271" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637647094306058197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_271" xlink:to="us-gaap_StatementTable_637647094306058197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637647094306058197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637647094306058197" xlink:to="srt_ProductOrServiceAxis_637647094306058197" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637647094306058197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637647094306058197" xlink:to="srt_ProductsAndServicesDomain_637647094306058197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637647094306058197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637647094306058197" xlink:to="us-gaap_ProductMember_637647094306058197" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637647094306058197" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637647094306058197" xlink:to="us-gaap_LicenseAndServiceMember_637647094306058197" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637647094306068079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637647094306058197" xlink:to="us-gaap_StatementLineItems_637647094306068079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637647094306068079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306068079" xlink:to="us-gaap_Revenues_637647094306068079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_637647094306068079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306068079" xlink:to="us-gaap_CostOfRevenue_637647094306068079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637647094306068079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306068079" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637647094306068079" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_637647094306068079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306068079" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_637647094306068079" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637647094306068079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306068079" xlink:to="us-gaap_OperatingIncomeLoss_637647094306068079" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_637647094306068079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306068079" xlink:to="us-gaap_OtherNonoperatingExpense_637647094306068079" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637647094306068079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306068079" xlink:to="us-gaap_OtherNonoperatingIncome_637647094306068079" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_637647094306068079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306068079" xlink:to="us-gaap_NonoperatingIncomeExpense_637647094306068079" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome_637647094306068079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306068079" xlink:to="us-gaap_OtherIncome_637647094306068079" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637647094306068079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306068079" xlink:to="us-gaap_NetIncomeLoss_637647094306068079" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_637647094306068079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306068079" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_637647094306068079" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637647094306068079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306068079" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_637647094306068079" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_411762" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637647094306078177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_411762" xlink:to="us-gaap_StatementTable_637647094306078177" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637647094306078177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637647094306078177" xlink:to="us-gaap_IncomeStatementLocationAxis_637647094306078177" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637647094306078177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637647094306078177" xlink:to="us-gaap_IncomeStatementLocationDomain_637647094306078177" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember_637647094306078177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637647094306078177" xlink:to="us-gaap_CostOfSalesMember_637647094306078177" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637647094306078177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637647094306078177" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637647094306078177" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637647094306078177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637647094306078177" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_637647094306078177" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637647094306078177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637647094306078177" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637647094306078177" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637647094306078177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637647094306078177" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637647094306078177" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637647094306078177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="us-gaap_StatementTable_637647094306078177" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637647094306078177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637647094306078177" xlink:to="us-gaap_StatementEquityComponentsAxis_637647094306078177" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637647094306078177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637647094306078177" xlink:to="us-gaap_CommonStockMember_637647094306078177" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637647094306078177" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637647094306078177" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637647094306078177" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637647094306088105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637647094306078177" xlink:to="us-gaap_RetainedEarningsMember_637647094306088105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637647094306088105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637647094306078177" xlink:to="us-gaap_EquityComponentDomain_637647094306088105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637647094306088105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637647094306078177" xlink:to="us-gaap_StatementLineItems_637647094306088105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637647094306088105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306088105" xlink:to="us-gaap_StockholdersEquity_637647094306088105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637647094306088105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306088105" xlink:to="us-gaap_SharesOutstanding_637647094306088105" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_637647094306088105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306088105" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_637647094306088105" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares" xlink:label="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_637647094306088105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue_637647094306088105" xlink:to="plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares_637647094306088105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants" xlink:label="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants_637647094306088105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306088105" xlink:to="plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants_637647094306088105" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637647094306088105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306088105" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637647094306088105" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637647094306088105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_637647094306088105" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637647094306088105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_StockIssuedDuringPeriodValueSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodValueSalesAgreement_637647094306088105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306088105" xlink:to="plx_StockIssuedDuringPeriodValueSalesAgreement_637647094306088105" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_StockIssuedDuringPeriodSharesSalesAgreement" xlink:label="plx_StockIssuedDuringPeriodSharesSalesAgreement_637647094306088105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueSalesAgreement_637647094306088105" xlink:to="plx_StockIssuedDuringPeriodSharesSalesAgreement_637647094306088105" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637647094306088105" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306088105" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637647094306088105" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_637647094306098072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306088105" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_637647094306098072" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsExercises_637647094306098072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306088105" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsExercises_637647094306098072" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsExercises_637647094306098072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsExercises_637647094306098072" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsExercises_637647094306098072" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637647094306098072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306088105" xlink:to="us-gaap_NetIncomeLoss_637647094306098072" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637647094306098072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306088105" xlink:to="us-gaap_StockholdersEquity_637647094306098072" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_637647094306098072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306088105" xlink:to="us-gaap_SharesOutstanding_637647094306098072" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical" xlink:type="extended" xlink:title="00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637647094306108058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637647094306108058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637647094306108058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockSharesAuthorized_637647094306108058" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637647094306108058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637647094306108058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637647094306108058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637647094306108058" xlink:to="us-gaap_NetIncomeLoss_637647094306108058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637647094306108058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637647094306108058" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637647094306108058" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637647094306108058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637647094306108058" xlink:to="us-gaap_ShareBasedCompensation_637647094306108058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_637647094306108058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637647094306108058" xlink:to="us-gaap_Depreciation_637647094306108058" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637647094306108058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637647094306108058" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_637647094306108058" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_637647094306108058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637647094306108058" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_637647094306108058" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637647094306108058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637647094306108058" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_637647094306108058" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637647094306108058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637647094306108058" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637647094306108058" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637647094306108058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637647094306108058" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_637647094306108058" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637647094306118060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637647094306108058" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637647094306118060" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637647094306118060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637647094306118060" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637647094306118060" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637647094306118060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637647094306118060" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637647094306118060" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_637647094306118060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637647094306118060" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_637647094306118060" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_637647094306118060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637647094306118060" xlink:to="us-gaap_IncreaseDecreaseInInventories_637647094306118060" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637647094306118060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637647094306118060" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_637647094306118060" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637647094306118060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637647094306118060" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637647094306118060" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637647094306118060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637647094306108058" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637647094306118060" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637647094306118060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637647094306118060" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_IncreaseDecreaseInBankDeposits" xlink:label="plx_IncreaseDecreaseInBankDeposits_637647094306118060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637647094306118060" xlink:to="plx_IncreaseDecreaseInBankDeposits_637647094306118060" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ProceedsFromSaleOfShortTermDeposits" xlink:label="plx_ProceedsFromSaleOfShortTermDeposits_637647094306118060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637647094306118060" xlink:to="plx_ProceedsFromSaleOfShortTermDeposits_637647094306118060" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637647094306118060" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637647094306118060" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_637647094306118060" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637647094306128097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637647094306118060" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_637647094306128097" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_IncreaseDecreaseInRestrictedDeposit" xlink:label="plx_IncreaseDecreaseInRestrictedDeposit_637647094306128097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637647094306118060" xlink:to="plx_IncreaseDecreaseInRestrictedDeposit_637647094306128097" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637647094306128097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637647094306118060" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_637647094306128097" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637647094306128097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637647094306118060" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637647094306128097" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637647094306128097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637647094306128097" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_637647094306128097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637647094306128097" xlink:to="us-gaap_RepaymentsOfNotesPayable_637647094306128097" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637647094306128097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637647094306128097" xlink:to="plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637647094306128097" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637647094306138097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637647094306128097" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637647094306138097" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637647094306138097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637647094306128097" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637647094306138097" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637647094306138097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_637647094306138097" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637647094306138097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637647094306138097" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637647094306138097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637647094306138097" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_6376470943061380971" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_6376470943061380971" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637647094306138097" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637647094306138097" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment" xlink:label="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_637647094306148144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637647094306138097" xlink:to="plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment_637647094306148144" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637647094306148144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637647094306138097" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_637647094306148144" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost" xlink:label="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637647094306148144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637647094306138097" xlink:to="plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost_637647094306148144" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637647094306148144" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637647094306148144" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet_637647094306158134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637647094306148144" xlink:to="plx_InterestReceivedNet_637647094306158134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637647094306158134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_637647094306158134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10201 - Disclosure - INVENTORIES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_637647094306158134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="us-gaap_InventoryDisclosureTextBlock_637647094306158134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="10301 - Disclosure - FAIR VALUE MEASUREMENT">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_637647094306168096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="us-gaap_FairValueDisclosuresTextBlock_637647094306168096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenues" xlink:type="extended" xlink:title="10401 - Disclosure - REVENUES">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_RevenueDisclosureTextBlock" xlink:label="plx_RevenueDisclosureTextBlock_637647094306168096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="plx_RevenueDisclosureTextBlock_637647094306168096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactions" xlink:type="extended" xlink:title="10501 - Disclosure - STOCK TRANSACTIONS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637647094306168096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_637647094306168096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="10601 - Disclosure - SUBSEQUENT EVENTS">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_349978" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637647094306168096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_349978" xlink:to="us-gaap_SubsequentEventsTextBlock_637647094306168096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock_637647094306168096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock_637647094306168096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637647094306178276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637647094306178276" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637647094306178276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637647094306178276" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_637647094306178276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_637647094306178276" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="30203 - Disclosure - INVENTORIES (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637647094306178276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_637647094306178276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementTables" xlink:type="extended" xlink:title="30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_129" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637647094306178276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_129" xlink:to="us-gaap_StatementTable_637647094306178276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637647094306178276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637647094306178276" xlink:to="us-gaap_DebtInstrumentAxis_637647094306178276" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637647094306178276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637647094306178276" xlink:to="us-gaap_DebtInstrumentNameDomain_637647094306178276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_Notes2021Member" xlink:label="plx_Notes2021Member_637647094306178276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637647094306178276" xlink:to="plx_Notes2021Member_637647094306178276" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637647094306178276" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637647094306178276" xlink:to="us-gaap_StatementLineItems_637647094306178276" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637647094306188101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306178276" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_637647094306188101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesTables" xlink:type="extended" xlink:title="30403 - Disclosure - REVENUES (Tables)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_637647094306188101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_637167842398709852" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_637647094306188101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_177" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_637647094306188101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177" xlink:to="plx_SignificantAccountingPoliciesTable_637647094306188101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637647094306188101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637647094306188101" xlink:to="us-gaap_TypeOfArrangementAxis_637647094306188101" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637647094306188101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637647094306188101" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637647094306188101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_637647094306188101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637647094306188101" xlink:to="plx_AmendedPfizerAgreementMember_637647094306188101" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_637647094306188101" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637647094306188101" xlink:to="plx_ChiesiAgreementsMember_637647094306188101" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChiesiUSAgreementMember" xlink:label="plx_ChiesiUSAgreementMember_637647094306197816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_637647094306188101" xlink:to="plx_ChiesiUSAgreementMember_637647094306197816" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_637647094306197816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ChiesiAgreementsMember_637647094306188101" xlink:to="plx_ChiesiExUSAgreementMember_637647094306197816" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SarcomedUsaInc.AgreementMember" xlink:label="plx_SarcomedUsaInc.AgreementMember_637647094306197816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637647094306188101" xlink:to="plx_SarcomedUsaInc.AgreementMember_637647094306197816" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637647094306197816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637647094306188101" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637647094306197816" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637647094306197816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637647094306188101" xlink:to="dei_LegalEntityAxis_637647094306197816" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637647094306197816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637647094306197816" xlink:to="dei_EntityDomain_637647094306197816" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_637647094306197816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637647094306197816" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_637647094306197816" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637647094306197816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637647094306188101" xlink:to="srt_StatementGeographicalAxis_637647094306197816" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637647094306197816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637647094306197816" xlink:to="srt_SegmentGeographicalDomain_637647094306197816" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_BR" xlink:label="country_BR_637647094306197816" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637647094306197816" xlink:to="country_BR_637647094306197816" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637647094306208854" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637647094306188101" xlink:to="srt_RangeAxis_637647094306208854" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637647094306208854" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637647094306208854" xlink:to="srt_RangeMember_637647094306208854" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637647094306208854" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637647094306208854" xlink:to="srt_MinimumMember_637647094306208854" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637647094306208854" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637647094306208854" xlink:to="srt_MaximumMember_637647094306208854" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637647094306208854" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637647094306188101" xlink:to="us-gaap_DebtInstrumentAxis_637647094306208854" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637647094306208854" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637647094306208854" xlink:to="us-gaap_DebtInstrumentNameDomain_637647094306208854" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637647094306208854" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637647094306208854" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637647094306208854" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637647094306218230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637647094306188101" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637647094306218230" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637647094306218230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637647094306218230" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637647094306218230" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember_637647094306218230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637647094306218230" xlink:to="plx_AtMarketEquityOfferingMember_637647094306218230" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_637647094306218230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637647094306188101" xlink:to="us-gaap_ShortTermDebtTypeAxis_637647094306218230" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_637647094306218230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis_637647094306218230" xlink:to="us-gaap_ShortTermDebtTypeDomain_637647094306218230" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember_637647094306218230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain_637647094306218230" xlink:to="us-gaap_ConvertibleNotesPayableMember_637647094306218230" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_637647094306218230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_637647094306188101" xlink:to="plx_SignificantAccountingPoliciesLineItems_637647094306218230" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_LicenseAgreementInitialCashPayment" xlink:label="plx_LicenseAgreementInitialCashPayment_637647094306218230" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637647094306218230" xlink:to="plx_LicenseAgreementInitialCashPayment_637647094306218230" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_TermToSignSupplyAgreement" xlink:label="plx_TermToSignSupplyAgreement_637647094306228064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637647094306218230" xlink:to="plx_TermToSignSupplyAgreement_637647094306228064" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637647094306228064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637647094306218230" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637647094306228064" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637647094306228064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637647094306218230" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637647094306228064" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice_637647094306228064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637647094306218230" xlink:to="plx_SaleOfStockMaximumOfferingPrice_637647094306228064" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_637647094306228064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637647094306218230" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_637647094306228064" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637647094306228064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637647094306218230" xlink:to="us-gaap_SharesIssuedPricePerShare_637647094306228064" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_UpfrontNonrefundableNonCreditablePaymentReceivable" xlink:label="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_637647094306228064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637647094306218230" xlink:to="plx_UpfrontNonrefundableNonCreditablePaymentReceivable_637647094306228064" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_AdditionalAmountsPayableToCoverDevelopmentCosts" xlink:label="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637647094306228064" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637647094306218230" xlink:to="plx_AdditionalAmountsPayableToCoverDevelopmentCosts_637647094306228064" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear" xlink:label="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_637647094306238088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637647094306218230" xlink:to="plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear_637647094306238088" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_AgreementAmendmentPaymentReceivable" xlink:label="plx_AgreementAmendmentPaymentReceivable_637647094306238088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637647094306218230" xlink:to="plx_AgreementAmendmentPaymentReceivable_637647094306238088" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_637647094306238088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637647094306218230" xlink:to="plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones_637647094306238088" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones" xlink:label="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_637647094306238088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637647094306218230" xlink:to="plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones_637647094306238088" order="13" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_PaymentOnNetSalesPercentage" xlink:label="plx_PaymentOnNetSalesPercentage_637647094306238088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637647094306218230" xlink:to="plx_PaymentOnNetSalesPercentage_637647094306238088" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_637647094306238088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637647094306218230" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_637647094306238088" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637647094306238088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637647094306218230" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637647094306238088" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent_637647094306248041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637647094306218230" xlink:to="us-gaap_ConvertibleDebtCurrent_637647094306248041" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637647094306248041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637647094306218230" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637647094306248041" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_RevenuePerformanceObligationNumber" xlink:label="plx_RevenuePerformanceObligationNumber_637647094306248041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637647094306218230" xlink:to="plx_RevenuePerformanceObligationNumber_637647094306248041" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637647094306248041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_637647094306218230" xlink:to="us-gaap_DebtInstrumentFaceAmount_637647094306248041" order="20" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - INVENTORIES (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_637647094306258198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_637647094306258198" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_637647094306258198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_637647094306258198" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_637647094306258198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_637647094306258198" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_637647094306258198" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryNet_637647094306258198" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails" xlink:type="extended" xlink:title="40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_566" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637647094306328053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_566" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637647094306328053" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637647094306328053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637647094306328053" xlink:to="us-gaap_DebtInstrumentAxis_637647094306328053" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637647094306328053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637647094306328053" xlink:to="us-gaap_DebtInstrumentNameDomain_637647094306328053" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637647094306328053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637647094306328053" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637647094306328053" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637647094306328053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637647094306328053" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637647094306328053" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637647094306328053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637647094306328053" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637647094306328053" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637647094306328053" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637647094306328053" xlink:to="us-gaap_FairValueInputsLevel3Member_637647094306328053" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_637647094306338031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637647094306328053" xlink:to="us-gaap_MeasurementInputTypeAxis_637647094306338031" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_637647094306338031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_637647094306338031" xlink:to="us-gaap_MeasurementInputTypeDomain_637647094306338031" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_637647094306338031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637647094306338031" xlink:to="us-gaap_MeasurementInputSharePriceMember_637647094306338031" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_637647094306338031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637647094306338031" xlink:to="us-gaap_MeasurementInputExpectedTermMember_637647094306338031" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_637647094306338031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637647094306338031" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_637647094306338031" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_637647094306338031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637647094306338031" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_637647094306338031" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_MeasurementInputYieldMember" xlink:label="plx_MeasurementInputYieldMember_637647094306338031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_637647094306338031" xlink:to="plx_MeasurementInputYieldMember_637647094306338031" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637647094306338031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637647094306328053" xlink:to="us-gaap_StatementLineItems_637647094306338031" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="us-gaap_DebtInstrumentMeasurementInput_637647094306338031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306338031" xlink:to="us-gaap_DebtInstrumentMeasurementInput_637647094306338031" order="1" use="optional" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_584" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637647094306338031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_584" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637647094306338031" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_637647094306338031" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637647094306338031" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_637647094306338031" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637647094306348093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_637647094306338031" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637647094306348093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_637647094306348093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_637647094306348093" xlink:to="us-gaap_FairValueInputsLevel3Member_637647094306348093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637647094306348093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637647094306338031" xlink:to="us-gaap_DebtInstrumentAxis_637647094306348093" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637647094306348093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637647094306348093" xlink:to="us-gaap_DebtInstrumentNameDomain_637647094306348093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637647094306348093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637647094306348093" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637647094306348093" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637647094306348093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_637647094306338031" xlink:to="us-gaap_StatementLineItems_637647094306348093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_637647094306348093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306348093" xlink:to="us-gaap_ShortTermBorrowings_637647094306348093" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637647094306348093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306348093" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637647094306348093" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_637647094306348093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306348093" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_637647094306348093" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637647094306357841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_StatementTable_637647094306357841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_637647094306357841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637647094306357841" xlink:to="srt_ProductOrServiceAxis_637647094306357841" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_637647094306357841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_637647094306357841" xlink:to="srt_ProductsAndServicesDomain_637647094306357841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_637647094306357841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637647094306357841" xlink:to="us-gaap_ProductMember_637647094306357841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_637647094306357841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_637647094306357841" xlink:to="us-gaap_LicenseAndServiceMember_637647094306357841" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637647094306357841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637647094306357841" xlink:to="us-gaap_TypeOfArrangementAxis_637647094306357841" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637647094306357841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637647094306357841" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637647094306357841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChiesiUsAgreementAndChiesiExUsAgreementMember" xlink:label="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637647094306357841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637647094306357841" xlink:to="plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_637647094306357841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChiesiExUSAgreementMember" xlink:label="plx_ChiesiExUSAgreementMember_637647094306357841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637647094306357841" xlink:to="plx_ChiesiExUSAgreementMember_637647094306357841" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637647094306357841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637647094306357841" xlink:to="srt_StatementGeographicalAxis_637647094306357841" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637647094306357841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637647094306357841" xlink:to="srt_SegmentGeographicalDomain_637647094306357841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_637647094306357841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637647094306357841" xlink:to="plx_PfizerMember_637647094306357841" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_BR" xlink:label="country_BR_637647094306357841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637647094306357841" xlink:to="country_BR_637647094306357841" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember_637647094306357841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637647094306357841" xlink:to="plx_ChiesiMember_637647094306357841" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_637647094306368058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637647094306357841" xlink:to="us-gaap_ChangeInAccountingEstimateByTypeAxis_637647094306368058" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_637647094306368058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis_637647094306368058" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_637647094306368058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember" xlink:label="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_637647094306368058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateTypeDomain_637647094306368058" xlink:to="us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_637647094306368058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637647094306368058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637647094306357841" xlink:to="us-gaap_StatementLineItems_637647094306368058" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_637647094306368058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306368058" xlink:to="us-gaap_Revenues_637647094306368058" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ReductionToAccumulatedRevenueRecognized" xlink:label="plx_ReductionToAccumulatedRevenueRecognized_637647094306368058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306368058" xlink:to="plx_ReductionToAccumulatedRevenueRecognized_637647094306368058" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_VariableConsideration" xlink:label="plx_VariableConsideration_637647094306368058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306368058" xlink:to="plx_VariableConsideration_637647094306368058" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_ProceedsFromVariableConsideration" xlink:label="plx_ProceedsFromVariableConsideration_637647094306368058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637647094306368058" xlink:to="plx_ProceedsFromVariableConsideration_637647094306368058" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637647094306368058" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637647094306368058" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637647094306378291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637647094306368058" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637647094306378291" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637647094306378291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637647094306378291" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637647094306378291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_637647094306378291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637647094306378291" xlink:to="us-gaap_PrivatePlacementMember_637647094306378291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_AtMarketEquityOfferingMember" xlink:label="plx_AtMarketEquityOfferingMember_637647094306378291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637647094306378291" xlink:to="plx_AtMarketEquityOfferingMember_637647094306378291" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637647094306378291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637647094306368058" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637647094306378291" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637647094306378291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637647094306378291" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637647094306378291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_637647094306378291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637647094306378291" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_637647094306378291" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SaleOfStockMaximumOfferingPrice" xlink:label="plx_SaleOfStockMaximumOfferingPrice_637647094306378291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637647094306378291" xlink:to="plx_SaleOfStockMaximumOfferingPrice_637647094306378291" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_637647094306378291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable_637647094306378291" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637647094306378291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637647094306378291" xlink:to="us-gaap_SubsequentEventTypeAxis_637647094306378291" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637647094306378291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637647094306378291" xlink:to="us-gaap_SubsequentEventTypeDomain_637647094306378291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637647094306378291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637647094306378291" xlink:to="us-gaap_SubsequentEventMember_637647094306378291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637647094306378291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637647094306378291" xlink:to="us-gaap_DebtInstrumentAxis_637647094306378291" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637647094306378291" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637647094306378291" xlink:to="us-gaap_DebtInstrumentNameDomain_637647094306378291" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SevenPointFivePercentageConvertibleNotesMember" xlink:label="plx_SevenPointFivePercentageConvertibleNotesMember_637647094306388098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637647094306378291" xlink:to="plx_SevenPointFivePercentageConvertibleNotesMember_637647094306388098" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637647094306388098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637647094306378291" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_637647094306388098" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_637647094306388098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637647094306378291" xlink:to="us-gaap_SubsequentEventLineItems_637647094306388098" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings_637647094306388098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637647094306388098" xlink:to="us-gaap_ShortTermBorrowings_637647094306388098" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637647094306388098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637647094306388098" xlink:to="us-gaap_DebtInstrumentFaceAmount_637647094306388098" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637647094306388098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637647094306388098" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637647094306388098" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_DebtConversionConvertedInstrumentAmountCash" xlink:label="plx_DebtConversionConvertedInstrumentAmountCash_637647094306388098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637647094306388098" xlink:to="plx_DebtConversionConvertedInstrumentAmountCash_637647094306388098" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_DebtInstrumentConvertibleConversionShareNumber" xlink:label="plx_DebtInstrumentConvertibleConversionShareNumber_637647094306388098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637647094306388098" xlink:to="plx_DebtInstrumentConvertibleConversionShareNumber_637647094306388098" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_DebtInstrumentConvertibleBaseValueForConversionRate" xlink:label="plx_DebtInstrumentConvertibleBaseValueForConversionRate_637647094306388098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637647094306388098" xlink:to="plx_DebtInstrumentConvertibleBaseValueForConversionRate_637647094306388098" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_637647094306388098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637647094306388098" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_637647094306388098" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="plx-20210630.xsd#plx_PercentageOfPremiumToClosingPriceOfStock" xlink:label="plx_PercentageOfPremiumToClosingPriceOfStock_637647094306388098" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637647094306388098" xlink:to="plx_PercentageOfPremiumToClosingPriceOfStock_637647094306388098" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_637647094306398075" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637647094306388098" xlink:to="us-gaap_DebtInstrumentTerm_637647094306398075" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>plx-20210630x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:plx="http://www.protalix.com/20210630"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="plx-20210630.xsd" xlink:type="simple"/>
    <context id="Duration_6_7_2021_To_6_7_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_hHEjR2Bo5EuYhi_31RGp8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-07</startDate>
            <endDate>2021-06-07</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jpLE-akMakyV3Jbk_35Y5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_coEbyffChUiacKC7c4wHAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7dJe2GnFOEGyYLG5fG1hgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TInNrhsHD0-stLLDv404XQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_QRSFKQURbUe6hHXKoDRu9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zpuoYmPfdkek3USyWn91Qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zVn_KJPePkOTFIcmvJNdvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WNnhvQfFrEymbDn9Ce7FGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6nrUDBCtt06YRW-L2OEYxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8Jw06A2_s02mFX7Ni3WLQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JwuKoUeMXUSq0ARxWqpE6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_ZFXxvJmOEUaEgQwjPNZzDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZYngxRQFYkWwRhWxM0SkzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K5lGRruMjUWFHxHMZFMGmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_vViOT2LFf0axMCBfeZUuig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_c92pTwX33UuIlz_FfqiOGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QPt03YiNMEyRlDDY1cIgVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Aw21LWNb10edAAVCUPhNiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q55XKvKM6UWzjFvtkRLLmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7koqe4XbrU2iAVQ8xtCh9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4cR5rGHxsEuH26ppUkiILQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_2_17_2021_I73LVvhcdECPyti0oudI0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-02-17</instant>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_3FiFNKmCaEy9ibcMUQ7VXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_0ROHtRtUikyYBfN1q0FG8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_lNGq93994UKs__wHyGDgeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_5O4qCJrVG0eoNBly8DogRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_9dHpxsKaGEaFqtY_iDBcKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_iX-tLkOGFEuB3AcNqYn0Rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_Ho_xcKWNEEuICmELxx2gig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_Ov94iWapwECTWXr04PGCzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:ChiesiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_Q6m-H8y14kKGpOowck7pfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_8zn7u60jckyDuh3BmFc7oQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_y9t0G7VzUk-YnlJjmRCq3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_mYAzB56-cUCdOTNVt0yw5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_Pp2mgbyjGkO2esZcL0xKKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_4d1okvan3EClXL0thoxjqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Z_KtMWQs0Uujw0cnqYs6lQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_wgEii3xYtU2zfwp11IyUzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_0Dtxw3_Y9E6sb-ILAujQMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">plx:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_vAeDA4nbuUyblocjjCUcbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_IvlRKs5dAEuQ7xeqDJDHLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_YnQnoi6e-EudGaXDEpkpwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_pMCN5439iEi2rGvtFhU0-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_2_17_2021_To_2_17_2021_eP-kucV1pUWTbBXr7TaMSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-02-17</startDate>
            <endDate>2021-02-17</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0-Eu2_lbZUioiYvNP-u1Jg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gJteVLZhPUKl-E3d6202xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ED-14lWq4kqXAYP7X69qhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9IdhTME8lUGRXZwzJDuW3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_yMRhv1-EBUyjv67c4vnBIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:Notes2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_-UCWB1XwmECspjYijNZ7Jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_mufBZIm2IkKt0BdUQt8lTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_B-IrvzpQnE-E4laCHJyHig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_MB3j5xcttkmq-uspEaqDzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_TXQdyNOI60W_tZ_1z-7XnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">plx:MeasurementInputYieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_eC_j6cyaVEe4nMowIWMQlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_CocxRZ8sAUy7n9e-67jKfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-12</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_-tsX_jEa10aFdesmgIQc1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_NaNGoBKCkEiu7vUtu1FpeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_9pT5j3bp9kOxck8vgMJvsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-18</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_UTfTJ92Crkail7a-VOYa5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_tP37cYnQBEy-ajyGcP9j2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_wDSeLRz8j0mcVlFQpqqNGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Sxq30RrND0uqWIoDHU4HbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_B2vkFxAj30mgjYvbaeB7XQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_jyn3lwbXOESy8Z3KX8YCGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_iiC6Yn_rdkWx9W-FzaEoiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_2I_j-CG2WE-GsdeFUO0uXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5PQNzgrw3U21fmcnTdCH2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Okh2sy6Wwku5BgEkLA_q-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_hDBte-t0lUWwnjhjyGWBOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_bqX3cUtNBESnhgaklTJZew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9wfTwEjjqEi90jMNxt9LuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_PDlyFNQ9d0677vNqirp86w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_AI0MTldNw0S-WidGYq9XRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_5jiTZMuakUK7bv_eFjH6Tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4hdRC028OESAjUPcR-4qZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fmr_C6CM1EmRY2waHRcinA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gsX0p07goEqvnOBN9SVuGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h_6cg02980C2C6q1_vdErg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_36UqK7xw-keHI8meiWi3Lw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_Icszi70YU0WMX60GBUG0ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ChangeInAccountingEstimateByTypeAxis_us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_zOqqkDVmMEqqtqAQg4AvEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">us-gaap:ChangeInAccountingMethodAccountedForAsChangeInEstimateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUsAgreementAndChiesiExUsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_lC9sVFpteUu2iOBXmvyCnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_cT_q_tep9EOn9lbEWZblFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_3jQI-P9cnkOUP6jE77HynA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-23</startDate>
            <endDate>2018-07-23</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_hO2OX0CkykSDtEZGjleYjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_eVJdA8NazEqDalQFFkRHrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-19</startDate>
            <endDate>2017-10-19</endDate>
        </period>
    </context>
    <context id="Duration_2_10_2021_To_2_10_2021_us-gaap_TypeOfArrangementAxis_plx_SarcomedUsaInc.AgreementMember_s6R6OeOa5EigE4cD9-rsoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:SarcomedUsaInc.AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-10</startDate>
            <endDate>2021-02-10</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MEoQBaAbc06IzFxMkQM1qg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5mBl3aHBi0KLliehuspORg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-12</instant>
        </period>
    </context>
    <context id="Duration_8_12_2021_To_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wp1PKGYOf02TVwTFOgkSpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="Duration_8_12_2021_To_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_0ds-0DyfXEGdaoZ3UfY54A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-12</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_T2MIzBKUik2fuPiyDHsRSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_W0s5POha_U6du1M7Hy-NoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-13</endDate>
        </period>
    </context>
    <context id="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_cUS14zPtB02emWZ8d9vIBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-13</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SQhCtGF5pEGEvL3YbxckPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_UXGhKrHKLEeju1LG7xvQ0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-23</instant>
        </period>
    </context>
    <context id="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_JPKl0rb7CE-Kwx4t4a5tFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiExUSAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-19</instant>
        </period>
    </context>
    <context id="As_Of_8_1_2021_j5jIo3nZTky_FHNtZBcwKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2021-08-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_agreement_roa1qYbSR0KRZqNYmT7fsA">
        <measure>plx:agreement</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tc_CEA06ZRVZkSs3Ggktmalsg_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tc_Jr0YqwOjkk6H4OJMLI0YuQ_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tc_7zqPV-CipUS_nCqpxiLtyg_4_1">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tc_ztFh9LAXvECnXgLj-EVwYw_5_1">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Narr_nzMb86XTSEqB6Dh-e9Mf3g">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Narr_mskxDydf80ao09jqB_bkrA">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Narr_oRFu-dto-Ui53ztjRYgm7g">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Narr_t36IKXyq1UGxZ-sw2Jid7Q">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Narr_xykXs06lHEW3uJ1MxW0h8g">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Narr_kkcGM1133ESMALX_kNLgPw">001-33357</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Narr_QpyiNWvG1EO8JnU8U_CFlg">PROTALIX BIOTHERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tc_GOP988dHFEi6BaZ2OC6qeA_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Narr_iX83J41tFEOuIzCpUUgIYQ">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Narr_4s2wLOKE80GYy_FQAH_l2Q">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Narr_XhkrVibkjUuMPU8GOWWE8Q">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Narr_OLFeqwV8KEOUkpUcUp6Hgg">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Narr_zrB_JEv91Em4s8SxBawvCA">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tc_fh7YdW8Yhkm5ZGVWzWRF3Q_4_1">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Narr_S9wuHBTC40SXuYdBA4obMA">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Narr_gPqXnkgRAkmiwbK9g_SzMQ">696-9345</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tc_EAzaOFeBnk-47TIzDGX57w_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tc_nBtAD13YXUi7EVilvZYzZQ_2_2">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tc_qwmR-qpBw0O-dLlrvqVqTQ_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Narr_5rdD5LEnN0iOWEQm15KjCQ">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Narr_5IsgIkLgP0ODvEseCkr7mw">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tc_BlFkyZ-r30mqOaG27hJ93Q_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tc_IRV2OwGApUKjz5dfeO5sRQ_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tc_qEMevcXUR0GftabPUMc27Q_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Narr_fHrnChwhsE2dno3rNMq1rg">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_8_1_2021_j5jIo3nZTky_FHNtZBcwKw"
      decimals="INF"
      id="Narr_9KRRpjjPs0efRaZJMdmH3w"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">45556647</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_oYDyycS-NkyzrLBQPq8nug_6_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">33882000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_P-quLJfEQ02lUohQuzWw6A_6_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">18265000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_AmGTHtXknEeK7YS5NZcbiA_7_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">43058000</plx:ShortTermBankDeposits>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_hWqNoSRBVE61B8x04OFWTw_7_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">20280000</plx:ShortTermBankDeposits>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_Z-D7bVqvK0OdxTi9pO6lIA_8_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">2330000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_4H3VVQSI606XRI9B5Ih9RA_8_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">2000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_fWKZUW2ztUaX-I0XLRp6hg_9_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">3013000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_tM-HzvLDGkqX_YolRWHtUA_9_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">2096000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_IPAaO4J8W0id4tNuqArdgA_10_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">13640000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_zoTHtde2NkihhJAMVVWRFw_10_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">13082000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_xURScdRXM0q-ZJpk7A_1hg_11_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">95923000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_7r3LkhFaV06iGrtp7e-tbg_11_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">55723000</us-gaap:AssetsCurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_x_gPdOg1VEekd-17enND_A_14_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">1884000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_m4Kh6JN7NEahb7NNKrBLKw_14_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">1799000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_Ze9FTTgB-U6sBRkkm8fSLA_15_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">4991000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_z-GXiANkiUyDEvgZ3ISVSw_15_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">4845000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_ubG-g77DHEKigNlfubV9HQ_16_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">5406000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_eXtoEJpTykmMxFYJ-zGlMA_16_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">5567000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_yPmDtbKLh0G6anIwdC2Onw_17_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">108204000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_wZtUl3ZusEKPDt0V3EkI6g_17_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">67934000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_0agt-nFxzkGqaLZS14JuPg_23_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">6128000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_QzpuLEhHXkWmfXwQhNFklA_23_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">7221000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_5IzUwkrZ2UupFhDT7G9RLA_24_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">14420000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_nLqkoTzyykiNPlRb12pxug_24_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">13926000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_tl6I-YBHi0OYB2zU1X25RA_25_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">1235000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_wxX7_xGd6EmwLpEqjBrJag_25_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">1420000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_9BYb00H2I0aMRx5J5GSk4A_26_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">18109000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_f19DtZ36Nkm173BTtfPS5w_26_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">5394000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_fP4B0HOLt06xx9XysgVwgQ_27_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">56355000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:ConvertibleDebtCurrent
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_OY7j7QmYM0aTbvCS_t3qDQ_27_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">54427000</us-gaap:ConvertibleDebtCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_qGJoO1qN0UGkXO3B_ECnRA_28_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">4086000</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_zDNZJSgHBke3eZgw-52TKA_29_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">96247000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_0M-EtjNlC0SdgCbNzwAJEA_29_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">86474000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_EiDTM_STN0u1DPEihx89PA_32_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">1269000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_X_CrU-hfD0Wel8BtEU-_qA_32_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">1716000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_k25TFj1hKkq2bLH-kws8hQ_33_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">2302000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_HKLdw-qF7EmnY2oKLE8O6Q_33_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">2263000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_WL1_1PNrwEay-O3kAmBrkg_34_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">4507000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_tBPt_KtYjUS0LntD7i-W1Q_34_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">4467000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_XKfGLf270ES8BRJza4Hxyg_35_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">38000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_CnHk7ehQaUqvE2g_3evJFg_35_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">51000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_sGEh409NqE25OvfCjZIH3Q_36_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">8116000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_ju-cd2Ho_kuKyT9GWDhpEw_36_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">8497000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_JPB-iDhNqUOhuozyc7KQnw_37_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">104363000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_IxN6RkCOjkySU6CarfT0QA_37_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">94971000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_p_n_AIah4UiUnPmTPLOo5w_39_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">3841000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_chpTdhNDnkuv7vwojstXOQ_39_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-27037000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_IRadxxcXkk2YlKJ6YqIBRw_40_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">108204000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_CvFMwQdzp0K0mMwpTR99BQ_40_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">67934000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_8zn7u60jckyDuh3BmFc7oQ"
      decimals="-3"
      id="Tc_2fvA8p4hlk2d-7ILNnbtcQ_3_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">7754000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_IvlRKs5dAEuQ7xeqDJDHLg"
      decimals="-3"
      id="Tc_LfS_FRa8sEuclDn9Z6yoaw_3_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">8679000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_5O4qCJrVG0eoNBly8DogRQ"
      decimals="-3"
      id="Tc_aFMyzxKWQU2Du3_HgF0oHA_3_9"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">3243000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_4d1okvan3EClXL0thoxjqQ"
      decimals="-3"
      id="Tc_wpEDY0w-80ysHAB_9MwD6w_3_12"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">3648000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_y9t0G7VzUk-YnlJjmRCq3w"
      decimals="-3"
      id="Tc_Dt377lxP9kCqpBwwXa-OpA_4_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">9993000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_YnQnoi6e-EudGaXDEpkpwA"
      decimals="-3"
      id="Tc___R-AtSu40aXX83BVNdQUw_4_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">23934000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_9dHpxsKaGEaFqtY_iDBcKQ"
      decimals="-3"
      id="Tc_-4Sz0kbUhEOJpCCv6GmAVA_4_9"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">3184000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Z_KtMWQs0Uujw0cnqYs6lQ"
      decimals="-3"
      id="Tc_ugiXj-CrDk6sjkTV-euRQQ_4_12"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">7319000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_EouYs3DR8EmTfQijLsEweg_5_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">17747000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_8cctxc8CdEajwKvRqWMdaA_5_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">32613000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ"
      decimals="-3"
      id="Tc_nua3PHVrVEuXY3H7rknjfA_5_9"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">6427000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg"
      decimals="-3"
      id="Tc_wQVpaF7CvEOdR1oLZYpxsg_5_12"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">10967000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_ja4zzCYhOEqCGEHrAQpQfg_6_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">9498000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_MOKYy9iWukWBlp9Cb8syFQ_6_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">5253000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ"
      decimals="-3"
      id="Tc_l5BWUd-RXUGbJZRQPvUhdw_6_9"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">4733000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg"
      decimals="-3"
      id="Tc_M3MdaWnkm0u3iCJrBVW49Q_6_12"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">1827000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_6PQnFa_8wEOkocugC-GiRA_7_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">14811000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_SOE0M9LJqEC9irlbFTBuww_7_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">19526000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ"
      decimals="-3"
      id="Tc_j20L-um0_UeQS6WljLnoLw_7_9"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">7689000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg"
      decimals="-3"
      id="Tc_UJDWbfys4UWta90TrpcD1g_7_12"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">9186000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_zZSlooWFp0SIFCb7s7p3xw_8_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">6309000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_6jhX9rTYhkan3hwzHYH8Zw_8_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">5381000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ"
      decimals="-3"
      id="Tc_c0sXX_tWXE2Thll3DxjFZg_8_9"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">3171000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg"
      decimals="-3"
      id="Tc_8pXFPCLHhEC0G7Z06IE0AQ_8_12"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">2194000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_192CDiW0FUGSNkaSOKiiLQ_9_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-12871000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_A-fSIf6_nkaBXv-ptX7pzg_9_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">2453000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ"
      decimals="-3"
      id="Tc_p7KRejpdzUiK_0AScxXZ5Q_9_9"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-9166000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg"
      decimals="-3"
      id="Tc_Lkn50MLR2k-meiNQlrFDig_9_12"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-2240000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_fWb4bftimU-yvpA0FtKdQg_10_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">4240000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_eGr1KFOACUyCGTpgaHfeUg_10_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">5177000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ"
      decimals="-3"
      id="Tc_F4oDvflQFkazpgaVhMaO0Q_10_9"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">2203000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg"
      decimals="-3"
      id="Tc_H6SItsFK5k2So-Hd2YCHIQ_10_12"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">1948000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_gTJ8lvkFE0m-cU6ZZ2lC-A_11_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">344000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_AYwZQAqqz0aFJyNiDgXcBg_11_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">241000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ"
      decimals="-3"
      id="Tc_y1bHzz8mmUusB6_4ZAlelg_11_9"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">128000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg"
      decimals="-3"
      id="Tc_e52TU4Ek60uwCAioCGGsxQ_11_12"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">38000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_J_29MhfnZEeO-cumpvig_w_12_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-3896000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_erPbEcoBiUus4-pIGZG4Dw_12_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-4936000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ"
      decimals="-3"
      id="Tc_bLrEcwn7JkaOdb9q72AVdQ_12_9"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-2075000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg"
      decimals="-3"
      id="Tc_z-wD7r6d8EabEMtaMvSzIg_12_12"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-1910000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:OtherIncome
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_rEwwiTjt80OLf8B9Vpt4Aw_13_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">51000</us-gaap:OtherIncome>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_DlQdogv42k6E_ViMQpb0tA_14_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-16716000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_wKH2GpjhQEeg4iSDU9v7Xg_14_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-2483000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ"
      decimals="-3"
      id="Tc_p864BxPahEK1Jsr__hFQDw_14_9"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-11241000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg"
      decimals="-3"
      id="Tc_4Fn0LZbMHUKpQuNAY5oSMg_14_12"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-4150000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="2"
      id="Tc_WkkUVrHczkaM9dBkexVMqA_15_3"
      unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ">-0.39</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="2"
      id="Tc_7CZt9odpGEO3vWEugZLV5A_15_6"
      unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ"
      decimals="2"
      id="Tc_S0Nah-0V702tHI7EPTiD9Q_15_9"
      unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ">-0.25</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg"
      decimals="2"
      id="Tc_SfRfgYgzM06CB6ayH0Ot6w_15_12"
      unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="0"
      id="Tc_BUFyFq4DIU6c6QjSXYtf5g_17_3"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">42744426</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="0"
      id="Tc_2FcaSaeaykqqwZ0i6wWbBg_17_6"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">19923935</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ"
      decimals="0"
      id="Tc_8bUyIq2TiUiAWpc5k8VmiQ_17_9"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">45436907</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg"
      decimals="0"
      id="Tc_BcsZeTKpx0uIc08jJavmDg_17_12"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">32442636</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_2I_j-CG2WE-GsdeFUO0uXg"
      decimals="-3"
      id="Tc_YLxcM57nLE6fHSSQ2cp6EA_18_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">152000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_B2vkFxAj30mgjYvbaeB7XQ"
      decimals="-3"
      id="Tc_GOzQj4y1qkCmVnPFZ96pgQ_18_9"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">43000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_iiC6Yn_rdkWx9W-FzaEoiA"
      decimals="-3"
      id="Tc_Cn6gmWtGfU6BvBCnXotl5w_19_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">370000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_bqX3cUtNBESnhgaklTJZew"
      decimals="-3"
      id="Tc_hfK1SP-rUkurhJ2pU1WebQ_19_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">73000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Sxq30RrND0uqWIoDHU4HbQ"
      decimals="-3"
      id="Tc_6L59W8fuwkODdIBVszNqnw_19_9"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">160000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Okh2sy6Wwku5BgEkLA_q-A"
      decimals="-3"
      id="Tc_2asen8q9iEupcsLJs-cRhw_19_12"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-5000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_jyn3lwbXOESy8Z3KX8YCGA"
      decimals="-3"
      id="Tc_NF-yfjTgLUG2NitONkSdCA_20_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">872000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_hDBte-t0lUWwnjhjyGWBOA"
      decimals="-3"
      id="Tc_RpkMgThRo06HcpefASkrew_20_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">625000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_wDSeLRz8j0mcVlFQpqqNGw"
      decimals="-3"
      id="Tc_qdmsySA110Gzkny74Ilm-w_20_9"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">375000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5PQNzgrw3U21fmcnTdCH2w"
      decimals="-3"
      id="Tc_gsFuvlVnsEWMJSW8qIpAYw_20_12"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">272000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4cR5rGHxsEuH26ppUkiILQ"
      decimals="INF"
      id="Tc_Y_wQ9oJdU0Cs2MvW3iyoGg_6_2"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">14838213</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4cR5rGHxsEuH26ppUkiILQ"
      decimals="-3"
      id="Tc_qx6djsyPxEibxqAViCF7kA_6_5"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_K5lGRruMjUWFHxHMZFMGmg"
      decimals="-3"
      id="Tc_HK1RYSYU10-VLuRFY6jXBA_6_8"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">270492000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ZYngxRQFYkWwRhWxM0SkzA"
      decimals="-3"
      id="Tc_QOetX-qrzE6Ca6PEP5ESXw_6_11"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-340829000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_tP37cYnQBEy-ajyGcP9j2g"
      decimals="-3"
      id="Tc_A8ZkGXfEv0CsywiFZt0kiQ_6_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-70322000</us-gaap:StockholdersEquity>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MEoQBaAbc06IzFxMkQM1qg"
      decimals="INF"
      id="Tc_3GEBVpZPv0aBDLyXOLJfqQ_8_2"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">17604423</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MEoQBaAbc06IzFxMkQM1qg"
      decimals="-3"
      id="Tc_3p0KdHyldE2K7MQdDzh95g_8_5"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">18000</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SQhCtGF5pEGEvL3YbxckPA"
      decimals="-3"
      id="Tc_v68_VkMrKEyPlBvRRc54_Q_8_8"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">41325000</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue>
    <plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_QGhGkkuUP0aXTySRjtuZ4w_8_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">41343000</plx:IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue>
    <plx:AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SQhCtGF5pEGEvL3YbxckPA"
      decimals="-3"
      id="Tc_2s86sOY4A0ipOvPx5sdvvA_9_8"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">4000000</plx:AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants>
    <plx:AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_BwrMt41Zn0-ydoZVIhUg7A_9_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">4000000</plx:AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_SQhCtGF5pEGEvL3YbxckPA"
      decimals="-3"
      id="Tc_wtGa9m7F60u-GHmbL-zxIw_10_8"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">698000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_oEqtjCkOlES8f67mgWyrCw_10_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">698000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9IdhTME8lUGRXZwzJDuW3w"
      decimals="-3"
      id="Tc_o6wDMW8M9Ui6rBwUWoDM8A_11_11"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-2483000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_h8KYwr9u60ua2XTZVhDhTQ_11_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-2483000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q55XKvKM6UWzjFvtkRLLmQ"
      decimals="INF"
      id="Tc_d828K6Ue1EKmOTX4if5wtA_12_2"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">32442636</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q55XKvKM6UWzjFvtkRLLmQ"
      decimals="-3"
      id="Tc_Rd0sxG7V60a--gvNicRKJg_12_5"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6nrUDBCtt06YRW-L2OEYxQ"
      decimals="-3"
      id="Tc_r3F9jJB3ikSnO90GpK0ZFA_12_8"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">308515000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WNnhvQfFrEymbDn9Ce7FGA"
      decimals="-3"
      id="Tc_2Q6aDGpsxkChHS9ejp_Pjg_12_11"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-343312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_UTfTJ92Crkail7a-VOYa5g"
      decimals="-3"
      id="Tc_tMXiMT7aGku5FGguGEklpA_12_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-34764000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Aw21LWNb10edAAVCUPhNiA"
      decimals="INF"
      id="Tc_L-kjd32hckOMkpdSFE_lCw_13_2"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">34765280</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Aw21LWNb10edAAVCUPhNiA"
      decimals="-3"
      id="Tc_UlvM9qM78kiAzC7JssEfDw_13_5"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">35000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zVn_KJPePkOTFIcmvJNdvw"
      decimals="-3"
      id="Tc_fAyeECfvwUC_yZB1e1thtQ_13_8"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">320280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zpuoYmPfdkek3USyWn91Qw"
      decimals="-3"
      id="Tc_PuuNkH_6KUuqsvOvMZY0rg_13_11"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-347352000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_TxdH0dmLd0KD6xOsxwbCkw_13_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-27037000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fmr_C6CM1EmRY2waHRcinA"
      decimals="INF"
      id="Tc_fWUbFYN1xk-LXIllRu6nHw_15_2"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">8749999</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fmr_C6CM1EmRY2waHRcinA"
      decimals="-3"
      id="Tc_SZZLozZTWkG_GDEI_QaWMQ_15_5"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">9000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h_6cg02980C2C6q1_vdErg"
      decimals="-3"
      id="Tc_5MRZKfh6vkW4u_8lNTQFxw_15_8"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">37616000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_P3MjYIhKa0qaRu8a9Jhrpg_15_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">37625000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <plx:StockIssuedDuringPeriodSharesSalesAgreement
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fmr_C6CM1EmRY2waHRcinA"
      decimals="INF"
      id="Tc_SZB0Vh2-y0ueWL3uSkF-tg_16_2"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">1867552</plx:StockIssuedDuringPeriodSharesSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fmr_C6CM1EmRY2waHRcinA"
      decimals="-3"
      id="Tc_d2LZkdagqkSFg0t_8Lwgwg_16_5"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">2000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h_6cg02980C2C6q1_vdErg"
      decimals="-3"
      id="Tc_WBu60lNzx0aQJNnHZ59pBg_16_8"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">8573000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <plx:StockIssuedDuringPeriodValueSalesAgreement
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_0YNk0Iv0sEag3H3Ssc_K9w_16_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">8575000</plx:StockIssuedDuringPeriodValueSalesAgreement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h_6cg02980C2C6q1_vdErg"
      decimals="-3"
      id="Tc_8QUkSZ7QqE-OVknEwcZjyg_17_8"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">832000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_2O_Zd97tpkS-UXr9yA_opg_17_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">832000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h_6cg02980C2C6q1_vdErg"
      decimals="-3"
      id="Tc_29HeWklg1k-Va5WxfkdfHQ_18_8"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">562000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc__J00KLo4IU2ObPclobYMwg_18_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">562000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_fmr_C6CM1EmRY2waHRcinA"
      decimals="INF"
      id="Tc_DLD9rpvbDUe1SXmJYhMFyA_19_2"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">173816</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gJteVLZhPUKl-E3d6202xw"
      decimals="-3"
      id="Tc_Vi9MBbhbY02OtHYED8u3kw_20_11"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-16716000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_1uSjA1PcGkeD4jHxpUZz0g_20_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-16716000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_c92pTwX33UuIlz_FfqiOGA"
      decimals="INF"
      id="Tc_0LvczoWAP0eRWIM1krg6yA_21_2"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">45556647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_c92pTwX33UuIlz_FfqiOGA"
      decimals="-3"
      id="Tc_ygEQZQyRAk--zs5_0h8JzA_21_5"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_coEbyffChUiacKC7c4wHAw"
      decimals="-3"
      id="Tc_DMBorGRo8U29lvKDDhVIkw_21_8"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">367863000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jpLE-akMakyV3Jbk_35Y5A"
      decimals="-3"
      id="Tc_4dw9XJwIF0KKT2kj3ICTHg_21_11"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-364068000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_Au2GeM7ctky7cY-9l2JstQ_21_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">3841000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7koqe4XbrU2iAVQ8xtCh9A"
      decimals="INF"
      id="Tc_5XZuCtKy4E-SGrsC5_ENoA_22_2"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">32442636</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_7koqe4XbrU2iAVQ8xtCh9A"
      decimals="-3"
      id="Tc_r0L0kobOSkuj-ecNRizByQ_22_5"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JwuKoUeMXUSq0ARxWqpE6w"
      decimals="-3"
      id="Tc_MGDysUTFZ0qJlIxkcVNXRw_22_8"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">308248000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8Jw06A2_s02mFX7Ni3WLQg"
      decimals="-3"
      id="Tc_pkKd2s2qEESxqM2kcwK45Q_22_11"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-339162000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2020_ZFXxvJmOEUaEgQwjPNZzDg"
      decimals="-3"
      id="Tc_xhBsnRE7l0yxCKhEyCPQnA_22_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-30881000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9wfTwEjjqEi90jMNxt9LuQ"
      decimals="-3"
      id="Tc_CUyGegf6mEa4suEx3YEmyA_24_8"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">267000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg"
      decimals="-3"
      id="Tc_jJt5neZLY0GR929XMQHRvg_24_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">267000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ED-14lWq4kqXAYP7X69qhA"
      decimals="-3"
      id="Tc_cikzyb2lPkCTen4BWtjoaQ_25_11"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-4150000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg"
      decimals="-3"
      id="Tc_mwkcKGHzO0OV-8UHi5TEVg_25_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-4150000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q55XKvKM6UWzjFvtkRLLmQ"
      decimals="INF"
      id="Tc_URYSXaY8RE6lUkg-Wo5WBw_26_2"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">32442636</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Q55XKvKM6UWzjFvtkRLLmQ"
      decimals="-3"
      id="Tc_r181hvLGe02FWq0sGGEsOQ_26_5"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6nrUDBCtt06YRW-L2OEYxQ"
      decimals="-3"
      id="Tc_w35ltaFoDU2o9nYDAAu1Qw_26_8"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">308515000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WNnhvQfFrEymbDn9Ce7FGA"
      decimals="-3"
      id="Tc_LWv0EP4fUUaSqpe4vQzdtA_26_11"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-343312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2020_UTfTJ92Crkail7a-VOYa5g"
      decimals="-3"
      id="Tc_pL_EwypfpUKq6h9hlgpNSQ_26_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-34764000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QPt03YiNMEyRlDDY1cIgVA"
      decimals="INF"
      id="Tc_kJfgoliISkuMvHZqvexXNw_27_2"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">45382831</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QPt03YiNMEyRlDDY1cIgVA"
      decimals="-3"
      id="Tc_7LGLB9ycj0megTGq9q_V4Q_27_5"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TInNrhsHD0-stLLDv404XQ"
      decimals="-3"
      id="Tc_1KBxiaM-ckGT2GwFngeW5A_27_8"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">367285000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_7dJe2GnFOEGyYLG5fG1hgg"
      decimals="-3"
      id="Tc_ewDWS7gOBEqaIjj4p04keg_27_11"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-352827000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2021_QRSFKQURbUe6hHXKoDRu9g"
      decimals="-3"
      id="Tc_nVMvEDa-tEykkVt5XMSyyQ_27_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">14504000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gsX0p07goEqvnOBN9SVuGQ"
      decimals="-3"
      id="Tc_lnHnO3dOd02y1jEwt_87dw_29_8"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">322000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ"
      decimals="-3"
      id="Tc_XmWxBiWi-EuLrpH_xrGrXQ_29_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">322000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gsX0p07goEqvnOBN9SVuGQ"
      decimals="-3"
      id="Tc_a5USoUyGBkO3QM5yJ4CO-w_30_8"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">256000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ"
      decimals="-3"
      id="Tc_LZQs6fhWl0qscMhOhvMirQ_30_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">256000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4hdRC028OESAjUPcR-4qZA"
      decimals="INF"
      id="Tc_xhyd6qZM0EqWTnOsnJdgUA_31_2"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">173816</plx:StockIssuedDuringPeriodSharesWarrantsExercises>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0-Eu2_lbZUioiYvNP-u1Jg"
      decimals="-3"
      id="Tc_dEqgTBqQ1ECLVbitYTC45w_32_11"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-11241000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ"
      decimals="-3"
      id="Tc_nD-FWaWr9kaE23wRgl4s8A_32_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-11241000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_c92pTwX33UuIlz_FfqiOGA"
      decimals="INF"
      id="Tc_pxTp2QsKZ0-w6FRLwU0S2w_33_2"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">45556647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_c92pTwX33UuIlz_FfqiOGA"
      decimals="-3"
      id="Tc_HLLJFfuVrUu9IpvsO_GnMA_33_5"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">46000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_coEbyffChUiacKC7c4wHAw"
      decimals="-3"
      id="Tc_bX_a8XfIUU6S0Kvk8o6gOw_33_8"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">367863000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_jpLE-akMakyV3Jbk_35Y5A"
      decimals="-3"
      id="Tc_ABOpezugTE-zQIhDtz25Kw_33_11"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-364068000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_sxhXmnWWqkeZbLIaBVGvRQ_33_14"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">3841000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2020_UTfTJ92Crkail7a-VOYa5g"
      decimals="INF"
      id="Narr_MN6oR9tva0eOko_DwSn37Q"
      unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2020_UTfTJ92Crkail7a-VOYa5g"
      decimals="INF"
      id="Narr_48WV2mIZ-U-kBvBAE1SB-A"
      unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="INF"
      id="Narr_2Ee2NnAypka5Z0dgoPfOlA"
      unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="INF"
      id="Narr_8-yiVwrMtUacMGDXQy6VMA"
      unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2020_UTfTJ92Crkail7a-VOYa5g"
      decimals="0"
      id="Narr_f9UCpOua8EKN2vXVgRS2PQ"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="0"
      id="Narr_3aZh5KRNc0i8Jd9RA5hI9g"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">120000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_TlRLxf7Q3EaY2TWHu58Yhg_4_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-16716000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_VAuGlRv9mkCvbypCIr5Jig_4_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-2483000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_ggE5FcNOP0e3Au9wDuDyYg_6_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">1394000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_yhoWoRExE0aCp6bJo-AH7Q_6_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">698000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_u54pJXgxjEupa5jwXDZBXA_7_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">574000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_hj-_JXxXKUGmiff6BwA0dA_7_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">710000</us-gaap:Depreciation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_kJQ4Xynklky7Ezvbq-D_LA_8_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">121000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_lJEC8iQkL0q04Sf1ZatXBg_8_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">250000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_Aq6N-7AnokaSeQyFEkGuLA_9_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">70000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_S08ad_yk_kqeVBviHZr_XA_9_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">107000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_ZM0W5AD3t0yDBsrSfXOzuQ_10_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">56000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc__IDWrZSBgEifk32Ovt-OcQ_10_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-22000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_DpT6BGHft0SM_B96zliDWg_11_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">51000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_evhDwYKnsUmpvp4ruYSe-A_12_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">1928000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_P8uAUDupdkqeEQKrrNZ_qA_12_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">1665000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_tsBVJLcxT0KXfBCY-820xQ_14_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">12268000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_vMxylCRdK066dT_5udKdBw_14_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-10841000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_qF7CJuWOhUmieS5bb8gSNw_15_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">1587000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_BhdvTXQgAk2lWldWa4nfyg_15_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">1621000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_ZyErllxORE6nO4N3dgDW2A_16_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-94000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_UdSOQxuonUCJryx6ztuO2A_16_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-27000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_jGcVTSAyO0mJDoDgmatv2w_17_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">558000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_1fBrcTxZ4kmCOhTcJG-13Q_17_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">2910000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_5oMyMM1NBkCtzNHSaAKO8A_18_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-544000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_KJ1KotEH3kyV9kOgei3_7Q_18_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">309000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_EnpIBGLrIkOZIldtYBHZfA_19_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-13000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_ToVhfW5pHU69c63WyGx-Sg_19_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-385000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_oYNItzAOwEWGvhP4PSLSuw_20_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-3318000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_PxXcOHtNFU-2DtXUilhM4Q_20_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-14952000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_BJ-72eVGh0GLAyekHn58ew_23_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">37835000</plx:IncreaseDecreaseInBankDeposits>
    <plx:IncreaseDecreaseInBankDeposits
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_qgjmA-yxL0aFOSZjyOZxYQ_23_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">35000000</plx:IncreaseDecreaseInBankDeposits>
    <plx:ProceedsFromSaleOfShortTermDeposits
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_TN6RyEa3LEu-MTsksE4Aig_24_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">15000000</plx:ProceedsFromSaleOfShortTermDeposits>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_RkNvgTRDZU64TbrSd1P9rw_25_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">667000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_vC9NYmf6QE-3QhRPcU-1nA_25_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">278000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_b_hbfKpsTkaxNGJyNhqUCg_26_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">53000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <plx:IncreaseDecreaseInRestrictedDeposit
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_Aw74M6bg00GOauG_QLmiMA_27_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-359000</plx:IncreaseDecreaseInRestrictedDeposit>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_4RnT_CPq4Eqk6cFuGvdNvw_28_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">54000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_i3gMpc8L1EyxR5WN7bq24A_28_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">69000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_L8c_oMuwrU6ihwTYJOMMJg_29_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-23144000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_QYxT0-Qp-kqugRyfXcgIPw_29_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-35347000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_lvvMpyJ2EUugTg_XmXs-_Q_32_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">4086000</us-gaap:RepaymentsOfNotesPayable>
    <plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_hSEjzVfv_Uevch2wdlenNg_33_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">37625000</plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost>
    <plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_cBany3g_rEi96Qcin_vDTQ_33_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">37343000</plx:ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_4CU_mFKk-k-Eor62rvA3eg_34_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">8575000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_JHcSkxac2EixiIVH9y7S0w_35_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">42114000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_Ko-HsQIO0EuqH11e5zaFyA_35_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">37343000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_8pLARPLHxUanUPMy5hUbSQ_36_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-35000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_p6lh24zApkOm2VzfLi9viQ_36_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">7000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_akdVF0WP90y7grRuUtOJ9w_37_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">15617000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_A0aipssqlkO_sRsF8dvgVA_37_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">-12949000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_nLHiGCB5nEuNxUkLciS5Cw_38_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">18265000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2019_tP37cYnQBEy-ajyGcP9j2g"
      decimals="-3"
      id="Tc_R54jhFTBlU61ptuHFE26Gw_38_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">17792000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_0lKeG9nL3USJM8OTj1TSww_39_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">33882000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2020_UTfTJ92Crkail7a-VOYa5g"
      decimals="-3"
      id="Tc_33yc4DL_vE-hxMELva9e_Q_39_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">4843000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_KH8nsF4u10-6-vZPjC2CWw_4_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">372000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
    <plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_paYEHVLHFEWGjVPe2mRaiA_4_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">50000</plx:IncreaseInLiabilitiesForPropertyPlantAndEquipment>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_T3q9hdY4DUqp7AapEGhCcQ_5_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">232000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_da7qFnTYJUupCPlnJBRnoQ_5_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">362000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <plx:NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="-3"
      id="Tc_UFmE5N2CIUKriQZjQJT55A_6_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">4000000</plx:NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="-3"
      id="Tc_XVtqcwAQM0SAcYN9dwDkZg_9_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">307000</plx:InterestReceivedNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tb_KYfz-pb650KCeRDzdf1zJQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The most advanced investigational drug in the Company&#x2019;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies: the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study, the &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study and the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study. The studies are designed to evaluate the potential superiority of PRX-102 over current therapies in a head-to-head study and a switch-over study, evaluate the potential for improved efficacy and better quality of life for patients with Fabry disease and evaluate the safety of our drug/therapy. The &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; and &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; studies have been completed, and the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study is fully-enrolled. See Part&#160;1, Item&#160;2, Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x2014;Pegunigalsidase Alfa (PRX-102) for the Treatment of Fabry Disease for details regarding the current status of these studies and of available clinical trial results.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;A BLA for PRX-102 for the treatment of adult patients with Fabry disease was submitted to the U.S.&#160;Food and Drug Administration (the &#x201c;FDA&#x201d;) on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, which was subsequently accepted by the FDA and granted Priority Review designation. The FDA also indicated in its BLA filing communication letter that it did not plan to hold an advisory committee meeting to discuss the application. Based on the interim analysis of the 12-month data generated from the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study that the Company announced in June 2021, and in combination with previously reported positive data from the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; and &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; studies, the Company and Chiesi intend to submit a Marketing Authorization Application (an &#x201c;MAA&#x201d;) to the European Medicines Agency (the &#x201c;EMA&#x201d;) for PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On April&#160;28, 2021, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;), announced that they received a Complete Response Letter (CRL) from the FDA regarding the BLA. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#x2019;s manufacturing facility in Carmiel, Israel, including the FDA&#x2019;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#x201c;COVID-19&#x201d;), the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (the &#x201c;FFDCA&#x201d;) in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In addition to the foregoing, in the CRL, the FDA noted that agalsidase beta (Fabrazyme&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;), a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#x201c;available therapy,&#x201d; which must be addressed in the context of any potential resubmission of a BLA for PRX-102. The Company intends to work collaboratively with the FDA to identify the most expeditious pathway to approval, and is confident that it will be able to work with the FDA to resolve these issues and provide a new, alternative drug to Fabry patients. On August&#160;2, 2021, the Company &lt;span style="letter-spacing:-0.15pt;"&gt;announced that a Type A Meeting request has been submitted to the FDA to discuss the CRL. The Type A Meeting is expected to occur within 30 days of the FDA&#x2019;s receipt of the meeting request&lt;/span&gt;; however, the Company cannot anticipate the timing of such a meeting nor the additional steps that may be required in connection with any potential resubmission.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In addition to PRX-102, the Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which is subject to an exclusive worldwide license agreement with SarcoMed USA, Inc. (&#x201c;SarcoMed&#x201d;) for use in the treatment&lt;/span&gt;&lt;span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat refractory gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July 2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;). The Company sold a total of 3,296,123 shares of common stock pursuant to the sales agreement with BofA Securities for total gross proceeds of approximately $13.8&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;10, 2021, the Company entered into an exclusive worldwide license agreement with SarcoMed with respect to PRX-110 for use in the treatment of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery. Under the terms of the agreement, SarcoMed will be responsible for the identification and selection of pharmaceutical candidates under the license, and the clinical research and development of such candidates. The Company is entitled to an initial cash payment of $3.5&#160;million, subject to certain conditions, and to additional regulatory and commercial milestone payments and tiered royalties on net sales of products that are commercialized under the license agreement. In addition to the foregoing, the parties agreed to commence negotiation of clinical and commercial supply agreements for alidornase alfa. As part of the arrangement, the parties agreed to negotiate and sign a supply agreement within 60 days of the execution of the license agreement, and SarcoMed has the right to terminate the license agreement if the parties do not successfully do so.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;17, 2021, the Company issued and sold 8,749,999 shares of its Common Stock in an underwritten public offering raising gross proceeds of approximately $40.2&#160;million at a price equal to $4.60 per share, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities acted as book-running manager for the offering with Oppenheimer &amp;amp; Co. acting as co-manager.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#x201c;Amended Pfizer Agreement&#x201d;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;), for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#x2019;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. We continue to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company believes that its cash and cash equivalents and bank deposits as of June&#160;30, 2021 are sufficient to satisfy the Company&#x2019;s capital needs for at least 12 months from the date that these financial statements are issued. See also Note&#160;6 regarding the exchange agreements relating to the 7.5% convertible secured promissory notes due 2021 (the &#x201c;2021 Notes&#x201d;) signed in August 2021 which are subject to certain closing conditions.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed by the Company with the U.S. Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2020.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) are computed by dividing net loss by the weighted average number of shares of the Company&#x2019;s Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include 18,445,764 and 26,322,164 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of outstanding 2021 Notes and outstanding warrants for the six months ended June 30, 2020 and 2021, respectively, and 25,997,289 and 25,874,641 shares of Common Stock underlying outstanding options and shares issuable upon conversion of outstanding 2021 Notes and outstanding warrants for the three months ended June 30, 2020 and 2021, respectively because their effect would be anti-dilutive.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;d.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;1.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenues from selling products&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <plx:NatureOfOperationsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tb_ZUUXfGrr8ESuQsimGH-9uA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#x201c;Company&#x201d;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#x201c;Subsidiaries&#x201d;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#x2019;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The most advanced investigational drug in the Company&#x2019;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies: the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study, the &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; study and the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; study. The studies are designed to evaluate the potential superiority of PRX-102 over current therapies in a head-to-head study and a switch-over study, evaluate the potential for improved efficacy and better quality of life for patients with Fabry disease and evaluate the safety of our drug/therapy. The &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; and &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; studies have been completed, and the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study is fully-enrolled. See Part&#160;1, Item&#160;2, Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x2014;Pegunigalsidase Alfa (PRX-102) for the Treatment of Fabry Disease for details regarding the current status of these studies and of available clinical trial results.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;A BLA for PRX-102 for the treatment of adult patients with Fabry disease was submitted to the U.S.&#160;Food and Drug Administration (the &#x201c;FDA&#x201d;) on May&#160;27, 2020 under the FDA&#x2019;s Accelerated Approval pathway, which was subsequently accepted by the FDA and granted Priority Review designation. The FDA also indicated in its BLA filing communication letter that it did not plan to hold an advisory committee meeting to discuss the application. Based on the interim analysis of the 12-month data generated from the &lt;i style="font-style:italic;"&gt;BALANCE&lt;/i&gt; study that the Company announced in June 2021, and in combination with previously reported positive data from the &lt;i style="font-style:italic;"&gt;BRIGHT&lt;/i&gt; and &lt;i style="font-style:italic;"&gt;BRIDGE&lt;/i&gt; studies, the Company and Chiesi intend to submit a Marketing Authorization Application (an &#x201c;MAA&#x201d;) to the European Medicines Agency (the &#x201c;EMA&#x201d;) for PRX-102.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On April&#160;28, 2021, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;), announced that they received a Complete Response Letter (CRL) from the FDA regarding the BLA. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#x2019;s manufacturing facility in Carmiel, Israel, including the FDA&#x2019;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#x201c;COVID-19&#x201d;), the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (the &#x201c;FFDCA&#x201d;) in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In addition to the foregoing, in the CRL, the FDA noted that agalsidase beta (Fabrazyme&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;), a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#x201c;available therapy,&#x201d; which must be addressed in the context of any potential resubmission of a BLA for PRX-102. The Company intends to work collaboratively with the FDA to identify the most expeditious pathway to approval, and is confident that it will be able to work with the FDA to resolve these issues and provide a new, alternative drug to Fabry patients. On August&#160;2, 2021, the Company &lt;span style="letter-spacing:-0.15pt;"&gt;announced that a Type A Meeting request has been submitted to the FDA to discuss the CRL. The Type A Meeting is expected to occur within 30 days of the FDA&#x2019;s receipt of the meeting request&lt;/span&gt;; however, the Company cannot anticipate the timing of such a meeting nor the additional steps that may be required in connection with any potential resubmission.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In addition to PRX-102, the Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which is subject to an exclusive worldwide license agreement with SarcoMed USA, Inc. (&#x201c;SarcoMed&#x201d;) for use in the treatment&lt;/span&gt;&lt;span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat refractory gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On July 2, 2021, the Company entered into an At The Market Offering Agreement (the &#x201c;Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $20.0&#160;million (the &#x201c;ATM Shares&#x201d;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt; Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#x201c;BofA Securities&#x201d;). The Company sold a total of 3,296,123 shares of common stock pursuant to the sales agreement with BofA Securities for total gross proceeds of approximately $13.8&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;10, 2021, the Company entered into an exclusive worldwide license agreement with SarcoMed with respect to PRX-110 for use in the treatment of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery. Under the terms of the agreement, SarcoMed will be responsible for the identification and selection of pharmaceutical candidates under the license, and the clinical research and development of such candidates. The Company is entitled to an initial cash payment of $3.5&#160;million, subject to certain conditions, and to additional regulatory and commercial milestone payments and tiered royalties on net sales of products that are commercialized under the license agreement. In addition to the foregoing, the parties agreed to commence negotiation of clinical and commercial supply agreements for alidornase alfa. As part of the arrangement, the parties agreed to negotiate and sign a supply agreement within 60 days of the execution of the license agreement, and SarcoMed has the right to terminate the license agreement if the parties do not successfully do so.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;17, 2021, the Company issued and sold 8,749,999 shares of its Common Stock in an underwritten public offering raising gross proceeds of approximately $40.2&#160;million at a price equal to $4.60 per share, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities acted as book-running manager for the offering with Oppenheimer &amp;amp; Co. acting as co-manager.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;) with respect to the commercialization of pegunigalsidase alfa in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#x201c;Chiesi Agreements&#x201d;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#x201c;Amended Pfizer Agreement&#x201d;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;), for taliglucerase alfa. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#x2019;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. We continue to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company believes that its cash and cash equivalents and bank deposits as of June&#160;30, 2021 are sufficient to satisfy the Company&#x2019;s capital needs for at least 12 months from the date that these financial statements are issued. See also Note&#160;6 regarding the exchange agreements relating to the 7.5% convertible secured promissory notes due 2021 (the &#x201c;2021 Notes&#x201d;) signed in August 2021 which are subject to certain closing conditions.&lt;/p&gt;</plx:NatureOfOperationsPolicyTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_NaNGoBKCkEiu7vUtu1FpeQ"
      decimals="INF"
      id="Narr_1OabiNxmr0GRUF_a0g9oFw"
      unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_36UqK7xw-keHI8meiWi3Lw"
      decimals="-5"
      id="Narr_dqKOktjaUkqeVpzU5MfdpA"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_36UqK7xw-keHI8meiWi3Lw"
      decimals="INF"
      id="Narr_GshUqNSWokCRIhu1pJrR5w"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">3296123</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_36UqK7xw-keHI8meiWi3Lw"
      decimals="-5"
      id="Narr_BJ_zcN8yCkeID3m2lxpDxA"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">13800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <plx:LicenseAgreementInitialCashPayment
      contextRef="Duration_2_10_2021_To_2_10_2021_us-gaap_TypeOfArrangementAxis_plx_SarcomedUsaInc.AgreementMember_s6R6OeOa5EigE4cD9-rsoA"
      decimals="-5"
      id="Narr_zhD_-mW0UUOunyeteQ3oSw"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">3500000</plx:LicenseAgreementInitialCashPayment>
    <plx:TermToSignSupplyAgreement
      contextRef="Duration_2_10_2021_To_2_10_2021_us-gaap_TypeOfArrangementAxis_plx_SarcomedUsaInc.AgreementMember_s6R6OeOa5EigE4cD9-rsoA"
      id="Narr_R6gsLslJDkGQMPSgMLNbEQ">P60D</plx:TermToSignSupplyAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_17_2021_To_2_17_2021_eP-kucV1pUWTbBXr7TaMSA"
      decimals="INF"
      id="Narr_NyBq1s4VU0GrdyvkGfm-bg"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">8749999</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_2_17_2021_To_2_17_2021_eP-kucV1pUWTbBXr7TaMSA"
      decimals="-5"
      id="Narr_8Rcw4VjYtkK347nqxLcJiA"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">40200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_2_17_2021_I73LVvhcdECPyti0oudI0A"
      decimals="2"
      id="Narr_-LYFBnry_UG3m6ZUUfvVcA"
      unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ">4.60</us-gaap:SharesIssuedPricePerShare>
    <plx:UpfrontNonrefundableNonCreditablePaymentReceivable
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_5jiTZMuakUK7bv_eFjH6Tg"
      decimals="-5"
      id="Narr_BNnFeUkUwUeNBDTn2gch1w"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">25000000.0</plx:UpfrontNonrefundableNonCreditablePaymentReceivable>
    <plx:UpfrontNonrefundableNonCreditablePaymentReceivable
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_AI0MTldNw0S-WidGYq9XRg"
      decimals="-5"
      id="Narr_bOnj7Rk-oE21Nk2jWnde-Q"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">25000000.0</plx:UpfrontNonrefundableNonCreditablePaymentReceivable>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_JPKl0rb7CE-Kwx4t4a5tFQ"
      decimals="-5"
      id="Narr_kEooiGmDU0yzgk_W5ffh3Q"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">25000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_JPKl0rb7CE-Kwx4t4a5tFQ"
      decimals="-5"
      id="Narr_dKkyV0WJHkiqKR0U8sIMUw"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">10000000.0</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_10_19_2017_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_JPKl0rb7CE-Kwx4t4a5tFQ"
      decimals="-5"
      id="Narr_bZ79yioZyUKcnHy3A4w7uw"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">320000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:AdditionalAmountsPayableToCoverDevelopmentCosts
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_UXGhKrHKLEeju1LG7xvQ0w"
      decimals="-5"
      id="Narr_zYZsZWj9YUuaiOvF5geLhQ"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">20000000.0</plx:AdditionalAmountsPayableToCoverDevelopmentCosts>
    <plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_UXGhKrHKLEeju1LG7xvQ0w"
      decimals="-5"
      id="Narr_XqC6MykOc0WnMBp1bCFbCA"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">7500000</plx:MaximumEntitlementOfDevelopmentCostsToCoverPerYear>
    <plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="As_Of_7_23_2018_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_UXGhKrHKLEeju1LG7xvQ0w"
      decimals="-5"
      id="Narr_lLdoaSWSy0abYVOVAzxNXA"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">760000000.0</plx:AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_hO2OX0CkykSDtEZGjleYjg"
      decimals="INF"
      id="Narr_WvPt1IxOuUaAMTFbPzSR5Q"
      unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_10_19_2017_To_10_19_2017_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_eVJdA8NazEqDalQFFkRHrg"
      decimals="INF"
      id="Narr_ICcNU38xZEyBUg61sPcBig"
      unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q">0.35</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_cT_q_tep9EOn9lbEWZblFQ"
      decimals="INF"
      id="Narr_qcfgvH3GNEmFWWQbaXAqnw"
      unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q">0.15</plx:PaymentOnNetSalesPercentage>
    <plx:PaymentOnNetSalesPercentage
      contextRef="Duration_7_23_2018_To_7_23_2018_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUSAgreementMember_3jQI-P9cnkOUP6jE77HynA"
      decimals="INF"
      id="Narr_RafWJnAD90y-8OV__ySjWA"
      unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q">0.40</plx:PaymentOnNetSalesPercentage>
    <plx:AgreementAmendmentPaymentReceivable
      contextRef="As_Of_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_cUS14zPtB02emWZ8d9vIBw"
      decimals="-5"
      id="Narr_7MEalrDUaU2FdwG0vL5YsQ"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">10000000.0</plx:AgreementAmendmentPaymentReceivable>
    <plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones
      contextRef="Duration_5_13_2021_To_5_13_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_W0s5POha_U6du1M7Hy-NoA"
      decimals="-5"
      id="Narr_u8XQ1_9xnkKjuRI-ibx5aw"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">25000000.0</plx:ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones>
    <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage
      contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_T2MIzBKUik2fuPiyDHsRSA"
      decimals="2"
      id="Narr_87cGcWsZ0kSoiLzmG1AyXQ"
      unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q">1</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_eC_j6cyaVEe4nMowIWMQlA"
      decimals="INF"
      id="Narr_M3yu-HyoJkW4zpTX8SpC5g"
      unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q">0.075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tb_IQCzmrfOeUCWPkDCmg6vHw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed by the Company with the U.S. Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2020.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tb_5yLby7RZhUygB61nWKhtBQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) are computed by dividing net loss by the weighted average number of shares of the Company&#x2019;s Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include 18,445,764 and 26,322,164 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of outstanding 2021 Notes and outstanding warrants for the six months ended June 30, 2020 and 2021, respectively, and 25,997,289 and 25,874,641 shares of Common Stock underlying outstanding options and shares issuable upon conversion of outstanding 2021 Notes and outstanding warrants for the three months ended June 30, 2020 and 2021, respectively because their effect would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_6_30_2020_FuoudWjT0k6ShKn6JUOY9Q"
      decimals="INF"
      id="Narr__Nw57U9up0WxCyhkf0e6Vw"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">18445764</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      decimals="INF"
      id="Narr_IuSyqm0w5kS3HukfJeLyow"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">26322164</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2020_To_6_30_2020_m3ILLHWq5UyPiHbYf7ITvg"
      decimals="INF"
      id="Narr_EvC6_dR2DEePmp3e9NGjUg"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">25997289</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ"
      decimals="INF"
      id="Narr_gHrrn_DoJUKhC97TAmc73w"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">25874641</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tb_hFekH7RbbUC2KJpmsjn3zw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;d.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue recognition&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#x2019;s rights regarding the distinct goods or services to be transferred (&#x201c;performance obligations&#x201d;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;1.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenues from selling products&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;2.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from Chiesi Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:54pt;padding:0pt;"/&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;3.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;Revenue from R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"&gt;Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <plx:RevenuePerformanceObligationNumber
      contextRef="As_Of_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_Icszi70YU0WMX60GBUG0ew"
      decimals="INF"
      id="Narr_-m4xc5H2HkaYdUh-8qGLyw"
      unitRef="Unit_Standard_agreement_roa1qYbSR0KRZqNYmT7fsA">2</plx:RevenuePerformanceObligationNumber>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tb_6sty8IRiUUWGJKyeJm59Ew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;2&#160;- INVENTORIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at June&#160;30, 2021 and December&#160;31, 2020 consisted of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,046&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,347&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,529&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,848&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,640&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,082&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tb_CrpPvSGH8UWdDPRJVL6sdw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at June&#160;30, 2021 and December&#160;31, 2020 consisted of the following:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,046&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,347&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,065&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,887&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,529&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,848&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,640&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,082&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_AOYT8AhT9E2g5aCA2ydaTg_3_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">3046000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_Q8XEbWlTv0C4BhvJ6bfHvw_3_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">3347000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_-251H_nGOUq604XydKSxrw_4_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">3065000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_lZGe9yEQxk2PBSuKi6edUA_4_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">2887000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_MMEA2CyLl0eEO32f8b_5Hg_5_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">7529000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_rx-w7WyKe0WeUH12H8nx7g_5_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">6848000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg"
      decimals="-3"
      id="Tc_ZkGAKezIDkextUVHCcbr8w_6_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">13640000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2020_VCzXyaFs3EiRukKDNpU00A"
      decimals="-3"
      id="Tc_ZAavO0uwVEycZClUjIUnQQ_6_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">13082000</us-gaap:InventoryNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tb_KnyX-Uf5Zku6hDLWmEmPeQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;3&#160;&#x2013; FAIR VALUE MEASUREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;"&gt;As of June&#160;30, 2021, the carrying amounts of short-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;"&gt;The fair value of the $57.9&#160;million aggregate principal amount of the Company&#x2019;s outstanding 2021 Notes as of June&#160;30, 2021 is approximately $57.6&#160;million based on a Level 3 measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;The Company prepared a valuation of the fair value of the Company&#x2019;s outstanding 2021 Notes&#160;(a Level 3 valuation) as of June&#160;30, 2021. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.91&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.05&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 77.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.16&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_-tsX_jEa10aFdesmgIQc1g"
      decimals="-5"
      id="Narr_t1v17gkiRU6FAGh1dwKVRA"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">57900000</us-gaap:ShortTermBorrowings>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_-tsX_jEa10aFdesmgIQc1g"
      decimals="-5"
      id="Narr_lQC17fBPxUWMFNub7R-V7A"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">57600000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_yMRhv1-EBUyjv67c4vnBIA"
      id="Tb_O-xnjDlMjEO9ertSea_7Vw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;"&gt;The Company prepared a valuation of the fair value of the Company&#x2019;s outstanding 2021 Notes&#160;(a Level 3 valuation) as of June&#160;30, 2021. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&#160;Notes&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock price (USD)&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.91&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.05&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 77.42&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;"&gt;Yield&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.16&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_-UCWB1XwmECspjYijNZ7Jw"
      decimals="2"
      id="Tc_I_kH3BkMtU6-yk5k1VVPZw_2_2"
      unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ">1.91</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_MB3j5xcttkmq-uspEaqDzA"
      decimals="2"
      id="Tc_qn65mnA6PEql57yTXzMKWg_3_2"
      unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q">0.38</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_mufBZIm2IkKt0BdUQt8lTg"
      decimals="2"
      id="Tc_goNXD8iK10SoOdzPhQ5NpA_4_2"
      unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q">0.05</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_B-IrvzpQnE-E4laCHJyHig"
      decimals="2"
      id="Tc_c_sDCPQlukSL67lGLDeXVg_5_2"
      unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q">77.42</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_plx_MeasurementInputYieldMember_TXQdyNOI60W_tZ_1z-7XnA"
      decimals="2"
      id="Tc_r3GwqCjat0mf347flyAxxg_6_2"
      unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q">11.16</us-gaap:DebtInstrumentMeasurementInput>
    <plx:RevenueDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tb_ItCXELvKjEGVifnxh-IzHQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;4&#160;&#x2013; REVENUES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,237&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 663&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,748&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,679&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 988&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,985&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 988&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,243&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,648&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,754&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,184&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,319&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,993&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,934&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 36pt;"&gt;During the six months ended June&#160;30, 2020, and following the CRL received from the FDA, the Company changed its estimate for total costs expected to be incurred until satisfying the performance obligation under the Chiesi Agreements. This resulted in a reduction to accumulated revenues recognized in respect of this performance obligation in the amount of $4.1&#160;million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 36pt;"&gt;&lt;span style="background-color:#ffffff;"&gt;During the six months ended June 30, 2021 and 2020, the Company recognized revenues of approximately &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;$0.9&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;million and &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;$1.2&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;million, respectively, and during each of the three months ended June 30, 2021 and 2020, the Company recognized revenues of approximately &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;$0.5&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;million all related to a &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;$10.0&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;million future milestone payment, which was accounted for as a variable consideration. The &lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;$10.0&lt;/span&gt;&lt;span style="background-color:#ffffff;"&gt;&#160;million payment was received in June 2021.&lt;/span&gt;&lt;/p&gt;</plx:RevenueDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tb_xV85TSXMHE--8uVdcxoMBA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,237&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 663&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,748&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,679&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Brazil&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 988&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,985&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 988&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,243&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,648&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,754&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,679&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,184&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,319&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,993&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,934&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_3FiFNKmCaEy9ibcMUQ7VXg"
      decimals="-3"
      id="Tc_znKvUkrsukG7JhhqgFuYBQ_3_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">2237000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_mYAzB56-cUCdOTNVt0yw5A"
      decimals="-3"
      id="Tc_gl2dCgXppUqJdZce6AmXkw_3_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">663000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_Ho_xcKWNEEuICmELxx2gig"
      decimals="-3"
      id="Tc_vo9Mdr2oVUOdmdk-xQzieg_3_9"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">6748000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_PfizerMember_0Dtxw3_Y9E6sb-ILAujQMA"
      decimals="-3"
      id="Tc_1X2928liu0Ov0j2khiIDjQ_3_12"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">2679000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_lNGq93994UKs__wHyGDgeg"
      decimals="-3"
      id="Tc_rNeYgJ2Snkujrz8XVvjAug_4_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">988000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_Pp2mgbyjGkO2esZcL0xKKQ"
      decimals="-3"
      id="Tc_i_F6UpcsCUqscizffuqaUg_4_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">2985000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_Q6m-H8y14kKGpOowck7pfA"
      decimals="-3"
      id="Tc_e9NZsKZfvUO5Nba3JGnz9A_4_9"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">988000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_country_BR_vAeDA4nbuUyblocjjCUcbw"
      decimals="-3"
      id="Tc_ifTlH_40p0ar6Y_337mz1w_4_12"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">6000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_0ROHtRtUikyYBfN1q0FG8Q"
      decimals="-3"
      id="Tc_ziec0Vdo4Ea1dRMnsEeDQw_5_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">18000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_srt_StatementGeographicalAxis_plx_ChiesiMember_Ov94iWapwECTWXr04PGCzQ"
      decimals="-3"
      id="Tc_PV5GCMu5Y0uQvKvNu7ladA_5_9"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">18000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_5O4qCJrVG0eoNBly8DogRQ"
      decimals="-3"
      id="Tc_bTj3DyV0QE-t1LpGYUbYzA_6_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">3243000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_4d1okvan3EClXL0thoxjqQ"
      decimals="-3"
      id="Tc_q8411OMrAUKP2Ktocs7RNw_6_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">3648000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_ProductMember_8zn7u60jckyDuh3BmFc7oQ"
      decimals="-3"
      id="Tc_qCBZvmMkC0GhqRIz3CA0rw_6_9"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">7754000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_ProductMember_IvlRKs5dAEuQ7xeqDJDHLg"
      decimals="-3"
      id="Tc_rvq8aZnGqEyazxe_jeSyLw_6_12"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">8679000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_9dHpxsKaGEaFqtY_iDBcKQ"
      decimals="-3"
      id="Tc_rI5bCE4fj0uY7VLEVlVJ9Q_7_3"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">3184000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Z_KtMWQs0Uujw0cnqYs6lQ"
      decimals="-3"
      id="Tc_N4bZ9bFEd0W20D4NwwAxBA_7_6"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">7319000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_6_30_2021_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_y9t0G7VzUk-YnlJjmRCq3w"
      decimals="-3"
      id="Tc_wxaNK6wl3kuR6oFwecNcFQ_7_9"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">9993000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_YnQnoi6e-EudGaXDEpkpwA"
      decimals="-3"
      id="Tc_WCue0PNsbkefEiKcjU1-fg_7_12"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">23934000</us-gaap:Revenues>
    <plx:ReductionToAccumulatedRevenueRecognized
      contextRef="Duration_1_1_2020_To_6_30_2020_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_us-gaap_ChangeInAccountingEstimateByTypeAxis_us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiUsAgreementAndChiesiExUsAgreementMember_zOqqkDVmMEqqtqAQg4AvEw"
      decimals="-5"
      id="Narr_MuKx6M6xLkumo_uHPCWgbQ"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">4100000</plx:ReductionToAccumulatedRevenueRecognized>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_PDlyFNQ9d0677vNqirp86w"
      decimals="-5"
      id="Narr_FzSxGM5oXkSXdTcL90xCcQ"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2020_To_6_30_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_pMCN5439iEi2rGvtFhU0-Q"
      decimals="-5"
      id="Narr_wmil8nVCMEuSWH_FixMa9A"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">1200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2020_To_6_30_2020_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_wgEii3xYtU2zfwp11IyUzQ"
      decimals="-5"
      id="Narr_x_9W5D6xfkikc6J_7hQCTg"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_4_1_2021_To_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_iX-tLkOGFEuB3AcNqYn0Rw"
      decimals="-5"
      id="Narr_ypzPMRXeA0WT6kPE89adVg"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">500000</us-gaap:Revenues>
    <plx:VariableConsideration
      contextRef="Duration_1_1_2021_To_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_PDlyFNQ9d0677vNqirp86w"
      decimals="-5"
      id="Narr_Yv5y7n4RVUSa5P6CKnk0Xw"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">10000000.0</plx:VariableConsideration>
    <plx:ProceedsFromVariableConsideration
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_lC9sVFpteUu2iOBXmvyCnQ"
      decimals="-5"
      id="Narr_IEE9VJia30C2b4KwH7UxFA"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">10000000.0</plx:ProceedsFromVariableConsideration>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tb_FMVZFX5Lt02Sk7qTGTFv4g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 5 &#x2013; STOCK TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;On June&#160;7, 2021, the Company issued &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;173,816&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; shares of Common Stock in connection with the cashless exercise of a warrant to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;2,816,901&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; shares of Common Stock issued on March&#160;18, 2020, as part of the Company&#x2019;s private placement of Common Stock and warrants. The Company did not generate any proceeds from the cashless exercise.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"/&gt;&lt;td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;On July 2, 2021, the Company entered into the Sales Agreement with the Agent. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent ATM Shares having an aggregate offering price of up to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;$20.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;&#160;million. &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;The ATM Shares will be issued pursuant to the Company&#x2019;s shelf registration statement on Form&#160;S-3. The Company intends to use the net proceeds from the offering, after deducting the Agent&#x2019;s commissions and the Company&#x2019;s offering expenses, for general corporate&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; purposes. &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt;Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering&lt;/span&gt;&lt;sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;text-align:left;top:0pt;vertical-align:top;"&gt;SM&lt;/sup&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"&gt; Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_7_2021_To_6_7_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_hHEjR2Bo5EuYhi_31RGp8A"
      decimals="INF"
      id="Narr_VzGuVH-Fwkqc7GNs71Aofg"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">173816</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="As_Of_3_18_2020_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_9pT5j3bp9kOxck8vgMJvsA"
      decimals="INF"
      id="Narr_ZeNo0zeF3UCmztbmrpVZoA"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">2816901</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <plx:SaleOfStockMaximumOfferingPrice
      contextRef="Duration_7_2_2021_To_7_2_2021_us-gaap_SubsidiarySaleOfStockAxis_plx_AtMarketEquityOfferingMember_36UqK7xw-keHI8meiWi3Lw"
      decimals="-5"
      id="Narr_eZyA0EiCbE2YNGbTYa4VyQ"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">20000000.0</plx:SaleOfStockMaximumOfferingPrice>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g"
      id="Tb_KKtOkvYUQU6wfA3m34QVHg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 6 &#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;As of June&#160;30, 2021, the Company has outstanding $57.9&#160;million aggregate principal amount of 2021 Notes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;On August&#160;12, 2021, the Company entered into definitive agreements relating to private exchanges (the &#x201c;Exchanges&#x201d;) of an aggregate of $54.65&#160;million principal amount of the Company&#x2019;s outstanding 2021 Notes for an aggregate of $28.75&#160;million principal amount of 7.50% Senior Secured Convertible Notes due 2024 (the &#x201c;2024 Notes&#x201d;), $25.90&#160;million in cash, and accrued and unpaid interest through the issue date. The Exchanges are expected to close as soon as practicable, subject to satisfaction of certain closing conditions. The initial conversion rate for the 2024 Notes is 563.2216 shares of Common Stock for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of the Common Stock), subject to adjustment in some events, which is based on a 32.5% premium to the closing price of the Common Stock on the NYSE American at the close of trading on August&#160;13, 2021, the exchange date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;The 2024 Notes will be issued pursuant to an indenture to be entered into between the Company, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent. Interest on the Notes will be paid semi-annually at a rate of 7.50% per annum. The Notes will mature three years after the issuance thereof, unless earlier purchased, converted, exchanged or redeemed and will be guaranteed by the Company&#x2019;s subsidiaries. The 2024 Notes will be secured by perfected liens on all of the assets of the Company and its subsidiaries.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShortTermBorrowings
      contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_vViOT2LFf0axMCBfeZUuig"
      decimals="-5"
      id="Narr_lvSRvP9970mbJhxa3LAnVg"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">57900000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_CocxRZ8sAUy7n9e-67jKfA"
      decimals="-4"
      id="Narr_jAOz1E3qIUSMMOzXopFnIw"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">54650000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5mBl3aHBi0KLliehuspORg"
      decimals="-4"
      id="Narr_DJMNTpNsB06FZX8Av-yZJA"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">28750000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5mBl3aHBi0KLliehuspORg"
      decimals="4"
      id="Narr_rPFVg1RajUKD39hDjEBibw"
      unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <plx:DebtConversionConvertedInstrumentAmountCash
      contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_0ds-0DyfXEGdaoZ3UfY54A"
      decimals="-4"
      id="Narr_UytZL8CW302EGuN59vU0Sw"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">25900000</plx:DebtConversionConvertedInstrumentAmountCash>
    <plx:DebtInstrumentConvertibleConversionShareNumber
      contextRef="As_Of_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5mBl3aHBi0KLliehuspORg"
      decimals="4"
      id="Narr_-DL1sTZKhE-jYU8jd5Qz8g"
      unitRef="Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g">563.2216</plx:DebtInstrumentConvertibleConversionShareNumber>
    <plx:DebtInstrumentConvertibleBaseValueForConversionRate
      contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wp1PKGYOf02TVwTFOgkSpw"
      decimals="0"
      id="Narr_TLuUeHwsOUOLOiunqINnvg"
      unitRef="Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw">1000</plx:DebtInstrumentConvertibleBaseValueForConversionRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5mBl3aHBi0KLliehuspORg"
      decimals="4"
      id="Narr_erPg1M9uukyXSJeWnt1Kdg"
      unitRef="Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ">1.7755</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <plx:PercentageOfPremiumToClosingPriceOfStock
      contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_0ds-0DyfXEGdaoZ3UfY54A"
      decimals="3"
      id="Narr_IaR00lQU6UumRqG6Q2iQmw"
      unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q">0.325</plx:PercentageOfPremiumToClosingPriceOfStock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_5mBl3aHBi0KLliehuspORg"
      decimals="4"
      id="Narr_GZU49VaWbEe9Va_KLcR-TA"
      unitRef="Unit_Standard_pure_5c80ao6mpEi28ZApVjUX0Q">0.0750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_8_12_2021_To_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_0ds-0DyfXEGdaoZ3UfY54A"
      id="Narr_cIzXv0IZt0WQ1_l-brZikA">P3Y</us-gaap:DebtInstrumentTerm>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_3GEBVpZPv0aBDLyXOLJfqQ_8_2"
          xlink:label="Tc_3GEBVpZPv0aBDLyXOLJfqQ_8_2"
          xlink:type="locator"/>
        <link:footnote id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:label="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; Authorized &#x2013; as of June&#160;30, 2021 and 2020 - 120,000,000 shares.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_3GEBVpZPv0aBDLyXOLJfqQ_8_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_SZB0Vh2-y0ueWL3uSkF-tg_16_2"
          xlink:label="Tc_SZB0Vh2-y0ueWL3uSkF-tg_16_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_SZB0Vh2-y0ueWL3uSkF-tg_16_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_DLD9rpvbDUe1SXmJYhMFyA_19_2"
          xlink:label="Tc_DLD9rpvbDUe1SXmJYhMFyA_19_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_DLD9rpvbDUe1SXmJYhMFyA_19_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_xhyd6qZM0EqWTnOsnJdgUA_31_2"
          xlink:label="Tc_xhyd6qZM0EqWTnOsnJdgUA_31_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_xhyd6qZM0EqWTnOsnJdgUA_31_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Y_wQ9oJdU0Cs2MvW3iyoGg_6_2"
          xlink:label="Tc_Y_wQ9oJdU0Cs2MvW3iyoGg_6_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Y_wQ9oJdU0Cs2MvW3iyoGg_6_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_5XZuCtKy4E-SGrsC5_ENoA_22_2"
          xlink:label="Tc_5XZuCtKy4E-SGrsC5_ENoA_22_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_5XZuCtKy4E-SGrsC5_ENoA_22_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_URYSXaY8RE6lUkg-Wo5WBw_26_2"
          xlink:label="Tc_URYSXaY8RE6lUkg-Wo5WBw_26_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_URYSXaY8RE6lUkg-Wo5WBw_26_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_d828K6Ue1EKmOTX4if5wtA_12_2"
          xlink:label="Tc_d828K6Ue1EKmOTX4if5wtA_12_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_d828K6Ue1EKmOTX4if5wtA_12_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_L-kjd32hckOMkpdSFE_lCw_13_2"
          xlink:label="Tc_L-kjd32hckOMkpdSFE_lCw_13_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_L-kjd32hckOMkpdSFE_lCw_13_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_kJfgoliISkuMvHZqvexXNw_27_2"
          xlink:label="Tc_kJfgoliISkuMvHZqvexXNw_27_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_kJfgoliISkuMvHZqvexXNw_27_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_pxTp2QsKZ0-w6FRLwU0S2w_33_2"
          xlink:label="Tc_pxTp2QsKZ0-w6FRLwU0S2w_33_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_pxTp2QsKZ0-w6FRLwU0S2w_33_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_0LvczoWAP0eRWIM1krg6yA_21_2"
          xlink:label="Tc_0LvczoWAP0eRWIM1krg6yA_21_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_0LvczoWAP0eRWIM1krg6yA_21_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_fWUbFYN1xk-LXIllRu6nHw_15_2"
          xlink:label="Tc_fWUbFYN1xk-LXIllRu6nHw_15_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_fWUbFYN1xk-LXIllRu6nHw_15_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_MOKYy9iWukWBlp9Cb8syFQ_6_6"
          xlink:label="Tc_MOKYy9iWukWBlp9Cb8syFQ_6_6"
          xlink:type="locator"/>
        <link:footnote id="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" xlink:label="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_MOKYy9iWukWBlp9Cb8syFQ_6_6"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_M3MdaWnkm0u3iCJrBVW49Q_6_12"
          xlink:label="Tc_M3MdaWnkm0u3iCJrBVW49Q_6_12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_M3MdaWnkm0u3iCJrBVW49Q_6_12"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_ja4zzCYhOEqCGEHrAQpQfg_6_3"
          xlink:label="Tc_ja4zzCYhOEqCGEHrAQpQfg_6_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_ja4zzCYhOEqCGEHrAQpQfg_6_3"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_l5BWUd-RXUGbJZRQPvUhdw_6_9"
          xlink:label="Tc_l5BWUd-RXUGbJZRQPvUhdw_6_9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_l5BWUd-RXUGbJZRQPvUhdw_6_9"
          xlink:to="_decff55c_b6f1_4b4f_9c4c_20bfc2a1e99e"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_SOE0M9LJqEC9irlbFTBuww_7_6"
          xlink:label="Tc_SOE0M9LJqEC9irlbFTBuww_7_6"
          xlink:type="locator"/>
        <link:footnote id="_8530ca94_6c84_4f48_984f_7cc5a2959400" xlink:label="_8530ca94_6c84_4f48_984f_7cc5a2959400" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_SOE0M9LJqEC9irlbFTBuww_7_6"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_UJDWbfys4UWta90TrpcD1g_7_12"
          xlink:label="Tc_UJDWbfys4UWta90TrpcD1g_7_12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_UJDWbfys4UWta90TrpcD1g_7_12"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_6PQnFa_8wEOkocugC-GiRA_7_3"
          xlink:label="Tc_6PQnFa_8wEOkocugC-GiRA_7_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_6PQnFa_8wEOkocugC-GiRA_7_3"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_j20L-um0_UeQS6WljLnoLw_7_9"
          xlink:label="Tc_j20L-um0_UeQS6WljLnoLw_7_9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_j20L-um0_UeQS6WljLnoLw_7_9"
          xlink:to="_8530ca94_6c84_4f48_984f_7cc5a2959400"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_6jhX9rTYhkan3hwzHYH8Zw_8_6"
          xlink:label="Tc_6jhX9rTYhkan3hwzHYH8Zw_8_6"
          xlink:type="locator"/>
        <link:footnote id="_64475d15_2bf5_4e75_bed3_14deb6a39d55" xlink:label="_64475d15_2bf5_4e75_bed3_14deb6a39d55" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</xhtml:b></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_6jhX9rTYhkan3hwzHYH8Zw_8_6"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_8pXFPCLHhEC0G7Z06IE0AQ_8_12"
          xlink:label="Tc_8pXFPCLHhEC0G7Z06IE0AQ_8_12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_8pXFPCLHhEC0G7Z06IE0AQ_8_12"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_zZSlooWFp0SIFCb7s7p3xw_8_3"
          xlink:label="Tc_zZSlooWFp0SIFCb7s7p3xw_8_3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_zZSlooWFp0SIFCb7s7p3xw_8_3"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_c0sXX_tWXE2Thll3DxjFZg_8_9"
          xlink:label="Tc_c0sXX_tWXE2Thll3DxjFZg_8_9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_c0sXX_tWXE2Thll3DxjFZg_8_9"
          xlink:to="_64475d15_2bf5_4e75_bed3_14deb6a39d55"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765323632504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTALIX BIOTHERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,556,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765323636680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 33,882<span></span>
</td>
<td class="nump">$ 18,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShortTermBankDeposits', window );">Short-term bank deposits</a></td>
<td class="nump">43,058<span></span>
</td>
<td class="nump">20,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">2,330<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">3,013<span></span>
</td>
<td class="nump">2,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">13,640<span></span>
</td>
<td class="nump">13,082<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">95,923<span></span>
</td>
<td class="nump">55,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">1,884<span></span>
</td>
<td class="nump">1,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,991<span></span>
</td>
<td class="nump">4,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">5,406<span></span>
</td>
<td class="nump">5,567<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">108,204<span></span>
</td>
<td class="nump">67,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">6,128<span></span>
</td>
<td class="nump">7,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">14,420<span></span>
</td>
<td class="nump">13,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,235<span></span>
</td>
<td class="nump">1,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contracts liability</a></td>
<td class="nump">18,109<span></span>
</td>
<td class="nump">5,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible notes</a></td>
<td class="nump">56,355<span></span>
</td>
<td class="nump">54,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,086<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">96,247<span></span>
</td>
<td class="nump">86,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contracts liability</a></td>
<td class="nump">1,269<span></span>
</td>
<td class="nump">1,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">2,302<span></span>
</td>
<td class="nump">2,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">4,507<span></span>
</td>
<td class="nump">4,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">8,116<span></span>
</td>
<td class="nump">8,497<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">104,363<span></span>
</td>
<td class="nump">94,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</a></td>
<td class="nump">3,841<span></span>
</td>
<td class="num">(27,037)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (net of capital deficiency)</a></td>
<td class="nump">$ 108,204<span></span>
</td>
<td class="nump">$ 67,934<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShortTermBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShortTermBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765327508680">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,427<span></span>
</td>
<td class="nump">$ 10,967<span></span>
</td>
<td class="nump">$ 17,747<span></span>
</td>
<td class="nump">$ 32,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF GOODS SOLD</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(4,733)<span></span>
</td>
<td class="num">(1,827)<span></span>
</td>
<td class="num">(9,498)<span></span>
</td>
<td class="num">(5,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">(7,689)<span></span>
</td>
<td class="num">(9,186)<span></span>
</td>
<td class="num">(14,811)<span></span>
</td>
<td class="num">(19,526)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(3,171)<span></span>
</td>
<td class="num">(2,194)<span></span>
</td>
<td class="num">(6,309)<span></span>
</td>
<td class="num">(5,381)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING INCOME (LOSS)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,166)<span></span>
</td>
<td class="num">(2,240)<span></span>
</td>
<td class="num">(12,871)<span></span>
</td>
<td class="nump">2,453<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,203)<span></span>
</td>
<td class="num">(1,948)<span></span>
</td>
<td class="num">(4,240)<span></span>
</td>
<td class="num">(5,177)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">128<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">344<span></span>
</td>
<td class="nump">241<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL EXPENSES - NET</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,075)<span></span>
</td>
<td class="num">(1,910)<span></span>
</td>
<td class="num">(3,896)<span></span>
</td>
<td class="num">(4,936)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">OTHER INCOME</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS FOR THE PERIOD</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (11,241)<span></span>
</td>
<td class="num">$ (4,150)<span></span>
</td>
<td class="num">$ (16,716)<span></span>
</td>
<td class="num">$ (2,483)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.39)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC AND DILUTED</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">45,436,907<span></span>
</td>
<td class="nump">32,442,636<span></span>
</td>
<td class="nump">42,744,426<span></span>
</td>
<td class="nump">19,923,935<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,243<span></span>
</td>
<td class="nump">$ 3,648<span></span>
</td>
<td class="nump">$ 7,754<span></span>
</td>
<td class="nump">$ 8,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,184<span></span>
</td>
<td class="nump">$ 7,319<span></span>
</td>
<td class="nump">$ 9,993<span></span>
</td>
<td class="nump">$ 23,934<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(1) Includes share-based compensation</b></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(2) Includes share-based compensation</b></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><b style="font-size:8pt;font-weight:bold;">(3) Includes share-based compensation</b></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765327325624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">160<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">$ 272<span></span>
</td>
<td class="nump">$ 872<span></span>
</td>
<td class="nump">$ 625<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765328375288">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 270,492<span></span>
</td>
<td class="num">$ (340,829)<span></span>
</td>
<td class="num">$ (70,322)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">14,838,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue', window );">Issuance of common stock and warrants, net of issuance cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">41,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares', window );">Issuance of common stock and warrants, net of issuance cost (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">17,604,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants', window );">Note receivable from issuance of common stock and warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,483)<span></span>
</td>
<td class="num">(2,483)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">308,515<span></span>
</td>
<td class="num">(343,312)<span></span>
</td>
<td class="num">(34,764)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">32,442,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">308,248<span></span>
</td>
<td class="num">(339,162)<span></span>
</td>
<td class="num">(30,881)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">32,442,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,150)<span></span>
</td>
<td class="num">(4,150)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">308,515<span></span>
</td>
<td class="num">(343,312)<span></span>
</td>
<td class="num">(34,764)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">32,442,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">320,280<span></span>
</td>
<td class="num">(347,352)<span></span>
</td>
<td class="num">(27,037)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">34,765,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">37,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance cost (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">8,749,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">8,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesSalesAgreement', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,867,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">173,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,716)<span></span>
</td>
<td class="num">(16,716)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">367,863<span></span>
</td>
<td class="num">(364,068)<span></span>
</td>
<td class="nump">3,841<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">367,285<span></span>
</td>
<td class="num">(352,827)<span></span>
</td>
<td class="nump">14,504<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45,382,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">173,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,241)<span></span>
</td>
<td class="num">(11,241)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 367,863<span></span>
</td>
<td class="num">$ (364,068)<span></span>
</td>
<td class="nump">$ 3,841<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">45,556,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Common stock, $0.001 par value; Authorized &#8211; as of June&#160;30, 2021 and 2020 - 120,000,000 shares.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from receivables from sale of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents issuance of common stock, net of issuance cost, in shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents issuance of common stock, net of issuance cost, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Sales Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during period for exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765326729176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKOLDERS' EQUITY (CAPITAL DEFICIENCY)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765326865400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,716)<span></span>
</td>
<td class="num">$ (2,483)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,394<span></span>
</td>
<td class="nump">698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">574<span></span>
</td>
<td class="nump">710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial income, net (mainly exchange differences)</a></td>
<td class="num">(121)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Loss (gain) on amounts funded in respect of employee rights upon retirement</a></td>
<td class="num">(56)<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of fixed assets</a></td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs and debt discount</a></td>
<td class="nump">1,928<span></span>
</td>
<td class="nump">1,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase (decrease) in contracts liability (including non-current portion)</a></td>
<td class="nump">12,268<span></span>
</td>
<td class="num">(10,841)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Increase in accounts receivable and other assets</a></td>
<td class="num">(1,587)<span></span>
</td>
<td class="num">(1,621)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in right of use assets</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(558)<span></span>
</td>
<td class="num">(2,910)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase (decrease) in accounts payable and accruals</a></td>
<td class="num">(544)<span></span>
</td>
<td class="nump">309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Decrease in other long term liabilities</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(385)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(3,318)<span></span>
</td>
<td class="num">(14,952)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseDecreaseInBankDeposits', window );">Purchase of bank deposits</a></td>
<td class="num">(37,835)<span></span>
</td>
<td class="num">(35,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromSaleOfShortTermDeposits', window );">Proceeds from sale of short-term deposits</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(667)<span></span>
</td>
<td class="num">(278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseDecreaseInRestrictedDeposit', window );">Decrease in restricted deposit</a></td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(23,144)<span></span>
</td>
<td class="num">(35,347)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Net payment for promissory note</a></td>
<td class="num">(4,086)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost', window );">Proceeds from issuance of common stock and warrants, net</a></td>
<td class="nump">37,625<span></span>
</td>
<td class="nump">37,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">8,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">42,114<span></span>
</td>
<td class="nump">37,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(35)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">15,617<span></span>
</td>
<td class="num">(12,949)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">18,265<span></span>
</td>
<td class="nump">17,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">33,882<span></span>
</td>
<td class="nump">4,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">372<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost', window );">Note receivable from issuance of common stock and warrants, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_InterestReceivedNet', window );">Interest received</a></td>
<td class="nump">$ 307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deposits held with banks.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseDecreaseInRestrictedDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseDecreaseInRestrictedDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in liabilities for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_InterestReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash received for interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_InterestReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note receivable from issuance of common stock and warrants, net of issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock and warrants, net of issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromSaleOfShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of short-term deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromSaleOfShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765330708504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies: the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The studies are designed to evaluate the potential superiority of PRX-102 over current therapies in a head-to-head study and a switch-over study, evaluate the potential for improved efficacy and better quality of life for patients with Fabry disease and evaluate the safety of our drug/therapy. The <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies have been completed, and the <i style="font-style:italic;">BALANCE</i> study is fully-enrolled. See Part&#160;1, Item&#160;2, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Pegunigalsidase Alfa (PRX-102) for the Treatment of Fabry Disease for details regarding the current status of these studies and of available clinical trial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">A BLA for PRX-102 for the treatment of adult patients with Fabry disease was submitted to the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, which was subsequently accepted by the FDA and granted Priority Review designation. The FDA also indicated in its BLA filing communication letter that it did not plan to hold an advisory committee meeting to discuss the application. Based on the interim analysis of the 12-month data generated from the <i style="font-style:italic;">BALANCE</i> study that the Company announced in June 2021, and in combination with previously reported positive data from the <i style="font-style:italic;">BRIGHT</i> and <i style="font-style:italic;">BRIDGE</i> studies, the Company and Chiesi intend to submit a Marketing Authorization Application (an &#8220;MAA&#8221;) to the European Medicines Agency (the &#8220;EMA&#8221;) for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On April&#160;28, 2021, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), announced that they received a Complete Response Letter (CRL) from the FDA regarding the BLA. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#8217;s manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#8220;COVID-19&#8221;), the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (the &#8220;FFDCA&#8221;) in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to the foregoing, in the CRL, the FDA noted that agalsidase beta (Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>), a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102. The Company intends to work collaboratively with the FDA to identify the most expeditious pathway to approval, and is confident that it will be able to work with the FDA to resolve these issues and provide a new, alternative drug to Fabry patients. On August&#160;2, 2021, the Company <span style="letter-spacing:-0.15pt;">announced that a Type A Meeting request has been submitted to the FDA to discuss the CRL. The Type A Meeting is expected to occur within 30 days of the FDA&#8217;s receipt of the meeting request</span>; however, the Company cannot anticipate the timing of such a meeting nor the additional steps that may be required in connection with any potential resubmission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which is subject to an exclusive worldwide license agreement with SarcoMed USA, Inc. (&#8220;SarcoMed&#8221;) for use in the treatment</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat refractory gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July 2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). The Company sold a total of 3,296,123 shares of common stock pursuant to the sales agreement with BofA Securities for total gross proceeds of approximately $13.8&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;10, 2021, the Company entered into an exclusive worldwide license agreement with SarcoMed with respect to PRX-110 for use in the treatment of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery. Under the terms of the agreement, SarcoMed will be responsible for the identification and selection of pharmaceutical candidates under the license, and the clinical research and development of such candidates. The Company is entitled to an initial cash payment of $3.5&#160;million, subject to certain conditions, and to additional regulatory and commercial milestone payments and tiered royalties on net sales of products that are commercialized under the license agreement. In addition to the foregoing, the parties agreed to commence negotiation of clinical and commercial supply agreements for alidornase alfa. As part of the arrangement, the parties agreed to negotiate and sign a supply agreement within 60 days of the execution of the license agreement, and SarcoMed has the right to terminate the license agreement if the parties do not successfully do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;17, 2021, the Company issued and sold 8,749,999 shares of its Common Stock in an underwritten public offering raising gross proceeds of approximately $40.2&#160;million at a price equal to $4.60 per share, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities acted as book-running manager for the offering with Oppenheimer &amp; Co. acting as co-manager.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#8217;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. We continue to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company believes that its cash and cash equivalents and bank deposits as of June&#160;30, 2021 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued. See also Note&#160;6 regarding the exchange agreements relating to the 7.5% convertible secured promissory notes due 2021 (the &#8220;2021 Notes&#8221;) signed in August 2021 which are subject to certain closing conditions.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed by the Company with the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2020.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include 18,445,764 and 26,322,164 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of outstanding 2021 Notes and outstanding warrants for the six months ended June 30, 2020 and 2021, respectively, and 25,997,289 and 25,874,641 shares of Common Stock underlying outstanding options and shares issuable upon conversion of outstanding 2021 Notes and outstanding warrants for the three months ended June 30, 2020 and 2021, respectively because their effect would be anti-dilutive.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenues from selling products</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765326412856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at June&#160;30, 2021 and December&#160;31, 2020 consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,046</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,347</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,529</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,848</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,640</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765326711000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is usually identical or close to their carrying value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.45pt;">As of June&#160;30, 2021, the carrying amounts of short-term deposits approximate their fair values due to the stated interest rates, which approximate market rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 35.45pt;">The fair value of the $57.9&#160;million aggregate principal amount of the Company&#8217;s outstanding 2021 Notes as of June&#160;30, 2021 is approximately $57.6&#160;million based on a Level 3 measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The Company prepared a valuation of the fair value of the Company&#8217;s outstanding 2021 Notes&#160;(a Level 3 valuation) as of June&#160;30, 2021. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.91</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.05</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.16</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765326711000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenueDisclosureTextBlock', window );">REVENUES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;4&#160;&#8211; REVENUES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The following table summarizes the Company&#8217;s disaggregation of revenues:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,237</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 663</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,748</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,679</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 988</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,985</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 988</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,184</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,319</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,993</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,934</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 36pt;">During the six months ended June&#160;30, 2020, and following the CRL received from the FDA, the Company changed its estimate for total costs expected to be incurred until satisfying the performance obligation under the Chiesi Agreements. This resulted in a reduction to accumulated revenues recognized in respect of this performance obligation in the amount of $4.1&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 36pt;"><span style="background-color:#ffffff;">During the six months ended June 30, 2021 and 2020, the Company recognized revenues of approximately </span><span style="background-color:#ffffff;">$0.9</span><span style="background-color:#ffffff;">&#160;million and </span><span style="background-color:#ffffff;">$1.2</span><span style="background-color:#ffffff;">&#160;million, respectively, and during each of the three months ended June 30, 2021 and 2020, the Company recognized revenues of approximately </span><span style="background-color:#ffffff;">$0.5</span><span style="background-color:#ffffff;">&#160;million all related to a </span><span style="background-color:#ffffff;">$10.0</span><span style="background-color:#ffffff;">&#160;million future milestone payment, which was accounted for as a variable consideration. The </span><span style="background-color:#ffffff;">$10.0</span><span style="background-color:#ffffff;">&#160;million payment was received in June 2021.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenueDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure pertaining to revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenueDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765326699224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; STOCK TRANSACTIONS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On June&#160;7, 2021, the Company issued </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">173,816</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> shares of Common Stock in connection with the cashless exercise of a warrant to purchase </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">2,816,901</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> shares of Common Stock issued on March&#160;18, 2020, as part of the Company&#8217;s private placement of Common Stock and warrants. The Company did not generate any proceeds from the cashless exercise.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">On July 2, 2021, the Company entered into the Sales Agreement with the Agent. Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent ATM Shares having an aggregate offering price of up to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">$20.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">&#160;million. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">The ATM Shares will be issued pursuant to the Company&#8217;s shelf registration statement on Form&#160;S-3. The Company intends to use the net proceeds from the offering, after deducting the Agent&#8217;s commissions and the Company&#8217;s offering expenses, for general corporate</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> purposes. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;text-align:left;top:0pt;vertical-align:top;">SM</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765325159000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">As of June&#160;30, 2021, the Company has outstanding $57.9&#160;million aggregate principal amount of 2021 Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On August&#160;12, 2021, the Company entered into definitive agreements relating to private exchanges (the &#8220;Exchanges&#8221;) of an aggregate of $54.65&#160;million principal amount of the Company&#8217;s outstanding 2021 Notes for an aggregate of $28.75&#160;million principal amount of 7.50% Senior Secured Convertible Notes due 2024 (the &#8220;2024 Notes&#8221;), $25.90&#160;million in cash, and accrued and unpaid interest through the issue date. The Exchanges are expected to close as soon as practicable, subject to satisfaction of certain closing conditions. The initial conversion rate for the 2024 Notes is 563.2216 shares of Common Stock for each $1,000 principal amount of 2024 Notes (equivalent to an initial conversion price of approximately $1.7755 per share of the Common Stock), subject to adjustment in some events, which is based on a 32.5% premium to the closing price of the Common Stock on the NYSE American at the close of trading on August&#160;13, 2021, the exchange date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">The 2024 Notes will be issued pursuant to an indenture to be entered into between the Company, the guarantors party thereto, The Bank of New York Mellon Trust Company, N.A., as trustee and Wilmington Savings Fund Society, FSB, as collateral agent. Interest on the Notes will be paid semi-annually at a rate of 7.50% per annum. The Notes will mature three years after the issuance thereof, unless earlier purchased, converted, exchanged or redeemed and will be guaranteed by the Company&#8217;s subsidiaries. The 2024 Notes will be secured by perfected liens on all of the assets of the Company and its subsidiaries.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765327675176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiaries, the &#8220;Company&#8221;) and its wholly-owned subsidiaries, Protalix Ltd. and Protalix B.V. (collectively, the &#8220;Subsidiaries&#8221;), are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed taliglucerase alfa (marketed under the name BioManguinhos alfataliglicerase in Brazil and certain other Latin American countries and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company has a number of product candidates in varying stages of the clinical development process. The Company&#8217;s strategy is to develop proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The most advanced investigational drug in the Company&#8217;s product pipeline is pegunigalsidase alfa, or PRX-102, a therapeutic protein candidate for the treatment of Fabry disease, a rare, genetic lysosomal disorder, which is the subject of a phase&#160;III clinical program. The PRX-102 phase&#160;III clinical program includes three separate studies: the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. The studies are designed to evaluate the potential superiority of PRX-102 over current therapies in a head-to-head study and a switch-over study, evaluate the potential for improved efficacy and better quality of life for patients with Fabry disease and evaluate the safety of our drug/therapy. The <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies have been completed, and the <i style="font-style:italic;">BALANCE</i> study is fully-enrolled. See Part&#160;1, Item&#160;2, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Pegunigalsidase Alfa (PRX-102) for the Treatment of Fabry Disease for details regarding the current status of these studies and of available clinical trial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">A BLA for PRX-102 for the treatment of adult patients with Fabry disease was submitted to the U.S.&#160;Food and Drug Administration (the &#8220;FDA&#8221;) on May&#160;27, 2020 under the FDA&#8217;s Accelerated Approval pathway, which was subsequently accepted by the FDA and granted Priority Review designation. The FDA also indicated in its BLA filing communication letter that it did not plan to hold an advisory committee meeting to discuss the application. Based on the interim analysis of the 12-month data generated from the <i style="font-style:italic;">BALANCE</i> study that the Company announced in June 2021, and in combination with previously reported positive data from the <i style="font-style:italic;">BRIGHT</i> and <i style="font-style:italic;">BRIDGE</i> studies, the Company and Chiesi intend to submit a Marketing Authorization Application (an &#8220;MAA&#8221;) to the European Medicines Agency (the &#8220;EMA&#8221;) for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On April&#160;28, 2021, the Company, together with its development and commercialization partner for PRX-102, Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;), announced that they received a Complete Response Letter (CRL) from the FDA regarding the BLA. The CRL did not report any concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package. In the CRL, the FDA noted that an inspection of the Company&#8217;s manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, is required before the FDA can approve a resubmitted BLA. Due to travel restrictions, the FDA was unable to conduct the required inspection during the review cycle. The FDA explained in the letter that it will continue to monitor the public health situation as well as travel restrictions, and is actively working to define an approach for scheduling outstanding inspections. With respect to the third-party facility in Europe at which fill and finish processes are performed for PRX-102, due to the novel coronavirus disease (&#8220;COVID-19&#8221;), the FDA reviewed records under Section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (the &#8220;FFDCA&#8221;) in lieu of a pre-licensing inspection. In the CRL, the FDA stated that it will communicate remaining issues to the facility in order to seek prompt resolution of any pending items.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to the foregoing, in the CRL, the FDA noted that agalsidase beta (Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>), a therapy used to treat Fabry patients, was recently converted to full approval and is now an &#8220;available therapy,&#8221; which must be addressed in the context of any potential resubmission of a BLA for PRX-102. The Company intends to work collaboratively with the FDA to identify the most expeditious pathway to approval, and is confident that it will be able to work with the FDA to resolve these issues and provide a new, alternative drug to Fabry patients. On August&#160;2, 2021, the Company <span style="letter-spacing:-0.15pt;">announced that a Type A Meeting request has been submitted to the FDA to discuss the CRL. The Type A Meeting is expected to occur within 30 days of the FDA&#8217;s receipt of the meeting request</span>; however, the Company cannot anticipate the timing of such a meeting nor the additional steps that may be required in connection with any potential resubmission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In addition to PRX-102, the Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">alidornase alfa, or PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1, or DNase, which is subject to an exclusive worldwide license agreement with SarcoMed USA, Inc. (&#8220;SarcoMed&#8221;) for use in the treatment</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat refractory gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase I product candidate being designed to elongate half-life in the circulation for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On July 2, 2021, the Company entered into an At The Market Offering Agreement (the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). Pursuant to the terms of the Sales Agreement, the Company may sell from time to time through the Agent shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $20.0&#160;million (the &#8220;ATM Shares&#8221;). Upon execution of the Sales Agreement, the Company terminated the ATM Equity Offering<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">SM</sup> Sales Agreement it had entered into on October&#160;1, 2020 with BofA Securities, Inc. (&#8220;BofA Securities&#8221;). The Company sold a total of 3,296,123 shares of common stock pursuant to the sales agreement with BofA Securities for total gross proceeds of approximately $13.8&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;10, 2021, the Company entered into an exclusive worldwide license agreement with SarcoMed with respect to PRX-110 for use in the treatment of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery. Under the terms of the agreement, SarcoMed will be responsible for the identification and selection of pharmaceutical candidates under the license, and the clinical research and development of such candidates. The Company is entitled to an initial cash payment of $3.5&#160;million, subject to certain conditions, and to additional regulatory and commercial milestone payments and tiered royalties on net sales of products that are commercialized under the license agreement. In addition to the foregoing, the parties agreed to commence negotiation of clinical and commercial supply agreements for alidornase alfa. As part of the arrangement, the parties agreed to negotiate and sign a supply agreement within 60 days of the execution of the license agreement, and SarcoMed has the right to terminate the license agreement if the parties do not successfully do so.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On February&#160;17, 2021, the Company issued and sold 8,749,999 shares of its Common Stock in an underwritten public offering raising gross proceeds of approximately $40.2&#160;million at a price equal to $4.60 per share, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities acted as book-running manager for the offering with Oppenheimer &amp; Co. acting as co-manager.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On October&#160;19, 2017, Protalix&#160;Ltd. and Chiesi entered into an Exclusive License and Supply Agreement (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Protalix Ltd. granted to Chiesi an exclusive license for all markets outside of the United States to commercialize pegunigalsidase alfa. On July&#160;23, 2018, Protalix&#160;Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;) with respect to the commercialization of pegunigalsidase alfa in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under each of the Chiesi Ex-US Agreement and the Chiesi US Agreement (collectively, the &#8220;Chiesi Agreements&#8221;), Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of each agreement. In addition, under the Chiesi Ex-US Agreement, Protalix&#160;Ltd. is entitled to additional payments of up to $25.0&#160;million in pegunigalsidase alfa development costs, capped at $10.0&#160;million per year, and to receive additional payments of up to $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Under the Chiesi US Agreement, Protalix&#160;Ltd. is entitled to payments of up to a maximum of $20.0&#160;million to cover development costs for pegunigalsidase alfa, subject to a maximum of $7.5&#160;million per year, and to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. To date, Protalix Ltd. has received the complete amount of development costs to which it is entitled under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Under the terms of both of the Chiesi Agreements, Protalix Ltd. will manufacture all of the pegunigalsidase alfa needed under the agreements, subject to certain exceptions, and Chiesi will purchase pegunigalsidase alfa from Protalix, subject to certain terms and conditions. Under the Chiesi Ex-US Agreement, Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales outside of the United States, as consideration for product supply. Under the Chiesi US Agreement, Chiesi is required to make tiered payments of 15% to 40% of its net sales, depending on the amount of annual sales in the United States, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On May&#160;13, 2021, the Company signed a binding term sheet with Chiesi pursuant to which the Company and Chiesi amended the Chiesi Agreements in order to provide the Company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to the Company before the end of the second quarter in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. The Company received the payment in June&#160;2021. The Company also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, taliglucerase alfa has been marketed by Pfizer in accordance with the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement (the &#8220;Amended Pfizer Agreement&#8221;) pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;), for taliglucerase alfa. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz under the Brazil Agreement, and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">COVID-19, which was declared by the World Health Organization to be a global pandemic on March&#160;11, 2020, has had numerous adverse effects on the global economy. To date, the Company&#8217;s clinical trials have not been adversely affected by COVID-19, although certain practices the Company has adopted in its offices and facilities in an effort to promote social distancing have resulted in minor delays in the performance of administrative activities outside of the clinical programs. We continue to face uncertainty as to the degree and duration of that impact going forward. The Company does not know the length of time that the pandemic and related disruptions will continue, the impact of governmental regulations or easement of regulations in response to the strengthening or weakening of the pandemic, or the degree of overall potentially permanent changes in consumer behavior that may be caused by the pandemic.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company believes that its cash and cash equivalents and bank deposits as of June&#160;30, 2021 are sufficient to satisfy the Company&#8217;s capital needs for at least 12 months from the date that these financial statements are issued. See also Note&#160;6 regarding the exchange agreements relating to the 7.5% convertible secured promissory notes due 2021 (the &#8220;2021 Notes&#8221;) signed in August 2021 which are subject to certain closing conditions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed by the Company with the U.S. Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2020 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2020.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss per share</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) are computed by dividing net loss by the weighted average number of shares of the Company&#8217;s Common Stock attributable to common stockholders outstanding for each period. The calculation of diluted LPS does not include 18,445,764 and 26,322,164 shares of Common Stock underlying outstanding options and shares of Common Stock issuable upon conversion of outstanding 2021 Notes and outstanding warrants for the six months ended June 30, 2020 and 2021, respectively, and 25,997,289 and 25,874,641 shares of Common Stock underlying outstanding options and shares issuable upon conversion of outstanding 2021 Notes and outstanding warrants for the three months ended June 30, 2020 and 2021, respectively because their effect would be anti-dilutive.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">d.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-weight:bold;">Revenue recognition</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company accounts for revenue pursuant to Accounting Standards Codification, Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;). Under ASC 606, a contract with a customer exists only when: the parties to the contract have approved it and are committed to perform their respective obligations, the Company can identify each party&#8217;s rights regarding the distinct goods or services to be transferred (&#8220;performance obligations&#8221;), the Company can determine the transaction price for the goods or services to be transferred, the contract has commercial substance and it is probable that the Company will collect the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">Revenues are recorded in the amount of consideration to which the Company expects to be entitled in exchange for performance obligations upon transfer of control to the customer.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenues from selling products</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company recognizes revenues from selling goods at a point in time when control over the product is transferred to customers (upon delivery).</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from Chiesi Agreements</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company has identified two performance obligations in Chiesi agreements as follows: (1)&#160;the license and research and development services and (2)&#160;the contingent performance obligation regarding future manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The Company determined that the license together with the research and development services should be combined into single performance obligation since Chiesi cannot benefit from the license without the research and development services. The research and development services are highly specialized and are dependent on the supply of the drug.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The future manufacturing is contingent on regulatory approvals of the drug and the Company deems these services to be separately identifiable from other performance obligations in the contract. Manufacturing services post-regulatory approval are not interdependent or interrelated with the license and research and development services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">The transaction price was comprised of fixed consideration and variable consideration (capped research and development reimbursements). Under ASC 606, the consideration to which the Company would be entitled upon the achievement of contractual milestones, which are contingent upon the occurrence of future events, are a form of variable consideration. The Company estimates variable consideration using the most likely method. Amounts included in the transaction price are recognized only when it is probable that a significant reversal of cumulative revenues will not occur. Prior to recognizing revenue from variable consideration, the Company uses significant judgment to determine the probability of significant reversal of such revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Since the customer benefits from the research and development services as the entity performs the service, revenue from granting the license and the research and development services is recognized over time using the cost-to-cost method. The Company used significant judgment when it determined the costs expected to be incurred upon satisfying the identified performance obligation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from additional research and development services ordered by Chiesi is recognized&#160;over time using the cost-to-cost method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:54pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Revenue from R&amp;D services</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;">Revenue from the research and development services is recognized over time using the cost-to-cost method since the customer benefits from the research and development services as the entity performs the service.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765330569448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at June&#160;30, 2021 and December&#160;31, 2020 consisted of the following:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,046</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,347</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,065</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,887</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,529</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,848</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,640</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765326688648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_Notes2021Member', window );">Notes 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of liability component based on income approach</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 35.3pt;">The Company prepared a valuation of the fair value of the Company&#8217;s outstanding 2021 Notes&#160;(a Level 3 valuation) as of June&#160;30, 2021. The value of these notes was estimated by implementing the binomial model. The liability component was valued based on the Income Approach. The following parameters were used:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021&#160;Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Stock price (USD)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.91</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Risk free rate</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.05</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 77.42</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:84.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0.05pt 0pt;">Yield</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.16</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_Notes2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_Notes2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765326669512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Company's disaggregation of revenues</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The following table summarizes the Company&#8217;s disaggregation of revenues:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,237</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 663</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,748</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,679</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Brazil</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 988</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,985</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 988</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,648</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,754</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,679</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,184</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,319</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,993</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.26%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,934</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765246283224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 13, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 17, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 10, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 23, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 19, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,749,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Convertible Debt, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,874,641<span></span>
</td>
<td class="nump">25,997,289<span></span>
</td>
<td class="nump">26,322,164<span></span>
</td>
<td class="nump">18,445,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares) | shares</a></td>
<td class="nump">3,296,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SaleOfStockMaximumOfferingPrice', window );">Sale of stock, maximum offering price</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds</a></td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes [Member] | Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement [Member] | Protalix Bio Therapeutics Incorporation [Member] | Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative Arrangement Revenues and Expenses Sharing Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember', window );">Chiesi Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_RevenuePerformanceObligationNumber', window );">Revenue, Performance Obligation, Number | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember', window );">Chiesi US Agreement [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts', window );">Additional Amounts Payable To Cover Development Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear', window );">Maximum Entitlement Of Development Costs To Cover Per Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AgreementAmendmentPaymentReceivable', window );">Agreement Amendment Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones', window );">Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones', window );">Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PaymentOnNetSalesPercentage', window );">Payment On Net Sales Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_SarcomedUsaInc.AgreementMember', window );">SarcoMed USA, Inc. Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_LicenseAgreementInitialCashPayment', window );">License Agreement, Initial Cash Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_TermToSignSupplyAgreement', window );">Term to sign supply agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember', window );">Chiesi US Agreement and Chiesi Ex US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_UpfrontNonrefundableNonCreditablePaymentReceivable', window );">Upfront Nonrefundable Non-Creditable Payment Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount payable to entity for the achievement of regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AdditionalAmountsPayableToCoverDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to the entity to cover development costs under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AdditionalAmountsPayableToCoverDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AgreementAmendmentPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement Amendment Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AgreementAmendmentPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_LicenseAgreementInitialCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of initial cash payment under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_LicenseAgreementInitialCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount payable to entity to cover development costs in any year under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PaymentOnNetSalesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the payment as a percentage of future net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PaymentOnNetSalesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_RevenuePerformanceObligationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Performance Obligation, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_RevenuePerformanceObligationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SaleOfStockMaximumOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, maximum offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SaleOfStockMaximumOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_TermToSignSupplyAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term To Sign Supply Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_TermToSignSupplyAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_UpfrontNonrefundableNonCreditablePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_UpfrontNonrefundableNonCreditablePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_SarcomedUsaInc.AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_SarcomedUsaInc.AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765335354360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 3,046<span></span>
</td>
<td class="nump">$ 3,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">3,065<span></span>
</td>
<td class="nump">2,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">7,529<span></span>
</td>
<td class="nump">6,848<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 13,640<span></span>
</td>
<td class="nump">$ 13,082<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765335399736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details) - 2021 Notes [Member] - Fair Value, Inputs, Level 3 [Member]<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">1.91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">0.38<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">0.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">77.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">Measurement Input, Yield [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Debt Instrument, Measurement Input</a></td>
<td class="nump">11.16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=plx_MeasurementInputYieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765336883592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT - Additional Information (Details) - 2021 Notes [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term Debt</a></td>
<td class="nump">$ 57.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term Debt</a></td>
<td class="nump">57.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Debt, Fair Value Disclosures</a></td>
<td class="nump">$ 57.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765326846584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUES - Company's disaggregation of revenues (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,427<span></span>
</td>
<td class="nump">$ 10,967<span></span>
</td>
<td class="nump">$ 17,747<span></span>
</td>
<td class="nump">$ 32,613<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember', window );">Chiesi Ex US Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_VariableConsideration', window );">Variable Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ProceedsFromVariableConsideration', window );">Proceeds From Variable Consideration</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,243<span></span>
</td>
<td class="nump">3,648<span></span>
</td>
<td class="nump">7,754<span></span>
</td>
<td class="nump">8,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member] | Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,237<span></span>
</td>
<td class="nump">663<span></span>
</td>
<td class="nump">6,748<span></span>
</td>
<td class="nump">2,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member] | Brazil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="nump">2,985<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods [Member] | Chiesi [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,184<span></span>
</td>
<td class="nump">$ 7,319<span></span>
</td>
<td class="nump">$ 9,993<span></span>
</td>
<td class="nump">23,934<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services [Member] | Chiesi US Agreement and Chiesi Ex US Agreement [Member] | Change in Accounting Method Accounted for as Change in Estimate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_ReductionToAccumulatedRevenueRecognized', window );">Reduction To Accumulated Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromVariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Variable Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromVariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ReductionToAccumulatedRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reduction to accumulated revenues recognized in respect of performance obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ReductionToAccumulatedRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_VariableConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable consideration payable under the contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_VariableConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiExUSAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=plx_ChiesiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=plx_ChiesiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiUsAgreementAndChiesiExUsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765246227768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCK TRANSACTIONS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jun. 07, 2021</div></th>
<th class="th"><div>Feb. 17, 2021</div></th>
<th class="th"><div>Mar. 18, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,749,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,816,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember', window );">ATM Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="nump">3,296,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_SaleOfStockMaximumOfferingPrice', window );">Sale of stock, maximum offering price</a></td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SaleOfStockMaximumOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, maximum offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SaleOfStockMaximumOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139765326831624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Aug. 12, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember', window );">2021 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short-term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">7.50% [Senior] Secured Convertible Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentConvertibleBaseValueForConversionRate', window );">Debt Instrument Convertible Base Value For Conversion Rate</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 2021 Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">54,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | 7.50% [Senior] Secured Convertible Notes due 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtConversionConvertedInstrumentAmountCash', window );">Debt Conversion Converted Instrument Amount, Cash</a></td>
<td class="nump">$ 25,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DebtInstrumentConvertibleConversionShareNumber', window );">Debt Instrument Convertible Conversion Share Number</a></td>
<td class="nump">563.2216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
<td class="nump">$ 1.7755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_PercentageOfPremiumToClosingPriceOfStock', window );">Percentage of premium to closing price of stock</a></td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Mature term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtConversionConvertedInstrumentAmountCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a cash transaction. "Cash" refers to that portion of the transaction resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtConversionConvertedInstrumentAmountCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentConvertibleBaseValueForConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Convertible Base Value For Conversion Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentConvertibleBaseValueForConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DebtInstrumentConvertibleConversionShareNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Convertible Conversion Share Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DebtInstrumentConvertibleConversionShareNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfPremiumToClosingPriceOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of premium to closing price of stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfPremiumToClosingPriceOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>39
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M7)D'X/Y"2KT_,2\H=HC[_P-02P,$%     @ .3H04P\_^2^#!0  214  !@
M  !X;"]W;W)K<VAE971S+W-H965T,BYX;6R=6&UOXC@0_BL66FF[TK;X):\5
M1:+ 7MECH5?HG?9C&DR)FL19Q[3+OS\[T 02Q^7N"\0P,WYF,GZ>27IOC+_D
M&TH%^)W$:7[3V0B177>[>;BA29!?L8RF\I\UXTD@Y)(_=_.,TV!5."5Q%T/H
M=),@2CO]7O';/>_WV%;$44KO.<BW21+PW2V-V=M-!W7>?WB(GC="_=#M][+@
MF2ZH>,SNN5QURRBK**%I'K$4<+J^Z0S0]9! Y5!8_!W1M_SH&JA4GAA[48O)
MZJ8#%2(:TU"H$('\>J5#&L<JDL3QZQ"T4^ZI'(^OWZ-_*Y*7R3P%.1VR^)]H
M)38W':\#5G0=;&/QP-[NZ"$A6\4+69P7G^!M;^O*'<-M+EAR<);K)$KWW\'O
M0R&.')#5XH /#OA<!W)P($6B>V1%6J- !/T>9V^ *VL935T4M2F\9391JF[C
M0G#Y;R3]1'\XGXW&L\5X!.358CZ=C 9+N;@=3 >SX1@L[L;CY0)<@L?%"%Q\
M^@(^@2@%RPW;YD&ZRGM=(3&H2-WPL-_M?C_<LM_W;7H%"/P*,,1(XSXTNX]H
M*-U1X0Y/W;LR\S)]7*:/BWBD+?W'AX?Q; D&BX7,\]H0D90121'1:HL8Y!L@
M:P-"=4%_;:/7(*:IT-9J'\HI0JD#]]HGQ/-PK_MZ7)*F%?*P8Y=6)SBM$J=E
MQ+G8,"XN!>6)/ ;IBVS]C.61'N8^DGT$P"+0]FHPFU;R)GE0#],N8=I&F(,P
M9%M9/4D9(96E?(JI[,8E#U94A]1N8B $UH!JC"!LP>F4.!TCSKG84 Z"/*?Z
M$CJ-/0E$I :L:82A[^B!N24PUPALDK[*[F,\HEI<;F-+1!RK7C&=%3SJTQ-D
M7HG,,R);,A'$DN,XEP -I?,:F_NVC^NU:UK9MGMD=0+1+R'Z1GJ8S6>7YU,$
M@A7I0F/JW[:2/!63<IIG4M  6P.:9#';40JX4IX<;+-"*$7$J91-H:5:V+PO
MGF?5*J.S<GU?7QET)!S(F,,]E[,$%[N"[!3/90KF5Y!2/5;4)!'?1W6L&BO/
M:J$Z5+$\PN;3*9$&(DJ?04REYN]+K(J^E8OVSCM$/6DJ"SIUS!HKVW%;,%<Z
M@LQ"LC\>!G"D>5OEF82-V]^T<UR?6"WX*OU EO%LE,R<!;N"EE4?!&'(MT&<
M&X])Q?W(3/ZM-(^:%.X@7!<DC96+,6I)O&)Z= ;5:U$U^1M9%JZ3J<Z,^+B%
MYU%%],C,]/4FCZ/@*8HCT<+\2$/JF-AUL!JKXY1.L5;4C\S</V2IX'*$STN4
M.RW&)JLC#T&_#E)#_L1OZ_"*_)'_$<A7R7"1:NZ4B98R^LV]'6(WZJ@QD[W1
MPA*X4A)L5A+)PDF4YXSO"HBZB1HW^=^"7DN[X8K_L9G_3^7[@V;#35[W'6RY
MM2IIS#S'<EON)#Z:\LUC_G0^^P,LQP\_P'0RN)U,)\O)V"CEN*)I_,&\?UXG
M8PU;8Z?>R#HK%[7=JHJJL7G6G[XC _*Y__\,&E@SVQ-8?T[166&G903#E0I@
MLPK\1U[#3=:W;-CH-(V5U2;:N-(&?,YC0,PDV.+1ZB.LFL>"NHII;.P6#<.5
M5F"S5NP/[_DXFRK@(50?A'16EM]6TTHK\#G/"1\AU"@%M(A3?TS0V/D28UM!
M*ZW 9JU8+.?#/^_FT]'X8?$9C/]ZG"Q_@HOAX'ZR'$S!:/QM,IR,9\.?7[3@
MF^) /*L^&VNL+K$+24N!2:4AQ*PAC0(7HUPN6/BR8?&*\OQS,>!+_KB0T[V:
MF\,@BY33BJZC,*)IN-,F=MCXY-6%;D;5V.EFU.[1>R[UDO%'P)^C5#(O74L_
M>.7*VO#]>[O]0K"L>/7UQ(1@27&YH7*FY,I _K]F4C,/"_4VK7Q[VO\74$L#
M!!0    ( #DZ$%.D*7/%L@4  '86   8    >&PO=V]R:W-H965T<R]S:&5E
M=#,N>&ULI5AM;^(X$/XK%EJ=NM)MB9WW'D6"8&CN($&$=D^J]D,*;D%+$BX)
M[=Z_/SND@3J3M+?[I4V<YYGQ/!X\8_=>DO1[MF$L1S^B79Q==S9YOK_J=K/5
MAD5A=IGL6<R_/"9I%.;\-7WJ9ON4A>N"%.VZ1%&,;A1NXTZ_5XS-TWXO.>2[
M;<SF*<H.412F_P[9+GFY[N#.Z\!B^[3)Q4"WW]N'3RQ@^>U^GO*W;F5EO8U8
MG&V3&*7L\;HSP%=C0@2A0-QMV4MV]HQ$* ])\EV\N.OKCB)FQ'9LE0L3(?_W
MS!RVVPE+?![_E$8[E4]!/']^M3XN@N?!/(09<Y+=U^TZWUQWK Y:L\?PL,L7
MR<L-*P/2A;U5LLN*O^BEQ"H=M#ID>1*59#Z#:!L?_X<_2B'."*K50" E@4@$
M[A@FJ"5!E0E: T$K"=I'/>@E0?^H!Z,D&(7V1[$*I4=A'O9[:?*"4H'FUL1#
ML5P%FPN\C45F!7G*OVXY+^\[OC>B7D!'B#\%_M0=#9;\)5CR?S/J+0/DCY$_
MIXO!TN4 ] 7=!B-T\>DS^H2V,5INDD,6QNNLU\WY;(3-[JKT[!P]DP;/*IHE
M<;[)$(W7; WP:3O?:.%WN0J5%.15"H>T&OSS$%\B5?D=$85@8#ZCC],5*)Q?
M\S[^:>]OQ%"KO% +>UJ#O:6_'$S1@MY1[Y9"BWND&P5=;%_/?4,C9J_[?*Y8
M'805VY!0%$"9IB:AQG642@RL5J@W86I5F%IKF(X?+$6&3WQ_%"">_R,@UF&[
MC7O\#1+H2-+/YOM%,U554@A 84O6D0(H6[,M22$ I1.]02&]4DAOC6Y! SI8
M.#=HX(W0B.?#U)^+C0'1O^=BXP@@P=I-WA-0,+T^?=.P;$DP &5CRY $ U!8
MLS"6%(-@MDX,6#*CDLQHC2^@TZGK37Y'$^KQC7-:2#<8S5S/#99B([VCK>JU
M6[]70?6,>B@J-J6 1P"*8%N3U -0AJI(*S$&4+IJ85@[L]+.;(VN+#7>!+F>
MX\\HNICZ0? 9BMB$,L&0,F$$H C1%"EB (6))<LWKL.(UO0#LZJ(K=:(QZXW
M\!R7ITE+3C@6%(8B[R8 BJ^NM$]0 *75)!D#*)WORW"P=A6L_<%@C\L+A6K7
M'/.ED *M8U0Y2@"B28D^KF.(UI# 6#EU5,K_7%#>-7ET";9("K"NBJE+X4(P
M;&,YBR&8:MG23V(,P31;;=CU\%DKB=M_N\L;NFA>6%K2S_WJ36J3DU/2ZI0+
MB\06@<;^ O$)(+Z!N#Y4QIW2DO%&17R^XJ7: $[#>DUMR)QAXIK< (YH5L.V
M@4\=&FYOT8JH>;0HN!DLJ.ABN/ SW^/-N^_\Q7-N. A<YUBWW>DM;^M!48Y.
MS//9*9>DEH$@#*NR)B!,E4M'@S72(,FIF\/MK=A7ZDYNQ/EE<,?+R(0B[W8V
MY IQ;0J1@II*M^+HXWIB<'Y;U!U)UH_*6&^^-%U3#5N1>V( J1)-(X8J-S&0
M36)J BOK64=BVR:JK>H-DI[:/]S>K$V29)VA^QF+'ECZK>5D@4_M$6[O8-X]
M6Y3\M[V^)A<["&74BAV ,DU=+@0 RC),NT&\4S.#V[N9Z7;%XHPA?D)&B]_"
M:/\'/UJS])D/?TS34Q.!V[N(]S6UZFIA2Y,UK:-,%=NRIG64;=NJK&D=)3)2
M:Q!5M!!OS^VGBDO:*RY\ AN^P[K GY$;KW:'-5^,;!.F[(NXHUJC51+M^;*%
MXNJK[5[A5!A)>V&$#SS#=U@7Y!?G=ZJAI+V&PD>*X3NL"_4GY]<]NZZ*6/I4
M7"QFG':(\^-)H1JM+B^'Q96=-.[@JQ$&QBF^&D/C VQ?49YH]2\\5ZXHSQ?H
M"^9?(&M<'_ZEF%?W%,;Q1G86ID_;.$,[]LA#4BY-OLFFQTO.XTN>[(M+N8<D
MSY.H>-RP<,U2 >#?'Y,D?WT1#JJKYOY_4$L#!!0    ( #DZ$%-X=S)]1@,
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MBM(8T/>U$/IY81S4X^_X'U!+ P04    "  Y.A!30;'*E3X'  "W(P  &
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MULQIH:(T"72_$D(_.69FNQ4=_ )02P,$%     @ .3H04V'HO6+_!P  6!\
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MU=:H(\W=#QFXN%ZOM6+$;LEH4L*%O .7CYFB\HPC6%:@)50B@;P=I^9L(DW
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M,-3S$FNFVW*)@DX64M7,D*F*4"\5LMR!ZBJ,HZ@7UHR+8-AWOALU[,N5J;C
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M1L'\U".J7W!ZPLC6+15;:7!%<9\U[H2@K #R2RG-D; .ABUS_2=02P,$%
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MFYQ&XK$&8&'+81;HLF-*-+D?4U3_.KNPBBQ9 ,C6=!?E_&=#M8=#2H,D53M
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M+_B@QC-484456JKP!-5*7XJXH(!X@F8\WV'V\D6BF$B<I@)2;$^:M@EX E:
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MK]WO.DB4D[P4%-_9Z;GA2L]BN\STXP?" +0]X5P=!1.@>DXG?P!02P,$%
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M'O83&>'T##2"GO!^$?CK= &>H+RJ_8V*9[RJ38D/GS#P7G^A'?+>>\5HW/
MDF7C:5ZQRW3A42C&SE'RH?"+]3WZ<+GT9>!)D'>!"O./#&H E #HE)]IP+;I
M;$<L%E7%Z3JWT[(L8H5KK.?D-"_,5Q )$60AOU\=^J3<E;W%'Y3P2B_=@T7A
M.K5.*@3C!@3O1[$(XC5T/D,/ELUSX?H#72<!$8R_H2&P1S9+0!L?9*=^ (6)
M196=T'7N0SG";D\38D5EK&^$=:L:-N+4C](,M%CHE@*S=91NV5(@M?0@A81D
M"8C0'15(MG^Q'O/7#1I-IX'REL*PU= P-V0@VP,Z4Z63'>LH@5?,M/3,_)'
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M!F_:)^*K!GT] RW)F^ZDVU$D=#[>K<I3E!]OIAR%0^<H.'04#AT]O)ZV*\[
MV!V+.%TET9)D!Z+1OT><0CU+;UNU!=?.X?GM^[J:[>C&8=E,NJ4W4.0+7U/"
MUWX4HX"N0,XX=8&D/'N'*KL1;)N^E+)@0K PO=Q0LJ1<#H#O5XR)W8U\SZ5X
MD^WB?U!+ P04    "  Y.A!32&M!*%D"   9!@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6R-55UOFS 4_2L6ZD,K;8'P%581I#5IM4Y:%R7]>';#
M3;!J;&8[H?WWLPU!:4*RO8"O?<_Q.=?XDM9<O,D"0*'WDC(Y=@JEJFO7E<L"
M2BP'O *F5U9<E%CI4*Q=60G N065U/4]+W9+3)B3I79N)K*4;Q0E#&8"R4U9
M8O%Q Y378V?H[";F9%TH,^%F:877L #U5,V$CMR.)2<E,$DX0P)68^?[\'H2
MFWR;\$R@EGMC9)R\<OYF@OM\['A&$%!8*L. ]6L+$Z#4$&D9?UI.I]O2 /?'
M._8[ZUU[><42)IR^D%P58R=Q4 XKO*%JSNL?T/J)#-^24VF?J&YRPY&#EANI
M>-F"M8*2L.:-W]LZ[ &&X0F WP+\_P4$+2"P1AMEUM84*YRE@M=(F&S-9@:V
M-A:MW1!F3G&AA%XE&J>R^X?GVX?'W_/[VP6ZG(+"A,HK]!4]+:;H\N(*72#"
MT&/!-Q*S7*:NTGL:I+ML^6\:?O\$_\\-&Z# ^X)\SQ_VP"?GX5-8:OC0PKW/
M<%<[[>SZG5W?\@7_MGN&+>C8 LL6GF";XUJ?A0)!,.VM30./+=S<IVT6>&&<
MNMO]"O0D!>&H2_JD+.R4A6>5O>B[8TZN$GPM0/:*:QBB3^+BZ$#<<9*?)"?$
M19VXZ*RX.\*(_F)SM.:\_YN*CG8=1?ZW VG'27$2)OW2XDY:?%;:(U>8ZL)M
M@2DN/OJTQ4?'-0SBT#L0UY?E)?Z!.G?OXIJF^0N+-6$245AIG#<8:7>B:41-
MH'AE[_(K5[HSV&&A>S<(DZ#75YRK76#:0_<WR/X"4$L#!!0    ( #DZ$%/6
MB4MUQ@(  #\(   9    >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;+66;6_:
M,!#'O\HIVHM-8N2!YPJ0Z I:IU(A:)FF:2],<A"K3IS9#K3??K:39G2%"5[P
MAOCA[G_WN\0^^CLNGF2,J. Y8:D<.+%2V97KRC#&A,@ZSS#5.VLN$J+T5&Q<
MF0DDD75*F!MX7MM-"$V=8=^NS<2PSW/%:(HS 3)/$B)>KI'QW<#QG=>%.=W$
MRBRXPWY&-KA ]9C-A)ZYE4I$$TPEY2D(7 ^<D7]U[5L':[&DN)-[8S H*\Z?
MS.0V&CB>R0@9ALI($/W8XA=DS"CI/'Z7HDX5TSCNCU_5)Q9>PZR(Q"^<?:>1
MB@=.UX$(UR1G:LYW7[$$:AF]D#-I?V%7VGH.A+E4/"F==08)38LG>2X+L><0
M-(\X!*5#8/,N MDL;X@BP[[@.Q#&6JN9@46UWCHYFIJWLE!"[U+MIX:3T>T<
MEJ.[QS%,QZ/%XWP\'=\_P&=XB!$8)2O*J'J!D"<93S%5L",2MH3E&-EJ1*!+
MJ[3M;:IM$$99)C@)8_AX@XI0)C]IK< +?+CG"B7\G&*R0O%+KTX(%; T4C7M
MG>5*UN .M\B@49GU7:4A3:IN6 )=%T#!$:!O>5J'AE>S03^ "S(F N5;(5=7
MJ2I54)4JL,K-(\I3)#(7F)@JV'QKL##:,!,TQ",IOXG4J"(U_AOI!E<FA%0B
M-]%J\"[TH;H4FCVK:0[C=NC7>W[?W1[(I%EETCR7>?R<Z1.E7_P#BN04ZE85
MJW4!ZM8[:J_>Z!ZF;E>9M,^EGE/Y!!.!YD-7J#\H!7.B3GKKG2IJYP+\G0/\
M7NLP?[?*I'LN?_&-+SDCJK@13@#O5>%Z%P#OO0/O=.K-X#"Y[_V]#[USV7]0
M9-$IP/[>K>M? +D4?7/$_;K?_H?9W6L'IK5.B=C05 +#M?;SZAU]9D31K8J)
MXIGM$"NN=+^QPUAW>!3&0.^ON;Z[RXEI.M5_AN$?4$L#!!0    ( #DZ$%-G
MWN*%0 (   D%   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;*546V_:
M,!3^*T=1'UJ)D@O0;E6(!(5J3*5",-C#M =##L2J8V>V ]V_G^VD&9L 3=I+
M?#OGNYP<.SX(^:HR1 UO.>.J[V5:%P^^KS89YD2U18'<G&R%S(DV2[GS52&1
MI"XI9WX4!'=^3BCWDMCMS602BU(SRG$F095Y3N3/(3)QZ'NA][XQI[M,VPT_
MB0NRPP7J93&39N4W*"G-D2LJ.$C<]KU!^##LV7@7L*)X4$=SL$[60KS:Q23M
M>X$5A PWVB(0,^SQ$1FS0$;&CQK3:RAMXO'\'?W)>3=>UD3AHV!?::JSOO?!
M@Q2WI&1Z+@Z?L/;C!&X$4^X+ASHV\&!3*BWR.MDHR"FO1O)6U^$H(0K/)$1U
M0N1T5T1.Y8AHDL12'$#::(-F)\ZJRS;B*+<_9:&E.:4F3R=/@\D<5H/GY1BF
MX\%B.1]/QR]?X!8&:4IMW0B#":]^OJWB]0@UH4S=F) HB$)X$1H5?)MBOD;Y
M':Z <IA2QDRPBGUM)%HB?U/+&59RHC-R/I>\#9V@Y;"7BQ%<7]W\B>(;@XW+
MJ'$9.=CN&=A%)J2^U2AS&.%:G])5 82!0["MO$]Z]^V/L;\_P=MI>#L7>9\(
ME; BK,26J6)1:M6"9]PC@TY3L@OVN@U-]W_M50!A^$_V>@UO[R+OH^![E)JN
M&3KB%OPV#".J-DRH4N+)/NB=K/?=7X+\H\ZVC\24R!WE"AAN35K0OC<PLKIX
MU4*+PC7[6FAS==PT,V\52AM@SK?"]&N]L/>G>?V27U!+ P04    "  Y.A!3
M^WUPBD $  #($   &0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6RE6&UO
MHT80_BLKZ]3>26U@ 8-)'4N)C?NBIHJ22_JAZH>-&>/5 >O;7>S<J3^^NY@
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MP/W-8)">58(=G3TTYXUC2<XD:03Z\'^]6K$LE32-T"W(#0M?5R!$:OI%1-3
M@9!4C80PZ*56G0J_U:K"[#"L?F3:>Y9D,='^B[>MKBL6I:JZ=TT(R\)Z_5TY
MN/4Y&[5!*P$>Y2.Q0'FHAR-MN5J.W=?YL-E8G^/+!>Y8#_28G@]VE?G#C']+
M>$13@6)8*U?FA:<2AA_&YL.#9-M\S'MF4@V-^>T&B#J#:(#Z?<V8?'W0#LI_
M7LS^!U!+ P04    "  Y.A!311#HW L#  "3"0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6S-5EU/VS 4_2M7T1Y 8N2CWZBM5%*FL0U6T6Y[0'MP
MT]O6PHD[VZ'P[W?MA*P;;<8+$GUH;,?GW'./[5SWMU+=Z36B@8=49'K@K8W9
MG/F^3M:8,GTJ-YC1FZ54*3/452M?;Q2RA0.EPH^"H.VGC&?>L._&)FK8E[D1
M/,.) IVG*5./YRCD=N"%WM/ #5^MC1WPA_T-6^$4S;?-1%'/KU@6/,5,<YF!
MPN7 &X5G%Z$#N!G?.6[U3AML*G,I[VSG<C'P JL(!2;&4C!ZW&.,0E@FTO&K
M)/6JF!:XVWYB_^"2IV3F3&,LQ0^^,.N!U_5@@4N6"W,CMQ^Q3*AE^1(IM/N'
M;3DW\"#)M9%I"28%*<^*)WLHC=@!A,T#@*@$1"\%-$I XZ6 9@EHOA30*@$N
M=;_(W1DW9H8-^TIN0=G9Q&8;SGV')K]X9C?*U"AZRPEGAM/9U_@SS&Y&U]-1
M/+O\>CV%HS$:QH4^AO?P;3J&HW?'\ YX!E=<"%I<W?<-1;9X/RFCG!=1H@-1
M/N7B%(+H!*(@"O? X__!,X)W#L+']? /.#^%\##\HAY^Q13!NPX>_ WWR>W*
M\JBR/')\C4.6KYG"]W9W+R"6*1UYS=RA&2G%LA72,30P?X3=>1/VZ(9'6Z86
M</N%*.'28*I_U@AJ5((:3E#S@*#K/)VC KD$;4-JX%KG%/2(UKP8.=YG>D':
M<J3V>W0_['::/?KU_?L]:IJ5FF:MFHGB]\P@3 1+"B]NK] *K$NU59&WWH;W
M[4I0^Q6\C]O/O \[C6[8WF]]IQ+3J143"Z:UU?*#63L,2 6N=)S 'YU33'+%
M#2>M,1."M))?%RQ9/T/M.VJ=9\(CDMT+POW*NY7R;JWRT>RJ6#-=LR:]BJSW
M-C9)&/SY2@>OL$W.2]9=NQM1KQU&C?UVASME(ZP5-&4"G1PCD[L36Y%XFJ<T
MLD3%LQ5L%$]PKZ2"M[V[ X)_U/@[]<Q>5^@+O.*9!H%+ @6G'4I(%3> HF/D
MQI6XN314,%US3;<F5'8"O5]*:9XZMFI6][#A;U!+ P04    "  Y.A!3#Y+P
M^(H#  !,#   &0   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6RU5U%OVS80
M_BL'805:(+5$R9+BPC80.RF682G<:,D>@C[0\MD2(HDN2=DML!\_4E(E89'9
MI6W\(),B[[OOCL?/Y^F1\4>1($KXDF>%F%F)E/MWMBWB!',J1FR/A5K9,IY3
MJ:9\9XL]1[JIC/+,=ATGL'.:%M9\6KU;\?F4E3)+"UQQ$&6>4_YU@1D[SBQB
M?7MQF^X2J5_8\^F>[C!">;=?<36S6Y1-FF,A4E8 Q^W,NB#OEF2B#:H=]RD>
M16\,.I0U8X]Z<KV968YFA!G&4D-0]77 )6:91E(\/C>@5NM3&_;'W]#?5\&K
M8-94X))E?Z<;F<RL<PLVN*5E)F_9\7=L O(U7LPR43WA6.\-)A;$I9 L;XP5
M@SPMZF_ZI4E$SX",3QBXC8'[?PV\QL"K JV956%=4DGG4\Z.P/5NA:8'56XJ
M:Q5-6NACC"17JZFRD_/H;A%=?;R[^O 77-VK9P2O+U'2-!-OX"W<19?P^K<W
M4ULJ5]K CAO810WKGH"]*'<C(.X9N(Y+!LR79O,_RF($GC-D;JL VRC=-DJW
MPAN?P-,P\(%)%/!P@_D:^2<#JM>B>A6J=RIWY5K@YQ(+"5<'_7SX4^V :XFY
M,.&/6_RQD764,"[?2N0Y7.):#J6Q!@@J 'UC#W,_G#CZ,[4/ Z[]UK5O=!V.
M?.<5/$18I(Q_@@CCDN,&EJPX()?I.L,FG9L2]2&-#>$&K<_@1=(9MOBA,2:=
M0[@NA.1EKN'[P2R4$L ]S50T2AV:I4JJ;JG$H?H/GV2>G,SZ><OPW'S@_\W
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M1S %H %#PK!Z#^Z\CX+U>RIH?^<<_P902P,$%     @ .3H04Y>*NQS
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M0$BH8G,Z8[!H+]WM'P8W/P%02P,$%     @ .3H04Z_LDZ4X 0  'P\  !H
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ML@HJ9!54R"JHD%50(:OX3[*^.[?\ZR_5=BV,5/;@S[K? ;-/4$L! A0#%
M  @ .3H04P=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    "  Y.A!3WE!I8NX    K @  $0
M    @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  Y.A!3F5R<
M(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM
M;%!+ 0(4 Q0    ( #DZ$%.?=(3 5P4  "T6   8              " @0T(
M  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  Y.A!3#S_Y
M+X,%  !)%0  &               @(&:#0  >&PO=V]R:W-H965T<R]S:&5E
M=#(N>&UL4$L! A0#%     @ .3H04Z0I<\6R!0  =A8  !@
M ("!4Q,  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( #DZ
M$%-X=S)]1@,   H+   8              " @3L9  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    "  Y.A!30;'*E3X'  "W(P  &
M        @(&W'   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ .3H04ZR01YY? @  K@4  !@              ("!*R0  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( #DZ$%-AZ+UB_P<  %@?   8
M              " @< F  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    "  Y.A!3T TN1NX8  ! 2@  &               @('U+@  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ .3H04Y'/$7>. @
M&@8  !@              ("!&4@  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( #DZ$%/Y^;<=>04   H-   9              " @=U*
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ .3H04W8@
M[3(<!   <0H  !D              ("!C5   'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    "  Y.A!3\)EBM[$#  !\"   &0
M    @('@5   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M #DZ$%/,WR\]WP0  /D*   9              " @<A8  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ .3H04TB#M:T?&0  E$L  !D
M             ("!WET  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    "  Y.A!3\]]RQ98"   0!@  &0              @($T=P  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( #DZ$%/RZJ>B^P(
M %(&   9              " @0%Z  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ .3H04WA1L73A @  6@<  !D              ("!
M,WT  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  Y.A!3
M!JUK5>H'  #5)@  &0              @(%+@   >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( #DZ$%-(:T$H60(  !D&   9
M      " @6R(  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ .3H04]:)2W7& @  /P@  !D              ("!_(H  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  Y.A!39][BA4 "   )!0
M&0              @('YC0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( #DZ$%/[?7"*0 0  ,@0   9              " @7"0  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ .3H04T40Z-P+
M P  DPD  !D              ("!YY0  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    "  Y.A!3#Y+P^(H#  !,#   &0
M@($IF   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( #DZ
M$%,\5="H1 ,  /04   -              "  >J;  !X;"]S='EL97,N>&UL
M4$L! A0#%     @ .3H04Y>*NQS     $P(   L              ( !69\
M %]R96QS+RYR96QS4$L! A0#%     @ .3H04TDF6CS" @  M!    \
M         ( !0J   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( #DZ$%.O
M[).E. $  !\/   :              "  3&C  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( #DZ$%/^WU#H;P$  !80   3
M      "  :&D  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     @ "  EP@
' $&F      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>106</ContextCount>
  <ElementCount>223</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>34</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenues</Role>
      <ShortName>REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactions</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>30203 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventories</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureFairValueMeasurement</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>30403 - Disclosure - REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesTables</Role>
      <ShortName>REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureRevenues</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>40201 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails</Role>
      <ShortName>REVENUES - Company's disaggregation of revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40501 - Disclosure - STOCK TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactionsDetails</Role>
      <ShortName>STOCK TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureStockTransactions</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20210630x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40601 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>24</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="plx-20210630x10q.htm">plx-20210630x10q.htm</File>
    <File>plx-20210630.xsd</File>
    <File>plx-20210630_cal.xml</File>
    <File>plx-20210630_def.xml</File>
    <File>plx-20210630_lab.xml</File>
    <File>plx-20210630_pre.xml</File>
    <File>plx-20210630xex31d1.htm</File>
    <File>plx-20210630xex31d2.htm</File>
    <File>plx-20210630xex32d1.htm</File>
    <File>plx-20210630xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>plx-20210630x10q005.jpg</File>
    <File>plx-20210630x10q006.jpg</File>
    <File>plx-20210630x10q007.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>44
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plx-20210630x10q.htm": {
   "axisCustom": 0,
   "axisStandard": 14,
   "contextCount": 106,
   "dts": {
    "calculationLink": {
     "local": [
      "plx-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "plx-20210630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "plx-20210630x10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20210630_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20210630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 255,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 38,
   "keyStandard": 185,
   "memberCustom": 14,
   "memberStandard": 20,
   "nsprefix": "plx",
   "nsuri": "http://www.protalix.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.protalix.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - FAIR VALUE MEASUREMENT",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurement",
     "shortName": "FAIR VALUE MEASUREMENT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - REVENUES",
     "role": "http://www.protalix.com/role/DisclosureRevenues",
     "shortName": "REVENUES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:RevenueDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - STOCK TRANSACTIONS",
     "role": "http://www.protalix.com/role/DisclosureStockTransactions",
     "shortName": "STOCK TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.protalix.com/role/DisclosureSubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - INVENTORIES (Tables)",
     "role": "http://www.protalix.com/role/DisclosureInventoriesTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_yMRhv1-EBUyjv67c4vnBIA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - FAIR VALUE MEASUREMENT (Tables)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
     "shortName": "FAIR VALUE MEASUREMENT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_us-gaap_DebtInstrumentAxis_plx_Notes2021Member_yMRhv1-EBUyjv67c4vnBIA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - REVENUES (Tables)",
     "role": "http://www.protalix.com/role/DisclosureRevenuesTables",
     "shortName": "REVENUES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_2_17_2021_To_2_17_2021_eP-kucV1pUWTbBXr7TaMSA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_2_17_2021_To_2_17_2021_eP-kucV1pUWTbBXr7TaMSA",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - INVENTORIES (Details)",
     "role": "http://www.protalix.com/role/DisclosureInventoriesDetails",
     "shortName": "INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg",
      "decimals": "-3",
      "lang": null,
      "name": "plx:ShortTermBankDeposits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_-UCWB1XwmECspjYijNZ7Jw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
     "shortName": "FAIR VALUE MEASUREMENT - The liability component was valued based on the Income Approach (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_-UCWB1XwmECspjYijNZ7Jw",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_vViOT2LFf0axMCBfeZUuig",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - FAIR VALUE MEASUREMENT - Additional Information (Details)",
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
     "shortName": "FAIR VALUE MEASUREMENT - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_-tsX_jEa10aFdesmgIQc1g",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - REVENUES - Company's disaggregation of revenues (Details)",
     "role": "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
     "shortName": "REVENUES - Company's disaggregation of revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:Revenues",
       "span",
       "p",
       "plx:RevenueDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_us-gaap_TypeOfArrangementAxis_plx_ChiesiExUSAgreementMember_iX-tLkOGFEuB3AcNqYn0Rw",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_2_17_2021_To_2_17_2021_eP-kucV1pUWTbBXr7TaMSA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - STOCK TRANSACTIONS (Details)",
     "role": "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
     "shortName": "STOCK TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_6_7_2021_To_6_7_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_hHEjR2Bo5EuYhi_31RGp8A",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageConvertibleNotesMember_vViOT2LFf0axMCBfeZUuig",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermBorrowings",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_8_12_2021_To_8_12_2021_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_wp1PKGYOf02TVwTFOgkSpw",
      "decimals": "0",
      "lang": null,
      "name": "plx:DebtInstrumentConvertibleBaseValueForConversionRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_fsKYAl-OZEmSIcgFdxcTNQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_B2vkFxAj30mgjYvbaeB7XQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00205 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_4_1_2021_To_6_30_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_B2vkFxAj30mgjYvbaeB7XQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4cR5rGHxsEuH26ppUkiILQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4cR5rGHxsEuH26ppUkiILQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_OyOu6CTUEU2_HKA2aB1-qQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "As_Of_6_30_2021_DqVos4VQtUqo7Uau0KhlWg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_dPxb5QRHME-PcLYjp3PL9g",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_zLn-xzMD-0CUB5hG64vUnw",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - INVENTORIES",
     "role": "http://www.protalix.com/role/DisclosureInventories",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210630x10q.htm",
      "contextRef": "Duration_1_1_2021_To_6_30_2021_J7Qf8SEk3Uip0HLrjIdX2g",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 34,
   "tag": {
    "country_BR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "B [R]",
        "terseLabel": "Brazil [Member]"
       }
      }
     },
     "localname": "BR",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "plx_AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount payable to entity for the achievement of regulatory and commercial milestones.",
        "label": "Additional Amount Payable For Achievement Of Regulatory And Commercial Milestones"
       }
      }
     },
     "localname": "AdditionalAmountPayableForAchievementOfRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AdditionalAmountsPayableToCoverDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to the entity to cover development costs under agreement.",
        "label": "Additional Amounts Payable To Cover Development Costs"
       }
      }
     },
     "localname": "AdditionalAmountsPayableToCoverDevelopmentCosts",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from receivables from sale of common stock and warrants.",
        "label": "Adjustments To Additional Paid In Capital Receivables From Sale Of Common Stock And Warrants",
        "negatedLabel": "Note receivable from issuance of common stock and warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalReceivablesFromSaleOfCommonStockAndWarrants",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AgreementAmendmentPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Amendment Payment Receivable",
        "label": "Agreement Amendment Payment Receivable",
        "terseLabel": "Agreement Amendment Payment Receivable"
       }
      }
     },
     "localname": "AgreementAmendmentPaymentReceivable",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_AmendedPfizerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Pfizer Agreement [Member]",
        "label": "Amended Pfizer Agreement [Member]",
        "terseLabel": "Amended Pfizer Agreement [Member]"
       }
      }
     },
     "localname": "AmendedPfizerAgreementMember",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_AtMarketEquityOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to At The Market equity offering.",
        "label": "At Market Equity Offering [Member]",
        "terseLabel": "ATM Shares"
       }
      }
     },
     "localname": "AtMarketEquityOfferingMember",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones",
        "label": "Change In Amount Receivable For Achievement Of Regulatory And Commercial Milestones"
       }
      }
     },
     "localname": "ChangeInAmountReceivableForAchievementOfRegulatoryAndCommercialMilestones",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ChangeInOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Change in Operating Lease Right Of use Assets.",
        "label": "Change in Operating Lease Right Of use Assets",
        "negatedLabel": "Changes in right of use assets"
       }
      }
     },
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ChiesiAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chiesi Agreements [Member]",
        "label": "Chiesi Agreements [Member]",
        "terseLabel": "Chiesi Agreements [Member]"
       }
      }
     },
     "localname": "ChiesiAgreementsMember",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiExUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi Ex U S Agreement [Member]",
        "terseLabel": "Chiesi Ex US Agreement [Member]"
       }
      }
     },
     "localname": "ChiesiExUSAgreementMember",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except Brazil and Italy",
        "label": "Chiesi [Member]",
        "terseLabel": "Chiesi [Member]"
       }
      }
     },
     "localname": "ChiesiMember",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiUSAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chiesi U S Agreement [Member]",
        "terseLabel": "Chiesi US Agreement [Member]"
       }
      }
     },
     "localname": "ChiesiUSAgreementMember",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ChiesiUsAgreementAndChiesiExUsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Chiesi Us Agreement And Chiesi Ex Us Agreement [Member]",
        "terseLabel": "Chiesi US Agreement and Chiesi Ex US Agreement [Member]"
       }
      }
     },
     "localname": "ChiesiUsAgreementAndChiesiExUsAgreementMember",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_CollaborativeArrangementRevenuesExpensesSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement revenues and expense sharing percentage.",
        "label": "Collaborative Arrangement Revenues Expenses Sharing Percentage",
        "verboseLabel": "Collaborative Arrangement Revenues and Expenses Sharing Percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenuesExpensesSharingPercentage",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_DebtConversionConvertedInstrumentAmountCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a cash transaction. \"Cash\" refers to that portion of the transaction resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion Converted Instrument Amount, Cash"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmountCash",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_DebtInstrumentConvertibleBaseValueForConversionRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Convertible Base Value For Conversion Rate",
        "label": "Debt Instrument Convertible Base Value For Conversion Rate"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleBaseValueForConversionRate",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_DebtInstrumentConvertibleConversionShareNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Convertible Conversion Share Number",
        "label": "Debt Instrument Convertible Conversion Share Number"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionShareNumber",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on amounts funded in respect of employee rights upon retirement.",
        "label": "Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement",
        "negatedLabel": "Loss (gain) on amounts funded in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseDecreaseInBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deposits held with banks.",
        "label": "Increase (Decrease) in Bank Deposits",
        "negatedLabel": "Purchase of bank deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInBankDeposits",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseDecreaseInRestrictedDeposit": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow during the period for the aggregate increase (decrease) associated with increase in restricted deposit",
        "label": "Increase (Decrease) In Restricted Deposit",
        "negatedLabel": "Decrease in restricted deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInRestrictedDeposit",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IncreaseInLiabilitiesForPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in liabilities for property, plant and equipment.",
        "label": "Increase In Liabilities For Property Plant And Equipment",
        "terseLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "IncreaseInLiabilitiesForPropertyPlantAndEquipment",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_InterestReceivedNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash received for interest.",
        "label": "Interest Received, Net",
        "terseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedNet",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents issuance of common stock, net of issuance cost, in shares.",
        "label": "Issuance Of Common Stock And Warrants, Net Of Issuance Cost, In Shares",
        "terseLabel": "Issuance of common stock and warrants, net of issuance cost (in shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostInShares",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents issuance of common stock, net of issuance cost, value.",
        "label": "Issuance Of Common Stock And Warrants, Net Of Issuance Cost, Value",
        "terseLabel": "Issuance of common stock and warrants, net of issuance cost"
       }
      }
     },
     "localname": "IssuanceOfCommonStockAndWarrantsNetOfIssuanceCostValue",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_LicenseAgreementInitialCashPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of initial cash payment under the license agreement.",
        "label": "License Agreement, Initial Cash Payment"
       }
      }
     },
     "localname": "LicenseAgreementInitialCashPayment",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MaximumEntitlementOfDevelopmentCostsToCoverPerYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount payable to entity to cover development costs in any year under agreement.",
        "label": "Maximum Entitlement Of Development Costs To Cover Per Year"
       }
      }
     },
     "localname": "MaximumEntitlementOfDevelopmentCostsToCoverPerYear",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_MeasurementInputYieldMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Yield [Member]",
        "label": "Measurement Input Yield [Member]",
        "terseLabel": "Measurement Input, Yield [Member]"
       }
      }
     },
     "localname": "MeasurementInputYieldMember",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_NatureOfOperationsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature Of Operations Policy",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "General"
       }
      }
     },
     "localname": "NatureOfOperationsPolicyTextBlock",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Note receivable from issuance of common stock and warrants, net of issuance cost.",
        "label": "Note Receivable from Issuance of Common Stock and Warrants, Net of Issuance Cost",
        "terseLabel": "Note receivable from issuance of common stock and warrants, net of issuance cost"
       }
      }
     },
     "localname": "NoteReceivableFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_Notes2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes2021 [Member]",
        "terseLabel": "Notes 2021 [Member]"
       }
      }
     },
     "localname": "Notes2021Member",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_PaymentOnNetSalesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the payment as a percentage of future net sales.",
        "label": "Payment On Net Sales Percentage"
       }
      }
     },
     "localname": "PaymentOnNetSalesPercentage",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_PercentageOfPremiumToClosingPriceOfStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of premium to closing price of stock.",
        "label": "Percentage of Premium to Closing Price of Stock",
        "terseLabel": "Percentage of premium to closing price of stock"
       }
      }
     },
     "localname": "PercentageOfPremiumToClosingPriceOfStock",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "plx_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except for Brazil",
        "label": "Pfizer [Member]",
        "terseLabel": "Pfizer [Member]"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock and warrants, net of issuance cost.",
        "label": "Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost",
        "verboseLabel": "Proceeds from issuance of common stock and warrants, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProceedsFromSaleOfShortTermDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of short-term deposits.",
        "label": "Proceeds from Sale of Short-term Deposits",
        "terseLabel": "Proceeds from sale of short-term deposits"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermDeposits",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProceedsFromVariableConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Variable Consideration",
        "label": "Proceeds From Variable Consideration"
       }
      }
     },
     "localname": "ProceedsFromVariableConsideration",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ProtalixBioTherapeuticsIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Protalix Bio Therapeutics Incorporation [Member].",
        "label": "Protalix Bio Therapeutics Incorporation [Member]",
        "terseLabel": "Protalix Bio Therapeutics Incorporation [Member]"
       }
      }
     },
     "localname": "ProtalixBioTherapeuticsIncorporationMember",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ReductionToAccumulatedRevenueRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reduction to accumulated revenues recognized in respect of performance obligation.",
        "label": "Reduction To Accumulated Revenue Recognized"
       }
      }
     },
     "localname": "ReductionToAccumulatedRevenueRecognized",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_RevenueDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure pertaining to revenue.",
        "label": "Revenue Disclosure [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueDisclosureTextBlock",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "plx_RevenuePerformanceObligationNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Performance Obligation, Number",
        "label": "Revenue, Performance Obligation, Number"
       }
      }
     },
     "localname": "RevenuePerformanceObligationNumber",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "plx_SaleOfStockMaximumOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, maximum offering price.",
        "label": "Sale Of Stock Maximum Offering Price",
        "terseLabel": "Sale of stock, maximum offering price"
       }
      }
     },
     "localname": "SaleOfStockMaximumOfferingPrice",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SarcomedUsaInc.AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to SarcoMed USA, Inc. licensing agreement.",
        "label": "Sarcomed Usa Inc. Agreement [Member]",
        "terseLabel": "SarcoMed USA, Inc. Agreement [Member]"
       }
      }
     },
     "localname": "SarcomedUsaInc.AgreementMember",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_SevenPointFivePercentageConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Seven Point Five Percentage Convertible Notes [Member]",
        "terseLabel": "2021 Notes [Member]"
       }
      }
     },
     "localname": "SevenPointFivePercentageConvertibleNotesMember",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to seven point five percentage senor secured convertible notes due 2024.",
        "label": "Seven Point Five Percentage Senior Secured Convertible Notes Due2024 [Member]",
        "terseLabel": "7.50% [Senior] Secured Convertible Notes due 2024"
       }
      }
     },
     "localname": "SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recognized equity-based compensation during the period for restricted stock awards.",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures",
        "terseLabel": "Share-based compensation related to restricted stock awards"
       }
      }
     },
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_ShortTermBankDeposits": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.",
        "label": "Short-term Bank Deposits",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "localname": "ShortTermBankDeposits",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Table].",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "plx_StockIssuedDuringPeriodSharesSalesAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Sales Agreement",
        "label": "Stock Issued During Period, Shares, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesSalesAgreement",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_StockIssuedDuringPeriodSharesWarrantsExercises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during period for exercise of warrants.",
        "label": "Stock Issued During Period, Shares, Warrants Exercises",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercises",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "plx_StockIssuedDuringPeriodValueSalesAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in a sales agreement.",
        "label": "Stock Issued During Period, Value, Sales Agreement",
        "terseLabel": "Issuance of common stock under the Sales Agreement, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSalesAgreement",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_StockIssuedDuringPeriodValueWarrantsExercises": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during period for exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercises",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercises",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_TermToSignSupplyAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term To Sign Supply Agreement",
        "label": "Term To Sign Supply Agreement",
        "terseLabel": "Term to sign supply agreement"
       }
      }
     },
     "localname": "TermToSignSupplyAgreement",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "plx_UpfrontNonrefundableNonCreditablePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront, non refundable and non creditable payment receivable under the agreement for licensing rights.",
        "label": "Upfront Nonrefundable Non-Creditable Payment Receivable"
       }
      }
     },
     "localname": "UpfrontNonrefundableNonCreditablePaymentReceivable",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "plx_VariableConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable consideration payable under the contract.",
        "label": "Variable Consideration"
       }
      }
     },
     "localname": "VariableConsideration",
     "nsuri": "http://www.protalix.com/20210630",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r140",
      "r141",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r213",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r140",
      "r141",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r213",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r104",
      "r124",
      "r126",
      "r196",
      "r212",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r104",
      "r124",
      "r126",
      "r196",
      "r212",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r131",
      "r140",
      "r141",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r213",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r131",
      "r140",
      "r141",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r213",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r105",
      "r106",
      "r124",
      "r127",
      "r215",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r105",
      "r106",
      "r124",
      "r127",
      "r215",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accounts payable and accruals:"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r6",
      "r33"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r6",
      "r33"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r22",
      "r108",
      "r109"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, Net, Current",
        "terseLabel": "Accounts receivable - Trade"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r147",
      "r148",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r142",
      "r143",
      "r151",
      "r152"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation related to stock options"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r143",
      "r145",
      "r150"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r63",
      "r177"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs and debt discount"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r70",
      "r93",
      "r96",
      "r102",
      "r111",
      "r157",
      "r159",
      "r165",
      "r198",
      "r206"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r44",
      "r70",
      "r111",
      "r157",
      "r159",
      "r165"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r32",
      "r65"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r60",
      "r168"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r81",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r81",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change In Accounting Estimate Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingMethodAccountedForAsChangeInEstimateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A change from one acceptable accounting method to another based upon a revision in estimated future benefits or obligations.",
        "label": "Change In Accounting Method Accounted For As Change In Estimate [Member]",
        "terseLabel": "Change in Accounting Method Accounted for as Change in Estimate [Member]"
       }
      }
     },
     "localname": "ChangeInAccountingMethodAccountedForAsChangeInEstimateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r73",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiencyParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r122",
      "r123",
      "r125"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contracts liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r122",
      "r123",
      "r125"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contracts liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Convertible Debt, Current",
        "verboseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r15",
      "r199",
      "r204",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Notes Payable [Member]"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r50",
      "r70",
      "r111",
      "r165"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "negatedLabel": "COST OF GOODS SOLD"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost Of Sales [Member]",
        "terseLabel": "Cost of Sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r199",
      "r200",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r176",
      "r178"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate",
        "verboseLabel": "Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Mature term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r13",
      "r128",
      "r129",
      "r130",
      "r139",
      "r197",
      "r205"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Funds in respect of employee rights upon retirement"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r63",
      "r115"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Schedule of Company's disaggregation of revenues"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK TRANSACTIONS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "verboseLabel": "LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r66",
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r168"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r77",
      "r82",
      "r84",
      "r90",
      "r112",
      "r119",
      "r120",
      "r147",
      "r148",
      "r149",
      "r154",
      "r155",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r217",
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "verboseLabel": "Schedule of liability component based on income approach"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r161",
      "r186",
      "r187",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r161",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r186",
      "r187",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r64",
      "r166",
      "r167"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), Unrealized",
        "negatedLabel": "Financial income, net (mainly exchange differences)"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Gain on sale of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase (decrease) in accounts payable and accruals"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Increase in accounts receivable and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Increase (decrease) in contracts liability (including non-current portion)"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Decrease in other long term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r26",
      "r113"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r42"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r113"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r27",
      "r113"
     ],
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r36",
      "r70",
      "r97",
      "r111",
      "r158",
      "r159",
      "r160",
      "r165"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r70",
      "r111",
      "r165",
      "r201",
      "r208"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity (net of capital deficiency)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY (NET OF CAPITAL DEFICIENCY)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r37",
      "r70",
      "r111",
      "r158",
      "r159",
      "r160",
      "r165"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r17",
      "r18",
      "r70",
      "r111",
      "r158",
      "r159",
      "r160",
      "r165"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG TERM LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License And Service [Member]",
        "terseLabel": "License and R&amp;D Services [Member]"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input Expected Term [Member]",
        "terseLabel": "Measurement Input, Expected Term [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input Price Volatility [Member]",
        "terseLabel": "Measurement Input, Price Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input Risk Free Interest Rate [Member]",
        "terseLabel": "Measurement Input, Risk Free Interest Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input Share Price [Member]",
        "terseLabel": "Measurement Input, Share Price [Member]"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r60",
      "r61",
      "r64"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r45",
      "r46",
      "r48",
      "r64",
      "r70",
      "r76",
      "r78",
      "r79",
      "r80",
      "r81",
      "r83",
      "r84",
      "r85",
      "r93",
      "r95",
      "r98",
      "r101",
      "r103",
      "r111",
      "r165",
      "r202",
      "r210"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "NET LOSS FOR THE PERIOD",
        "verboseLabel": "Net loss for the period"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "FINANCIAL EXPENSES - NET"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Promissory note"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r93",
      "r95",
      "r98",
      "r101",
      "r103"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING INCOME (LOSS)"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r211"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "OTHER INCOME"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Expense",
        "negatedLabel": "FINANCIAL EXPENSES"
       }
      }
     },
     "localname": "OtherNonoperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "FINANCIAL INCOME"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r55",
      "r57",
      "r71"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Amounts funded in respect of employee rights upon retirement, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r19",
      "r128",
      "r129",
      "r130"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.",
        "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent",
        "terseLabel": "Liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Changes in accrued liability for employee rights upon retirement"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under the Sales Agreement, net",
        "verboseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Goods [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r116",
      "r209"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Net payment for promissory note"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r153",
      "r231"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development Expenses [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r77",
      "r82",
      "r84",
      "r112",
      "r147",
      "r148",
      "r149",
      "r154",
      "r155",
      "r217",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "verboseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r47",
      "r70",
      "r91",
      "r92",
      "r94",
      "r99",
      "r100",
      "r104",
      "r105",
      "r107",
      "r111",
      "r165",
      "r203"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues.",
        "terseLabel": "TOTAL REVENUE",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r181",
      "r182"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r7",
      "r29",
      "r30",
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r144",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "SELLING, GENERAL AND ADMINISTRATIVE EXPENSES"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling General And Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Shares Issued, Price Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r14",
      "r199",
      "r207"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short Term Debt Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r41",
      "r73",
      "r74",
      "r75",
      "r77",
      "r82",
      "r84",
      "r90",
      "r112",
      "r119",
      "r120",
      "r147",
      "r148",
      "r149",
      "r154",
      "r155",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r217",
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementAdditionalInformationDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementLiabilityComponentWasValuedBasedOnIncomeApproachDetails",
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKOLDERS' EQUITY (CAPITAL DEFICIENCY)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r90",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurementTables",
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperationsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance cost (in shares)",
        "verboseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r119",
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock, net of issuance cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r23",
      "r24",
      "r70",
      "r110",
      "r111",
      "r165"
     ],
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityCapitalDeficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r69",
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "STOCK TRANSACTIONS"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r175",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r175",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r175",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r175",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r183",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "SUPPLEMENTARY DISCLOSURE ON CASH FLOWS"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/DisclosureRevenuesCompanySDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "verboseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC AND DILUTED"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031898-161870"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r232": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r233": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r234": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r235": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r236": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r237": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e777-108305"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>45
<FILENAME>0001558370-21-011752-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-21-011752-xbrl.zip
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MZ2FJHR4]^-SJ=6_;W6'[5G\:]CKVK36"AQNK8W5;;33\U&Z/AE>-;5+;LP3
M5(_]:CZ#44H@;A9.^T6$'8%D83K8<P*O!.**LW2\Z-M86=]3A\M1V9OT?"*,
M1+F4F8*9K=6SO%H=CN#??;L[&J+>'>KUVP-K9 / 4;_E]=O"<G;G\:?"ZETA
M9FOW;3GMMJSA)W37Z?U^U.Z.=F^I=#PN T%L]@C"<D&)O"4*4R]28R9$EK[>
M@C<V04<K O!@=S^#6GH#NSU$;R(J/Q_5<HB@VL=0;J@9413D+!]A-\GL"[?O
M7A9NT9N-Z8Z6\)+P.\-L2J3-AHH[7V?<<V$7W/X64/7<PCX%NE 54H?JFK1P
MA"Y".]MFSDL&\4]6]R,$#;L+ [W6/S_U.K?MP? GU/[7@SWZ@MZTK+X]LCKH
MMGUGM^QVM_7E:$T_R)I>%'G*3[3/SDK%IC)V=HQB^<N,.TS%9^P%Y)Y@_:QU
M,\)CC^R4&QF069H_!\V?;Y<==Y8]0)^MSD,;W;>MX</ *!R]">D=%9:AL"&=
M,@H.B)FR'-/$HVS:!T]VTBO%7#C9M6-SMW8<VA^[-CB=!9JS6JW>0W=D=S^B
M/GARZUA/OL#_.A2/J:<#+I_[G,$WOV-I@%S3UNXQFP$I8OE &3NS%*T?DG2V
M<9SO&D>*A]?1:$:0%W.!G)@-](0E>C2,H''<NX<(CD)^4,S0T:K*6I7ENH89
M[-ELPL7<2%3 =#+Q]]G'66[[6$V#UN8YJCV/V@?DD;" 2.W<F#T/801/IX),
MC1B]23R>HO6BZ-E*?[L;% ;MS^WN Z0&*/[".7Z2R-V8!?$)$M$\1Z7G*@AT
MG3X2F$GLF(Y!6A&0!I>MQG<)B5\7XF@TL+I#JQ7U#8Z:RJ&I8"S)MP $;NO.
M7:JB4L"R]?0^04\/-T/8)NFXJAUO=%13EIJB4P?Q?XNY;:B3U?-:%HHTE0<R
M>S-\>J&;+C&!]8^8N2BDMI[^CNHJN2$JM!/*5%JSQ!;HJ+9<[S<R7FSL44GV
M&XWC\A?;(>39!>Q12.Z=X%$W^\OXM/I\CPXR"N_CJA>HH_<6T'OTD*MR/FHD
M?[V\KU#>HX\\%?)1'24+K5(%5Z[""W+\;OMH;^\Y)GW<Z>2KP9+?^>P"9+_J
M.=M]U;-QPN3X?B=W\D]6R-9HMC;>[FICV8'[/U*%_J-?*0S(!)GS\9?Z5.UU
M3=*Y[^ECW>:[F2"3ZYKO+>KQ"=X_0=J3Q=R+(33YC)/61H_;"Q3-&Y.(CCQG
M']\'(MPG0H'3-6+>:ZAQ**E@08M*M:F#"LKDX7%1F0"%>!45!YREJ#A;_G5X
MH:X:ZT?,X6GS"/H5R,2%0BSQA'S:C8KPYDR'.X90!HI^JL=X=?U5O7E6/V^>
M+*0;\UB$A95\Q5B(\0JSD'S')>?D,8*>]5TYD2]",V'Z-8N^?9!G9D^(#2P]
M_846NOF^@-!I]Y^2.)!I2/I#?85=8@UVK[CD68)MK,)+D./*3#$^..N69&7]
MVI%6J]RKCE@;B9>N&L13<DFKL'(R+W*59T9_4YZ7[0M6N?B(D4(>]*V=HO/O
MO9B7RU?6$>.'-%:BNTF&E^O:<(8%,><_]&M9PJ299D"D CLSYP.Y\]5ZPL*5
M7:)ZDSLN)H0J*"FA0 USFKE%=SGGC"@LGFU%YKH2JR$\!B+84=>U"?;,I3L#
M"'F&<G=D4-U 1&]7&/4\799>UY0(2%C[0F+\\T7\R0!8@ >-\E'PP(^9I<!D
MS,\XO*IT77,$<:G:6:>8DX^8L@Z7LL>LN5YA>1<PE[BV9L8G#LS=AMS.GPD9
MT.E,R0=?\ZEHW& -U_O%5+;6*5L%N18@62'Y%B<4*CPX:K/HZ#J;=H@N0K0
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M3M"39804MNA4""D(32\92MCB7P'M;[:"/^K0[-OA^$&(1$89)8:1LJADR*(
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MWA70>'0Z^9I[H>ZYU$V.F7.CP)5" 3Q(!L!P&COH11"QX]"J$[3C]P(9(B@
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MQ-&K'[KJ %<%CJP<"O:E&G($BZ<F4D9:=:4(7W,\'(5YB)+4"?ZOO].NA^3
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M@<>JVM(B0+UVBP(8H8*+EA-)'9>&HI-W&0I2*--5A*9O)U=D/ETC>_AVKSX
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MLGY)-#^,XF3S?((*982@[S+#T.+F%!I@90<K/T*;OM'8]1.YB^N&/YCUI%Y
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M\=S28K;%0W$7_CT/56-'H-@0P/8G6=BS".<TA6,P*,'@@DX]R]8<6FC[5F_
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MH!Y8EK?::3&<%KNY.Z\!:D]'D(&3)(O-S[P@5KJ(E]!015PK9_ZG*-(P<8*
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M^_1$:*I[/U=&1:09(3LUQ,62:0)SF@I[KR<JX(326D'/(Z,FT?0H.G2\R+R
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MX!BF)X'IH1S$&/ULC 9D/O^RJP-3VW;0[-2T547,TUA;]GHROD:9CA4#\SJ
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MME2;E;//[D4Q[A3K[>L0&\FT.L0(-HGQ!$_/<'FN"4YD3?"H0^SK=GT?CBQ
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M]Y.+3OCF1\9VH$B'8+P-MQG@&V6[KBN6MOMHH+L0HYL 1)!&#L5J$.RS6T,
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MYII".L65X"(D-'*"T&S(%$NQB0A@BK>#"\J#O4SX*C3.PL2FE&(J0:7%Q@@
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MVVH 2[>=QZF4$UB"(*.0A'\UX>#+8/>.2B0@$]G0N0?Q&,Y1A3-5UBW04 ;
M6SU&[64"HY@D'@&YNIJ0;[39'%"';,C;W[R)81M5V";$H !<WMK4I0IJJ]$,
M2V!1R -ZA&SBHB$;81:'E"%[I,5 C2I0:6$YTONZY\I)@DTDHA#T? 0H?=$
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M>/[D8W9' +WH>9))]GQ7*%;3'M8B!2-/#P- 0Z.+9FY9,L;S%4;R(N>47K!
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MD)$3K'+_W13Y8S+WNX_<O TZ@DL%7 G-O_?1N?UH3SH"+@9X#11Q@,2@XFD
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MQ/ALDY!],>_V"-CM$;$:M1=&"Q\U!8/WZGFCB0ZP*106V/1@7'3)F W7T])
MH"<Z.DJ7R_-$+6QZ,*ZL.&WZ"=KO&%FJAF')%C-O>+6@Z<&XT!9AJ\U%A<5H
MQT_,6V2U-I^%30_'56\Y)=05[10&!JY$$DURZK0@!4= @-9J_EI+=](2D>?K
M)&< P\E!%AQ!@66LIL*HYQ<QD2?<Z823#*X+I_8(##IH0>RDAVP5\X=U=VPI
MP,Q7AT'3 V[E*MF&EDCW#&FRZ$/9IFM3EJX%30^X5<VN9QTZY9L8D54P;Z[E
M\YE9V.L!M\BBB.JHO.P+Z!BK3<CA6/7$D-9#;I49O.?UTDS:T*OTLJS,7:.I
M0 J.@#;OZ(I-\-.JT%ZL9VF)QXAY@@N:'HP+N/F)T<GD-6DV(U Z4\AG\,0B
M:'HPKE['K&:,?)\6%%K*J4U*[]4J< DZH@KZ?3.5FC:@E01X@<3*"\<J@T70
M](  M;I<> NOZ FTM9KW\")CS8Q:T/2  ,+*C46"I@RI2%GI;M[KD\4,%S0]
M8*R3-V:^5B[4C%E[+<P<CH/Z.NSU@;%A .7!;=O$"]7 H)JZX'[W8M_V"+;2
MMJY;8+:K&W-_YY:&/A6*W6$$PS!4$G_F;>V%F+:^UA//Z0Y+A,Z3Y^PHVCX)
MW]@TO[W_2C%WU*N;CWM^R=XC;?B8@6DO=B;2[CT:='V_<5@7D&=O^HI;RRM\
M\*ZITG=MT_? 9SB.+X?<GD:V/A2?V/Y]U\;X-BI/X_$D?-TDO(0.["[)QO,2
MO7G!L3#P%4],Y"8F5F21G)=8D45S7@)%1L<3$\&)B159).<E5F31G)=8D45U
M8F)%%LEYB159-.<E5F11"(AA=_2K1\GC2?B426!B%76^2?C@P?(W(_5?QH3D
M!YAPNICX)0U7M<W@PW]O$C>_N2P1Y!W[M4<FDV^DUGRT#H&^1,KPXY&+")8&
M-.1$E08B+38'?/@2.:*N28Z:(P> /Y*D=QD<EZ1M3K"T7\QPXT4T<@HR^18#
M7H/S)A?X\.\!IA]4(?&[JA#'[_"K4H4%WP(;;I'8-JDZ.!-Z*0OK)<D-??UR
M@\5R$\O-->L;YF-RL_G-7>*8&1_+473U3Z0M^S]U"'^7)1&V_O^()2>HR?/;
MF;)?NY#5A990D80&DJF+9:0AE$KY2A;)BF*Z\1*0?JM:T57'5TXL,F_M\9U=
M8LY;2N.M),Q3KS.?7R@C[0>WH]N6C,OXIKY.T]XKMN,ZGEQU;,U7/=%I &>N
MJX!;ZJZ\+82Q^[(,)GW@R,FUQ?@T-E:-5=H?D:E)1F7LVF]7V:B#.;#\H]<(
M$(,YEYQ2(],@-)3)ERI6WU.#PVODS2_FEDE\;BV-2*N,6$.<5T.\NI=^?1H"
MV]<0V$<U1'YNUHMN0N,$O\8LP2Q=2.=*OU^]ZQ4-41HTY$Q=2;J"KYIIB^W1
M*UL)CLR&][S1#!MKB%A#Q!KBE!J".H4-D1"I&5]P6ED,V)64N4JF[6']+#:$
MDBFOULMBNR81:9^4<\,,9N>"H_)L4"&:H-YWMUBL(6(-$6N(CVF(/[,A* VW
MC;EBD0)O=DJ8-[*7X]E9-,1B*J2[V )-8BLWQZ5DMKQ(TX$-@1.!BJ"IY%E4
M1&2C>I\?>(AL-.^$\;NOW<X_84RNE.>#6E$(5TDC]?]5)M._TTA#J+?@QR^&
MZ+Y[).ZWEL(OWAEYC6.[3:$_WQW#]DK_16$3Z.M=[X\:UB7X@>6"H$+MYMOM
M KIB/2S+M-:2@78MLS">U/D9N3C' IKV2(8QEU76X&?3U&+145!QRD$S@+SY
MQ=ZR[%FN[XVTVHBUQ,FU1*2VBK]>2WS4N'Y)2W2MFF7K-$ %7\LJG;0P-::+
MWR^9_8J6D.4ZRGD-G\*43B=)IEH5K28%Y>6"FUG(=U?&CM5$K"9B-7&N*-U+
M:H+5<M.E6U2R@I*9>5U93Z?4XEF\<91JK#&C+XT$L3#E^3F=G7"MP)@(XW5X
M,M82L9:(M<371NI>TA(]N>B5VS47D_SQ E.M6=>ES;-H"7^H=\8H[Z0-VAT;
MS18*_'JM%HR'"%(#2/Q]&W_?+S3WC2-POQ65C'AHKAG4HD>V ;HX0>Y:MZXN
M=U<OSJXK,+5!LB$8I*1/L5S)&>>U#G&69!C!]KLNF:XGA4ES4-/')5=8@*&<
M"&^L8VX9ZO#NTWBO.U88T6+-=]HH/Q[+R_BVK[7'3<R@&Z.B11<DL<N>Q8I.
MJJJW5).\)BCC17%>G[7+6GB/ PU];>*6QD^;'#.!TF2"6#O$VB'6#K\=PANX
MQ2YGHF)/F#3RZC"C+=5FY2S:P?(5LIIK.2W![W3)'.,8UG@0: ?VYA=]2Q&Q
M-1$14,3Z(M87+P;S)F2^5,JU9PEI5=5S_>Z R3?G9W$_%K765,DP_%P0M3IN
MEWK=Z=(-W(\@)H=CMRQ]'HUQQ=&Z.)'NJA+I>+'1#*Y2#(^S(@VQE$9^X'_%
M27,GW,&ZEAVJKXV9'8P-^7'103/>=KW_G[UO;5)4V=+^/A'S'XR>,Q%[OZ$]
MW(4^,SL"$>^*BGC[0B"@(@C(Q=NO?TFLZJYNK&JKVE+4G(BI4^7.QB0SGV>M
M?'+E6L+TR78=,5T+A=CON=%<X%=<F:]X;,?M3&>@/R""C6"2$>!_PU-GB-E4
M.9J7Q^SGZE:_PVQ3J(]VC#$(S4'!<AEN0ON[4B?J#_7E'S*+D4GM"F(68O9A
M,7L1->EWF+7(PD#2<MVA5)[4QMU.>RW--5 .F/GR#Y'-XQ"S$+,0LY=5='YK
M9_&FI@QL<XF$N,'5O$)_0## SL:R3I8^H@._![1WK-X\L$CS,-G*1)[M<I7X
M,F21[_,-H=WD6[T,/VR#2Y)BYB_L57T'AF7=^KG(QZW>_817W9M4U-5]7?'4
M.6MKQ<@F6HZ[U.V W[H@XOF(>:3:';NDR/2&%TQ'#6=<KFQT63D?!UT161I%
M3S./\)P4\L$]G'?>FPSU7CX0!1YI,HW:BN<8P[,FI5XAW&PB/J B/F"R)$9!
M/H!\ /G@5B6N]_+! D,:N7")R)+>$:F!M6C83@/P 0,N*E%T\J(2I -(!Y .
M;D0]>R\=2+7B8#+=^80T"!0&Z7FN6D1G$1T -8W)HO0GN0=W++/!(*F3@Z1N
M5&9[*@.0S93Y%M]E&['<QA:;U595['797K7/OU#<<!A1!7,"W%L:LGN3V43=
MLJ+Q*^NV[BE69#U9;6G8AA]X<0WEUPWH?BQ:CC,HN8A8+7&3O)]W\>U&IH'>
M1F5QY$1_&KK-D QN-D'(O6EL'R8#:C$?,EYO-#<5&Y]O]I51A1X#,HACP'#Z
M1.T=D@$D T@&*1'8/DP&*N(/AW(P&/)8;VY9>'&[*(UG$1D<,H?E(1E ,H!D
M<%ORVH?)@':'I3;7J,QY#BGGQPA5Y1&V$Y$!T-FP+,HD\PC"J#48M79_&<*$
M-@\4LE8Y4VUQ0I//_-401!$&I5WWE.DFK>69@]:@&;V8VB:X.O@Z>U:U56>I
M-QP?7."/7CUZSA'CB3(85S0&2$DJBRU3$86Z830Z,A/'M&%9^E17&AY:0SJY
MV*%VBNGDSC**'6>37TF$S4W%ZI22;5,I#-<Y-QCFW?TL(A&0[S]+'+F?"2D$
M4@BDD*M[)!=1^=[ID;CY>E=?N-I>,NHRPHKJ=C@F@4?"Q%$S% RJA6P"V23%
M;/*Y,N$[V:1AVB32;'0Q,[?4C5;'\DI% [@F!W$0(Q 8A >#\!XY4UFIVF);
M7)5M?(^K@S%U,!,#O'KZN2I=,->]EF,[S];L]>.MZ6!"3*:!L91RN[7+(J6@
MKG5F,HH B8XXW8)!O_>A\?LP=T$NHXN=CE^][*'UDL!RTHXK]]R94IGJ4HS?
M.'(-S?]94A6(7XC?N\+O932IT_%;(ISB>FIU2J:RC]#;GS<5 >D _#+Q#A*!
MF<P@?B%^+ZP"G8[?"B56 []4)TU,='(5#1MQE6J,WT-6,X;XLY2_=ZST/+"@
M<X_Q83^4GD-\& P,@P<G,# L-9$<%U:<#N<G1PSFK%>CK;59XI%E3I6H\1BS
MN!PKHR@0G'#BM*KL\/@5L@@\?KV_>+"3680=;<8==K7:(TJIMFL9Q=E0+<P
MBX"@,"(95@I9!+((9)%KL\AUU+=7662'3BK[/;U<2J%?H&1BS%JZ%;,( ^+3
MDSMWR"*012"+I(1%+JP!OLHB.HGU)((W*23<<*SA<.6RO^T %@$2(/XY+'+'
MNB", +OS"+ ,>'$4_7>FQ?=@-!@\S8+18)^JS26-V(_CK%<CFVLRQC3G4WO,
MZT).#9?NVIC)F\BBQ3)=EF9.O"@!G>"'1O+#G$M?1!_[$))UKSWA5:=@1)M<
M(N=6R^,R48R13($(3P:'2(9(ADB^K$;U(21/&AZO;NQ\S50$;<*L\AC;USH
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M'_KJ6VKL+<3%I/[,!,;3/((MA4XI]#TA+" L4@^+=Y]+GSVD^C:5(U9;A'X
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M#@IV'=EM#;$X6'JDP&YD%$TVS2W<Z<@@QC6I3B!<Q>F@N44W6DU8LJG0\JD
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M=XBS>N0FRB$AQ=+5;3_V;^%&[C8W<J_3U^T9[40"R'/G>+RL\!)#K0"0QKT
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MO)8^=^WU377U!W:/\/NBK/9[(KL3D&6MZ!1GT;>LL8V,'E+MD\G#4JBJ00*
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M,#CM\A,*U_!-K^'K!V*E8D+OR?K>WN;^*8EZ._34.8@_<J:9B6*;&4UW'=^
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M24A9 '% ,4+4 ,)5+0J7O8^0'=.$]<$]'KVYF+"0VE38K\S4\4<.@7M&@"*
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MCX&+5(3*PE%-E*T$4$R\+: #RCTXM)V)OWT*\*)#*!Q-L$"H+@2E2+=H^5!
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M(:/F4[)I0@DS'Y I ^*$.Q7,8W@VS\3-7GA#MDG\Z7<\GR'QAGR*^*LS*#Y
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M.X TUG/I)1NYGM@XT8N-<3F]23[.>[?9[KR0&N_/6OM?=T(#M6TM+%TC=)0
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M%P^+] Q;TKSV]L+(-&:"130->^6/#4.QOE_0^U?K?'\EM27,[ E@=L5P<)C
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M.]K_@@H(8Q0!OF(YIY()5&9Z&=U*A)MJ-O[IBDW0PR:VX<" ,O,D77;F$HC
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MCD;JT*'6';7$3%L'-OLIG.(W'X@EM]P'3PKP>%J=@0MJS'%;%.IP+4874/F
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M7-\ '59OQI9NL-Q9/D_%PJ0( ;M"8 >#A(3]\GWM<IF1@U0+F3%"%T["-8E
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M@FQX^#RQOCCT>=I#^?P(/79*W5"IB!/!Y0[2"==DXOOQ5$VI=A*K1Y#.=,"
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M:'!'/]*9S0<3XWFFFI4%N*PZ1UA5'5LO]F^+%B"#<G629J97J5!&1K!MA=O
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MY;.\& 0'I]6%C@??BJ%MJ1"F5LVAKQ\$VP8[$J>P]S1$RN<FBQ0>2=B^LTE
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ML[T]E>=&D'RUJ%!V"N5YG" "" 9>/.?BSW]JM+IOP5 *$2<#CDV$4-:AQ2Q
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M(75Y9D&L'2H\_MGD6IMEKK7,M;ZH7.M?\L!UA3)AS)2A\8).X3PBK^HK9A+
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MOY<J>3]4\F::%QF&C>J[\&[B*)XNG).;S(\(!/-\,/&GGE;II5(LE6*I%'^
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MVD547-69JZ+*_4H7<BY7HU[%P7!-,:HIP.C'PP7\SR2;AG_[_U!+ P04
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M5S RGE1"3DT/"BVWQ@6^F<L,*@$=S^;;R[^D_4/9?XRPD/\EROX[8?]*%Q2
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M[RH'+&45<K@FSO\J_;0**:440 U(JPP! ?9R+GX<\-W-':F/%.FU>-'H\(U
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M?P#6:W:-EX80/DYQIM.D:*S^!8:P]D\3FTH=^D:=XY_7V@.<5:+B ;UQ@8J
MT^+RE;5 I;GRBBKVLS"/^[=:A$M#SJ8)W<24,21=7WDR$>F2/G:"EHW/(D:L
M'F$2;> 40?N.S]9Y0YMCF6:35Z3?<HA@%':GUC0X$Y*.6&A^#G(<BZ$E/CW9
M\K0U@Z+2\AIMX>F:T.IC782O)<@G\-/$ZHH.]40(6V/S2*1FJLYW2/UZY=0Z
M7'PVU/.]OL@O)OQ4Z@+M6Z]K#EL^AH9*D+AIBXK'^O':U1+?VJ@-,44FESFN
M"D6;,QS/-I:?LS6@R9]5,"ALQ%O22<?;P/HPY@:A_H/R"O-^(8_PM[G&HP>+
M&M[."%++8B\A0;PVN2U9^$>IC\#);PL:I]'#4T) I'$98EI(5CC ;5[[G7>%
M(7]4_9.];MP2,HVE)M*X64'0(01P>JR5<RG4F-WH*62YFR=?/ET_(.Y=;_&<
M$_6.<ATVB+^XTF-HH&:=B/AF;,7+D=8Z1-<#&%],%QR:,->\5Q2(G5-=VQPQ
M:TMQQ^^5MYH=4ZJ"J2*LAKB&/VSS^%*8CJ>=ZA.0Y\O;8\OY%"8_[<,G,91-
MUV#L1* _XF3_-B5F]R05F[C]FU3$>R3X1GER7\R.8KCLW!;Q!Z5=9:G+G;DS
MS"S\=I<\O])E\U7<A,-HCPHVU7[PH_YD[<H4=03^MU]>.YS=<.M!?,655H&X
MOT%*D6?EY]N<O;% ++#\ZA*\R:U86LD0R$S^#&$RT]?)%46B<1(?HKS*OHHC
M>"^BAO@;/[7 WACJR<\W9>YJ+=KXDTOP;G_OAEE>5.@'W-9#_WC7LE[H>P:^
M=9?2%"Y,$*+K5"6'\#22G(R9S!9]^J!NWJQ3^AZ37VH#*3^+^VX3$([\6C.U
M_V+M;7EIJL<).PFQR>\5O]$6ZCBJ.'<>F%EU@[6FJ(!%$JY#_NK(35LVB,:W
MY.(1.(RA[>@Y5C]EOT>$@ATH[\[<:$'&>W-- $5;6DA<H:L$N2C^A#BH0NKM
MHW_%!A]0/!'69+/:_SY H.3C /B8[-37W--\]SV]9I8I%_4&=HCWE#D(<,!8
MZ?-SX,Y%\O.U_@1\=;$3K9\+=\AGOF0S+E4S6[=,H[,_@'Y"C^L5 STZCX/>
M]<\M6@R5VE0O;C#3ZCH^7R(1O[O7 KFN3WIZ>1?4U7 /"IHX[F%3W_^HXB67
M^Q2R-9,+@IHD"+*$<)XH3/D 5G);;B\-WK(7"/EO1*"@TTC6_TJTAOED39=E
ME+RY]<T\(K!AR4C?L/^3?T)O?5S;V2FSO.#CI03IO+8H0Y194U-*I=O*DF-N
M G:%OFG@MXTWDE1Q@VE_ "@N)<[L<<5R.Z.T+:QOOG)/)Y+N33T)#@#<DK7>
M?;W5[V!?GSDYU?, ;](""[R0?F\QMUR&)QY16G,H4N-X*SOOR348SSF>[D.X
M$!GA<G-;NAX^T%[+DVAESWA/.+[5E*J@.LBV%GF\*<HBD*U^KY+J?Y>:L?)=
MO;JUF7AGG^C^;Z6))OF[C\H:2,[P"U?]>X(FWS"&U[_ A][B^_R+./X?P ^X
M*-/4?.T^_=7!,$->4?W:4#G0"8VNNMM/!O_96O2-1)@I!TU1RH%'T/+18OI7
MW5FFU)/+$OG&/+<Q,JS!5N#'/I^ &IY$([IHBZ"5:JS@^HP7[W/-_8N %!&N
MP?>'>R*.Q&^9AX<Y"N0/!]!,K#X9OQ&;LP6R52;P7(V_I>?-!!B_JQKWHEW/
M>EVVHRA;1TKYEO=/'"UA/)%IGS*+BM8$;RN$G9!MP>45Q,UOWS?_Y'2ZS?)-
M6DA413IT6<E'9U@";ZV:&7DXKOW:[P!8OXNUU(UV/?#D1-Z3+W02)*(*;/42
MN3T0TC!XV!6O/[L9/OW@4J[QK>!:_<7"X'D8A5FLH>I=^,UA]&[8,D1^QT]A
M3>Q,G+D<@C)KWFP;OX9>'_[Q%%V=/YJ/,'L"72@-;,3:#"+>;_TI")HD5@PX
MXV5=NR<SORQA:_>]6]'7JI^UA&QMV5)?);IU6Q!/;O=0W.:\"[E)R_%:,L"8
M&0P&FQ%[^,]BF9]K+#^HJKP>0%[070B3D277!WW6/OB,VT/E,_*O5I>23LA\
M#4X.&AJP7PL$H;N-5W)J&+SLO$#4V6WU!5Z!=ZP:E)PI;,]-LC<&9-BW>PU4
MTR<FL\9*5]'@N#87^>5)%55>V9\]CP9BGNF+GD8.LI0W9:E)9H'N+EYX6?'O
MN%%$O-SU=?0&N8&,'2 FF'[0\/*!<_3E@U9E5KFQZB:&M%JB)C]'VAU?-P"J
MLBZ.6D<85O^0+9]NO]PXGH24OIM9V^5F<4>1XH*!.?E3(4M9E?OD^OQGZLBO
M:T@@"044=LU@UT^TXFCQ3<-\:FOX4T5+ZDFM;:"5G%@4DP&EDUXGA/_Z9J>S
M?K8HG=B18!U[C[D^6G(**1O>/+T.*;0B.SB;I+)ZFL?J'=NY3K&QA+"F[SD<
ME >[IXA;K]=1PYL6AT.]'CMY:,W\6!I P9T637"8I[)X92#:MI(6[^V0)[@V
M'4W1@-'4K\028Z:/4)?9Z(0Z$W\RGD<')(O-H+BML=[T%QHXS8^;LC5)V+VF
M2ZX3KNYA5=5S,,*;,^T ;V),ZWKB EJ<<<!/_50"\-.(RDUQL]L*[1U"%MTK
MI[^A'^+B5<0<7+Z=)PR(O2.,*IAC]^AHUQAA'B^]',VGV3]'O[SI*:OQXOX0
M:3W>-*O$B+8ONI+V!BX>ORX>0<%^$X-]<81*E7:(=G2*M2!=UC3$ -*NANCS
ML,'ZCG<PR1G>R?&>KR#_XW[N[>&]*FVH'@EE)*56!WC!7\B>B8 N4V0$_S[/
M3?R=])!B+"6"[9O\8;'Y8SIE5-94]%X\44V8I]SZ"C=??>&?#0-=$U<$F/JT
M=OMD/M>J$CROOI#$_]L F]8_.2W7W]>WA=-_35IXUS^ H?:N,_XKWATCU N+
MQ_N(@:EG.I*8#"R>A(9ZI!TJ"M_[1^WJ-\A4T2$<DL6LY:PW*X%U2] ^(*:2
MMS.5YLC19T;)Z<UV\YQE+]]-X%Z663F-EBSK/NN)CD5ZJ-8BP:+:Q5T61F$*
M^6:- J[:?.>.M)/,<UQ OG;VNJ[>$<$$T-L)OQ\K9F:T+7E[_A._CUA:(+K:
MNNU=$[84(.;M5XX//M8% .^BD'RN8PI.CY:0G8X6>GOW%5*(M_JA\FP%VQ_
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M!!;\?/G1X+"1/P[.8+F'6[_Q0"E;3/?66-'V].H9_L>9<ZOJ,UC4\Z6#\ _
MH@(KTOB*^DC\ NLWNK9LNGNR]I7QD"WJNF*;10859M\TY#>"T-DD]&7YM(IM
MNSGXY<:E<E=<7>-./O^V9?_1L\]]WNV8B1?KS5$J7Q6./%"W4S(>&8YN ZM
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MQ^R_8\4Z*=?FL[ J=H%VY5DMTTZ0C1)V+0-@2?[J\^^95#%.=9PN4A3I?G/
M"KTSU56UU88C*16^4A L.N[G<4=9ZVM.B5H-]:^\G1U\*UO3"=AFZ>+<;,]*
M<W)D@2;9T?'!88X2[\D=)"LM[8QT@U=5PQ;I$6D_L$!&:)&))VFQ<K!  (=-
M6S"A<H^/XMOQ^*";J*IJ([E]&P71XFY"<9+O.T^W6R/AY)N"T.Y8?HIO#->8
M/=Q,MI8W%JF5Z5/ON;>5'"YG)<8.E5M7"X\N9[=@B([NZ),*LRU(&R>Z85B-
MI^(?QHKMKDU(RY,DJ//GQ@I&I*#$Z 5H:2R$*A';&1VFO\%;+N_&W1."\-.$
MU5U=R=Z95[R67JI=?N&*T);^:N-*KFH>!V+MK96M5V4F^7HSRKRHVU%H3I@^
M)VQV^.,;P,FN![.H?'+1H+QWS?$]\]4G[;>S2WJ$-8W-$X/ P\U.KI^S-R.'
M<L*C:.<;3 667B+VJC# D^ 9MN1B=(Q<\Y4V/6T)<#?0H2A^%#K^@VM]P+HM
M0;X#?&TC^6Z,&;"1]*+V,DC:8QUK49Y+ A;@FPA95&92., ,=\=U$6%D*L*T
MR_8>O;&MX.3 ..G$;.XF1Z<2,KS&ZR%H>!K)5_DU2(&)8+C%?-UTA\'QB,V8
MG.#4/U4):37>,AA^D&N9L)^FM#M/+"X:5QM84B89H=$#TZ&VOA:_/[YZ^@NX
MJQ5JQ#I=C:69(BN>8"LP$<@E-R6:;*)*_MEMVJF*7UA!EUEMO\K[R;%W]OLV
ML=7X@(P+:=6>,45JO;&Q<3[I.5;+-)5^2FQ$_O)U>@A[8'>Q6./Y%;G#7B#=
MC-<@8ISPCE!N;LN?47GZO+Z\P'H_[S5$"9 7WLWF,=4]CWTW4]$'8SN_PJ:'
M:]E[4G.BZ ^AMWQ*!Q@VW?1Q@.7PGSW2?2JQB*"^&A;@)2Q2 ( KCR8BJ/60
MAUD4=/M]6,4DL'?=RHJJ<8M1XE'N#C\<)6F_<-([";+MGV.,-^+@TU*&S$_D
M@B(ZK!U]K5)"6$@W?_^:)6V8QIH1J7.BFYSSE"3:!N>W\V^:AELR+B=? EF;
M+F_FJ?DT>>!"_8F#KZ,'N&G@@0^C?G]OD\GQ-*R*(7!$*WN$T$YD@R[%LJ4M
M0Y9[?Q<9 $W).6X47I6K)]?..&!') $<<1>A#N$G+AMDV,ZY4Z74:XX?<2+#
MX7)L&^[$S?_+$18*S]CM-\< L=RC^%SAK>U^:V^;Z_K<@$ +@@9P3CM[_;84
M1Y\Z[P64AMDRX6%N3[HHEH?_#9Q-("\RM-U&D/IQ /#\H3,$)<AVDU>029ES
M<7*D?C<Q@AD3-JN?+R)O,2%Z1]X?:V[?T/QY0)@&>2K]!G.GT2!=N;>KKYW-
MT^ICP=F( 9]0-/G*CQC_E4E '&2;2=$6MJ?1+%.B]:$ "Z3XO[0#8TSE;RFP
MN('!Y%PSS:GOLLYG$*9$HK;OJJ3QX"*]\W=P0)'#:1^;.F]Q<"4++6Q04B2@
MBS5;]K>G-R/FYLS99K3CUI9<..&)!3A+RWDG3A<LSBD?5_K<&0L2SPL"&04\
M0*(^M&&*#"0,;_MX1*85 '>OO,29[6;$I,518"X786X*%X7KX"B70:=?Q=J*
M34<HS#P)PIT*@5*)0I<$'H.ZA,$Y36WZB/&.V"X2&-B6V.QB"HJ)HK-GMH==
M'7'ZM,\)9^_PX*8V?>+N VF0:8#^H8+-2F&]*$B^^XE<VLLTRQ&<*JW2///Q
MF%4,_28^ @T))Q#SW"->@B/9V:.;416_-X\6.Y* WI<I!M(@/BL4_M-'-10^
MK-@[XO+,CHU'ER'@=!TQ\[->"-S6F$K?\OQY3U_U9%;)@2U8F@4KN^W#.)HI
MVV/"JA1RKH6].U(!#GE%T&>$,#?98_6&^$J@QN<.@KV/ IXX2;8((G<UV4.Z
MN@M];D8;48C<+$086#(:;F*")6(Q//ST/I\5F:1P%2ZRCATNCXFW;BR6CWJD
MEV"XT^N@-LFU!**.Q*I?E7.5>IL3'^;L,!()4?7A-L3)?O=3+P=T7>X33*%O
M"E,HEK#RUI$=\'*E+N%-)>-LM1&8C<'=PC1LB,QOB>&OPY?R-GOFZYT:J7O9
MZ]U'J-*GI8F_PK,'"Z9R*[/R6BN+KA&<?;98%9O+P^8J4L6Q=W1&<$S,._*E
M467<*II"]8-Z3ZON&<2"E/\"4*%GN*.I2E5.8,0P;S,73M_?()3%"\OV9RX#
M2;.MWJDUCB)3D/P]DVE+8/K%=6"1TPZ3V4:RDAJR26*=T9:B/])F<%\'H]L'
M<S-=X8:CP1?[L#]1KQY_&LG6<3P()^-3KM,&W7P?0^;HDQQ*VI8N+J0"LR ,
MWA9>(PA>@C;@G!Z=PD0NE@S - ?]Y=C,73'&)QZ0MJ?68B9,J=]IK.LFGVB-
MR-S;\QA<VQE[)U>OLP>>;^N887R? (]OUE=P@QG8;/Q9T#BQ*T'*#LW7LL4<
M95)54\W$UHLOB\7A *B@:68ID:DA0>5/IH:,?]D<B+3IJO)3)A3\!7RF)IBS
M>4%+O_2H,;2O+ \KU(GBIK1YELS]PE$]2&QBR)*Z$.UW OI=1VJ[0-,>*<E[
M'4'I3S2WBK>\T+;V &ON)%WC^L(Q@4+[[YG/C9V.CG\^"/:/:P\[ ]7-7G+(
MF&Y75RO4'=UUP^?L2&8B.(:8D&*C=H^1@AZ([EZ9*I_QJY,LGX7]Z8&3O3)D
MA=UWE1U%UGM#!C^]:^NL4*C]$'X78SJ_X<;O =-?$R'K5FEB;)-4+R7=VX:(
M+]\Y=B!UF_8&828CKMR_QELV/I_C(FL;+X8N>=.C-.*OL.9^Z8RZ,)!DQ7II
M6^-2KXROE)F>,/^*#G7%27)Q$S.Q%9_U<\8S':LT-$*%O4P$+:5H01_,,J]@
M,R)W,R98PN/@!"HY*[-F]DT@/]-#UUCCJ>%,Z6DBTR288/1?I'$D%"10SGU7
M@@3F7VTYO-NN!66019Y@+8;@ZG8G3?I:X$RQ+BY0/Z*HP F\.A217!;/O*_M
M8_)Z8/I0WS$=Q<,XQK\I<3J(@C\_8H%A)XCSG>[+;./X<8?(IQ0[P< F]?<%
M#/@O@Q%DO!Q%#0P(A?'#WM?29 \RRZ/G+OPRQI6TRP6%6)7\#]5%!C\*#UEL
MIK^V#%)92>$P'D8M\E'P7R57>%*N=QAJ!TU@$GHA#X;V7@4%GO%[.'+NO&I'
M]I"%IQ+-$8\=IHL3J]E[$P3AM'2CS!2JLK+?I(DS#S@Y'1/79A/F%8.U<9_F
MI][73S\C</(NEEOQ!8"2W>-.W\8<[U5;'G%>_Q,$MO^"0,OEU(O@#%$GI1A-
MS1QE2T06*K6]F^3:I^GU4RBF+'G\/?QD*:>+Y<:@FPSJUCP")#5 M5K*AOSW
MJ3-0(S\21R92CN,814!@5F"_!WF!NR/5N.WYRSC>)XXD^->=*01\ZB46X<PD
M?MID:RCQ9V+)]0EBHHF)DC"!J1_89UF$=-OJSBYS9'2\4023A-8HM-Y4CM!*
M>U/8C#XH'MTEC- JR[0UZRL 550M<,#-?6)4T-V 0)2TI>UVNH;LR!-U=[BV
M0@*( 9=4">*-K13I<^&)[([C5&@8'/WW'X4KJCN#(45&;G5F,F2T(C\VN7Y@
MI[+TPVSKD0'YN_MB$ 9)^=X[>%0"F9K2P_K2BT .,S:.PG9D33(GN9#ZXLC=
M)#%X6>AG+Z_Y'F$7F:341WMM<6JQ'I%JS"C$I]>#3X&^;W$L(.LT2NJ;%@%M
M>NK6":#'F(J[NO$YI*+@%^2R+4M_F+6%^2L^0O\BZM9<M<!1SX<J?9Z]7MZF
M_#!V2P:NTY>:5#L2#S0=)@9L0JR0\"O,Z%\P263SP09[!Y=X@0Z/9ZV."*!2
M>8:.V5^ #_022@D2[Z=?-ENZN'0B %M_[\0MCB76H=L,/Q(0,"UJ)&>J=!1<
M"!WILQ^!B _*2*5(.#>\.ZJS@V 65:ZCVX)*S0]CMG*1+0$6>=C$Z?9/;>Z;
M^C32PDV<A'D,\D+$\OLBFRFR%O-'K<?@ABMGQ\B*95L03\,I;>)8#NGT)EK6
MKI6?Y]V,Q['TDG+C>O\02GJOUU9X8R.XT ,DDE+2&NZ$;6'V1MG[Z%4"-V/@
M$_:F++JOIP.AMG%:Q6RH#]C)_8/8249OXBO"Z.^,O3/%\"T+[JLGG,WA5^I?
MXM3Q-M7TE4RN;8$\PQ+UCN,Q:>%3E*PJP44\;&O,CW\!,O&Y = ;K+NB[:?G
M^4YD_?]'CP!\ZW]Z%)>*KHI O"'"8_O+_48]MA-(I3G!C%!/TO3W^YDB&A+_
M3#R=U_X9=15-ODS["U#8O;-#)Y6=E:H,EFY F](/2#ICDWN9S=\KV/ \_A(<
M\1= ;?P1BN,**G-]2^%_(>FFC*H2G#X3?'1,GN(!G],Z;&XBCW]+%U,CHSS5
M9 ANJ5IS"H9A3<?+1.XMPT;*2X$^7^QHZ0]3*%2AHS)"X)'7P[9^VL*M<K6-
M&"MA,@N>^'("1\DI-$-LZ5[R*+FY<ST3VIZN^!%=+KSMAB1=%!12 ='7L],M
M=9U+*_5/6H\4L0&XJL0G%]HJ&YHI0U0D/QP#&99Q%Q%PA>CVZ^OQ6^ 0X0J\
MZZNO6)S;I]"[+(77;Y+8QP-182H9"IY<S1W980P/F,56OI3?O"K+VVQH'9T\
M^;)U%*(@-T>HD,^'EBFLLHT\4.^?3,HFEPN6,N(;999F$I0&/T"G!PX_MYP[
ME8:0@,!6/IZ)K=B2GD\,PZD<B,$<ZF*')('*9=VEHCI;6_$8<0UGWAAW3UHZ
MN7G"T)L: V*)<5:4Y66:.$TF^:!\\5?(P<%^EN),-$;B'VR[A<=DX759! 2L
MPO9<=UK?",SMMHVFM&[/1G.F6Z<779Y\?T^R6>H0N&T9]#"4"A'SPL]P^/*T
MH4GMGP=YV@:!U.0YO"IN8R*?ZB#[MJM+O\=Z,#@'M2P!?AIT::TJ^)<?/P\"
M85LO=;4+-(H.I/'11J%CI_HX<]0V:=CXJP";S?U8>D<X4A/4!1;'=J*KS#P9
M'6KC*'Z(4!#/Z<(,D>4FU-4IK.\O0"KWZP6!/&D1WY&U:"U36;A>S PB>A_N
M)#(ME<5YW&B%_% FK9RFAG(^WVI3#*NN S% &+9+"7+E$ZP8;F$LQI&IK^Z#
MG]F@;3IJ/UR.Z,F<Z=CWNARG;2(/RDSVQ!UIT1&.V!;;94HU6KS/+/LHFOQ+
MT(YA*2U(\A'$\QTRJQ1_3',X>_'L9Q$7KYQYU-RQ"1B6B$&@E-*ZK+KA/M&S
M;%M%DWLA^58^.Q/LC@600G1(_ME1@B[/L9KF8D=VX3U?G$[,1W=L)AK?VVZT
M%"!;+4VSODZT/,&$S"Q84'0ZXA9F\5KK^Q>07?874*(UOYECL!("F?,S]&[B
M?_M1X;:8_%'%<_.B[J-@0&-SIVLM(=@,8\0K345OUZ9H*B_N7=^(AA@8>T>P
M W54%5%'IGQ4Q,V2I==ZKU=@%IE+X[25YG/]VI' 7X!(%3YKW'&WR<:6;)V/
MR8T#4ZY*B>_QS"'@%FD4.N9<8;]^!KY?)426%;#H=G%-G?%=SBN?<D O#S78
MK3U@^ TKJN S7GY?&RL\@< LO-><OMAC;+!JSV;90Q%@*P%Y-12A?<,UY&Z2
MFSB2_L(9.&/=&5]_R4;C,4J#Y%[P(37)U40/4G#N;>-XGSU5FR9% >71V#'L
ML4Q]V9>1W WQ>Y5V4ZGP%5(P#9UO6E[\<>9_'^I/?AC"T>SXPU\D216_SDAL
MR#"[>ZD1/<6K)PE GESAC7\^_Z-55_@L]3!=CJ$T;CFD_KVS<G\_N&WBZW'>
MVN>6RZY$_ [</DL^%)X?TH OZW_<2(7J%$/=F=,DC@AM$+BX[BQ.?^.C^>@Q
MGR76&(D6I#U.?%'WBIX->N/#G^/_SY[T8]G('*.A1)WC"Q<C]!B0DEV[BIO,
M9;G['PW9/9%L]O1:(Y%Z0KI])@L21PTW.:";K,B3KJPTP SB8P>R1N,Q[&B6
M'&528JPEF'4;RB(K0%"3WOW3%Q&U_V27266+';."%C88.G[)8<R"!S?;&5FX
M+S#S5N?J[4Z#"K:.)?R"4(!$9@E--ZBI8K2_L:=P(/#Y+,0Q #@6J&M30\;;
M)K/YD6?+HUCG;QB-J^J(K48>719X..<BN$3[JW]B@52C.U!0(.#D(HYUY>OQ
ME84KX#;N/\)VMB\B)/KZ&X$5X^W=?'!Q6#D'!92S=5AH35W1)*"YM=VBN;CE
MT5ZM8Z#3F>Q-0]R_-8B.U!8.QW^IML M"SI5N4LY2/[J%V?WJXP&%>;ID&][
M$/NE^W,B5@&>A8"8![2K(2D.,*J*.4A&^&N$J]S;%2CNB#*%QLYQKMW8Q[@*
MPW"W3^<I,(<++4[L5E\Q2IPH\/K/)"6U=K>FD'J=AT4#SJ*^YOJXH87,*-3Z
MG#Z:CI2-P'B-0HB/XF4FC229V#:I:^3]F,*I;3&FHS"=(P@6F57GZN@.\'@6
M3]3KX9A I! CZ48.)<,2"FSPQ0#_W&S[P>7]&'OI"XIC0& -Q/ST(MPCI+)'
M\#%!#L\F*1HE_'?]N1B:LAW+\%_ ABY%P'Q,YY@SF3F[&UHUT5,XN,?@7\W8
M\NMU-BM=T3$ V->5B;'X6LB_7'W&6SWJN@.R/R/Q.T/>X&P+^GS.#N$J\*K+
M4$,R5ABW-PBX3Z:ERO3*0@ &>>K_SGKVWJ#NM:TD*-U2S2+"=.]%:5QL.RE&
M2QGSZ9RU*A#IS"C1_1+^HQM:]+.U,8"/'':X.>/+^'&R4ET]2-:T9[?H<+'S
MG_?8_LA6Y<V/^->INAUII0A$8K^OXD<K^^&NP^K!W4T2PH?YPY'!$$U4N;^P
MO4X:X.;BXW9S]*#^87MS8UW9O;M8VTBE&(-\2\MUEJFT/>E,*+Z(5WS>B4(2
MAO %6D4>3-(N#3"OBBX/>ZWH6*$/6SC@_%X[',WLMS>^"?>[^NA7_R,K,%D]
MC]XAN6U@BB0=X>'\(?0WS[RZ.'&'@>-,G@RI9J'W+?KT36D1GTC(&T $R>Y_
ML,?_+RV=?P.A .P9*+-X?R1DVHH*@T4<3R<T6_02C=/"ESKZO?&EK4^S"/@,
M?TUIIG>['#"ZD5W6E6+)K+^ L?0YS>83M81W!V*UR_)FF[O4?VR-'+(0D)@5
M#-*"FQW:CV]V/E+%TP_\-1::,%T%H% U2N(ZG[$_\XO<*N=UE6V%Z:(@HL87
M(JL0TM[15 ;BSG_O*;?#[^/T+26"JE7\!?39KZPD@FX8C27()JO<HHUVYU&0
M@FOM_0J"[17G6B]:69KQFTB#%GV"?GRSWSA?!=_XOG.:>]]:SO)<ZGV T7&S
MZ7GB;DQS*N@FV_S5\:?C>IL,8*, >EIH9ZC4[%_>[2"G=,+>H&;IIXF0VP?F
M$?J&O?5Q!=15$([+(&IO/C!FFK]3R63P=O_&=([.9.>86I6X?I#'N5E-#C _
MU_W1PKV_Q+=6O,4^'&WV&/U=VK=DW=3(4%Y8X=0IH0Y'3;<@.)**G>9:IH33
M2(4VU"*,8</ZIR(7F8W GO_O.F70&<Z98@678=L-IV.77M((XH>PWI[K,9[^
M#H(8(U ;[;1:<@0E9U+(LY9BN=V4/?CG)!PZ^70^\KN[8DP')7 C:&08=X)L
MA+JKR'=BBHD,+OW!YU0'Y+DE^>!>GZ4&5*3,/0KCRU9SP_0Y'SCF:8'09<V7
MTZMV<)1\U)PB(CY_7)K--+.*,VT>[,=&=&P**/88@5L>:5F^8GXA)?^]B)X?
M'D*\''K+"R=<B&POE/]-_<Y8=-/4X%VX'-$P40VI5N)$;_@<R$-]#3*",$C>
MYX">I@^?6"7B4RE1L;;A&Z1<SO%HF0$)#_.;1^%BB[M2SNF*XT].1YO@C)D@
M*W ;"3%UJJQ2]E=+$RC? 6QY.98DFED[<<UM'T!/1,X=?XNP*O?^?K9&ZQ7G
M2( [U1#--@>^1UC_^<5F>ZK)K+,1'")P;HI]1EC?<7IO2R?!) ^<]")/3'#9
M8>N>&/NNDVR\;-;3E2!_'^[J-4$JBY/QN43B4=R\R\^CH> $8B'9E(_NS*+7
M9<IL]F%YJ6+1XS$B3)&?=&8PH/B8G $A_R\@(ERS^T-5-J+B^_SILW%Y-W0,
MEQT&_J>XIIZ1I_%X 44?*^6FIL@"CHW4V\O=Z_FD+0=?CRD\C3H[ +(80TCX
M9;#WZ<1^7IYVA#?-(?.N?LB 2S@WW*2^0_;]/3BU5Y;[5@(^]D!GMY>/F<\,
M2K'.4^%>=Z;3Q3EA;Q:3ROU+Q@H0)CM=$JHBVB6FL&9,JR*WS=,20ML )D5&
MG75]S+-;X![%03!WCND_OAPC/X$_8_?00<26D< [ PP,_'\CW?^/!/S$&V?P
MV&S\V\6/:=VB,R I.?7@\Z^"5RF+)]W2 +-.WTN/P&2TE)9KX&3N@<>FC,/<
MZN?O78N.TR9*K5)<8?'NI%\X)5"B[N:.C3R_;%98-&2DJ?,&$?-3T+J>$05#
MVY?.N')![42Z FU]P+^ 'O<WGND L9:>YFL.Q6H#&@E:(-E+U6(/O^.VL;M)
ME%S%.R%''49Q$3\2 </2DNW]C.QV-YAYC_)I9T\'4V@_49D >?P_'%/;&?M3
MM.</O]YP4]'SL=CX6Z;*HG(G;U!7]#^<%-=<KWAD;S MBU3&QO 7T,\>+"7-
M8J?_@/<F5(:YH]GMJ*O'P3?C%%>6_GKUUNXI2GR-\:#K<)\Z:$'DLNFR=N)+
M+J:P^]LP):\QAGQ4J\WLC?-+55-?&@M'TH4O9VO2V,<-L7$-K31[.2>[RJ+4
M,U2DG40]^6I?U\\$7^!O!MQ\R9/8'0A'_#QSEP_RB!5C,7\-XR3<"^ 7[;T:
M+XVTI.?B_;34+/2S07QROS*)/!QL/,$Q,E[_F<Y!(T8G<8.Q:^,E(J@SK^$B
M7W KKS!^VVO(S<%*!)=4AO_^9LK^]) AU5!@_/11UXB;-"9[*@G_9V'^THL#
MW9U-9\%/#-OSA\S')X]:^1*NM'4/9PAT>H,XV28-&=G]H17<&<"S^UR$&Q^E
M6 V#)NSVLEX4B7]B)5]WI8Y':8#4. !=V2&6RA>2 HCP0:7I=DZAY ._C#LR
MJ]H^G'7$^K?G\;G #1#OJ1K<^L=6+5^6YLG#+L-F4^HG"+-0J0K#R>(N>,Y7
MLW_>WZ]B?TII1GIJ24@Z7HT[-&-'3L(VSG6B14 XQ) -'N+QEA3\8X9]DHT6
MW,^4CLN,M-R_1(V*N;AVW,#4N(*U_KL[741/ESIQ8=-%'HGWF6RQ2#RI?KNO
M.\+NGH:;&M@[@,FILCPG5E(#NWM'O\J"D4;P90&CJ/@O@&2D*]_2P$8HPW0N
MX5DV+C#CN7U*9>=[C.OO!OO&'5EM$9J9'*#%OHC!%Q]MIN2!/&63(Z(+&B9J
MNUGM53%/UQ!7_:OJBH[68!M:*\B["EI^R-@_H_VRY]KM=O*^ F2.Q"]V8'ML
M.S3"C,R1PL,"/1D$5X^JH@?[L:@&T95:!]RG)LI4FNKRR ,9P ?T5G<8Y5^
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M*#%(NXK?+ W0*?RY?7SQ9O_AWAM7-HH60S#0GFZ1^1M0)K%C@OU;O_M4TE_
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MB?I M#<YCW-%Q1-6U0*%,=I*7;O9%>#MM[+%1A\OV4">S-A/9(NRQ'=JPVB
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MP6)] ZYA8 !G4Q15NVV8Z3F9BF99'O*"IW=)3@)5<=N7.M[X'F=&SXQZ"6R
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MXZZ>9G:XJ58)LM<UX4Y /Z2=E8AW>Q4,<?,N@KJC!A[F+2V1\M%3\,TA= 6
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MPE,H("NC^WQN1$K9Z+7T22-)@E()*#W-%K0R1QS#?U<>&N9\ Y=0+^^/"">
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M?1%>M7G128J2M@673NJ/]\-5YZ1>4CD?L=\+E*ADEU*>D[ZH[)-*SOQVD@D
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MK#N"BL3,%0IX\7S#V=<HNC!SFRE+:&?C&BCD ;A6[W3=T\;I&ZS+]^!V:4S
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MR=9R*7CQWN@ABQN?!R>@>)@I>DW1JC")109)(H$.F#C:C1I$.F],T#Q\,^1
M-KHXIP$VD-VG7<NX/^90QGDWM,3H9<I1J/LS[NWZV()L;=W3:Y$AN)'/XUQ6
M4X<\TTOZ#X#EU/WE.+O_E,5 ;^5<*T-* AGRX/-K2VM\O'\^D6TDGR $%JMO
M!^*XL!#XAH6B?*S2WQ.?F+M]5QW!85,58YULYQQ3J:'\D[M!-=11MWD\!\.0
M5<ZM5,]PV 9M_GG9MIF:US7!_UIIS)OU:%Q8(QTC:D E*!(<YV6:$? [B>LF
M*$5EMTR%"#-QW#DM_'Y<3R)G*;,X8!W3W\U"HR#-%2,P\-&B4[%'S@ L)T,T
MG,3W\BPUHBC(KY6(N+X-W#]Z=G2_*2(2?<"';VK(])9=#;=AYI*6TDY%EMKI
M-Q@65-NJ"*Z=PS:U'L,VG;+$65U$N&RH!^']?8T':,OG]N".,KIOV"H2L,@3
M<[=R) 9;7@U)';S7Z[P97/J7TO2BX_]H:+6'A&8JW81Z:''  CH34;2'^MP.
MI?**2W<MZ:88,SD/Z0QVS!L:-_K0W^H)KK%?]=25X6W. TN//XAB7XT(3;2;
M)-!E<(M&&;/%>:I__*TGG4,+9)$C["E6[[6_2BA-P ],0?@)MH@ ]-LA'9Z9
MVUDQ[<4P>/< B<^C\NX,N@X09HJ%B&;D N_U/\??.Q&VPUF](A\@G"PT6N6A
M6G4P%?7:<+PC,+  \(_RM\>A?PDQD8:=*?YU>9]=KL_X@,031RMY74W*<LS/
MH@J+ ;%6$4&+QJ6=!\)@BFB@= %<R^R^Y<TQ9:SOR0WT8<%^<$27HJA2$<&V
M=0:C#--XA0GT"IC0<;-V*SL*A:ZJ@C(X8Q(HG^EE?LK;)8!TM;XYOT]+]#_2
M.LQ#K&;::F].6-_F3*## Q<Z4]1M7E;'V\(/45E@,?KO9J_5_7*VI<S"4$RN
MEP"8&_ZVDYO[K+#6AV[VS0Z%O4(F)G..F'M'ACNDH3URHW$8M7WX?:'.JOBN
M,Q,^O]+V/Y@QK(1V%'],9J-=?,/]&,#.GQ;X!^ NE9WWO TQ FEF1,7).,88
MPC,&4S(L!J#S!1Y:[V'#A"($.7MYI9UC$8S%'XQN. $1NX^Q/_H)!FL;88 B
MB6B6AS4#3W?Q:'8G'.XF/>?^@B\UT=F=;&K,(3,I'5B.*A]S?+@W'#F=*:%9
MF\]+QLV@XC3Y;8^B6$9XMNJL_"?-5VR8Z"T(3H,<DFE<:29'B9;V6K9Z3G?F
MOK":'L?_^@_1?P6#HJZ*VZG&&Y?(Z-YC++3S%9>#IHY=8^U8> 1"2$3O*H):
MS=**JJL\BOMW&CX!X&!6%\"VIK,.0J$11T67R4>=*>MT^?P _K3X..^*_>RM
M,ALJ>#6X!\"M?(M1;]X+N$3#U,ZY-WE#C4'F<O7!H>JZCTIM*!*$[ .)?]+Z
M:II/\?EB*RRF^P_ P_^0O><-I](.)AS >.HP7_L2BL.#,^H$-G*DM3%NUA?#
M=H@55Q9.EHO0I</^OTIW_GO#P1EOX$ZY>-\'IE1Z2&XC3(F F[$>DY 01ZS
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MU425"&RN"KYS%C24Y/](O4H[+3W!@YL4\V+6\==0U\S]2I!X0YJ)9B2UH8[
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MN(I-3XL/+@[<$A>6!IH7A<-B<5@"L'_>O54;2+TMXT\;[6WQXKGIQN1[;LI
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MW!"-GF&?$?HNC;+AB"D#.M[5)Y>K3TK*]<U_H%2(OD58=#4'AJ':B8;+JC_
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MIE_8,I!UFPS_X<*ICCN5I5D_T(5!N=FQ!1KC;?Z:.Y/*OLKZ)3*A_#+_OH8
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M;0%4?G!F.F8"+&=,7:]@OG=99:!+(//'@2)-M[S? */6]O1-'!P$ YLNJ3(
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M>//S@EM9'Q3I//"6_,KE&WQ01/:@_(4$Y_]Y OR!Q/\!U=K-\_\#??RO%."
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M#09MJ70_&8H8YIZCR:RR02ERQ/WFI,FU4BC4M_-R?[&.ITW:$WS8TZ#N+KF
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MR6 A9'KJE -]"0*] L-KTP_COSK"%.G4'^-XXEG.LM2GSQ:%5\[I47![V@
M?DM&1<[2ROHS-@US%96%C<TB#AC4+K!%GR<)^IN.U]JEC7?^0:D2I4$6WS>]
MZXV82IUO>J#[1V 8D<=N&4V>,$:LO:=^CM;[>M1!D$F*=C*QR(H2OSQ9*TNP
M"JNCV<]H*X, .ZBJGJMTGN1S;GC'W$7S*^J*W[SLI.[8GL+JF(/-"YX&@];U
MW@-EZ+G%PLMH>\2S"D0;O[Q0CPW1@GM;\\%%_D)]I:Q3A@2V5[P/2UG5M\^*
M$DWMLOHS=HV3O =VC8VBB68\X> YIT>:^#HA.3LK.23?OVDXNKCLO&Z$.@N:
M9.1P6KV MKJ_S5%[/QJ[F%^35R-,LX_*&#5=03MMB:1@LMK%<?8MG5>T1)2;
M^L@KDNE2Z2B2 ?X3PB#["]CK1T;=Z)K]!7QC.'IDW'$ 4%<DT\90PM\CUD$Z
MBBRRG?_@*N3":DS!(O?>R(L?D%EOZU9K2G*_(#^^!1*P3['; 2G29HNP;;<3
MCU0PI/'F*KCA_:5[HL>[W@Y[.[YQ$AQ#S>(.C\1NXG67M=#&;=U$4W^ZO'LR
M,A+C-B8<.1;;IKPF"B?=\B<*.CC79\RM<X9-I#:W8CW9]S.]:=%E+5E?3#7Z
M&HL7>.(7"82O>P(6@KTSB)14]T/2;7:A$\=!I*:D=!_]S-1][_F\<W00C4C<
MW'D%=X]+W)="X53@",%V]!I)VYR\.]GJ<3PIZ4'B;^2SCORV'1>ESM1$Z>/?
M?X*JN;R:%F?V#XIN#>JA40ZQ_CMVI8BY>7A?8==YE?#$>8"YL[D(G3QK,MF$
M0:A?7+Y/YCP'MAU\9O[0=:M^RO%$>([!\7XX;J%CEW\.(U4 QW\P.'7\:MK_
MG_"B0*[.:9U)B\0Q*)C9QUKD?$BNL'$0M5S8TR]Z-^*XW1^(@G[RWSE"O7WN
M4/<7@#\\?I=QE\+4RCE%_LS=/"?@WM36&W*03O\QUS1_NK+2IK8^?>]G6Y.U
M DL-7C@6Z[1UR[.QDW(]0$U!J%+<!ZN%-?I-VW@4<]OVWO3;MCKDS\FG?K_A
M*2P6W-3XHG*AD=L[(S_K/KE.<ZB;Y#;':L4G#_Z<,F0/G[=^6Y%57'*D?'$=
MJ;4_<$'$H'"MKSV^HRYE0YTR9-6:Q<\0[%G<M$-]424]*\PMJ2*E@89E"Q13
M.=3J2*X34,L[Z&077(PYDSZU!'E?2O0\3ZH7&I;)BW5V2T-290R\;4T2[\3+
MW9]*^@NH:N+Q]R;]FHNI*6"A# ,7HT#/#=KAI8XR$5(;$*A7HA0Q-$G,*J[0
M=VQ"$P^)T %/S;VQ?&JA"BGP\[R&8J<+"UZ'#1.1CO_8Y)(&A<,/^_4:9GB(
M?[-]P"C0-?=0ZGNQ%*@_S0O+D$25,#8Z>F?/F/>A\ WC,K$N=@JA]Y0-\*.?
M*)24IRKM=V?SA!TH%LL:_?6NL0S=Y/E'RUOZV;PS7J,W=YL@EI*SMLGO8HR;
M(KZ_G?;OO*W=][?]W4B_YN--M<%/73(J)%\'ZIXB)9\5\PV^PLZ:+"*1WQ:Q
MS'$R<UREVP_0J!9]SS0=472Z*MT05U=&[GLY4$=7@8#[V!;MR5:-_PGM#PS[
MY=1U_FHS_=7F4]\R]>Q1ZY!#HF'O^$&IA+B^'I[#OP"^W_!_5FUR]Q]_ 78"
M3KQY[=TN%O*W[]&>4M]Y:[[+\HFZHFY\<GG\(TB_YK55_8"8J9<#GY6@B!7S
M(4&8P"6_0S7:Z%@!^8@^$KQ&W$J0*++E@\S3*=(TGFJ"W/:/21%]I\9D[S82
M=^6 >JV(F;4.BG'7.G7B'C#S6Q9)?A)QZ>C?DFNS2T]FC!)WG2:<O 6<G(=]
MT\U/:WNSAL7LEOB#8NFD][\=QT]T+,BBB5(^4C?J>1#8XB=*7YYM7XQ)PG*I
MYZQNGO,'$OL%_@6@H<ZF?P'CT+N.5\_NTEE @C2N01ZD*0PKXVX([_6N=%DR
M9P&V;@OE$C_%=8>5ST^HORCAO58Z#!-.N;@*2GUEV];>%J99EWRX^Z>)R7RL
MYUF(WJFR@H5)*1!DE"[23A_\220JF9L%1Y J_,=@9N6A#\[8[P"'7&02Z^PF
M88F)*0K?YK[?CZDI_D, +A$]$ #T]L3G*/(MDJ0OH[VW[YF(*K+D=A\;#'\7
M]Z>X0_)&OTDFHFU'/U2]0G-[<5U5*ZT4%,W"9,<AD#7?SR*\K-:WV#=M,;71
M+"(!:]^JCTK@J?V!I9RLO.B#/[@?RN]T__WEV5,C:>9_;OG&, Z3-E'!?LQ^
M(EV)GA.U4P7F#<G\EV<X!_#@'?(17]M;Z9378(%#H.'I.!J^_?E^QS;PSY^F
ML>7OQ?X/L+0?8D3!8#9WBC%&=:,IJ>BS(IGA"37=?*@' (U]A^,A8BABV$%R
M?#>Z-R)\VR93QG<I>1S'<H8OCD^"<3 MK%!D["S:8H'RR5 UMRK*MG]Y7SRX
MU.4)K1LQB[N!]%(@NZ9V NDKL%.\T:/$(WIF?JT4Q@TGU-2R"O&?3+^'2CX_
M\_UX^:7"MFTE BF5"5MNLV68^N;KR3L:@#:W8#6L^6)>$5XQF&06$AGXNWL$
M3\I#2S@2_-ZQ= V>]P]XRNYK*_7A8: B(OW)HSISXT'1+T"Q;M8T% <TU%-B
MO48*XD<P^TI$92-2!\&U*96@.8<-*'ZG]IV9PT+K*WMJ0O,^E4S$MSVCXUU3
MU\M+R3]1E &_S3(#'JW!-$0(UD\<JE<@[?7-JKQV)L9^;Q2IAX(A8WX7W^ZY
M18BR&>^G07\!#:I_ ?* [R)7;UVQME!9J+K5*F<,^ESQ7272KY4N?8]Y9ROC
MW6[_-,/$GLK%Z2<QU0J*=]$:,:QS&S:>X/26IW@G"_R(+_K"'O%S^3'C7X#>
M5C5.HR-CJ+]C#(:S/_ABT]0[!Q(@<\2^(A*/KM0$#':6YD-X5)EW7$JLX^?C
MYM*N<GX'P&HJ!CU@EK6??J_G*2YE:R]7DXB#42$'R*)9!)47RI+<5/.4=_0@
M3LN%2HE=CO='0M-&*$D@YR&!17^!U8V^X=E=KLH;(>5:):T5]N7Y0VE]M/3^
M>-58UET=[ [!=K.*TRBAM1![Q%4#W2)M 7H?+!S,Q5#\X-4#UM>WF= O7X#?
M#-*CM3L9U];.T7F+?P$6\A/GK@P*BGYYL9Q/"<U!A?3TB/;V8'>?^<K*#MUF
MVC5BE*?_/?GW-:3J.SJ/B6%/%I>,[WRO"=4H ZS63H%T);L>-4@K>%]^4[HD
M$.3&+LD<3=CZ9%)N4#;)+S*R\N?TQLQ&?9PSDZN=G^/T5K8HCT#("QGO(>CE
MEYTJ<J41$[/A,A0P5JDV0SG="#Y9[+2HSQAJJM6V@3K95ZTI\&](*6$OLZ;;
MU#;KI4U;;'Q"M4H'ER;5T24<(+XUCAS]T</.%?;C63#T K>MSK!67=457)0]
M-*P)Q#<=,%?VV&.U4D\=<97U2Y#8/.]UJ?P(]ED7CKA_N^>3_AS_,,U"Q$\_
MLPGO*X"+\92K_9]WG*<<Q1>;_G2*4-&%BH+,;N&ON-ZO,Y8[PMJA*U3-.<8M
M;4@^G7R/4KL2?UQ->Y9])A;9WTC<,FNBS[YSVE[>S1'N?)1\J\RURJU.8^)'
M<I._<I_!B?6G852O@(9-#:M;Y;6O?2I)-FV*CP<J,1TCIOM7G%52YC[Y!K]^
M>[S\IA@0?H\71>*/$7>6[A-)X03#"91/*R]L:8=WY>-=/KNN5+5>3G4$'<3!
MA'$^J72=Y[7M=$[)NU>]JBA3".B@$#+OG,['Q.]?9$ED5 F4'[<0L/@HAT.F
M(Q<:PYF+^5](>-WWU3IO_OD=6AJ$3M:@Y)O)0XXO_Q+Z4N]X.ZG<C.<2W>$:
MU8IQ1NTAE-V_DHSJ7C0O,#SI B-XBX1Z1&L6-ZVRM:0,L\C-QI#-4C7MOVWV
M_(E\G@?.B$!0Y2E"!)NW<@Z&[F9A23(;A8;34GSQBN];0G\,^PZV4%&C2S1S
M!*ZC.1(TO+ST]$#&FD_<MJB% ZC#?_D*H=<H-K9EQ;"POM/ZZQM9,$P=68@V
MU9,,A I$6C<K*[HRI ;0(K/(FG,@IY5]X.V0PM6AVJ5%;L$2K:28")U)%6Q,
MZ8\F,3\6"0?=UJ-XIO+Z1@BZ#'X)3-B43RJN= TUUKPFIM1J<-$CH]$HDU0X
MJUD$'OGLR%PHZQV?JA?3N.!7I,#Z%^D<^10$]A2XEHJ7# _(N"27:/4,!=ID
M\V424L#<BMMFP]MDD9*/,8(QI')**](YOS8LSRN]>#' F1>C\(@S+_@_(Z:6
MOP!]V14RA4M08\Z>\NV/9-(63DS_?WH% YWR@HD25QXF!8L#^<_TU"(T<.ET
MO=*J8(2.A#4=@YZV3_F@$732?E0R%V6*6,P-C1%C2&X7KR?=3['?T)&1 $H0
MW/@P<Y'U'YO?$R7( C^&?;(U+,F5$P/8G?R3]?]#B?M*6J5Y,8 ')P&"B@\!
MA=_M+YC@(8];MHL4 *6#$>'-0>PK L_=Q<7H!)U'R0!V-Y,)#XX](I5^.+Y8
M !W/JWH?IXPN;:]KC.:D!HN=4^D8EN2%1&A54,O4_VM\8ENWJV6NQ3VO*I[O
M+0(AT2);?S*\GA2A!SLO7CG\JVDNST -M@?EZ?^"^M&_'97]'[ +/UA4!/RC
M3!'@Z-PBY5\2A5@^**]YU@ 4']$(FZ'/A4O&U%A;NQ>9*(-<RVO8M49Z4Q,\
M53D25%D3#9UR;39OTM\F*I+A/ZB+V6:H7QS&R^"QL$DZ8P)7-A\6UY0ZY=J[
M$%()HZC*#\+P\ZEH,GA4Q5FS-Q-492X<8C@?_V/^P;/L\_]0!?]7TG^LJ*.M
MOC7JI&OQRK9PS>A2K3Z<.4^G;_.R%#&L.TR#O'2VBB\5)6(PN]_5W__*']8Z
MC(&1X41<@^XFE9-SELGV. F)_V'_]"_RVA0T_[#3/\CIE>3RB/[#+O4@5ZPC
M9^S^#[O?@YQF7G#U_ZJ9%Y;,^'A#,L>%C1]%[B85_P)N0NZ/"QMN\X)K9/\K
M[?QO@O/_F_G_BID/VIX W(=O_[H_8B8;D]H8O18^IY_\LI;B]/R2J:ZUE#[G
MSEGX0'[]>,]O5'@+)AQNFVUH8J/;C3'0Q0KK5RND*?L+ ,[_]-W\II8!#$H:
M6X_9=GNG[AV*/B446]6L^=(M)/Q!I<<6HA-GY=B\G0MVVEU,;O=ZD_@MPSZ"
M=XD"UHDE+:@ES%FG:LM5?.?M=A\@5)'7W"RE"BFZJZ7310I <!H7]7X?FIA#
M&ZD9K39CG) 73[P:?) >'!GV;'TV29_D+_TQ2:7NOS0;WR,TT7<,1<4:BI[(
MEN6EAL7 [#30,S/ISRW6PJ,(HUQM/];$?7.V^H1A,&UB]^;0$*%RD\CT;CPR
MDH92K<WYC^RQS*DI9UY\]?]D]^B_[R+IZ?P%?(+<7^7-'3[2T+J73KD[42Q>
M(L/P_&>-BOMD.GS"<[IX96F83?!</+\N:7)FK0R;]8E9<<0C,V<*#?0J95NX
M:'S@LXI6NO9!.8'=\4)\^JBC7Y7Z5[T??&+O,AB;IW^F W_%KBE4/\WWE@%?
M#:!W%J.D["8C$@VGMJ?7 I3;0I7B[<Z>D%%@D[9T/ND%P/2-GMB>/$<>O/21
M!R33F/"MPPGGM_FB!!7 8WV;'M"+]>(@,BG=!4MGPQ0*;01BM%.QR1"73=]J
M)#?PT)=Z8U488U['3#JG)P"8ZAX+1%U/F*KZD'E8*HN<RR?0.'B+LH3EE/9:
M-)[$]CE*-*3PY3Q?>'7^UMZ$*)Y/U(ZTI=MC8R58XAMW8A#UJ+4U!%;N-$?Q
M*"KAM:F!_6=)L,'+3J5!:NQC\5%%ZQ-,Y&G?05O4"AKWH^'*U)YD"%=\0ZZ1
M'KP=&J>-9ZOHN8A;7&IQE:$?J=V8,-$+=E.L^:(2H_JNMGJ/!&_+8+7WF8FY
MACO8&AH@=5/0$-]W^0C _?A=J/)0F]?!N,47C/E)L[<=W+.5[L).!_6K;"OW
MZNJ_+&#7)H\SL>!*,JYQCE1'F@U7'XN77" +.,' 80C::8LR/NUM1D-<=U:7
M*MW[3&T$WM=%'3.KD]X-DW[O=**/1'.A0T1F?+NL*T,> ITT_CF6SJV4,7RK
M&NU^PCX:K\>LR1KZMD3X]/EMF3I187/4Z%R)^=V22O:7%.KER@XLEK7C)%7D
M%4.*$D-QCY([86NA^'\4G5U:!J9@QDL%IW[^L-FQWB\O1%.JU^(\_=;0.Y4/
M)35AR*2.F5WVRYGLH=]TY =\EEH!J)>"7M;,P4*M#+"(-0^H 7 ="W3S/H-\
MDZ)?.WF2C\.D*N\#CO2#!0>QL0FQPP<E54VR5?M'DHO<25K/V69_/YF?3ZN@
M'Y/<=3/5SN,TKF:%;X)_29SI,_3X)QW6Y-<G4XI0^'!!>!S'#,\VGKB9=P8B
M?WE %28HBJ&*'LAL4:>^)%N<N!1!=7OLHYT5I=IJR!^,FNWJ?K%>YV7?O'5I
MW8  7OIM-'+J#?S0-]5!Q(J$7*(#"Q,RO9*%J*9C(^_K7X^-]3.<&M=L[FAN
M:FO[2*&>1/-6>0;^+%MB8R6_[81USF',JE$DG+E#O=6:D:A6*>QC-PL\]S9,
MO;#SH*22Z9V+#W']=\=)-[[<FOK0@+3%+05LW\;$ 9I4HI.^P!:#T: ^7:=@
MS1;G8;L:@FP_OHVHVOB<Y:_BGGANXNL9AEAE><W 3Y3F@:W:$</* :FNS*I%
M*>,$I_4!G09]JGV^=RX6<R;P2P,7=:\S9J!^$ZC;0S01 3G$D$WBQBA6A";Z
M9F_<&CKQ"@?$MG*;(%>V]]BIE<5N2V>#EP25-?W7R\8WJ'FEY'%S8$51N=EK
M0&6FUK@AXQWL'O%'D#GQ/K%<DLJ8S?(_]A (JY!&WBA)%MNT:6#5F%XT=C@&
M:@[$2(3F*/;W6A%,F.NAN E$IC.%KJ\!%?^C$NE^,E[Y7S O(]*??P'/5OM=
M7%\1TD3S;+<ESUO6?],\$WI!G.5];G:#/C+8FF._%1RILXC"22XZC("TI6X"
M'L^OP2']U$=R]"&*?M<G]$5NB*A*ZS37BL5!*]]*,M6S+WO>EV-:TW1[&^\4
MI^?,1-[(HZTA:#VNMD^C9Z+@\:0LE \DIY^J&.Q*Q^?]Q>AED6\[0NNQ5G&W
ME524O:^ICF?$&WM6^_7;H0(XJ?C >CV,9A!H-NTU;\?)2@H1P@JKX1>YYQG.
ML0)A5"E"O!F>U-\>.-.\,L9I[UEY(T@XL*A[S>@613=$0,L ^<SM8XITF"Y
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M(/PHQ?LUC>G,=!?[0PU L'>F4FNNBNR@(CR0#T9FR!?N(YQL^J%N8"JURLW
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M@9'-R.F>XO@%MH=S%>:^7=9^$$5Z[_6HP("&*XII'8_V@XN+E1NFHF)7^+O
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MKFF$Y=_\P5QW.-^]3M*ZYA]V03D/F7_#'.KP/3[ !:$;A$M@8'03)1/"6G8
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M^0]5(O[.O7C#=PMPDS+A&$H2F(&8:M_S*RR@DEW>3M$X#R4.,H_P7UKB<_M
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M3V O&37E&Y2\J[TOL[^%DSO>+8[V/V;Q5T\)U3GZZ+G>83%@YJ4XK+X &EX
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MR8\AC%OA:4YP;YKI,S9_*&O=5DSFQ)SO;W]J $J;L=8Q502,H#K.4>@#V._
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M4E6XQ7_^AP;H_L^0=]M1V;AX8U+7@<]_\O]ELW$,98U>'?>-!(FY[3$8#&;
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M'5?WM&X:7.X#\A(:E4(^11G$S;JDKY>B\&TMT2L(+"+2:W_1L\S(\OQ6[-G
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M+>DQ8J^#(_#[VR;-.O?<"-)J<5Z-%=X4C3Q<!-:$75MK%]Z*5-@,!$'O/1&
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MVV2]';-J,J(9GC+\TJ,_X2\]/EJ$.#?D/,S\+]W<U^0)_^'\]$'!7WH!,H9
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M,1]QQ;NA4VQ0W7RO(^ZL\J3FOB+-A7K9FQG@D-4>+;H G$#+Z)0CM#A>4)?
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MKH=K7;-=6_SO\+^(T4* O\/_(OZ']S^\_S,O"7G^RC_\PY^I_P902P,$%
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M,^P_Z;34-(*LPA;^N4Y1RO(_=2(P_LB[0_<F_Y,_O;H=2-8:!'(M% 6.;.5
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MI*3 B[[H/AY??OJL?G7"TN,[E>HBU\Y\+B5?GQP ZTRHO%D?'VEFZN27.P9
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MNF'W[>BCO%/GSJ/O?[@\WM/9.:R4*A<U-2,<-(:9LDDJF]>R'!L='1,<J9=
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M'A/,)$-T3WQWIZR!O8 Y,S-P%.Z!F ,&L<EG]E1W]UJ=AX,8Z1MBZ:%K%6)
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M@L]Q\%95HI48YN&ZX*9V;0A9<I-1:RZ.$ZV$,T([H;<<PWB)IOLA04\!7\T
MGVTA>5Q:M\RF4:8/D:"$;M&TIG.ELCZL, 7X,Z#);&K<+K4+$)97OLSWC4':
MH&"0V[_K/6W;'UXZ[C\ 4$L#!!0    ( #DZ$%,(-W?_8P@  +8F   7
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M-L#%I"[57*!W5B@?U?R.@P#0)\DH_0TS]3'-N7*A[^:C!:C.]4X6%S+#G!A
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M  !P;'@M,C R,3 V,S!?8V%L+GAM;%!+ 0(4 Q0    ( #DZ$%-)#8 B2A<
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M;'@M,C R,3 V,S!X97@S,60Q+FAT;5!+ 0(4 Q0    ( #DZ$%.20?]U=P@
M !XH   7              "  :XJ! !P;'@M,C R,3 V,S!X97@S,60R+FAT
M;5!+ 0(4 Q0    ( #DZ$%-A"2UV@@4  %(7   7              "  5HS
M! !P;'@M,C R,3 V,S!X97@S,F0Q+FAT;5!+ 0(4 Q0    ( #DZ$%-[K2(A
MA04  &P7   7              "  1$Y! !P;'@M,C R,3 V,S!X97@S,F0R
:+FAT;5!+!08     #0 - &L#  #+/@0    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
